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Abstract: Canada has a long and rich history of ground-breaking research in drug delivery within
academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery
refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical
compound in the body as needed to safely achieve its desired therapeutic effect. It may involve rational
site-targeting, or facilitating systemic pharmacokinetics; in any case, it is typically concerned with
both quantity and duration of the presence of the drug in the body. Drug delivery is often approached
through a drug’s chemical formulation, medical devices or drug-device combination products. Drug
delivery is a concept heavily integrated with dosage form development and selection of route of
administration; the latter sometimes even being considered part of the definition. Drug delivery
technologies modify drug release profile, absorption, distribution and elimination for the benefit
of improving product efficacy and safety, as well as patient convenience and adherence. Over the
past 30 years, numerous Canadian-based biotechnology companies have been formed stemming
from the inventions conceived and developed within academic institutions. Many have led to the
development of important drug delivery products that have enhanced the landscape of drug therapy
in the treatment of cancer to infectious diseases. This Special Issue serves to highlight the progress
of drug delivery within Canada. We invited articles on all aspects of drug delivery sciences from
pre-clinical formulation development to human clinical trials that bring to light the world-class
research currently undertaken in Canada for this Special Issue.
Keywords: drug delivery; pharmaceutics; drug development; formulation and dosage form
development; translational research; biologicals; small molecules; clinical trials; pharmacokinetics;
medical devices; route of administration
This special issue in Pharmaceutics, entitled “Drug Delivery Technology Development in Canada”
was put together to highlight the outstanding achievements and international impact of Canadian
scientists in the field of drug delivery. For over 30 years Canadian scientists from leading Canadian
research-intense academic institutions, pharmaceutical industry and the biotechnology community
have played a vital role in the development of and implementation of novel drug delivery technologies
that have made an impact on a number of diseases from cancer to infectious diseases.
Drug delivery encompasses a spectrum of approaches, formulations, technologies, and systems
for carrying active pharmaceutical ingredients into the body. The main focus is to achieve optimal
pharmacokinetic profile, often attained by active targeting. To achieve this goal, the drugs are
formulated in chemical drug delivery systems, incorporated in devices or combination of these two
strategies [1]. Drug delivery technologies modify drug release profile, absorption, distribution and
elimination for the benefit of improving product efficacy and safety, as well as patient convenience and
compliance [2].
This Special Issue on Drug Delivery Technologies in Canada highlights the progress of drug
delivery research and development within Canada. We invited articles on all aspects of drug delivery
sciences from pre-clinical formulation development to human clinical trials that bring to light the
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world-class research currently undertaken in Canada. In the next paragraphs we summarize the
contributions to our special issue.
Babu V.Sajesh et al. [3] discusses the limitations faced by therapeutic agents to reach their target in
the brain by crossing the blood-brain barrier by using HAV6, a cadherin binding peptide, the blood-brain
barrier was opened transiently, leading to improvement of the delivery of a therapeutic agent in a
murine brain tumour model. This proof-of-principle study is a novel avenue for drug delivery to the
central nervous system.
David Fortin [4] in his paper entitled “Drug Delivery Technology to the CNS in the Treatment
of Brain Tumors: The Sherbrooke Experience” also addresses challenges regarding drug delivery to
the central nervous system and reviews strategies encompassing the path of the drug discovery from
laboratory explorations to clinical applications.
Waleed Mohammed-Saeid et al. [5], in their article entitled “ Inclusion Complexes of Melphalan
with Gemini-Conjugated β-Cyclodextrin: Physicochemical Properties and Chemotherapeutic Efficacy
in In-Vitro Tumor Models” report on how β-cyclodextrin (βCD) has been widely explored as an
excipient for pharmaceuticals and nutraceuticals as it forms host–guest inclusion complexes and
enhances the solubility of poorly soluble active agents.
Asmita Poudel et al. [6], in their paper entitled “ Development and Characterization of Liposomal
Formulations Containing Phytosterols Extracted from Canola Oil Deodorizer Distillate along with
Tocopherols as Food Additives investigated formulation strategies for liposomes containing phytosterols
obtained from canola oil deodorizer distillate, and tocopherols to overcome the challenges of
thermo-sensitivity, lipophilicity and formulation-dependent efficacy of the nutraceuticals. The final
aim is the development of functional foods, enriched with phytosterols and tocopherols.
Jiahao Huang and colleagues [7], investigated the effect of phospholipids on a model compound,
rosmarinic acid, and established relationship between membrane permeability and bioavailability on a
dynamic gastrointestinal in vitro model, providing evidence for the complex interplay of these factors
influencing bioaccessibility.
Kevin Allen et al. [8] discuss highly reproducible method of determining its pharmacokinetics of
antibodies for further pre-clinical development using 111-indium-labeled antibody in a melanoma
tumour model, demonstrating superiority of this strategy compared to mass spectrometry.
Hoda Soleymani Abyaneh et al. [9], in their paper entitled “Modulation of Hypoxia-Induced
Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar
Carrier Versus Inhibition of the Mediators of Drug Resistance” assessed strategies to overcome
hypoxia-induced chemoresistance in a triple negative breast cancer cell line. They demonstrated that
pharmacological inhibition of hypoxia significantly enhances cytotoxicity ofcisplatin encapsulated in
in polymeric micelles.
Zaid H Maayah et al. [10], reported that by chemically conjugating Vit-D to DOX the delivery of
DOX into cancer cells increased and chemoresistance associated with DOX was mitigated via inhibition
of survival pathways and induction of apoptosis.
Griffin Pauli et al. [11], discuss the advantages of solvent-assisted active loading technology
(SALT) for liposomal encapsulation of compounds with low aqueous solubility. This new strategy is
characterized by complete encapsulation, high loading efficiency and stable drug retention, leading to
improvement of pharmacokinetic and pharmacodynamics parameters of the drugs.
Farinaz Ketabat et al. [12], review treatment options in development for oral squamous cell
carcinoma from new delivery systems to chronotherapy, and offer insight into future strategies in
the field.
Mahdi Roohnikan et al. [13], showcase research groups interested in the development of
state-of-the-art transdermal delivery technologies. Within this short review, they aim to provide a
critical overview of the development of these technologies in the Canadian environment.
Esen Sokullu et al. [14], present an overview of applications of plant viruses and phages in drug
discovery. Critical assessment of the status of virus-based materials in clinical research are summarized.
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The authors provide a critical assessment of challenges and opportunities presented by these highly
stable and versatile delivery systems.
Bahman Homayun et al. [15], in their paper entitled “Challenges and Recent Progress in Oral
Drug Delivery Systems for Biopharmaceuticals” outlines the advantages of oral drug delivery by
reviewing the advantages and disadvantages different administration routes. Additionally mitigation
strategies regarding challenges of each route are emphasized.
Courtney Van Ballegooie et al. [16], depict physical strategies aimed towards release of drugs
from liposomal formulation at their target site. The mechanism of drug release upon the use of energy
sources, including ultrasound, magnetic fields, and external beam radiationis explained.
Ada W.Y. Leung et al. [17], provides a high-level review the most successful Canadian drug
delivery systems translated to the clinic, leading to the formation of biotech companies. From the
creation of research tools (Lipex Extruder and NanoAssemblr™) todevelopment of pharmaceutical
products (Abelcet®, MyoCet®, Marqibo®, Vyxeos®, and Onpattro™) positive impacts on patients’
health are numerous. This review highlights the Canadian contribution to the development of these
and other important liposomal technologies that have touched patients.
Grace Cuddihy et al. [18], in their paper entitled “The Development of Oral Amphotericin B to
Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?” discuss the
development of an oral formulation of Amphotericin B to treat systemic fungal and parasitic infections.
Taken together, these articles published in our special issue represents only a fraction of the
drug delivery research and development ongoing within Canada but do serve as examples of the
outstanding contributions Canadian’s have made to the discipline over the past 30 years.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Raynaud’s Phenomenon is a vascular affliction resulting in pain and blanching of the skin
caused by excessive and prolonged constriction of arterioles, usually due to cold exposure. Nifedipine
is a vasodilatory calcium channel antagonist, which is used orally as the first-line pharmacological
treatment to reduce the incidence and severity of attacks when other interventions fail to alleviate
the condition and there is danger of tissue injury. Oral administration of nifedipine, however,
is associated with systemic adverse effects, and thus topical administration with nifedipine locally to
the extremities would be advantageous. However, nifedipine is subject to rapid photodegradation,
which is problematic for exposed skin such as the hands. The goal of this project was to analyze
the photostability of a novel topical nifedipine cream to UVA light. The effect of incorporating
the photoprotectants rutin, quercetin, and/or avobenzone (BMDBM) into the nifedipine cream on
the stability of nifedipine to UVA light exposure and the appearance of degradation products of
nifedipine was determined. Rutin and quercetin are flavonoids with antioxidant activity. Both have
the potential to improve the photostability of nifedipine by a number of mechanisms that either
quench the intermolecular electron transfer of the singlet excited dihydropyridine to the nitrobenzene
group or by preventing photoexcitation of nifedipine. Rutin at either 0.1% or 0.5% (w/w) did not
improve the stability of nifedipine 2% (w/w) in the cream after UVA exposure up to 3 h. Incorporation
of quercetin at 0.5% (w/w) did improve nifedipine stability from 40% (no quercetin) to 77% (with
quercetin) of original drug concentration after 3 h UVA exposure. A combination of BMDBM and
quercetin was the most effective photoprotectant for maintaining nifedipine concentration following
up to 8 h UVA exposure.
Keywords: nifedipine; emulsion; flavonoids; topical formulation; quercetin; photostabilizers
1. Introduction
Raynaud’s Phenomenon (RP) is a vascular condition that causes temporary arteriolar vasospasm
in cold-exposed hands and feet of affected persons, resulting in numb, ischemic digits. First, there
is a characteristic blanching of the skin as circulation is reduced; secondly, the affected area turns
a bluish color during resolution of the vasospasm caused by venous blood returning; and thirdly,
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redness as arteriolar flow resumes. Not only fingers and toes may be affected, but also the tip of
the nose, pinnae of the ears, and the nipples. Rewarming is a painful process. For those seriously
affected, RP adversely affects quality of life [1]. Thermoregulatory arteriovenous anastomoses, which
are enervated by sympathetic nerves, are responsible for the phenomenon, rather than capillaries,
which deliver normal circulation. Connective tissue disease, occupational exposure to vibration, and
smoking are risk factors, but RP is typically a primary condition, affecting approximately 3–5% of the
population or more, depending on climate [2]. Chilblains is a related cold-induced vascular disorder,
resulting in papules causing pain and pruritis [3,4]. RP is not always a benign condition; in severe cases
associated with scleroderma, rheumatoid arthritis, and other connective tissue diseases, diabetes, or
with certain drug exposures, secondary RP can result in tissue damage due to repeated and prolonged
ischemia, requiring medical intervention [5]. When adaptive measures to avoid cold exposure are not
effective and pharmacological treatment is required to reduce the impact of severe RP, or chilblains,
oral calcium channel blockers are the first-line medications, particularly nifedipine, a dihydropyridine
compound [6,7]. Alternatives for severe disease include sildenafil and intravenous prostaglandin
analogues [8]. Dihydropyridines bind to L-type CaV1.2 calcium channels [9], and in so doing, effect
smooth muscle relaxation including vasodilation of arterioles, the therapeutic target in this case. Other
drugs in this pharmacological class include diltiazem, nicardipine, felodipine, amlodipine, and related
analogues. Nifedipine has more vascular than cardiac effects [10] and has been demonstrated to have
moderate efficacy in the treatment of RP and chilblains [6,11]. Daily oral therapy with nifedipine is not
always well-tolerated, however, due to systemic side effects such as dizziness and flushing.
Currently, there is no effective nifedipine topical product marketed for acute RP treatment or
prevention of symptoms. Topical application of nifedipine would be advantageous as it would provide
a rapid effect on the local tissue while limiting systemic exposure. It is expected that topical nifedipine
would be extremely useful for reducing the risk of tissue damage in patients with scleroderma,
rheumatoid arthritis, systemic lupus erythematosus, and Sjögen’s syndrome, as a part of combination
pharmacological therapy for RP and for those who have outdoor occupations with cold exposure.
Furthermore, it is anticipated that topical nifedipine, or topical preparations of other calcium channel
blockers or vasodilators, will have utility in the future to augment wound healing [12–14] and peripheral
vascular insufficiency-related conditions, with a potential role in diabetic ulcer treatment [15–17].
Extemporaneously compounded topical nifedipine has been described, but it has inconsistent
efficacy; nifedipine is not stable due to the well-known ultraviolet (UV)-light sensitivity of the drug [18].
Exposure of nifedipine to UVA light (315–400 nm), which accounts for 95% of the UV radiation
that reaches the earth’s surface, results in the photodegradation of nifedipine to dehydronifedipine,
which can undergo further degradation to form dehydronitrosonifedipine [19–23], both of which
are inactive compounds (Figure 1). This degradation process is rapid, it is not sensitive to the
presence of oxygen, and it is mainly attributed to UVA irradiation [24–26]. One solution to this
problem would be to incorporate appropriate photostabilizers; that is, compounds that filter UV energy
by absorbing a certain range of high-energy UV wavelengths and releasing the energy at a lower
range. We hypothesized that incorporating UV blockers into topical nifedipine formulations would
prevent UV-induced decomposition of nifedipine. We describe here a preparation of 2% nifedipine
in an oil-in-water emulsion formulation containing photostabilizers that preserves nifedipine from
UVA-induced photodegration.
Photostabilization of light-sensitive medications in topical emulsion formulations is not isolated
to nifedipine, as a recent analysis of topical products in the United States Pharmacopoeia and the
European medicines databases indicated that up to 28% of approved drugs have the recommendation
to protect the product from light [27] and the list of new drugs with this recommendation continues to
grow [28]. Thus, there is a need for the development of compatible UV blockers for topical formulations.
Since topical medications are applied to external body surfaces, they have the potential for significant
light exposure. Typically, these preparations are applied as a thin film, which maximizes the surface
area of the formulation to UV and visible radiation. In addition to UV or visible light inactivation
6
Pharmaceutics 2019, 11, 594
of topical drug products, other photodegradation products can display toxicities or other unknown
effects [29]. Furthermore, light exposure may also influence the physical and technical performance of
a topical formulation, such as changes in viscosity, precipitation of components, changes in emulsion
droplet size affecting stability, and changes in chemical degradation of materials [27]. Photostabilizers
may also serve a role to maintain performance integrity of the topical formulation.
Figure 1. Ultraviolet (UV) radiation-mediated breakdown of nifedipine.
There are several common photostabilizers that could be appropriate for use in a topical nifedipine
formulation including butyl methoxydibenzoylmethane, BMDBM, (an approved sunscreen agent
also known as avobenzone) [30,31], and octocrylene, an approved photostabilizer sometimes used in
combination with BMDBM in sunscreen products [32]. We have recently been exploring the UV blockers
rutin and quercetin, polyphenolic compounds that are found to be upregulated by UV stress in a variety
of plant sources [33,34], with known antioxidant and UV-protecting properties [35–39]. Both rutin and
quercetin can act as photostabilizers via a number of mechanisms, including preventing photooxidation
or inhibiting radical formation, both steps involved in the photodegradation of nifedipine. Additionally,
these flavonoids and BMDBM (chemical structures are illustrated in Figure 2) are all characterized by
regions of broad absorption that overlap with the absorption of nifedipine, and quercetin has been
demonstrated to enhance the photostability of BMDBM in vitro, suggesting that both quercetin and
rutin may be suitable photostabilizers [40]. All three can then prevent photodegradation of nifedipine
through competitive absorption of photons, thus preventing or minimizing the generation of the first
excited state of nifedipine.
 
Figure 2. Photostabilizers under investigation in this study.
Extemporaneously compounded topical nifedipine has been observed to undergo UV-induced
decomposition during preparation and storage, contributing to the inactivation and inconsistency
of these formulations [18,41]. Nifedipine is not water soluble, which presents certain limitations to
the pharmacist such as having to use hydrophobic cream bases or to perform relatively complex
compounding procedures. The hydrophobic nature of nifedipine, however, makes the use of an
oil-in-water (O/W) emulsion an attractive approach. An added theoretical advantage is the solubility
of the photostabilizer compounds in the oil phase of the O/W emulsion, where nifedipine is also
solubilized and thereby co-localizing protectant and drug, which may be important for optimal
photostabilization. It is important to note that some photostabilizers degrade unless used in combination
with other UV blockers. BMDBM has been noted to have sensitivity to UVA irradiation, undergoing
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photoisomerization to the inactive diketone in non-polar solvents. BMDBM decomposes in aqueous
solution, but remains stable in polar solvents [42] and in mineral oil or isopropyl myristate [43]. In
order to minimize BMDBM degradation under broad spectrum UV light [UVA plus UVB (280–315
nm)], it is usually used in combination with a UVB blocker or a broad spectrum agent such as
octocrylene [32]. We hypothesize that the flavonols quercetin and rutin, through antioxidant and UV
absorption properties, will stabilize BMDBM and in turn stabilize nifedipine in our formulation [44,45].
In this report, we have compared quercetin + BMDBM vs. octocrylene + BMDBM on maintaining both
BMDBM and nifedipine stability to UVA and UVB light.
2. Materials and Methods
2.1. Chemicals
Glyceryl monostearate was purchased from Spectrum Industries (Gardena, CA USA). Stearic
acid and glycerin were from BASF (Ludwigshafen, Germany). Liquid paraffin, rutin (>94%),
quercetin (>95%), and white petrolatum were bought from Sigma-Aldrich (St. Louis, MO USA), and
mixed tocopherols from Lotioncrafter.com(Eastsound, WA USA). Sodium lauryl sulphate was from
BioRad(Mississauga, ON Canada). Nifedipine (>98%) was from Alpha Aesar (Ward Hill, MA USA).
Butyl methoxydibenzoylmethane (BMDBM) was purchased from Tokyo Chemical Industries(Tokyo,
Japan). Diethylene glycol monoethyl ether (Transcutol P®) was a gift from Gattefossé (Saint-Priest,
France). Water was purified by reverse osmosis (MilliQ systemFisher Scientific, Ottowa, ON Canada).
Analytical references standards of nifedipine, octocrylene and dehydronitrosonifedipine were from
Sigma-Aldrich(St. Louis, MO USA) (99% purity).
2.2. Preparation of Topical Nifedipine
Topical nifedipine was prepared as an oil-in-water emulsion using the beaker method [46].
In general, with this method, the water soluble and oil soluble components are separately dissolved
and heated, followed by addition of the water phase to the oil phase with continuous mixing for
formation of an emulsion, followed by cooling to solidify the cream. In this case, nifedipine was
incorporated into the internal oil phase of the emulsion. All excipients in the formula including
glyceryl monostearate, stearic acid, liquid paraffin, petrolatum, diethylene glycol monoethyl ether,
glycerin, and sodium lauryl sulfate were used within approved US FDA inactive ingredient levels.
The photostabilizer BMDBM was used within the US FDA approved usage level [47]. Flavonoids,
rutin, and quercetin were included in the formulation to investigate their potential as UV blockers to
facilitate photostabilization of nifedipine in the cream.
Where indicated, when quercetin, BMDBM, or rutin were incorporated into the cream, they also
went into the oil phase of the emulsion. Work was conducted under yellow light (577–597 nm), which
does not cause photodegradation of the compounds of interest. For the oil phase, glyceryl monostearate
(6.7% w/w of final preparation), stearic acid (9.5% w/w), liquid paraffin (9.5% w/w), petrolatum (9.5%
w/w), and Transcutol P (2% w/w) were weighed into a 250 mL beaker and warmed in a water bath
on a hotplate to 85 ◦C with stirring until homogeneous, followed by addition of the nifedipine (2%
w/w). Where indicated, the following additives were included in the oil phase: quercetin (0.5–2%
w/w), rutin (0.5–2% w/w), and/or BMDBM (0.5–2%). For the water phase, Milli-Q purified water (q.s.),
glycerin (13.4% w/w) and sodium lauryl sulfate (0.95% w/w) were warmed in a beaker to 85 ◦C using a
water bath with stirring. The water phase was added slowly to the warmed oil phase with continuous
stirring, and within a few minutes, emulsion formation was noted by a visual change to opacity as
well as a sudden increase in viscosity. The emulsion in the water bath was removed from heat and
stirred continuously at room temperature until reaching 40 ◦C, followed by homogenization (Virtex23
homogenizer, The Virtex Co., Gardiner, NY USA) for 5 min, then allowed to cool completely at ambient
temperature (18–21 ◦C). Prepared creams were protected from light and stored at 4 ◦C.
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2.3. Light Exposure
Photostability tests were conducted in a manner consistent with ICH photostability testing
guidelines [48], although conducted in an academic laboratory. Two F20T12/BL/HO UVA lamps
(National Biological Corp., Beachwood, OH, USA) filtered to remove UVC with an intensity of
740–750 μW·cm−2 at 365 nm as measured with a UVP UVX-36 sensor (Ultraviolet Products Ltd.,
Upland, CA, USA) were used for irradiation [35]. This level of flux is roughly equivalent to a
bright sunny day in mid-summer. Although the lamps used in these studies conform with ICH
guidelines, which focus on product/packaging stability (https://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Quality/Q1B/Step4/Q1B_Guideline.pdf), the focus of our study was on
UV-mediated degradation of a topically applied substance with the result that a flux level previously
used to mimic topical stability was chosen. The lamp apparatus was placed inside an enclosure with
an access door, to prevent ambient light entering and for worker safety. For samples exposed to
“ambient light”, these were placed on a laboratory bench where standard fluorescent lighting was
used. For UV exposure studies, sample handling was performed under incandescent yellow light
to prevent unintentional photodegradation of nifedipine. Nifedipine 20 mg cream samples were
spread evenly across the surface of a microscope coverslip to create a thin film. To prevent drying, the
samples were covered with Saran Wrap®, a plastic film that was determined to be UVA-transparent
(data not shown). After the allotted exposure time, the cream was scraped off the slide for extraction
with methanol. Samples that were exposed while in solution and not incorporated in a cream were
dissolved in methanol as a 20 mL solution in a 100 mL beaker.
2.4. Extraction of Nifedipine from the Cream
Solvent extractions were performed under yellow light. The sample was warmed in a water bath
to 85 ◦C to melt lipids, followed by addition of 5 mL of methanol, and vortex mixing. The samples were
centrifuged at 10,000 rpm for 5 min, and the supernatant retained for analysis by UV spectrophotometry.
The extraction efficiency (EE) was 90%, defined as: EE= (Nex/No)× 100%, where Nex is the concentration
of nifedipine recovered in the extract and No is the concentration of nifedipine in the original sample,
based on the measured amount of nifedipine added.
2.5. Spectrophotometric Assay
Nifedipine concentrations were measured in methanol on a UV spectrophotometer (Unico SQ-2800)
at 348 nm. The linear range was 5–100 μg/mL (r2 > 0.999). Values reported represent mean ± SD for
triplicate measurements.
2.6. Stability Studies
Nifedipine cream was prepared in replicates of 50 g batches and stored at ambient (21 ◦C) or
refrigerated (4 ◦C) temperatures, protected from light. At the indicated timepoints, triplicate samples
of 1 g were removed and extracted as described above, followed by HPLC analysis.
2.7. HPLC Assay
Nifedipine was quantified by reverse-phase HPLC at ambient temperature (23 ◦C) by an isocratic
method on a Waters 2690 instrument equipped with a photodiode array detector (Waters 996, Waters
Canada, Mississauga, ON Canada). The column was a C18 5 μm 4.6 × 150 mm (Phenomenex, Torrance,
CA USA) and the mobile phase consisted of acetonitrile: Sodium acetate (1 mM, pH 5.3 adjusted
with HCl) (70:30 v/v), generating a retention time of 2.9 min for nifedipine (λ = 348 nm; linear range
10–100 μg/mL, r2 > 0.99).
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2.8. Emulsion Phase Stability Analysis
A high-end Dispersion Analyzer [LUMiSizer® (LUM Corp., Boulder, CO USA)], which is a
multi-sample, temperature-controlled analytical photocentrifuge with dedicated software, was used
to predict long-term stability and optimization of nifedipine emulsions by means of creaming rate.
This allows for an approximation of the relative stability to phase separation of emulsions that
differ in the type or percentage of photoprotectant and for confirming batch-to-batch consistency in
stability against phase separation. For each sample type, triplicate samples of 2 mL were loaded into
photocentrifuge acrylic cuvettes. The samples were centrifuged at 42 ◦C × 12 h. Phase separation
was detected as an increase in light transmission at the top of the sample, which is interpreted as an
“instability index” reflecting the rate of change of light transmission.
2.9. High-Performance Liquid Chromatography–Photodiode Array (HPLC-PDA) For Ketoprofen Sparing
HPLC-PDA analysis was carried out at room temperature using either a Waters 2695 separation
module equipped with a Waters 2996 photodiode array detector (Waters, Milford, MA, USA), or an
Agilent Series 1200 quaternary pump (G1311A) with online degasser (G1322A), autosampler (G1329A),
and photodiode array detector (G1315D) (Agilent Technologies, Mississauga, ON, Canada). Aliquots
were injected onto a 250 × 4.6 mm Allsphere ODS-2 column, 5 μm particle size (Alltech, Calgary AB,
Canada). Data were processed using Empower software (Waters, Milford, MA, USA) or Chemstation
software (Agilent Technologies, Mississauga, ON, Canada). Elution was carried out in gradient mode
using two components: A = 1% formic acid in water, B = 1% formic acid in methanol (flow rate
1 mL/min). The gradient for the UVA experiments was as follows: 5 to 15 min linear gradient from 90%
A to 10% A; 15 to 19 min, isocratic 10% A; 19 to 22 min, linear gradient from 10% A to 90% A; 22 to
25 min, isocratic 90% A.
2.10. Time Course for UV Irradiation of Rutin and Ketoprofen
For photostability analysis, a 20 mL solution of rutin (50 μM) or ketoprofen (250 μM) in methanol
was placed in 50 mL quartz cells fitted with a septa. The quartz cells were exposed to UVA (740μW·cm−2
at 365 nm). For the methanol experiments, aliquots of 100 μL were taken in duplicate at each time
point and injected directly on the HPLC. The time-course samples were compared to the 0 h time
point to determine the amount of compound remaining by measuring peak area at the λmax for each
compound. Experiments were performed on at least 3 separate occasions.
2.11. Ketoprofen Sparing
A 20 mL solution of flavonol (50 μM) or ketoprofen (250 μM) in methanol was placed in 50
mL quartz cells fitted with a septa. The quartz cells were exposed to UVA (740 μW·cm−2 at 365
nm). Aliquots of 100 μL were taken in duplicate at each time point and injected directly on the
HPLC. The time-course samples were compared to the 0 h time point to determine the amount of
ketoprofen and flavonol remaining by measuring peak area at the λmax for ketoprofen and each
flavonol. Experiments for each flavonol were performed on at least 3 separate occasions.
2.12. Mass Spectrometry Analysis of Nifedipine and its Photo-degradants
The high-performance liquid chromatography (HPLC) MS/MS system consists of an Agilent series
1200 quaternary pump with an online degasser, auto sampler set to 4 ◦C, and DAD detector scanning
between 190 to 400 nm (Agilent Technologies, Mississauga, ON, Canada ) coupled to an AB Sciex
API 4000 QTRAP mass spectrometer. Photodegradants of nifedipine were identified following direct
infusion of 2.5 ng by observation of the appearance of the protonated and unprotonated product ions
for dehydronifedipine [M]1+ to [M− C17H16N2O6]+ (m/z 345 and 344) and for dehydronitrosonifedipine
[M]1+ to [M− C17H16N2O5]+ (m/z 329 and 328); peak areas were integrated by Analyst Software v1.6
(SCIEX, Redwood City, CA, USA) [43].
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2.13. Statistical Analysis
Descriptive statistics were generated in Microsoft Excel (Office 2016). Comparison of means was
analyzed by ANOVA with Tukey’s post-hoc test (Astatsa, 2016).
3. Results and Discussion
The goal of this study was to assess the ability of two polyphenolic flavonols, quercetin and its
3′-rutinoside analog rutin, for their ability to attenuate UVA radiation-mediated decomposition of
BMDBM and nifedipine in a topical formulation for the treatment of Raynaud Phenomenon. In order to
accomplish these goals, we developed oil-in-water (O/W) emulsions containing mixtures of nifedipine,
BMDBM, and either quercetin or rutin. We then exposed the nifedipine-containing emulsions to
UVA radiation and employed UV spectroscopy, HPLC, and mass spectrometry to assess the ability of
quercetin and rutin to act as photostabilizers.
3.1. UVA and Visible Decomposition of Nifedipine
Nifedipine in Methanol
The absorption spectrum of nifedipine (Figure 3) is characterized by strong absorbance at 240 nm
and a broad absorption peak near 350 nm. UV spectroscopy clearly shows the change in the absorption
spectrum of nifedipine in methanol after exposure to UVA radiation for 2 h with a decrease in
absorbance at both 240 and 350 nm and new absorption maxima appearing at 280 and 310 nm. These
are consistent with the results of Fasani et al. [49] who observed similar spectral changes for nifedipine
in ethanol following UV irradiation and others who have noted rapid degradation of nifedipine in
methanol solution exposed to laboratory light [50].
Figure 3. Ultraviolet (UV) absorption spectra of nifedipine as: Nifedipine solution 40 μg/mL in
methanol; methanol extract of nifedipine cream (2% (w/w) as O/W emulsion); nifedipine 40 μg/mL
solution in methanol after 2 h exposure to UVA light at a flux of 750 μW/cm2; methanol extract of
nifedipine cream (2% (w/w) as O/W emulsion) that was exposed for 2 h to UVA light at a flux of
750 μW/cm2 prior to extraction.
3.2. Characterization of Emulsion
We chose to prepare a 2% (w/w) oil in water (O/W) emulsion as our topical delivery vehicle because
nifedipine is readily incorporated into the internal oil phase, while a non-greasy feel is still achieved.
This is advantageous for patient acceptability, as an oily topical preparation is not desirable for use on
the hands and feet. In addition to the photostabilizers, the prototype nifedipine formulations contain
the approved topical drug penetration enhancer diethylene glycol monoethyl ether (Transcutol HP®).
Transcutol HP® is used in these formulations because of its established safety record [51,52], regulatory
approval for human use, and ease of incorporation into the emulsions. Nifedipine stability in the
cream prepared as 1% or 2% (w/w) nifedipine with or without Transcutol HP penetration enhancer (1%
or 2% w/w) was determined under light-protected conditions at 23 ◦C and found to be maintained at
>95% of original concentration for at least one month (Figure 4).
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Figure 4. Stability of nifedipine (N) 1% or 2% (w/w) cream prepared with or without Transcutol HP (T)
(1% or 2% (w/w)). The cream was stored protected from light at ambient temperature (23 ◦C). At 14,
21, and 28 days, nifedipine concentration was measured by UV spectrophotometry and reported as
percent of original concentration. Data represent mean ± SD (n = 3).
A methanol extract of nifedipine cream (2% (w/w) as O/W emulsion) shows a similar spectrum
as observed when dissolved in methanol. Upon exposure of a thin film of the O/W emulsion to
indoor fluorescent light (ambient laboratory light), nifedipine concentration began to decline at 20 min,
and was reduced to 75% of its original concentration by 1 h (Figure 5A). Formation of degradation
products was determined by the appearance of a new absorbance maximum at 280 nm, consistent
with formation of the aromatic groups in the degradation products and HPLC and mass spectrometric
analysis. We compared APCI/ESI (+) mass spectrometry results (discussed below) with literature
values to confirm the identity of the decomposition products (dihydronifedipine: m/z 345.10, [M+H]+
and dehydronitrosonifedipine: m/z 329.11, [M+H]+) [53]. Dehydronitrosonifedipine (DHN), the major
degradation product, began to appear by 1 h of exposure to visible light. UVA exposure (750 μW/cm2)
of a thin film of the O/W emulsion over 2 h also resulted in loss of nifedipine (Figure 5B), although
minimal degradation occurred in the first 45 min of exposure. After 2 h, 72 ± 7.86% of the nifedipine
remained, suggesting that the O/W emulsion imparts some, albeit incomplete, photoprotection of
nifedipine to UVA radiation.
 
 
Figure 5. Nifedipine (2% w/w) cream exposed as a thin film to (A) ambient light over 1 h; (B) UVA light
over 2 h. Data represent concentration vs. time (mean ± SD (n = 3)).
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3.3. Characterization of Topical Nifedipine Cream
3.3.1. Influence of Butyl methoxydibenzoylmethane (BMDBM), Quercetin, and Rutin on Nifedipine
UV Stability
In an effort to further improve nifedipine stability to light, we assessed the ability of three
photostabilizing agents, rutin, BMDBM, and quercetin, either alone or in combination in our O/W
emulsions. The photostabilizers were incorporated at varying concentrations up to 3% w/w in the
emulsion and then treated with UVA radiation. Unfortunately, none of the photostabilizers when used
on their own were effective in preventing UVA radiation-mediated decomposition of nifedipine when
exposed as a thin film. Incorporation of rutin at concentrations of 0.5–1% (w/w) showed insufficient
protection in reducing UVA-induced degradation of nifedipine over 3 h (Figure 6). No further studies
were done using rutin as an additive.
Figure 6. Rutin (0.1% and 0.5% (w/w)) was incorporated into the nifedipine cream and evaluated for its
ability to decrease nifedipine degradation in the cream due to UVA exposure over 3 h. Data represent
mean ± SD (n = 3).
Similarly, quercetin or rutin at 0.5% (w/w) or BMDBM alone were not effective as single agents in
protecting nifedipine from degradation. A combination of quercetin at 0.5% (w/w) and BMDBM 3%
(w/w), however, provided the best protection from UVA radiation-mediated decomposition in terms of
the original nifedipine concentration maintained after 8 h of UVA exposure (Figure 7).
Figure 8 illustrates the degradation profile for each combination, demonstrating a two-phase
process where the rate of degradation for the first two hours is greater than the rate for the period of 2–8 h.
Table 1 lists the first (0–2 h) and second (2–8 h) phase rates, which suggest that the photoprotectants
have the most significant effect on reducing the rate of degradation during the first two hours where
the rate k is defined as:
(%Nt1 −%Nt2)/(t2 − t1)
where %N is percentage of original unexposed nifedipine concentration in the indicated O/W cream
formulation and t1 and t2 represent exposure timepoints. Thus, in Table 1, k1 represents the rate of
degradation in the first 2 h, and k2 the rate for 2–8 h of continuing exposure.
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Figure 7. Quercetin or rutin (0.5% (w/w)) ± avobenzone (BMDBM) (3% (w/w)) were incorporated into
the nifedipine 2% (w/w) cream as photoprotectant(s). The cream was exposed as a thin film to UVA light.
Data represent percentage of original nifedipine concentration vs. exposure time (mean ± SD, n = 3).
N: Nifedipine only; NQ: Nifedipine with quercetin; NQB: Nifedipine with quercetin and BMDBM;
NR: Nifedipine with rutin; NRB: Nifedipine with rutin and BMBDM; NB: Nifedipine with BMDBM.
*Significantly different from N (p < 0.01); **significantly different from its counterpart without BMDBM
(p < 0.05).
 
Figure 8. Quercetin or rutin (0.5% (w/w))± BMDBM (3% (w/w)) were incorporated into the nifedipine 2%
(w/w) cream as photoprotectant(s). The cream was exposed as a thin film to UVA light. Data represent
percentage of original nifedipine concentration vs. exposure time (mean ± SD, n = 3). N: Nifedipine
only; NQ: Nifedipine with quercetin; NQB: Nifedipine with quercetin and BMDBM; NR: Nifedipine
with rutin; NRB: Nifedipine with rutin and BMBDM; NB: Nifedipine with BMDBM.
Again, the combination of quercetin with BMDBM is shown to be the most effective at reducing
the rate of photodegradation of nifedipine in the emulsion.
Octocrylene (2% w/w) was also tested as a potential photoprotectant for nifedipine topical emulsion,
prepared in the same way as described above, but it did not prevent nifedipine degradation under UVA
exposure (Figure 9). Octocrylene (2% w/w) with BMDBM (3% w/w) in combination in the nifedipine
cream was not physically stable in the O/W emulsion and was not further optimized.
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Table 1. Rate of nifedipine degradation vs. time in O/W formulations containing photoprotectants
as described in Figure 8. *Significantly different from formulation N (p < 0.5) within that phase.








N 14.3 ± 0.8 2.18 ± 0.7
NQ 8.21 ± 2.6* # 2.32 ± 0.49
NR 8.59 ± 2.87 3.5 ± 0.52
NB 7.86 ± 5.1 4.6 ± 0.46 *
NRB 5.26 ± 1.6 * 2.1 ± 0.26
NQB 3.7 ± 2.14 * # 1.4 ± 0.72*
Figure 9. Nifedipine cream was prepared with quercetin 0.5% (w/w) + BMDBM 3% (w/w) (NQB) or with
octylcrylene 2% (w/w) (NO) as photoprotectants. The cream was exposed as a thin film to UVA light.
Data represent percentage of original nifedipine concentration vs. exposure time (mean ± SD, n = 3).
We used mass spectrometry to determine if the same nifedipine degradation products are formed
following UV exposure when one or more of the photostabilizers (rutin, quercetin, BMDBM) is present.
Dehydronifedipine and dehydronitrosonifedipine were found in UVA-exposed creams as expected [22],
with no alternative degradation pathways identified in the presence of these photostabilizers based
on appearance of m/z consistent with their expected profiles. A peak for the parent nifedipine (m/z
of 347 [M]+ and m/z of 369.3 [M +Na+]+) can be seen in all panels of Figure 10. The mass spectrum
of nifedipine is shown in supplementary Figure S2. The appearance of m/z = 329 is consistent
with dehydronitrosonifedipine formation and was previously identified as the principal degradation
product by HPLC. The mass spectrum of pharmaceutical reference standard dehydronitrosonifedipine
is shown in supplementary Figure S3. The nifedipine was not protected from photodegradation by
rutin, and the product m/z = 329 again made an appearance. Further investigation of the various
photoprotectants indicated no unexpected fragment ion formation (data not shown) to indicate any
alternate degradation pathways in the presence of rutin, quercetin, or BMDBM. The three panels of
Figure 10 shows differential appearance of presumed photodegradation product m/z = 329 comparing
(A) nifedipine 2% cream containing 0.5% quercetin; (B) nifedipine 2% cream containing 0.5% quercetin
that was exposed to UVA × 2 h at 450 μW/cm2; (C) nifedipine 2% cream containing 0.5% quercetin
and BMDBM 3% that was exposed to UVA × 2 h at 450 μW/cm2. The presence of product ion
m/z = 329 is consistent with the HPLC results, which analyzed nifedipine and dehydronitrosonifedipine
concentration vs. exposure time, as discussed above, although it is acknowledged that secondary
MS/MS analysis will be needed to confirm the identity of m/z = 329.
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The reason behind the inability of two closely related flavonoids to act as photoprotectants was
unclear. The decomposition of quercetin in methanol to three major products when exposed to UVA
has been described previously [54], however when we examined rutin for UVA stability in methanol,
we observed minimal decomposition (Supplementary S1). Furthermore, quercetin has been shown
to protect the non-steroidal anti-inflammatory ketoprofen from UV decomposition in vitro [55]. We
examined whether rutin could also prevent ketoprofen degradation in an in vitro system. We first
confirmed that quercetin could spare UVA-induced ketoprofen degradation by irradiating a methanol
solution of ketoprofen with UVA in the presence of quercetin. Consistent with previous reports [55],
we observed a loss of quercetin over time and formation of quercetin degradation products, whereas
ketoprofen loss was minimal until all of the quercetin had been depleted. Conversely, UVA irradiation
of ketoprofen in methanol in the presence of rutin resulted in a more rapid loss of ketoprofen comparable
to control exposures and concurrent decomposition of rutin (Figure 11). Since the only structural
difference between quercetin and rutin is glycosylation at the 3′−OH of rutin, this suggests to us that
3′−OH substitution confers some UV stability to flavonols. Both quercetin and rutin possess a catechol
moiety in the B-ring that undergoes oxidation to an ortho-quinone, which in the case of quercetin,
appears to lead to photodegradation [54]. This may imply that the decomposition of quercetin is
associated with its photoprotective properties; the lack of a photostabilizing effect of rutin on BMDBM
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Figure 10. Mass spectrometry shows differential appearance of photodegradation product comparing
(A) nifedipine 2% cream containing 0.5% quercetin with no UV exposure; (B) nifedipine 2% cream
containing 0.5% quercetin that was exposed to UVA × 2 h; (C) nifedipine 2% cream containing 0.5%
quercetin and 3% BMDBM that was exposed to UVA × 2 h.
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Figure 11. Time-course decomposition for UVA (740 μW·cm−2 at 365 nm) exposed compounds in
MeOH: (top) (Δ) ketoprofen (250 μM); (bottom) (Δ) ketoprofen (250 μM) in the presence of () rutin
(50 μM). Data are the mean ± standard deviation of three separate experiments as determined by
HPLC-PDA at the λmax for ketoprofen and rutin and are reported as % remaining.
3.3.2. Effect of Photostabilizers on Emulsion Properties
Emulsion composition and viscosity are key features to minimize the potential for phase separation.
With our observation that a combination of quercetin and BMDBM can protect nifedipine from UVA
photodegradation, we next sought to assess whether the photostabilizers might reduce physical
stability of the emulsion by affecting viscosity or emulsion droplet formation. To accomplish this,
the creaming rate and extent were assessed in a temperature-controlled photocentrifuge whereby an
increased transmission to light indicates phase separation, which is then calculated as an instability
index. If an excipient caused a significant change in viscosity, for example, phase separation would
occur more quickly and adversely affect emulsion stability on storage. This information can drive
the decision to choose between two excipients that are otherwise performing similarly. In our
system, the incorporation of quercetin or BMDBM reduced the instability of the nifedipine emulsion
(Figure 12 and inset, showing differences between emulsion stability depending on presence of specific
photostabilizers), possibly by altering the emulsion viscosity. The improved emulsion stability, together
with nifedipine photostabilization, suggest that a topical formulation of nifedipine containing quercetin
and BMDBM may be an effective approach for local delivery of nifedipine for RP.
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Figure 12. Sedimentation analysis of nifedipine emulsions (N) containing quercetin (NQ) or quercetin
plus BMDBM (NQB) show differences in their tendency to exhibit phase separation (at 42 ◦C over 12 h),
as shown by an increase in light transmission at the top of the sample as the oil phase separates to
the top. A shift from red to green indicates a change in light transmission between the first and last
readings (example shown in inset). This rate of change in light transmission of the sample vs. time is
translated into an “instability index”.
4. Conclusions
Topical delivery of nifedipine as a treatment for Raynaud’s Phenomenon requires a photoprotectant
to prevent nifedipine degradation upon exposure to UV radiation. A combination of the flavonoid
quercetin and BMDBM in an O/W emulsion was able to protect nifedipine in vitro from UVA
radiation-induced decomposition, whereas rutin in combination with BMDBM did not. Although
quercetin and rutin share similar scaffolds, only quercetin was able to act as a photostabilizer of
BMDBM and nifedipine, the difference in photostabilizing properties would appear to be a function
of the unsubstituted 3′−OH in quercetin. Smith et al. [56] suggested that functionalization of the
3′−OH, or absence of a 3′−OH as in luteolin, confers photostability and that the instability of flavonols
with an unsubstituted 3′−OH is proposed to be the result of an excited state electron transfer step,
although how this would lead to photoprotection is unclear. Rather, it may be that quercetin more
readily directs absorption of UV radiation to degradation, thus sparing BMDBM, whereas rutin does
not have a comparable path and may form an excited state which then activates BMDBM. These
observations provide insight into the development of quercetin or other flavonoids as photoprotectants
for nifedipine or other pharmaceutical agents, which possess UV sensitivity. Follow-up studies will
include investigation of the effect of this topical nifedipine formulation on vasodilation in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/11/594/s1,
Figure S1: UV absorption spectra of quercetin and rutin before and after UVA exposure. Figure S2. Mass
spectrum of nifedipine extracted from the cream (Q1 scan) indicating m/z = 369. Figure S3. Mass spectrum of
dehydronitrosonifedipine (+MRM) indicating m/z = 329.
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Abstract: The blood-brain barrier (BBB) poses a major obstacle by preventing potential therapeutic
agents from reaching their intended brain targets at sufficient concentrations. While transient
disruption of the BBB has been used to enhance chemotherapeutic efficacy in treating brain tumors,
limitations in terms of magnitude and duration of BBB disruption exist. In the present study,
the preliminary safety and efficacy profile of HAV6, a peptide that binds to the external domains of
cadherin, to transiently open the BBB and improve the delivery of a therapeutic agent, was evaluated
in a murine brain tumor model. Transient opening of the BBB in response to HAV6 peptide
administration was quantitatively characterized using both a gadolinium magnetic resonance imaging
(MRI) contrast agent and adenanthin (Ade), the intended therapeutic agent. The effects of HAV6
peptide on BBB integrity and the efficacy of concurrent administration of HAV6 peptide and the small
molecule inhibitor, Ade, in the growth and progression of an orthotopic medulloblastoma mouse
model using human D425 tumor cells was examined. Systemic administration of HAV6 peptide
caused transient, reversible disruption of BBB in mice. Increases in BBB permeability produced
by HAV6 were rapid in onset and observed in all regions of the brain examined. Concurrent
administration of HAV6 peptide with Ade, a BBB impermeable inhibitor of Peroxiredoxin-1, caused
reduced tumor growth and increased survival in mice bearing medulloblastoma. The rapid onset
and transient nature of the BBB modulation produced with the HAV6 peptide along with its uniform
disruption and biocompatibility is well-suited for CNS drug delivery applications, especially in the
treatment of brain tumors.
Keywords: blood-brain barrier (BBB); drug delivery; transient modulation; HAV6 cadherin peptide;
adenanthin; magnetic resonance imaging (MRI); medulloblastoma
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1. Introduction
Chemotherapy and more recently targeted therapy directed at specific tumor targets, are important
modalities for treatment of pediatric brain tumors. Numerous chemotherapeutic drugs and small
molecule inhibitors that demonstrated significant antitumor activity in preclinical studies have failed
in human clinical trials [1]. These disappointing results can partially be explained by the ineffective
drug delivery to the CNS [1]. The anatomical features posed by the various specialized physiological
barriers (blood-brain barrier-BBB, and blood tumor barrier) together with the various active efflux
transporters expressed contribute to drug failure because of the inability to reach the desired target
at a therapeutically relevant concentrations [1]. The BBB prevents many drug molecules within the
systemic circulation from entering the brain. Even small hydrophobic drugs that could otherwise
partition into the plasma membranes and diffuse intracellularly through the vasculature have limited
brain penetration due to the presence of multiple efflux transporters [2,3] and drug metabolizing
enzymes [4,5] within the brain’s endothelial cells. For hydrophilic drugs and macromolecules,
the complex tight junctions that form between the brain endothelial cells limits the paracellular
diffusion pathway for brain penetration [6]. Indeed, it has been suggested that molecules with
hydrodynamic diameters larger than 11 Å or molecular weight of 500 D are too large to pass through
the BBB [6,7]. Under pathological conditions, such as brain tumors, the BBB within the tumor area
can become leaky, resulting in contrast enhancement on magnetic resonance imaging (MRI) of the
tumor [8]. Indeed, the leakage of the MRI contrast media into the tumor site has been cited as evidence
for a leaky BBB in brain tumors [9,10]. However, studies in mice have shown that despite the altered
BBB integrity within the tumor site at later stages of tumor development, the BBB is still functional
and limits solute and drug permeability in and around the tumor [11]. Furthermore, patients with
primary brain tumors have clinically significant regions of tumor with an intact BBB and failure to
deliver effective therapy to all regions of glioblastoma tumor contributes to treatment failure [12].
The cadherin proteins found within the adherens junction have an important role in the BBB for
establishing cell–cell contact and contributing to the tight junction complex. The formation of homodimer
complexes of cadherin proteins on adjacent brain microvessel endothelial cells act to physically restrict the
paracellular passage of solutes from the blood to the brain extracellular environment [6,7]. Molecularly,
the extracellular (EC) domain consists of five tandem repeated units (EC-1 to EC-5). Within the EC1
domain, the highly conserved region of His-Ala-Val (HAV) is crucial for the formation of the cis-dimer
formation of cadherins. Synthetic peptides targeting this HAV region sequence of the EC1 domain display
concentration-dependent binding to E-cadherin molecules and can prevent homodimer complex formation
in brain microvessel endothelial cells [13]. We have previously [14] shown that systemic (intravenous,
IV) administration of synthetic E-Cadherin peptide in Balb/c mice caused a reversible disruption of
BBB integrity and enhanced the accumulation of permeability markers of various molecular weights
((low molecular weight gadolinium diethylene-triamine-penta-acetate (Gd-DTPA), larger molecular
weight infrared Dye (IRDye800CW) and a drug efflux agent, rhodamine 800 (R800)). The magnitude
of increase in BBB permeability observed ranged from two-fold to five-fold (depending on size and
chemical properties of imaging agent), was rapid, (occurred within 3−6 min following injection of the
peptide) and reversible, with complete barrier integrity being restored within 60 to 90 min of injection [14].
Additional studies with both linear and cyclized cadherin peptides demonstrated that the duration and
magnitude of BBB opening could be selected based on the stability and binding affinity of the cadherin
peptides [14–16]. These studies provided the impetus for use of cadherin peptides to improve brain
delivery of therapeutics.
Medulloblastoma (MBL) is the most common malignant brain tumor of childhood and accounts
for 10% of all deaths from childhood cancer [17]. Current management consists of surgical resection
followed by ionizing radiation (IR) and chemotherapy. Outcome for high-risk patients remains relatively
poor, with a five-year event-free-survival of 25–40%. MBL comprises at least four distinct molecular
subgroups, with Group-3 having by far the worst prognosis with a 5-year survival of approximately
30% [17]. To date, no specific targeted therapy is available for Group-3 MBLs. Peroxiredoxin-1 (PRDX1)
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is a multifunctional protein that catalyzes hydrogen peroxide into water and oxygen and thereby
prevents free radical mediated oxidative stress [18]. Besides mediating radiation resistance in several
cancers, PRDX1 has been suggested to play a role in chemotherapy resistance, cell differentiation,
proliferation and apoptosis [18]. We recently validated PRDX1 as a therapeutic target in Group-3
MBL [19]. Ade, a diterpenoid compound isolated from the leaves of Isodon adenantha inhibits the
peroxidase activity of PRDX 1 and 2 [20]. Adenanthin has shown therapeutic activity in several cancers,
like leukemia and liver cancer [20,21], but there is an absence of data pertaining to its effectiveness
in treating brain tumors. In the present study, we demonstrated that Ade, when administered
alone, did not cross the BBB and was ineffective in treating D425 tumors in a mouse orthostatic
medulloblastoma tumor model. However, concurrent use of HAV6 peptide to transiently open the BBB
resulted in Ade entry into the brain and significantly prolonged the survival of mice bearing Group-3
MBL tumors. Those tumor bearing mice receiving HAV6 showed no additional adverse responses to
the treatment compared to mice receiving placebo. These findings provide proof-of-principle for the use
of cadherin peptides in the modulation of BBB permeability and improved treatment of brain tumors.
2. Materials and Methods
2.1. Chemicals and Reagents
Gadolinium diethylene-triamine-penta-acetate (Gd-DTPA) was obtained from Berlex (Lachine,
QC, Canada) and used as a contrast agent for MRI monitoring of BBB permeability. Analytical grade
Formic acid and HPLC Grade Acetonitrile were purchased from Fisher Scientific. Ultrapure water
from a Milli-Q® system (Millipore, Billerica, MA, USA) was used for mobile phase. All other reagents
and chemicals were purchased from Sigma Chemical Company (St. Louis, MO, USA).
2.2. HAV6 Peptide Synthesis
The HAV6 peptide (Ac-SHAVSS-NH2) was synthesized using solid phase Fmoc-chemistry
in a Tribute peptide synthesizer (Gyros Protein Technologies, Tucson, AZ), as described previously [13].
After removal from the resin, the peptide was purified using a semi-preparative C18 column in HPLC.
The pure fractions were pooled and lyophilized. The purity of the peptide was higher than 98%,
as determined by C18 analytical HPLC. The identity of the peptide was confirmed by mass spectrometry.
2.3. Adenanthin Source and Formulation
Adenanthin was isolated from the dried aerial parts of the leaves of Isodon Adenanthus Hara,
as described previously [20]. Ade (MW 490.549 g/mol) was reconstituted in 1% DMSO in phosphate
buffered saline (PBS) (KCl; 2.66 Mol, KH2PO4; 1.47 Mol, NaCl; 137.93 Mol, Na2HPO4-7H2O; 8.06
Mol; pH 7.40) at a final concentration of 1 mg/μL to obtain a 10X stock. The solution was diluted to
0.1 mg/μL in physiological saline and was administered to animals so that each animal got a final
concentration of 10 mg/kg body weight.
2.4. Animals and Ethics Statement
All experiments described in this study were done at the University of Manitoba and the Research
Institute in Oncology and Hematology, as described in animal use protocol 13-051 approved by
the Central animal care committee at the University of Manitoba in accordance with the guidelines
provided by Canadian council on Animal care on 18 November 2015. All surgical procedures were
performed under anesthesia induced and maintained by Isoflurane and every effort to minimize pain,
suffering and a reduction in the numbers of animals used were made.
2.5. MRI Imaging of BBB Permeability with HAV6 Peptide
The HAV6 peptide-induced BBB permeability enhancement in Ncr (nu-/nu-) mice was assessed
using MRI and Gd-DTPA contrast agent as described previously [11,14]. Briefly, the mice were
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anesthetized and placed in a 7 Tesla small animal Bruker Biospect MR with a 21 cm bore and
2.5 × 2.5 cm2 field of view for spectroscopy. Once secured into MRI, a series of T1-weighted coronal
images of the mouse brain were obtained before Gd-DTPA delivery as a contrast agent to acquire
background images of the mouse brain. Mice were then administered Gd-DTPA contrast agent
(0.4 mmol/kg) along with either HAV6 cadherin peptide (0.01 mmol/kg) or vehicle (PBS) via bolus tail
vein injection, and T1-weighted coronal images of the entire brain were obtained at 3 min intervals
throughout a 21 min imaging session. After the first imaging session, a second dose of Gd-DTPA was
administered and T1-weighted images obtained for an additional 30 min. Quantitative assessment
of Gd-DTPA enhancement in various regions of interest in the brain were obtained using Marevisi
7.2 software (Institute for Biodiagnostics, National Research Council, Canada). Changes in Gd-DTPA
intensity in the brain as a function of time and treatment were determined using a percent difference
analysis of brain slice images obtained as described previously [11,14,22] using the following formula.
(post-Gd-DTPA-T1-weighted image−pre-Gd-DTPA-T1-weighted image)÷pre-Gd-DTPA-T1-weighted
image) × 100.
2.6. LC-MS/MS Analysis and Conditions
The impact of HAV6 on the BBB permeability of Ade was assessed using the brain to plasma ratio
of Ade. For these studies, healthy female Ncr (nu–/nu–) mice were randomly selected to receive bolus
injections (1 mL/kg) of either vehicle (Physiological saline), Ade alone (10 mg/kg) or a combination of
HAV6 (0.010 mmol/kg) with various concentrations of Ade (5, 10 and 15 mg/kg,) via tail vein injections.
The mice were then sacrificed 20 min after the injections, and blood and various tissues, including the
brain, were subjected to LC-MS/MS analysis.
2.6.1. Sample Preparation
The extractions of Ade from the plasma and brain tissues were done using acetonitrile and
a mixture of acetonitrile with deionized water at a ratio of 2:1 respectively. Frozen plasma samples were
thawed followed by the addition of acetonitrile at a ratio of 2:1. For the brain tissue, the samples were
weighed, thawed and homogenized with the addition of acetonitrile and water (2:1) at the volume of 5×
the weight of the samples. The samples were then vortex mixed continuously for 5 min at a temperature
of 4 ◦C, followed by centrifugation at 4 ◦C for 10 min at a speed of 10,000 g (for brain) and 1875 g
(for plasma). The supernatants were collected and evaporated using a flow of nitrogen gas. Adenanthin
in methanol was added to 200 μL blank plasma or blank brain homogenate to achieve concentrations
of 0.1, 1, 10 and 100 μg/mL for standardization. Samples and standards were treated with 400 μL cold
acetonitrile (−20 ◦C) to precipitate proteins and were vortexed for 2 min, and centrifuged at 15,000 rpm
for 5 min. The supernatants were transferred to new tubes and evaporated to dryness using a Savant
SPD1010 SpeedVac Concentrator (Thermo Fisher Scientific, Inc., Asheville, NC, USA) without heat.
The dried samples were reconstituted in 400 μL of 50% aqueous methanol with 0.1% formic acid and
centrifuged at 15,000 rpm for 5 min. The supernatant was transferred to HPLC vials and 10 mL injected
into the LC-MS/MS system.
2.6.2. LC-MS/MS Analysis
A Shimadzu Nexera ultra high performance liquid chromatography system connected to an 8040
triple-quadrupole mass spectrometer (LC-MS/MS) (Shimadzu, Kyoto, Japan) was used to measure Ade.
A dual Electrospray ionization (ESI) / atmospheric pressure chemical ionization (APCI) ion source was
used in the positive mode multiple reaction monitoring (MRM) for the sodium adduct [M+Na+] of Ade
with the transition 513.2 > 453.1 m/z using a collision energy of 30 eV. The desolvation line temperature
was 250 ◦C; the heating block temperature was 400 ◦C; the nebulizing gas flow was 2 L/min; and drying
gas flowed at 15 L/min. An XTerra® MS C18 (3.5 μm, 2.1 × 50 mm) (Waters Corporation, Milford,
MA, USA) column was used with 0.3 mL/min flow rate at 30 ◦C. The mobile phases A (50% aqueous
methanol with 0.1% formic acid) and B (85% aqueous methanol), and 0.1% formic acid were used
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in a step gradient starting at 100% A for 1 min, then stepping to 100% B for 3 min and stepping back to
100% A for 2 min before the next injection.
2.7. MBL Xenograft and Animal Experiments
2.7.1. Cell culture and authentication
Early passage Group-3 Medulloblastoma cells (D425-MED) were a kind gift from Dr. Darell
Bigner, Duke University, and have been described previously [23]. Cells were cultured at 37 ◦C
in Minimum Essential Medium (Richter’s modification; ThermoFisher/Gibco™Markham, ON, Canada)
supplemented with fetal bovine serum (10%); ThermoFisher/Gibco™) in a humidified incubator with
5% CO2. These cells were transduced by a lentiviral infection to stably express firefly luciferase.
The resulting D425-Med-Luc cells were authenticated and validated by morphology and phenotype
during recovery from the frozen stock and growth characteristics during culture.
2.7.2. Animal Experiments
An orthotopic Group-3 medulloblastoma mouse model was used to evaluate Ade effectiveness,
both alone and in combination with HAV6 peptide for transient BBB disruption. Outbred homozygous
nude (NCr nu; Foxn1nu/Foxn1nu, female mice < 4 weeks old) mice with jugular vein access
(C20PU-MJV1301; Instech Laboratories, Inc.) and vascular access button (VAB62BS/25; Instech
Laboratories, Inc) were obtained from Charles River Laboratories, Saint Constant, QC, Canada. Group
3 MBL (D425-Med-Luc) cells were implanted into the cerebella of these mice as described previously [24].
All mice were serially imaged on an IVIS® spectrum (Perkin Elmer, Waltham, MA), small animal
imager, starting on day-7 post tumor cell implantation to confirm the presence and extent of tumor
growth using bioluminescence as described previously [25]. Tumor bearing mice were randomly
assigned into one of the following treatment groups (n = 6): (1) placebo (physiological saline); (2) Ade
(10 mg/kg) alone; or (3) HAV6 cadherin peptide (0.01 mmol/kg) with Ade (10 mg/kg). All treatments
were given as intravenous injection via the jugular access catheter. Treatments were begun on day-10
post tumor cell implantation. Each treatment cycle consisted of 3 consecutive days of treatment
followed by one day of rest, with a maximum of 5 cycles given to each mouse. Mice were assessed daily
for tumor progression using humane endpoints, including weight loss (>25% from original weight on
day of tumor cell implantation), limb paralysis, locomotion and seizure activity. Tumor progression
was monitored by bioluminescence imaging every 3 days starting at day 7-post tumor cell implantation
as described in Baumann et al. [25]. Upon reaching humane endpoints tumor-bearing mice were
euthanized by cardiac perfusion under iso-flurane anesthesia and the brains were removed and used
for histology. Survival data was recorded and Kaplan-Meier curves were generated using Prism6
(V6.0h; GraphPad Software, Inc.; San Diego, CA, USA).
2.8. Immunohistochemistry
When mice bearing tumors presented with moribund phenotype, they were euthanized as
described above. Subsequently, brains from each animal were extracted and fixed in 10% phosphate
buffered formalin (pH 7.4) for 24 h. They were dehydrated by immersion in graded alcohol solutions for
10 min each (50%, 70%, 80% NS 95%) and for 3 changes in 100% ethanol. Tissue was embedded in paraffin
and serial sections (6 μm) of the brain were collected on positively charged glass slides. Paraffin
was melted and removed from slides by placing in an incubator at 60 ◦C for 30 min. Subsequently,
slides were immersed in Xylene for 3 min, twice and rehydrated by immersion in a series of graded
alcohol solutions for 3 min each (100%, 95%, 80%, 70%, 50%) and were finally washed in deionized
water. Immediately, slides were immersed in 1X universal antigen retrieval reagent (ab208572, abcam,
Cambridge, MA, USA) and incubated for 20 min at 95 ◦C in a programmable pressure chamber
(Decloaking chamber NxGen, Biocare medical) following the manufacturer’s instructions. Slides were
stained to detect the expression of PRDX1 (abcam; Anti-PRDX1 antibody ab41906), γ-H2A.X (abcam;
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Anti-γ-H2A.X phosphorylated S139 antibody; ab2893), Ki 67 (abcam; Anti Ki67 antibody; ab 15580),
53BP1 (abcam; Anti-53BP1 antibody; ab21083) and cleaved caspase 3 (abcam; Anti-cleaved caspase
3 antibody; ab13847) using an HRP/DAB detection method by using a mouse and rabbit specific
HRP/DAB detection IHC kit (abcam; ab80436-EXPOSE mouse and rabbit specific HRP/DAB detection
IHC kit), following manufacturers recommendations with minor modifications. Using normal human
cerebellar cortex tissue as control, the optimal concentrations of each antibody and the incubation time
with DAB substrate was empirically determined to be 1:1000 with an overnight incubation at 4 ◦C.
Subsequently, stained tissue was imaged on a Cytation 5, a cell imaging multi-mode reader (Biotek
Instruments Inc, Winooski, VT, USA), and color bright field images were captured on a 16-bit Sony
charge coupled device Camera and Gen5 V.3.04 software. An image montage was obtained using
a 2.5X objective Meiji, Plan Achromat, working distance (WD) of 6.2 and numerical aperture (NA) of
0.07 to image the entire section. A region of interest was manually imaged using a 20X objective, Plan
Flourite, WD 6.6 and NA 0.45. Color images were processed using Gen5 V.3.04. Color images were
saved as high-resolution JPEG images and were imported into Adobe Photoshop Creative Suite CS5,
Adobe, San Jose, CA, USA to form image panels and additional illustration.
2.9. Cytotoxicity Studies
The D425-Med-luc cells were seeded onto a 96-well plate at a density of 5000 cells per well.
Twenty-four hours after seeding, HAV6 (final concentration of 0.01 mM) or phosphate buffered saline
(10 μL) was added to the culture media and cells were cultured for 48 h. Viable cells remaining at the
end of the experiment were fixed with 4% paraformaldehyde, nuclei were stained with Hoechst 33342
(H3570; Fisher Scientific Inc., St. Loius USA) and imaged on a Cytation 5, a cell imaging multi-mode
reader (Biotek Instruments Inc., Winooski, VT, USA) assay as previously described [26].
2.10. Statistical Analyses
Raw data was imported into Prism 6 GraphPad and analysis of variance was performed with post
hoc comparison of the means as indicated in figure legends. Survival curve analysis and analysis of
variance were performed with post-hoc nonparametric log-rank (Mantel-Cox) tests for significance.
Values were represented as mean ± SEM unless otherwise indicated in the figure legends.
3. Results
3.1. HAV6 Peptide Transiently Increases BBB Permeability In-Vivo
In order to test if the novel HAV6 peptide would increase the BBB permeability, we injected mice
with HAV6 peptide or vehicle and imaged their brains using MRI and Gd-DTPA contrast. As seen
in Figure 1, the BBB integrity was not compromised in vehicle treated mice as shown by similar
Gd-DTPA contrast enhancement in representative brain slice images at time 0 (prior to the injection
of vehicle) and at 6 min following vehicle injection (Figure 1A,B, respectively). These coronal slice
images show minimal Gd-DTPA, within the brain, consistent with its low BBB penetrance under
normal conditions (Figure 1A,B). However, there was a significant increase in the signal intensity of
the Gd-DTPA contrast agent in the brain (represented by white-gray appearance indicated by blue
arrows) following IV injection of HAV6 peptide (0.01 mmol/kg) (Figure 1).
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(A) (B) 
Figure 1. Representative MRI T1-weighted images of mouse brain taken at 0 min (A) and 6 min
(B) following the injection of Gd-DTPA in control (PBS) and HAV6 (0.01 mmol/kg) treated mice.
Blue arrows indicate regions of Gd-DTPA enhancement following the injection of the peptide. Scale bar
represent 2 mm.
Indeed, quantitative assessment of Gd-DTPA contrast enhancement across the various brain regions
indicated an approximately 2–4-fold increase in Gd-DTPA intensity in the HAV6 treatment group compared
to control, and this increase was most apparent at 6–9 min following the injection of the HAV6 peptide
(Figure 2A–C) and was consistent with our previous findings [14]. Furthermore, while the signal intensity
for Gd-DTPA varied as a function of brain region examined, the increases in Gd-contrast enhancement
in response to HAV peptide was observed in all regions of the brain examined, as indicated by examining
the resulting area under the curve (AUC) from the Gd-DTPA intensity versus time plots taken over a 51
min period following HAV6 administration (Figure 2D). These studies confirmed the rapid onset and
relatively brief BBB modulation following the administration of HAV6 cadherin peptide.
 
Figure 2. Analysis of pixel intensity for Gd-DTPA from T1-weighted images normalized to the pixel intensity
at time 0 of the injection in (A) the posterior, (B) midbrain and (C) anterior regions of the brain. (D) Area
under the curve for Gd-DTPA obtained from T1-weighted images over the span of 51 min. * p value < 0.05
in comparison to control group. Values represent the mean ± SEM for four mice per treatment group.
3.2. In Silico and In Vivo Determinations of Ade Permeability in the BBB
We employed the BOILED-Egg model (the Brain Or IntestinaL EstimateD permeation predictive
model) [27] to predict if Ade would cross the BBB and be available in the brain. The lipophilicity
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(determined by the n-octanol/water partition coefficient-WLogP) and polarity (determined by the
topological polar surface area-tPSA) values for Ade were calculated using the free online chemical
property calculation service provided by www.molinspiration.com. The canonical SMILES (Simplified
Molecular-Input Line-Entry System) and molecular structure of Ade was determined from a PubChem
search (https://pubchem.ncbi.nlm.nih.gov/compound/Ade). Applying this model, we show that Ade
has a low probability of crossing the BBB (Figure 3A) [27].
Figure 3. (A) Visual representation of in silico prediction of brain access and availability of Ade using the
BOILED-Egg model, adapted from Daina, A.; Zoete, V. A BOILED-Egg to predict gastrointestinal absorption
and brain penetration of small molecules. ChemMedChem 2016, 11, 1117–1121. [27]. The tPSA (x-axis) and
WLogP (y-axis) values are plotted and the intersect of those values can predict brain access if it falls within
the “yellow yolk”. If the intersect lies within the white ellipse, that indicates its gastrointestinal availability.
Based on this model, Ade may be available via a gastrointestinal method of delivery but may not access
the brain. Quantitative analysis of Ade in the brain using LCMS under control conditions and following
treatment with HAV6 after (B) a single treatment of different Ade doses and (C) three consecutive daily
treatments. * p-value < 0.05 in comparison to control group. # p-value < 0.05 compared to Ade group only.
Values represent the mean ± SEM for four mice per treatment group.
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Consistent with the initial in silico assessment, in vivo analysis in mice revealed that Ade,
when administered alone, had limited BBB permeability, with brain concentrations below the
quantitative limit (BQL; 0.1 mg/mL) (Figure 3B). However, when Ade was co-administered with
HAV6-cadherin peptide, there was a significant and substantial increase in brain concentrations of
Ade (Figure 3B). The resulting Ade brain concentrations were statistically similar at all doses of Ade
examined (Figure 3B), reaching levels of approximately 10–16 μM. In order to determine the tolerability
of a complete cycle of therapy, mice were administered HAV6 cadherin peptide on 3 consecutive
days. After three consecutive days of treatment Ade levels in the brain were detectable but below
the quantitative limit of analysis (Figure 3C). However when Ade was combined with the HAV6
peptide, brain concentrations of Ade were approximately 22 μM (Figure 3C). Furthermore, analysis of
brain samples from mice treated with consecutive injections of either HAV6 or combination of HAV6
and Ade showed no evidence of toxicity (Figure 4A,B), as indicated by absence of astrogliosis and
neuro-inflammation (microglia activation) following a complete cycle of HAV6 treatment to enhance
BBB delivery of Ade.
Figure 4. Representative immunofluorescence images of healthy mouse brain to detect (A) GFAP and (B)
Ibal1 following the three consecutive daily treatments of PBS, HAV6 and the combination of HAV6 +Ade.
The presence of HAV6 has no impact on the expression level of GFAP and Ibal1 compared to PBS control.
Scale bar in bottom represent 10 μm. (C) Graphical representation of viability of D425-Med-Luc cells treated
with either vehicle control (black bars; PBS) or HAV6 peptide (0.01 mmol; white bars). Values represent
mean ± SEM of viable cells from eight monolayers per treatment group. Data are expressed as the percent
viable cells compared to D425-Med-Luc cells receiving culture media alone. HAV6 has no negative impact
on cell viability; t-test indicated p-value is 0.496952 and is non-significant (ns).
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3.3. HAV6 Cadherin Peptide Improves Tumor Response to Ade
To functionally demonstrate that the HAV6 peptide can transiently disrupt the BBB and facilitate
delivery of Ade to the brain, and therapeutically target PRDX1 we treated mice bearing Group 3
D425-Med-Luc tumors with either Ade alone or Ade in combination with HAV6 peptide. The mice
receiving placebo or Ade alone had a median survival of 20 and 19 days post tumor cell injection
respectively (Figure 5C). Furthermore, none of the mice in the placebo or Ade treatment group were
able to complete the entire five cycles of treatment or survive past 22 days. In contrast, mice receiving
HAV6 peptide and Ade showed significant improvement in tumor response (Figure 5A,B) compared to
placebo or Ade alone, with median survival of 30 days post-tumor cell injection (Figure 5C). In addition,
half of the mice receiving HAV6 peptide and Ade completed all five cycles of treatment and survived
to 45 days post tumor cell injection with no sign of a tumor, as indicated by bioluminescence imaging.
Figure 5. (A) Representative bioluminescence image of tumors in mice prior to the treatments (top panels)
and following a 5-cycle treatment of control, Ade, or combination of HAV6 and Ade (bottom panel).
(B) Quantitative analyses of the bioluminescence from tumors as outlined in the regions of interest (ROI)
and normalized to background intensity for all tumor mice receiving control, Ade, or combination of
HAV6 and Ade. (C) Kaplan-Maier survival curve of MBL tumor mice following the five-cycle treatment of
control, Ade, or combination of HAV6 and Ade. Each treatment group consisted of six mice.
At the cellular level, tumor cells were positive for PRDX1, an ROS scavenging enzyme that is the
molecular target of Ade (Figure 6). Mice receiving placebo or Ade alone showed increased cellular
proliferation, compared to the animals that received both HAV6 peptide and Ade (Figure 6). Consistent
with the increased tumor responsiveness observed in mice treated with Ade and HAV6 peptide, there was
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increased intensity of staining observed for γ-H2A.X and 53BP1, surrogate markers of DNA double strand
breaks in the tumor cells (Figure 6). Similarly there was increased apoptotic death in tumor cells that received
Ade and HAV6. Taken together, the data suggests that HAV6 peptide facilitates the entry of Ade into the
brain, allowing Ade to reach therapeutically significant levels that can affect tumor cell death.
Figure 6. Magnification scans of whole brain sections stained with Hematoxylin and Eosin (H&E) of
representative animals that received placebo (control), Ade or a combination of Ade and HAV peptide
(Top panel). Arrows indicate those regions that were further examined for various tumor markers
(Bottom Panel). White line indicates a scale bar of 100 μm.
4. Discussion
The development of drugs for the treatment of many CNS disorders has long been a difficult
process, in part due to the inability of the drugs to reach relevant therapeutic concentration in the brain
and the spinal cord. This limited access to the brain and spinal cord for many drugs is a direct result of
the protective properties of the BBB and blood cerebral spinal fluid barrier (BCSFB). These barriers
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are composed of epithelial (BCSFB) or endothelial (BBB) cells with tight junctions and active efflux
transporters that together restrict both the paracellular and transcellular passages of solutes into
the brain [28,29]. While these barriers protect the brain and spinal cord from exposure to potential
neurotoxic agents, under pathological conditions, such as a brain tumor, these barriers represent
significant obstacles to therapeutic agents intended for treating these disorders. Several approaches
have been used in an effort to circumvent these barriers to improve drug penetration into the brain.
For treatment of brain tumors, transient disruption of the tight junctions of the BBB allowing more drug
to penetrate have been a successful approach both in preclinical and clinical studies [30–33]. This can
be done through the use of high concentration of osmotic agents (i.e., a high concentration of mannitol)
or bradykinin analogues [30–33], or more recently, through focused, high-intensity ultrasound [34–36].
Approaches such as osmotic disruption and focused, high-intensity ultrasound, have shown
promise in preclinical studies and have been used in the clinic to enhance chemotherapeutic drug
delivery to brain tumors. However, the long duration of BBB disruption (up to 8 h or more) can lead to
neurotoxicity and inflammation [37,38]. A long recovery time (6–72 h) has also been reported for focused
high intensity ultrasound [36,39]. Other approaches, such as use of bradykinin receptor agonists, result
in a shortened BBB disruption timeframe compared to either hyperosmotic or ultrasound disruption,
but lack clinical effectiveness, due in part to a non-uniform distribution of bradykinin receptors in the
brain microvasculature, resulting in a non-uniform distribution of the drugs [14,40]. Finally, none of
the current transient BBB disruption approaches provide much control over the magnitude of BBB
opening. Clearly the limitations of the existing transient disruption approaches highlight the need for
alternative methods of achieving a controlled BBB disruption profile that is able to uniformly enhance
BBB permeability to improve drug delivery to the brain.
Synthetic HAV6 peptide disrupts the BBB by inhibiting homodimer interactions between E-cadherin,
an essential protein that forms the adherens junctions of the BBB [13,40]. Based on our previous studies,
HAV6 peptide-induced changes in BBB permeability were apparent within 3 min with the HAV6 peptide
being able to produce similar magnitudes of BBB disruption in all regions of the brain examined [14–16].
Furthermore, these studies also demonstrated that the magnitude of disruption could be modulated with
some linear cadherin peptides, such as HAV6, producing BBB openings for small and medium sized
permeability markers for short time periods, while other cyclic cadherin peptides had longer durations of
action and enhanced BBB penetration of large macromolecules [14–16]. Based on these previous findings,
the HAV6 cadherin peptide was selected for the present study, as it demonstrated short durations of BBB
opening for small molecules without wholesale opening of the BBB to large macromolecules like albumin.
The initial characterization of HAV6 peptide mediated BBB disruption in nude mice was examined
using Gd-DTPA and MRI. Following HAV6 peptide administration, there was an approximately two
to four-fold enhancement in Gd-DTPA contrast throughout all areas of the brain examined. Both the
magnitude and time frame of BBB disruption mediated by HAV6 peptide in the current study were
consistent with our previous findings [14]. The ability to produce a rapid and uniform disruption
of BBB with the HAV6 peptide is crucial for eliminating the “sink effect” that is often observed with
non-uniform disruption approaches that result in reduced drug concentrations at the tumor site due to
the diffusion of drugs from an area of high concentration to an area of low concentration. Furthermore,
the Gd-DTPA contrast MRI studies also allowed a quantitative assessment of the duration of BBB
modulation produced with the HAV6 peptide and indicated that the time frame for BBB opening was
of short duration.
The anticancer properties of Ade were originally reported by Liu et al. [19] in studies examining
a series of diterpenoids that formed adducts with PRDX1 and PRDX2. While initially reported as a PRDX
selective inhibitor, there is evidence of potential inhibitory activity of Ade in both the thioredoxin
and protein disulfide isomerase enzymes that are involved in redox metabolism in cells [41]. Studies
in multiple cancer cells indicate Ade has cytotoxic responses linked with PRDX inhibition [19–21,42].
Ongoing work in our laboratory has shown that PRDX1 is overexpressed in Group-3 MBL and may
contribute to radiation resistance and poor outcomes [19]. While the effects of Ade in treating primary
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tumors of the central nervous system have not been reported, preliminary studies with Ade in the D425
Med cells indicated cytotoxicity with a fifty percent effective concentration (EC50) of around 1.0 μM [19].
Based on the available information concerning Ade’s effects in tumor cells, and its physico-chemical
properties, the compound seemed an ideal choice for examining our drug delivery approach.
Adenanthin had little to no permeability through the BBB when administered alone; however,
co-administration of Ade with HAV6 peptide significantly enhanced its accumulation in the brain.
The concentration of Ade in the brain following HAV6 administration was similar for all doses of
Ade examined. This could be due to the saturation of the influx of Ade into the brain following
the disruption with HAV6 peptide. Of importance for the present study is the observation that
concurrent administration of Ade (10 mg/kg dose) and HAV6 peptide resulted in brain concentrations
of Ade (>10 μM) that would be expected to be in the therapeutic range required for anti-tumor activity.
In addition, it should be noted that despite the large increases in Ade accumulation in the brain,
there were no overt clinical signs of toxicity (i.e., no weight loss and no changes in locomotive activity
in the mice receiving HAV6 peptide). Furthermore, examination of GFAP and Iba1 expression in the
brain showed no enhancement in these neuroinflammatory markers as a result of HAV6 either alone
or in combination with Ade. This is an important finding, as increased GFAP and Iba1 expression,
markers of reactive astrocytosis and activated microglia, respectively, have been reported with both
osmotic and focused ultrasound BBB modulation [43,44].
We had three cohorts of mice (placebo, Ade and Ade + HAV6 peptide) to evaluate the in vivo
effect of concurrent administration of Ade and HAV6 peptide in an orthotopic Group-3 MBL model.
The HAV6 peptide was not included as a cohort, as the peptide had no effect on Group-3 MBL cells
(Figure 4C). The average survival of animals receiving both HAV6 and Ade was 30 days post tumor
implantation, compared to 20 and 19 days for the Ade and placebo groups respectively. Furthermore,
a complete 5-cycle treatment was only possible in the Ade+HAV6 treatment group. Histological studies
also confirm the enhanced response of tumor mice to Ade in the presence of HAV6. Together these
findings suggest that the improved delivery of Ade to the brain using HAV6 cadherin peptide to
transiently open the BBB impacted favorably on treatment outcome.
In summary, we have shown that HAV6 peptide reversibly modifies BBB permeability allowing
for effective delivery of Ade for the treatment of brain tumors. The transient modulation of BBB
permeability produced by HAV6 cadherin peptide appeared to be well tolerated. While additional
studies are required to validate both the effectiveness of adenanthin and our drug delivery approach
in treating Group 3 MBL, the current studies suggest that HAV cadherin peptide can be used to enhance
the brain delivery and effectiveness of poorly BBB permeable therapeutic agents. The effects of cadherin
peptide based BBB modulation in terms of both the duration and magnitude of BBB opening, coupled
with its effectiveness in repeated use settings could prove advantageous for treatment of brain tumors.
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Abstract: β-cyclodextrin (βCD) has been widely explored as an excipient for pharmaceuticals and
nutraceuticals as it forms stable host–guest inclusion complexes and enhances the solubility of poorly
soluble active agents. To enhance intracellular drug delivery, βCD was chemically conjugated to
an 18-carbon chain cationic gemini surfactant which undergoes self-assembly to form nanoscale
complexes. The novel gemini surfactant-modified βCD carrier host (hereafter referred to as 18:1βCDg)
was designed to combine the solubilization and encapsulation capacity of the βCD macrocycle and
the cell-penetrating ability of the gemini surfactant conjugate. Melphalan (Mel), a chemotherapeutic
agent for melanoma, was selected as a model for a poorly soluble drug. Characterization of the
18:1βCDg-Mel host–guest complex was carried out using 1D/2D 1H NMR spectroscopy and dynamic
light scattering (DLS). The 1D/2D NMR spectral results indicated the formation of stable and
well-defined 18:1βCDg-Mel inclusion complexes at the 2:1 host–guest mole ratio; whereas, host–drug
interaction was attenuated at greater 18:1βCDg mole ratio due to hydrophobic aggregation that
accounts for the reduced Mel solubility. The in vitro evaluations were performed using monolayer,
3D spheroid, and Mel-resistant melanoma cell lines. The 18:1βCDg-Mel complex showed significant
enhancement in the chemotherapeutic efficacy of Mel with 2–3-fold decrease in Mel half maximal
inhibitory concentration (IC50) values. The findings demonstrate the potential applicability of the
18:1βCDg delivery system as a safe and efficient carrier for a poorly soluble chemotherapeutic in
melanoma therapy.
Keywords: cationic gemini surfactant; melphalan; inclusion complex; ROESY NMR spectroscopy;
3D spheroid; drug-resistant melanoma
1. Introduction
Melanoma, the malignant cancer of melanocytes, is the most aggressive form of skin cancer which
causes the most skin-cancer related deaths [1]. According to the World Health Organization (WHO),
over 132,000 new cases of melanoma are diagnosed annually [2]. In its early stages, melanoma can
be treated by surgical incision with high survival rate. In the stage of in-transit metastases, in which
the metastases are >2 cm from the primary lesion but within the nodal basin, the response to local
and systemic therapeutic options is moderate with 5-year survival of 32.8% [3,4]. However, advanced
metastatic melanoma shows limited response to current therapeutic options with very low survival
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rate of less than 5% over 5 years [5]. Systemic chemotherapy is the first-line option for most patients
with metastatic melanoma.
Melphalan (Mel) (Figure 1a) is used regionally as an adjunctive therapy for in-transit metastatic
melanoma [6]. The lipophilic nature of Mel requires the use of a co-solvent (e.g., propylene glycol) for
parenteral administration. Propylene glycol is known to cause toxicity that includes nephrotoxicity,
cardiac arrhythmia, and metabolic acidosis [7]. As a result, the use of Mel in melanoma therapy
is limited to isolated limb perfusion/infusion which is an invasive method that requires special
medical care [6]. Therefore, attempts to improve the solubility and stability of Mel were conducted
by either chemical modification of the molecule or by engineering novel drug delivery systems,
such as nano-systems [8–11]. A nanoscale drug delivery system has several advantages, it can:
(1) improve solubility of poorly soluble drugs, (2) enhance chemical/biological stability, (3) improve
pharmacokinetic profile and biodistribution, (4) increase tumor-specific uptake (passive targeting),
(5) minimize drug resistance, (6) achieve drug controlled release, and (7) afford delivery of multiple
drug components [12,13]. Our strategy is to create delivery systems that could improve the therapeutic
use of Mel addressing both issues of solubility and biological activity at the same time. Cyclodextrins
(CDs) form stable host–guest complexes with a variety of organic and inorganic molecules and have
been widely employed as versatile carriers for poorly soluble drugs [14]. CDs (Figure 1b,c) are naturally
occurring cyclic oligosaccharides consisting of 6 (αCD), 7 (βCD), or 8 (γCD) α-d-glucopyranose units
linked by (α-1,4) glycosidic bonds [15]. CDs form a truncated cone with a toroidal structure (Figure 1c)
in which the hydroxyl groups of glucopyranose units reside at the narrow (primary) and wide
(secondary) tori of the CD annular structure. The CD macrocycle has a hydrophilic outer surface and
lipophilic inner cavity that is capable of forming noncovalent inclusion complexes with a large variety
of guest molecules [16]. Capitalizing on the ability of the CDs to form host–guest inclusion complexes,
such systems have been used in pharmaceutical formulations to increase the apparent water solubility
of poorly soluble drugs so as to improve their bioavailability. In addition, CDs and its derivatives serve
to provide: (1) enhanced drug stability (thermal, photosensitivity, and chemical), (2) reduced drug
mucosal irritation, (3) reduced drug resistance, and (4) controlled release of the drug [17,18]. Several
synthetic strategies have been employed to engineer CD-based carriers with enhanced pharmaceutical
properties along with reduced systemic toxicity [18]. For example, the introduction of bulky derivatives
can limit the formation of intramolecular hydrogen bonding, consequently enhancing the aqueous
solubility of CDs while improving their inclusion capacity [14]. Luke et al. reported a 35-fold increase
in aqueous solubility for a sulfobutyl-ether-β-cyclodextrin (SEB-β-CD) derivative relative to native
βCD [19]. In addition to chemical derivatization, CDs have been chemically conjugated to a variety of
functional moieties (i.e., polymers, lipids, and peptides) to create biofunctional and supramolecular
complexes [20,21]. For instance, several amphiphilic moieties have been conjugated to CDs to create
self-assembling supramolecular structures with improved drug loading capacity and enhanced cellular
uptake [22–25].
In the present work, we evaluate a novel βCD-based carrier modified with an unsaturated
18-carbon chain gemini surfactant conjugate, herein referred to as 18:1βCDg (Figure 1d), as a potential
advanced drug delivery system for Mel in melanoma therapy. The objectives of the current study
are generally two-fold: 1) to synthetically engineer a novel CD-based carrier for Mel with improved
therapeutic efficiency and low carrier-cellular toxicity, and 2) to characterize the structure of the
host–guest interaction between the carrier and drug. The host–guest complex of the 18:1βCDg-Mel
system was investigated using 1D/2D 1H NMR spectroscopy in aqueous solution. NMR results
herein show the formation of well-defined carrier–drug inclusion complexes. We previously reported
a cationic gemini surfactant-βCD conjugate with 12-carbon chain (12 βCDg) for the delivery of
a poorly soluble drugs including curcumin analogs [26–28] and Mel in a melanoma cell line model [29].
The 12 βCDg-Mel complex significantly improved the efficiency of Mel drug and showed no intrinsic
toxicity as it did not alter the cellular death triggered by Mel [29]. However, the stability of the formed
host–drug inclusion complex and the efficiency of the produced 12 βCDg-Mel system were limited
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due to the self-inclusion/self-assembly of the terminal alkyl chains of the carrier agent within the
βCD cavity [27–29]. Therefore, the newly developed delivery system herein using a cationic gemini
surfactant-βCD conjugate with 18-carbon tail (18:1βCDg) is anticipated to overcome these limitations.
The in vitro efficiency of the 18:1βCDg-Mel complex using monolayer, 3D spheroid, and Mel-resistant
melanoma cell lines demonstrates the potential applicability of the 18:1βCDg delivery system as
a safe and efficient carrier for poorly soluble chemotherapeutic in melanoma therapy. This study is
anticipated to provide a greater understanding of the structure–function relationship of 18:1βCDg as
a carrier agent for poorly soluble drug with optimal therapeutic properties.
Figure 1. Chemical structures of (a) Melphalan (Mel), (b) β-Cyclodextrin (βCD) macrocycle, (c) βCD
toroidal structure showing cavity and external protons, and (d) 18:1βCDg host (carrier).
2. Material and Methods
2.1. Preparation of Inclusion Complexes
Melphalan (Mel) and β-Cyclodextrin (βCD) were purchased from Sigma-Aldrich (Oakville, ON,
Canada). Synthesis and characterization of 18:1-7NβCD-18:1 gemini surfactant [18:1βCDg] was
described elsewhere [26,30]. Figure 1 shows the chemical structures of Mel, βCD, and 18:1βCDg.
For physicochemical characterization, the complexes of Mel with βCD or 18:1βCDg were prepared in
different carrier-to-drug molar ratios (1:1, 2:1, 3:1, and 5:1). A stock solution of Mel (1 mg/mL) was
prepared in acidified ethanol (0.1% HCl). Stock solutions of βCD and 18:1βCDg were prepared in
Milli-Q water at 10 mM concentration. An appropriate volume of Mel solution was mixed with βCD
and an aqueous 18:1βCDg dispersion to yield the required carrier-to-drug molar ratios. Formulations
were frozen at −80 ◦C for 2 h and transferred to a cascade freeze dryer (Labconco, Kansas City, MO,
USA) at −80 ◦C and 0.03 mBar vacuum and lyophilized for 24 h. The lyophilized formulations were
rehydrated in water (or in deuterium oxide for 1H NMR and 1D/2D ROESY experiments) and shaken
in the orbital shaker for 1 h at room temperature prior to evaluation.
2.2. Physicochemical Characterization
2.2.1. Size and Zeta Potential Measurements
Eight hundred microliters of rehydrated formulations were transferred into a special cuvette
(DTS1061, Malvern Instruments, Worcestershire, UK) for size distribution and zeta potential
measurements using a Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK).
Each sample was measured in triplicate and the results are expressed as an average ± standard
deviation (SD), where n = 3 with a corresponding polydispersity index (PDI) value.
41
Pharmaceutics 2019, 11, 427
2.2.2. NMR Spectroscopy
1D/2D 1H ROESY NMR spectra in solution were recorded on a 500 MHz 3-channel Bruker Avance
spectrometer in D2O at 298 K. Chemical shifts (δ) are reported in ppm with respect to trimethylsilane
(TMS; δ 0.0 ppm) as external standard. 1H 1D spectra were obtained with water solvent suppression,
a 2s recycle delay, and a 90◦ pulse length (10 μs). 2D ROESY NMR spectra were obtained at variable
parameters which were optimized as follows: spin-lock time of 350 ms, recycle delay of 3 s with
8 scans and 1k data points. Complexation-induced chemical shift (CIS) values were calculated as
Δδ = δ free − δ complex.
2.3. In Vitro Evaluation
Human malignant melanoma (A375) cell line (ATCC®® CRL-1619™, Cedarlane, Burlington, ON,
Canada) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and 1% antibiotic and incubated at 37 ◦C under an atmosphere of 5% CO2/95% air. For all
experiments, culturing conditions and passage numbers were kept constant.
2.3.1. Determination of Half Maximal Inhibitory Concentration (IC50) in Monolayer Melanoma
Cell Culture
A375 cell lines were seeded at a density of 1 × 104 cells/well and incubated for 24 h. Cells were
treated with serial concentrations of Mel (32 nM to 250 μM), either alone or as 18:1βCDg-Mel complexes
at a 2:1 molar ratio, and 18:1βCDg alone (64 nM to 500 μM) in quadruplicate. After 24 h of treatment,
cell viability was assessed using MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide)
(Sigma-Aldrich, Markham, ON, Canada) assay. The supplemented DMEM containing the treatment
was removed from the wells and replaced with 0.5 mg/mL MTT in supplemented media and incubated
at 37 ◦C for 3 h. The supernatant was removed and each well washed with phosphate-buffered saline
(PBS). The formed formazan was dissolved in DMSO. Plates were incubated for 10 min at 37 ◦C.
Absorbance was measured at 580 nm using BioTek microplate reader (Bio-Tek Instruments, Winooski,
VT, USA). The half maximal inhibitory concentration (IC50) was determined by calculating the fraction
of dead cells and plotting the data with a 4-parameter curve generated by GEN5 software from BioTek.
2.3.2. In Vitro Efficiency in Spheroid Melanoma Cell
To evaluate the efficiency of developed formulations in three-dimensional cell culture, melanoma
cells (A375) were cultured at a density of 1 × 104 cells/well in 96-well spheroid microplate (Corning
Inc., Tewksbury, MA, USA). Cells were incubated at 37 ◦C under an atmosphere of 5% CO2/95% air
for 48 h prior to treatment with Mel and 18:1βCDg-Mel complexes. After 48 h, cells were treated
twice (2nd treatment 24 h after the first) with Mel alone and with 18:1βCDg-Mel complexes at 2:1
molar ratio with final Mel concentrations of 30 and 80 μM in quadruplicate. The CytoTox-ONE
Homogeneous Membrane Integrity Assay (Promega Corporation, Madison, WI, USA) was used to
determine the lactate dehydrogenase (LDH) activity 12 h after the 2nd treatment. An equal volume
of CytoTox-ONE™ Reagent (100 μL) was added to cell culture medium in each well and incubated
at 23 ◦C for 10 min. Fifty microliters of stop solution was added to each well and fluorescence was
measured using an excitation wavelength of 560 nm and an emission wavelength of 590 nm by using
a BioTek microplate reader. Maximum LDH release was used as a control by adding 2 μL of lysis
solution to 4 wells of nontreated cells. % cell toxicity was calculated as follows:
% Cell Toxicity =
(Experimental − Culture Medium Background)
(Maximum LDH Release − Culture Medium Background)
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2.3.3. In Vitro Efficiency in Mel-Resistant Melanoma Cell Lines
Mel-resistant melanoma cultures were created by using A375 cell line, as described previously [29].
In brief, A375 cells cultured in 25 cm2 tissue culture flasks and treated with increasing concentrations
of Mel from 100 nM to 60 μM over 9 weeks to induce drug resistance. The Mel-resistant cells were
seeded at a density of 1.5 × 104 cells/well in 96-well plate and incubated for 24 h. After the incubation
period, cells were treated with Mel alone and with 18:1βCDg-Mel complexes at 2:1 molar ratio with
final Mel concentrations of 30 and 80 μM in quadruplicate. The MTT assay, as described above, was
used to determine % cell toxicity (compared to nontreated cells).
2.4. Statistical Analysis
Statistical analyses were performed using SPSS software (v 24.0). Independent t-test and one-way
analysis of variance (Bonferroni’s post hoc tests) were used. Significant differences were considered at
P < 0.05 level.
3. Results and Discussion
3.1. Physicochemical Characterization
3.1.1. H NMR and 1D/2D ROESY
Several spectroscopy methods (NMR, circular dichroism, and FT-IR) have been utilized to
characterize the structure of host–guest inclusion complexes, along with X-ray diffractometry (XRD)
and mass spectrometry (MS) [31,32]. Solution state NMR spectroscopy is a powerful tool for elucidating
the molecular level structure and host/guest stoichiometry by analyzing the complexation-induced
shifts (CIS). In particular, two-dimensional NMR affords an understanding of the through-space dipolar
interactions and inclusion geometry of the guest within the βCD cavity [27,33,34]. In 2D ROESY NMR,
the nuclear Överhauser effect (NOE also ROE) is employed to elucidate the noncovalent interactions
between nuclei that reside in close spatial proximity (~5 Å) [35,36]. Although 2D NMR ROESY
cross-correlations are related to NOE, other correlations may arise due to chemical and conformational
(rotational) exchanges [37].
In the current work, 1D/2D 1H ROESY NMR was employed to elucidate the structure of the
18:1βCDg and its complexes with Mel. The 1H signals in Figure 2 were assigned according to previous
reports [27,38] and the simulated spectra (cf. Figures S1 and S2 Supporting information). Starting
with the 18:1βCDg carrier molecule, evidence of the formation of the gemini surfactant-grafted βCD
is shown by the substantial broadening of the βCD resonance lines (~3.0–4.5 ppm) relative to the
native βCD (Figure 2a,c, respectively), along with the emergence of the gemini surfactant signals
at δ ~0.5–1.0 ppm (Figure 2c). Similar line broadening effects were reported previously for grafted
βCD-based hosts in D2O [37]. The downfield shifts (Δδ ~0.04–0.10 ppm, Table 1) of the external
and framework protons of the 18:1βCDg (i.e., H1, H4, and H6; cf. Figure 1b) indicate an induced
conformational change of the βCD macrocycle upon grafting. The internal cavity protons H3 and H5
of the βCD moiety of the 18:1βCDg carrier (Figure 2 highlighted area II) are characterized by upfield
shifts (~−0.03 and −0.08 ppm; cf. Table 1) that indicate a possible inter- or intramolecular inclusion of
part of the gemini surfactant moiety (cf. Figure 2c), consistent with shielding effects [38]. The alkenic
signals of the gemini surfactant ~5.4 ppm (Figure 2 highlighted area I) are characterized by substantial
broadening and upfield shift indicating a change of conformation and/or environment upon drug
complexation as described above.
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Table 1. Complexation-induced chemical shift (CIS) data of the host (βCD and 18:1βCDg) and its
complexes with Melphalan. The CIS values (in brackets) were calculated as Δδ = δcomplex − δfree,
where negative and positive values represent shielding (upfield) and deshielding (downfield) effects,
respectively. * Chemical shift values are difficult to decipher.
Host:Guest Ratio
1H Nuclei
H1 H2 H3 H4 H5 H6


































































Figure 2. 1H NMR spectra of (a) βCD, (b) Mel, (c) 18:1βCDg, and (d) 18:1βCDg-Mel complex at 2:1
molar ratio obtained in D2O at 298 K. The insets show enlarged resonance regions for the alkenic signal
(H11) of the gemini (I) and βCD signals (II). Some signals for the drug (H’1, H’2) and the interior and
exterior protons of βCD are labeled.
In the case of the 18:1βCDg-Mel, various host:guest complexes (1:1, 2:1, 3:1 and 5:1) were
studied. The 1:1 and 2:1 18:1βCDg-Mel complexes showed the most affected CIS values as listed in
Table 2, indicating that the 18:1βCDg carrier forms 1:1/2:1 stoichiometry with the drug. The 1D 1H
NMR spectrum of the 18:1βCDg-Mel complex at the 2:1 mole ratio is represented in Figure 2d and
reveals substantial shielding of the βCD internal protons (~3.7–4.0 ppm) and the gemini surfactant
(~0.5–1.0 ppm) resonances. This provides evidence for the inclusion of the Mel within the cavity of the
βCD moiety with possible involvement of the gemini surfactant moiety.
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Table 2. Physiochemical properties (size and zeta potential) of different melphalan formulations.




nm ± SD PDI
Zeta Potential
mV ± SD
Mel (1 mM) – – –
βCD (2 mM) – – –
18:1βCDg (2 mM) 170 ± 17 0.329 ± 0.047 +14 ± 3
βCD-Mel (2:1 mole ratio) – – –
18:1βCDg-Mel (2:1 mole ratio) 160 ± 15 0.430 ± 0.04 +46 ± 2
The 2D 1H ROESY NMR spectra of 18:1βCDg and its complexes with Mel are shown in Figures 3–5.
In Figure 3, the spectra of the unbound 18:1βCDg carrier displayed cross-peaks due to typical
interactions between the backbone H1 proton of βCD with the cavity interior (panel a). Furthermore,
various cross-peaks are arising from intra-/intermolecular interactions of the 18:1βCDg carrier (Figure 3,
panel c). More recently, the self-inclusion of a 12-carbon chain gemini (12 βCDg) within the βCD
cavity was reported [27]. In Figure 3, cross-peaks between the βCD cavity and the alkyl chain of the
gemini surfactant (highlighted area b) are relatively weak and characterized by positive correlations
(green contours in Figure 3) due to possible conformation (rotational) and chemical exchanges [37].
The formation of host–guest inclusion complexes is expected to be thermodynamically more favorable
for a saturated long hydrocarbon chain than shorter ones [39]. However, intermolecular aggregation of
the gemini surfactant chain is anticipated to be more prominent in the case of 18:1βCDg due to the
presence of the unsaturated bond that causes the tail to bend with less flexibility, which can reduce the
self-inclusion of the tail region within the βCD cavity.
 
Figure 3. 2D ROESY 1H NMR spectra of unbound 18:1βCDg in D2O and 295 K. The inter- and
intra-molecular cross-peaks are shown as highlighted areas a–c, and the bar to the right shows positive
and negative correlations.
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Figure 4. 2D ROESY 1H NMR of the 18:1βCDg-Mel complexes at (a) 1:1, (b) 2:1, (c) 3:1, and (d) 5:1
mole ratios. The cross-peaks for the βCD-Mel and βCD-gemini surfactant interactions are shown in





Figure 5. Expanded 2D ROESY 1H NMR of the 18:1βCDg-Mel complex at 2:1 molar ratio in D2O at
295 K. The possible geometries are depicted in the insets.
The relative comparison of the 2D ROESY spectra of the complexes of 18:1βCDg with Mel at
various carrier:drug mole ratios (1:1, 2:1, 3:1, and 5:1) were used to further support the effect of
stoichiometry on maximum solubility (Figure 4). According to the 2D ROESY spectra in Figure 4,
the increased carrier–drug interactions at the 1:1 and 2:1 mole ratios are evidenced by the intense
cross-peaks and suggest optimal solubilizing conditions for the drug, more so at the 2:1 mole ratio due
to the much greater intensity. It is noteworthy that the interaction between the gemini surfactant and
the βCD moiety of the carrier in the presence of the Mel drug as a co-guest illustrates the importance of
“cooperativity” in the host–guest inclusion complex. Evidence of cooperative association was reported
recently for other βCD-based complexes [37,40]. In the present study, the “cooperative interaction”
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only occurred when Mel was added to the 18:1βCDg. The foregoing solubility results inferred from
the 2D NMR results agree with the CIS data herein (Table 1) and with solubility evaluation results
reported previously using mass spectrometry [41]. The 1H NMR CIS data in Table 1 provide evidence
of destabilization of the carrier–drug inclusion complex due to hydrophobic effects and conformational
motility of the 18:1βCDg at higher carrier loading, as indicated by the downfield shifts of the βCD
extracavity (or framework) nuclei (i.e., H1, H6, and H4). The efficiency of 18:1βCDg to increase
the aqueous solubility of Mel was evaluated using mass spectrometry, where the highest aqueous
solubility was determined at the 2:1 host–guest mole ratio [41]. Increasing the 18:1βCDg-Mel mole
ratios to 3:1 and 5:1 caused significant reduction in Mel solubility, consistent with the attenuated
βCD-Mel signals at the expense of the βCD-gemini surfactant signals for these systems (cf. Figure 4c,d).
The foregoing discussion suggests increased interaction of the gemini surfactant moiety with the βCD
cavity at higher host ratio, whereas an alternate geometry involves one 18:1βCDg unit interacting
with another 18:1βCDg unit inter-molecularly in a rotaxane-like fashion (cf. Scheme 1). The growing
interactions between the gemini surfactant moiety at the alkenic region (~5.4 ppm; Figure 4) with the
βCD interior/exterior protons at the higher host ratios indicates a possible intermolecular aggregation
of the gemini surfactant around the βCD and further support the rotaxane-like structure depicted in
Scheme 1. These proposed structures are further supported by the shielding and deshielding CIS trends
of the external and internal βCD resonances, respectively (cf. Table 1). It is noteworthy to mention
that the increased gemini surfactant-βCD interaction at the 3:1 and 5:1 mole ratios of 18:1βCDg-Mel
correlate with the limited solubility of the drug at these conditions (Scheme 1c).
 
Scheme 1. Schematic presentation of the possible inclusion geometry of the Mel and gemini surfactant;
(a) 1:1 βCD-Mel, (b) 18:1βCDg-Mel at 1:1 molar ratio, and (c) 18:1βCD-Mel at 3:1 molar ratio. Note that
other possible geometries are possible and also the structures are not drawn to scale.
The 2D NMR results for the 2:1 18:1βCDg-Mel complex are shown as an expanded plot in Figure 5
and reveals NOE correlations due to interactions between the internal cavity of the βCD moiety
(H3, H5) and the aromatic moiety of the drug at the H’1 and H’2 positions (cf. Figures 1a and 5).
These results provide unequivocal evidence for the formation of the 18:1βCDg-Mel complexes with
well-defined binding and geometry that are consistent with the 1D 1H CIS data. The more intense
cross-peaks at H5 compared to H3 in Figure 5 suggests that Mel is directionally encapsulated within
the βCD cavity of the 18:1βCDg carrier, as depicted in Figure 5 (see insets). Similar geometry was
deduced from the inclusion complex of Mel with pure βCD according to 2D ROESY NMR results of
the βCD-Mel complex (cf. Figure S3).
Higuchi and Connors described an analytical approach to study the CD/drug solubility relation
known as the phase-solubility method (Figure S4) [42]. This method examines the effect of a solubilizer
(CD or ligand) on the drug being solubilized (substrate). The phase-solubility relationship describes
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only the solubilizing effect of the CD on the drug molecule but not the actual formation of inclusion
complexes. Based on the phase-solubility diagram of Higuchi and Connors, the solubility evaluation
results reported previously using flow-injection mass spectrometry of 18:1βCDg-Mel [41] and the
NMR results discussed herein, we propose that the relationship between the solubility of Mel and
the concentration of the host (18:1βCDg) follows either AN or A-BS-type model. AN-type model
indicates the formation of a host–drug soluble complex with negatively deviating isotherms, whereas
the A-BS-type indicates the formation of a complex with limited solubility [43]. βCD-drug complexes
usually follow a B-type model as a result of the limited aqueous solubility of βCD (1.85 g/100 mL).
On the other hand, 18:1βCDg exhibits behavior characteristic of both βCD and cationic gemini
surfactant (amorphous molecule). The solubilization effect of 18:1βCDg is combination of formation of
host–guest inclusion complex and the association complex formation that involve moieties that lie in
the extracavity region of the 18:1βCDg (i.e., the gemini alkyl chain) as shown by the 2D NMR results
for the 2:1 18:1βCDg-Mel (Figures 4 and 5).
3.1.2. Size and Zeta Potential
Size of the carrier–drug complex can determine their route of administration and can affect
stability, cellular uptake, biodistribution, toxicity, and clearance pathway [44–46]. For instance, optimal
endocytosis requires particle size of the nanoparticles to be within the range of 100–200 nm [47].
In the current work, the particle size was measured for the 2:1 18:1βCDg-Mel complex with size of
approximately 160 nm (Table 2). Similarly, the 18:1βCDg carrier possesses an average size of ca. 170 nm
characteristic of nanoparticles. At identical concentration conditions, βCD-Mel complex and unbound
βCD failed to form particles with measurable particle sizes (Table 2). In a previous report, much
greater particle size was measured for a 2:1 12 βCDg:Mel complex (ca. 225 nm) in the presence of
0.5% methylcellulose as a suspending agent [29]. In the current work, the reported particle size of
18:1βCDg-Mel complex was measured in an aqueous medium without the need of a suspending agent
and no visible precipitation was observed even after 24 h. It is hypothesized that the replacement of
saturated 12-carbon tails with unsaturated 18-carbon alkyl tails in the case of 18:1βCDg results in the
formation of a stable inclusion complex.
Aside from particle size, the surface charge of a system can affect the physiochemical stability and
biological behavior of carrier-drug formulations [48]. In Table 2, the zeta potential (ζ) data reveals
much larger positive charge (ζ = 46 mV) for the 18:1βCDg-Mel complex compared to the uncomplexed
18:1βCDg carrier (ζ = 14 mV). This effect can be explained by the difference in the measured pH values
between the complex (pH 2.8) and the 18:1βCDg aqueous dispersion (pH 4.7). Low acidic pH can lead
to the protonation of melphalan, causing more positive ζ-values [49].
3.2. In Vitro Evaluation
The in vitro activity of 18:1βCDg-Mel complex, optimized at the 2:1 mole ratio, was evaluated in
different melanoma cell line models. The in vitro studies were performed to evaluate the ability of the
carrier to: (1) enhance the efficiency of Mel in standard monolayer cell lines; (2) enhance the penetration
of the Mel in 3D melanoma tissue culture; (3) overcome drug resistance in Mel-resistant cells.
A standard monolayer A375 cell line was used to determine the IC50 of Mel (cf. Table 3, Figure S5).
The concentration of Mel required to induce cell death in the presence of 18:1βCDg carrier at the 2:1
(18:1βCDg-Mel) molar ratio was significantly lower with IC50 values of 27 ± 1 μM compared to Mel-
alone with IC50 = 98 ± 1 μM (P < 0.05). Additionally, the IC50 value for the unbound carrier 18:1βCDg
was ~89 μM. These results indicate that the 18:1βCDg-Mel complex can significantly improve the
efficiency of Mel with low carrier-specific toxicity of the cells. Recently, we reported that βCD-gemini
system did not alter the cell death pathway induced by Mel, as shown by apoptosis and cell cycle
analyses, indicating that the βCD-modified gemini surfactant bears no intrinsic toxicity to the cells [29].
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Table 3. The 50% of inhibitory concentration (IC50) of: [A] Mel-alone, [B] 18:1βCDg alone, and [C]
18:1βCDg-Mel complexes at 2:1 molar ratio. IC50 determined in A375 monolayer cell lines by using
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay. IC50 was established by
calculating the fraction of dead cells and plotting the data with a 4-parameter curve. N = 3 ± SD.
Treatment IC50
[A] Mel 98 ± 1 μM
[B] 18:1βCDg 89 ± 2 μM
[C] 18:1βCDg-Mel [2:1 molar ratio] 27 ± 1 μM
To mimic the complex three-dimensional (3D) architecture of a solid tumor and to investigate the
cell penetration ability of the βCD-modified gemini surfactant and hence the improvement in the drug
permeability, a spheroid melanoma cell culture was created. Treatment of spheroid melanoma cell
culture with 30 μM 18:1βCDg-Mel complexes at Mel final concentration of 30 μM (the approximate
IC50 value in monolayer culture) caused 10% cell death, a three-fold increase in cell toxicity compared
to Mel alone (cf. Figure 6). These results are based on the differences in IC50 values for Mel (98 μM)
and 18:1βCDg-Mel (27 μM) in monolayer A375 cell lines (cf. Table 3). Similarly, treatment of spheroid
melanoma cell culture at greater Mel final concentration of 80 μM (recapitulating the IC50 value of
naked Mel in monolayer) showed 24% cell toxicity with 18:1βCDg-Mel complexes, compared to 14% for
Mel-alone at the same conditions (Figure 6). While cell toxicity for 18:1βCDg-Mel complexes (at both
30 and 80 μM) are lower than cell death in A375 monolayer cell lines, the results are encouraging
for future formulation development upon accounting for the higher complexity of the spheroid cell
culture and smaller direct contact area with the drug dispersed in the cell culture medium compared to
monolayer cultures. Nevertheless, formulating Mel with 18:1βCDg caused a significant increase in
the cytotoxicity of the drug at both concentrations. In our previous work, 12 βCDg did not improve
the delivery of Mel in the tumor spheroids of A375 cells as no such difference were found between
the IC50 values between Mel-alone and the Mel-12 βCDg formulation [29]. Thus, we hypothesize
that the 18:1βCDg, with unsaturated 18:1 tail, forms more favorable inclusion complexes with Mel
than the 12 βCDg with 12-carbon alkyl tail. This may be attributed to the combined effect of a more
prominent inclusion binding along with secondary interactions due to association of the non-included
C18:1 gemini chain that resides in the interstitial region of 18:1βCDg, as described in the NMR results
(Scheme 1).
Figure 6. Cytotoxic efficiency of the Mel-alone and 18:1βCDg-Mel complexes (at 2:1 molar ratio) in
3D spheroid A375 melanoma cells. A375 cells were seeded at 1 × 104 cells/well in Corning® spheroid
96-well microplates and treated twice (24 h and 36 h after seeding) with Mel-alone and 18:1βCDg-Mel
complexes with final Mel concentrations of 30 μM and 80 μM. Cell toxicity was reported as lactate
dehydrogenase (LDH) activity. N = 3 ± SD * indicates significance (P < 0.05).
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Advanced drug delivery systems can provide a potential avenue to overcome drug resistance by
enhancing the bioavailability of the drug target at the tumor site. This can be achieved by shielding
the drug molecule via complex formation to minimize its efflux from the cell [50]. Previously, we
reported that formulating Mel with 12 βCDg significantly improved the efficiency of the drug in
Mel-resistant A375, whereas Mel alone showed minimum cell death at the same concentration, in
line with the anticipated effect [29]. In the current work, we evaluated the capability of newly
designed βCD-modified gemini surfactant (18:1βCDg) to enhance the cytotoxic action of melphalan
in Mel-resistant cultures (Figure 7). The Mel-resistant A375 cells showed low cell toxicity toward
melphalan even at the highest concentration that was evaluated here (500 μM of melphalan). Therefore,
we used 30 and 80 μM melphalan based on the known IC50 values of melphalan and the corresponding
IC50 values of 18:1βCDg alone in a standard monolayer cell culture assay (Table 3, Figure S5). Treating
the Mel-resistant A375 melanoma cells with Mel-alone at 30 and 80 μM caused low cell death (4% and
27%, respectively). However, after treating the Mel-resistant cells with 18:1βCDg-Mel complexes at
final Mel concentration of 30 and 80 μM, a significant recovery of the activity was observed (46 and
76% cell death, respectively), as shown in Figure 7. These results suggest that the 18:1βCDg delivery
system was able to overcome the apparent drug resistance and enhance the treatment efficacy.
Figure 7. Cytotoxic efficiency of the Mel-alone and 18:1βCDg-Mel complexes (at 2:1 molar ratio) in
Mel-resistant A375 melanoma cells. A375 cells were seeded 1.5 × 104 cells/well in 96-well plate and after
24 h treated with Mel-alone and 18:1βCDg-Mel complexes with final Mel concentrations of 30 μM and
80 μM. Cell death was reported as using MTT assay in comparison with nontreated cells. N = 3 ± SD
* indicates significant (P < 0.05).
4. Conclusions
In this work, a novel carrier based on derivatization of βCD with an unsaturated 18-carbon chain
gemini surfactant conjugate (18:1βCDg) was characterized and its potential as an advanced drug
delivery system for Melphalan (Mel) drug in melanoma therapy was evaluated. The 18:1βCDg carrier
and its complexes with Mel drug were characterized using 1D/2D NMR spectroscopy, along with the
measurement of particle and zeta potential in aqueous solution. The 18:1βCDg carrier improves the
solubility of Mel through formation of favorable inclusion complexes at the 2:1 mole ratio, as supported
by 1D CIS data and 2D ROESY NMR results. The inclusion of Mel involves a well-defined geometry
where the drug is directionally encapsulated within the internal apolar cavity of the βCD carrier system,
according to 2D ROESY NMR results. The self-inclusion of the terminal part of the gemini alkyl chain
within the βCD cavity cannot be ruled out especially at equimolar carrier/drug ratios. However, these
effects are minimized at carrier mole ratios >1:1 due to hydrophobic aggregation of the carrier chains.
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The measured particle sizes of the unbound 18:1βCDg carrier (ca. 170 nm) and the 2:1 carrier: drug
complex (160 nm) are within nanoparticle size limits (100–200 nm). Thus, the 18:1βCDg carrier affords
optimum stability, cellular uptake, biodistribution, toxicity, and clearance pathway of the reported
formulation. As well, the in vitro evaluations of the optimized 18:1βCDg-Mel formulation in the
presence of various melanoma models (i.e., monolayer, 3D spheroid, and Mel-resistant melanoma cells)
resulted in significantly improved cytotoxic efficiency of the Mel in all cases. We are envisioning future
studies to elucidate the pathways of cell penetration and of mechanism overcoming drug resistance of
the 18:1βCDg-drug complexes. This knowledge will enable us to further optimize the structure that
aims to improve efficiency and increase penetration ability into spheroids.
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(www.nmrdb.org). Figure S3. 2D ROESY spectrum of βCD-Mel at a 2:1 host-guest mole ratio, showing cross-peaks
between βCD internal 1H cavity and Mel nuclei. Figure S4. Phase solubility diagram. Figure S5. Cytotoxic
efficiency of Melphalan in human malignant melanoma (A375) cell line). A375 cells were seeded at 1 × 104
cells/well in 96-well plate. Toxicity was reported using MTT Assay in comparison with non-treated cells (100%
viability). N = 3 ± SD.
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Abstract: Drug delivery to the central nervous system (CNS) remains a challenge in neuro-oncology.
Despite decades of research in this field, no consensus has emerged as to the best approach to tackle
this physiological limitation. Moreover, the relevance of doing so is still sometimes questioned in the
community. In this paper, we present our experience with CNS delivery strategies that have been
developed in the laboratory and have made their way to the clinic in a continuum of translational
research. Using the intra-arterial (IA) route as an avenue to deliver chemotherapeutics in the treatment
of brain tumors, complemented by an osmotic breach of the blood-brain barrier (BBB) in specific
situations, we have developed over the years a comprehensive research effort on this specialized
topic. Looking at pre-clinical work supporting the rationale for this approach, and presenting results
discussing the safety of the strategy, as well as results obtained in the treatment of malignant gliomas
and primary CNS lymphomas, this paper intends to comprehensively summarize our work in
this field.
Keywords: blood-brain barrier; intra-arterial chemotherapy; malignant gliomas; primary central
nervous system lymphomas
1. Introduction
Chemotherapeutic drug trials for brain tumor treatment have been conducted worldwide for many
decades, with marginal improvements in patient outcomes. Indeed, the standard of care in the 1st-line
management of glioblastoma (grade 4 primary brain tumors) was the addition of temozolomide, an
alkylating drug, to radiotherapy, which led to an improvement in survival of 2 months [1]. This regimen
is dubbed the “Stupp regimen”. Any further attempts to improve on the outcome have produced
disappointing results. Interestingly, one of the only reported approaches with seemingly improved
outcomes is the addition of a local device emitting low-intensity, intermediate-frequency alternating
electric fields (TTF) [2]. As this device is applied directly to the scalp, and its effect does not require a
specific delivery paradigm to reach the CNS. Indeed, amongst the factors that can explain a lack of
improvement in the care of brain tumor patients, one stands as a major culprit: Impaired delivery to
the CNS, related to the presence of the blood-brain barrier (BBB) [3]. Thus, in the presence of a brain
tumor, the first barrier to treatment options is just that, a barrier: The BBB.
2. The Blood-Brain Barrier
It has been a long process to recognize the extent to which the BBB really impacts CNS delivery. It is
often still debated in some publications, as some authors continue to argue that the presence of contrast
enhancement on computed tomography(CT) scans (iodine-based) or on magnetic resonance scans
(para-magnetic contrast) remains clear evidence that the integrity of the BBB is altered and access to the
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CNS is granted [4,5]. Hence, in that context, these authors claim that the BBB entity does not represent a
significant obstacle to therapeutic delivery to the CNS in the presence of pathological lesions, implying
that the breach in permeability is sufficient to allow adequate diffusion of therapeutics. This type
of all or none argumentation basically translates a lack of knowledge and understanding of BBB
alterations and CNS delivery subtleties in the presence of a tumor. Indeed, different pharmacokinetic
compartments are defined by the presence of a brain tumor, with a wide variation of the effects on the
BBB permeability, and thus, on delivery [6]. This aspect is frequently neglected and under-estimated.
Indeed, looking at modern data on the subject, there is no doubt that the BBB prevents
chemotherapy entry to the CNS, even in the presence of a lesion, thereby limiting therapeutic
concentration from reaching clinically efficient levels [7,8]. Part of the confusion arises from the
fact that within a brain tumor, as well as to the close proximity of the tumor nodule, the BBB is
often replaced by a brain-tumor barrier (BTB) which pertains to entirely different pharmacokinetics,
displaying a permeability that is classically intermediate between normal BBB and breached BBB.
This increase in permeability is a function of the breach in the integrity of the BBB and BTB, and is highly
variable, heterogeneous, and dependent on tumor size and type [9–11]. Thus, within any tumor, drug
distribution is inherently uneven, with preferential accumulation in the necrotic central core areas [12],
whereas drug penetration at the edge of the tumor is classically nonexistent, or marginal at best [13].
As such, although the BBB and the BTB are often partially breached, there remains a significant delivery
impediment, and therapeutic levels of drugs are insufficient within the breached areas to mount a
clinically significant response [6,14]. As was eloquently exposed by Reichel, despite enormous efforts,
achieving an effective concentration profile in the brain remains a significant challenge in CNS drug
development [6]. Another factor further complicates the matter: The majority of malignant brain
tumors are infiltrative, with tumor cells permeating at a distance from the main tumor nodule, and
away from even the most sensitive imaging MR scan sequence (FLAIR) [14,15]. Obviously in these
areas, the BBB permeability is unaltered, and tumor cells are shielded by an intact BBB.
3. Alternate Drug Delivery
Different approaches have been designed and tested to circumvent this delivery impediment,
bypass the BBB and BTB, and maximize therapeutics delivery to the brain. Indeed, in order to increase
the number of therapeutic options available to treat CNS tumors, alternative delivery strategies have
to be considered. For a detailed review on the subject covering different strategies, please consult the
review by Drapeau et al. [3]. Of all the approaches we have tested in the laboratory, one is currently
used in the clinic: The cerebral intra-arterial infusion of chemotherapy (CIAC) with and without BBB
permeabilization. This paper will give a thorough description of the efforts carried by our group to
successfully deploy this strategy in the treatment of brain tumors. Indeed, we have implemented a
continuum of translational research on this topic that will be described in detail in this publication.
The Cerebral Intra-arterial Infusion of Chemotherapy (CIAC) and the Blood Brain Barrier Disruption
(BBBD) Adjunct
When one realizes the extensiveness of the vascular network supplying the brain, it becomes
obvious that a global delivery strategy is rational and plausible by using this vascular network as
a delivery corridor [16]. The importance of this network has already been exposed by Bradbury
and colleagues, these authors claiming that the entire network covers an area of 12 m2/g of cerebral
parenchyma [17]. To understand the extensiveness of the cerebral vascularization in a more prosaic
statement, let us just consider that the brain receives 20% of the total systemic circulation even though
its weight amounts to less than 3% of the total body weight [9].
Interestingly, it is technically easy and actually commonly performed in the clinic to repeatedly
access this cerebral vascular network in a patient [18]. Via a simple puncture to access the femoral
artery, a catheter is introduced and navigated intra-arterially to reach one of the four major cerebral
arteries. Once in position, the chemotherapy is administered via the catheter that is withdrawn at the
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conclusion of the procedure. The CIAC produces a paradigm of regional chemotherapy distribution
within the area deserved by the vessel treated [19].
Through the first pass effect, an increase in the local plasma peak concentration of the drug
produces a significantly improved AUC (the concentration of the drug according to the time) [19,20].
This consequently translates in increased local exposure of the target tissue to the therapeutic
agent. Interestingly, as our lab has shown, it is also accompanied by a decreased systemic drug
distribution, hence reducing systemic toxicities and potential side-effects [21]. Classically, the
therapeutic concentration at the tumor cell target is increased by a 3.5–5-fold factor [20]. This procedure
is performed under local anesthesia, and typically lasts around 30 min.
The delivery can be further improved by adding as an adjunct to the procedure an osmotic
blood-brain barrier disruption (BBBD). This strategy is based on the cerebral intravascular infusion
of a hypertonic solution to produce a transient increase in permeabilization of the BBB and BTB,
prior to the administration of the chemotherapy. As with CIAC, the parent vessel treated is selected
based on the tumor localization in the brain. This approach, which is an adjunct to the CIAC, is
physiologically more demanding, requiring general anesthesia, and needs careful preparation, but
it does increase significantly delivery across the BBB and BTB [3,9]. It involves the IA infusion of a
hyperosmolar solution (usually mannitol) in a flow rate sufficient to allow a complete filling of the
vessel. Two parameters are paramount in the ability to mediate a hyperosmolar modification of the
barrier: The osmolality of the solution, and the infusion time. Using a solution of 1.6 molal arabinose
in pentobarbital-anesthetized rats, Rapoport determined an interval duration of 30 s as the optimal
infusion time to produce a BBBD [9]. The same infusion time was applied to the use of mannitol with
similar findings in the same animal model [9]. These parameters have made their way to the clinic,
albeit the anesthetic agents are now different.
The combination of IA infusion of a molecule with osmotic BBBD has been shown to further
increase the effect of the first pass through the brain, increasing maximal peak concentration as well as
AUC of the administered molecule [16,22,23]. Sato et al. elegantly presented in vivo data showing that
BBBD produces a marked increase in permeability at the edge of the tumor. Interestingly, this area is
typically associated with active tumor cells proliferation, whereas the permeability of the BBB and BTB
tends to renormalize [13]. Theoretically, the concept of beaching the permeability of the BBB is quite
compelling, as it could help evade the “sink effect” by providing higher and more uniform delivery to
a whole CNS vascular territory, allowing prolonged tumor cell exposure to higher concentrations of
the administered therapeutics [6,16]. This sink effect is triggered by areas of necrosis within the tumor,
which tends to attract and concentrate the chemotherapy crossing the CNS, stealing the peripheral
areas of the tumor where the drug would be most useful [16]. Obviously, this includes the neoplastic
cells at the tumor edges that are often the most proliferative and protected by an intact BBB and/or
BTB [14–16,24].
4. Pre-clinical Data
While numerous investigators have studied CIAC and BBBD over the years, we undertook a
thorough pre-clinical characterization in the Fischer-F98 model to ascertain, objectivate, and measure
the delivery advantage provided by both approaches. We first characterized the F98-Fischer glioma
model as a benchmark for our delivery studies. The model was found to be highly predictive and
reproducible in term of tumor growth dynamics and animal survival (Figure 1).
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Figure 1. The Fischer-F98 glioma model shows a reproducible and predictable growth pattern. (A) The
infusion of the cell suspension is accomplished using a slow steady perfusion with a micro-infusion
pump. Also, 10,000 cells are infused at a rate of 1 μL/min over 5 min. (B) Coronal views of an implanted
animal at days 3, 5, 7, 10, 14 and 17 post-implantation. Notice the gradual progression of the gadolinium
enhancement on the MR scans in the right hemisphere (arrows) depicting the steady tumor progression.
The animal starts to develop faint subtle symptoms (lateralization) at day 14, that culminate at day
26 ± 2 days.
Using a standardized implantation procedure, the tumor-take has systematically been 100%, with
a median survival of 26 ± 2 days [25,26]. Figure 1A shows the position of the animal in the stereotactic
frame for precise insertion of the needle in the brain of the animal using a precise and standardized
coordinate system [25]. This is paramount for reproducibility across experiments. Indeed, a free-hand
implantation technique which is frequently employed in the literature is inadequate for these types of
studies. Likewise, we found that the use of a micro-infusion pump is essential in minimizing tissue
damage and associated inflammatory reaction triggered by the implantation process [25]. The slow
(1 μL/min) and steady infusion rate and the low volume (10,000 cells in 5 μL) ensures minimized
cerebral tissue disruption and prevents the backflow along the implantation track commonly associated
with these models [25,26]. This produces a constant pattern of tumor growth in the right hemisphere
of the animal, where the tumor is already noticeable at day 3 post-implantation (Figure 1B), and starts
to produce an alteration in consciousness around day 26. Experimental treatments are performed at
day 10 post-implantation, when the tumor has reached a significant size (Figure 1B), without altering
the neurological functions of the animal [27–30].
Using this model, and based on slight alterations of the methods described by Neuwelt and his
team [16], we developed a technique allowing the perfusion of therapeutics via the intra-arterial (IA)
route in the carotid of the Fischer rats, while under general anesthesia in an MR gantry. This allowed us
to study the dynamics of real-time imaging during the infusion of any selected MR traceable molecule
(Figure 2) [22].
In this particular surgical montage, the right external carotid artery has been identified, incised,
and cannulated using a PE50 catheter. Once in position, any solution can be perfused in a retrograde
fashion via the external carotid artery into the internal carotid artery (Figure 2). When high flow
solutions are infused, such as when we perform a BBBD, a clip is secured on the common carotid artery
to isolate the system from the heart, and prevent downstream backflow of mannitol to the heart. Once
terminated, the clip is removed, the external carotid artery is simply ligated, and the incision is closed.
As an initial experiment, we first characterized the baseline level of CNS entry for 2 paramagnetic
compounds, Magnevist (743 Da) and Gadomer (17,000 Da) in tumor-bearing F98-Fischer rats. As
expected, the smaller Magnevist displayed a greater than 3-fold baseline penetration in the tumor
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compared to Gadomer across the BTB, whereas penetration in the BBB around the tumor was negligible,
and was no different than in the contralateral hemisphere for both molecules [22,23].
 
Figure 2. The surgical montage for intraarterial infusion and blood-brain barrier disruption (BBBD) in
the Fischer rat. Once the montage is ready, the animal can then be inserted in the magnetic resonance
(MR) gantry for real-time imaging. The intraarterial carotid perfusion is accomplished in a retrograde
fashion via the external carotid artery. As can be appreciated on this image, a clip is also placed on the
common carotid artery to prevent downstream backflow. As soon as the infusion is completed, the clip
is removed, and the external carotid artery is sutured.
Next, we studied the concentrations of different platinum drugs when administered via different
routes: Intravenous (IV), IA, and IA + BBBD using inductively coupled plasma mass spectrometry
(ICP-MS) in the Fischer-F98 rat model. We did so for 5 platinum: Cisplatin, Carboplatin, Oxaliplatin,
Lipoplatin and Lipoxal [28]. Figure 3 shows the summary of these experiments. Ten days after the F98
glioma cells implantation, the platinum drugs were administered according to the selected route of
administration. Equivalent doses of platinum to those used in humans were established based on the
body surface area of the animals [28]. Animals were euthanized 24 h after the drug perfusion, brains
were harvested, and cut in sections with a brain matrix [27]. The tumor was separated and divided
into cytoplasmic and nuclear compartments using a commercial Nuclear Extract Kit (Active Motif,
Carlsbad, CA, USA) for analysis by ICP-MS [28].
Looking specifically at the concentration of platinum reaching the nucleus of the tumor cells, we
observed significant differences between the different routes of administration (Figure 3). Comparing
IA against IV, an increase in the order of 20-fold was observed for IA Carboplatin, whereas it reached
40-fold for Lipoplatin and 90-fold for Lipoxal! Interestingly, these studies also depicted significant
neurotoxicity when experimenting IA infusion of either Oxaliplatin or Cisplatin, hinting at the fact that
these 2 drugs were not suitable candidates for IA delivery [27–29]. These increases in the tumor cells
nuclei delivery were even more dramatic when a BBBD was added to the IA infusion. Specifically
looking at Carboplatin, the IA + BBBD further increased the delivery by a 17-fold factor compared to
IA alone, a 320-fold factor compared to the IV infusion [29].
Using the same experimental design, we also assessed the delivery of Temozolomide.
Temozolomide is the first-line standard of care in the treatment of primary brain tumors. As the
bio-disponibility of the oral formulation is close to 100%, the IV formulation is available but rarely used
in the clinic. In the present study, the IV formulation was used to emulate clinical oral administration.
Hence, we tested the delivery of IA, IA + BBBD, and IV Temozolomide in the Fischer-F98 glioma
model. The animals were once again treated 10 days after implantation. Using liquid chromatography
with tandem mass spectrometry (LC-MS/MS), we measured Temozolomide in plasma, CSF and brain
at 3 timepoints post-Temozolomide infusion [21]. Compared to IV, we found a fourfold increase in
Temozolomide peak concentrations in brain tumor tissues with IA infusion, and a 5-fold increase with
BBBD [21] (Tables 1 and 2).
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Figure 3. A comparison of the 5 platinum drug accumulations as related to the route of infusion,
measured by inductively coupled plasma mass spectrometry (ICP-MS) in the Fischer-F98 rat. As can be
observed, the intra-arterial (IA) and IA + BBBD routes were not tested for Oxaliplatin and Cisplatin
because of significant toxicity. Results are reported as measurements of platinum (ng pt/g tissue) in
the nucleus, cytoplasm, and whole tumor. The magnitude of the increase observed for each platinum
agent can be appreciated in relation to the route of delivery. There is a significant increase in platinum
delivery (ng platinum/g tissue) with all molecules, except Oxaliplatin.
Table 1. IV administration of Temozolomide (TMZ) (200 mg/m2).
CNS Compartment Analyzed T1/2 (h) Tmax (h) Cmax AUC0–t
Plasma 1.08 0.25 63,581 μg/mL 53,409 h·μg/mL
CSF 0.87 0.25 7,628 μg/mL 6,658 h·μg/mL
Tumor 1.51 0.25 10,582 μg/g 9,521 h·μg/g
Lpsilateral brain 0.66 0.25 10,273 μg/g 8,530 h·μg/g
Contralateral brain 0.83 0.25 9,790 μg/g 8,547 h·μg/g
Table 2. IA administration of TMZ (200 mg/m2).
CNS Compartment Analyzed T1/2 (h) Tmax (h) Cmax AUC0–t
Plasma n/a 0.5 40,676 μg/mL 38,759 h·μg/mL
CSF 1.89 0.25 8,436 μg/mL 7,681 h·μg/mL
Tumor 0.34 0.25 42,989 μg/g 31,934 h·μg/g
Lpsilateral brain 0.35 0.25 31,056 μg/g 23,930 h·μg/g
Contralateral brain n/a 0.5 11,714 μg/g 10,130 h·μg/g
Temozolomide (TMZ) pharamacokinetic parameters measured by Liquid chromatography tandem-mass
spectrometry (LC-MS/MS) in Fischer-F98 rats treated 10 days after tumor implantation. Parameters are compared
between the IV route (Table 1) and the IA route (Table 2).
The increase was not as dramatic using the BBBD as an adjunct with IA of Temozolomide,
compared to the platinum compounds. The values of c max according to the route of delivery were
as follows: 10.582 (IV), 42.989 (IA), and 50.751 (IA + BBBD), respectively. In this paper, although we
could measure a significant increase in Temozolomide delivery as described above, we did not observe
a parallel increase in survival of the treated animals. In vitro characterization of the F-98 glioma cell
line showed it to be resistant to temozolomide [21]. Hence, it is obvious that delivery is not the only
factor at play, as will be discussed later.
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These pre-clinical results really highlight the potency of IA and IA + BBBD as an adequate
route of delivery to improve the different pharmacokinetic parameters of CNS therapeutic delivery.
The pre-clinical research continuum to improve and maximize these procedures continues, as each
therapeutic offered by this route first needs to be tested for innocuity in animal models to rule out
any major toxicities. Indeed, Taxol, cisplatin, and oxaliplatin were found to be extremely toxic in
pre-clinical testing, excluding these drugs as eventual candidates for IA delivery. Moreover, as can be
derived from the results obtained with the temozolomide experiments, an increase in delivery is not
necessarily associated with an improvement in outcome. Hence, delivery is only one of many aspects
of therapeutic success in the treatment of CNS tumors, albeit an important one. We will further discuss
this issue in the next section on the clinical applications of these procedures.
5. Clinical Procedures
The access to the arterial system is obviously accomplished differently in humans. The human
cerebral arterial system is organized in such a way that there basically are 4 major arteries responsible
for the brain irrigation (2 carotids, and 2 vertebral arteries). The vascular anatomy can be variable from
one individual to another, and thus the precise anatomy must be determined during the first treatment
session by a formal cerebral angiography. If a lesion covers more than one vascular distribution, or if
there are multiple lesions, the treatment is delivered by equally splitting the chemotherapy dose in
the different distributions (vessels) involved. Parameters such as catheter placement, dilution, and
rate of infusion are all standardized. In the human, the arterial system is accessed via a percutaneous
transfemoral puncture. Once accessed, the catheter is navigated in the arterial system using radiological
imaging (fluoroscopy). As shown in Figure 4A, the catheter has been placed in the left carotid artery,
and a contrast infusion shows the distribution of this vessel.
 
Figure 4. (A) Catheter placement in a glioblastoma patient treated for BBBD in the left carotid artery
(arrow). An iodine contrast was infused, opacifying the left carotid distribution, as well as the
contralateral carotid (double arrow) via the polygon of Willis. (B) The image produced by a BBBD of
the right carotid artery on a computed tomography (CT) scan in a patient afflicted by a primary central
nervous system (CNS) lymphoma after an infusion of iv iodine contrast. As can be appreciated, the
whole hemisphere is bathed by the contrast, an evidence by the fact that the BBB is breached.
The technique involves the following steps:
1. Selective catheterization is performed via percutaneous transfemoral puncture of the left
internal carotid artery, right internal carotid artery, left vertebral artery or right vertebral artery. The tip
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of the catheter is positioned at the C2-C3 vertebral level in the carotid (Figure 4), or at the C6-C7
vertebral level in the vertebral artery.
2. Infusion of the drug IA: When infusing intra-arterial solutions, the concentration of the
solution and the rate of infusion are critical factors that need consideration in avoiding neurotoxicity.
The phenomenon of streaming defines an inhomogeneous distribution of the administered solution
because of poor mixing at the infusion site [9]. Density and viscosity of fluid, lumen diameter of
the infused vessels, and velocity of flow are all important determinants to control in order to avoid
streaming. In this case, the Caelyx, Melphalan, and Etoposide phosphate are infused at a rate of 0.12
cc/s, whereas the Carboplatin and Methotrexate are infused at a standard rate of 0.2 cc/s.
3. In the case of a BBBD: BBBD procedures require general anesthesia. Hence, after general
anesthesia with Propofol, we proceed to a selective catheterization via percutaneous transfemoral
puncture of the treated artery. We then determine the individual rate of infusion of Mannitol. We use
iodinated contrast injection and fluoroscopy to establish, for each patient, the ideal infusion rate; it is
the rate that will fill the entire vessel distribution, without producing significant reflux in the common
carotid artery. Once established (usually between 3 and 6 cc/s × 30 s), the patient is prepared for the
hemodynamic repercussions of the procedure. Indeed, the osmotic disruption is a physiologically
stressful procedure. It can induce focal seizures in 5% of procedures. It can also trigger a vaso-vagal
response with bradycardia and hypotension. In order to prevent the occurrence of these adverse
effects, the following medications are administered just prior to the disruption: Diazepam 0.2 mg/kg
IV (maximum dose = 10 mg), and Atropine IV, titrated to increase heart rate 10–20% from baseline
(0.5–1 mg). We then proceed to the BBBD, after which IA infusion of chemotherapy is accomplished.
Figure 4B shows the repercussion of BBBD on delivery. In this image, an IV contrast material was
infused shortly after the BBBD (within 5 min), showing a diffuse penetration of the contrast compound
in the brain parenchyma (arrow).
5.1. CIAC or CIAC + BBBD? A Question of Intensity of Delivery
The question of whether to use CIAC alone or with an adjunctive BBBD really is a question of
intensity in the amount of delivery. There is no question that BBBD will increase delivery compared to
an isolated CIAC. When studying platinum compounds, this increase has been shown to be variable
for each molecule, providing a 2-fold increase for Carboplatin (overall), and up to a 5-fold increase for
Lipoxal compared to IA alone (Figure 3). However, the use of BBBD requires general anesthesia, and is
significantly heavier for the patient. Hence, its use can be limited by the availability of anesthesia and
all it implies (recovery room, etc.). On the other hand, CIAC is easy to perform, and virtually devoid
of these limitations. The procedure is cheap, and the only limitation is the access to the angiography
suit. Hence, we have traditionally reserved the use of BBBD for patients with potentially curable
diseases, such as primary CNS lymphomas (PCNSL). Metastatic brain disease, as well as glial tumors,
are typically treated by CIAC. We built most of our clinical studies around a model in which the patient
receives a monthly treatment session, typically up to 12 sessions. Only in patients of these 2 groups of
pathologies presenting a complete response or near-complete response will we consider using BBBD to
consolidate the treatment response in the last 2 cycles of treatment.
5.2. Clinical Data: Safety
Neurotoxicity is a legitimate concern when deploying a strategy that increases CNS delivery of
therapeutics. Indeed, transgressing the BBB could result in an increase in neurotoxicity. Thereby each
therapeutic used in the clinic has been previously tested in the animal model to screen for compatible
drug candidates for CIAC/CIAC + BBBD clinical use. Obviously, this does not entirely preclude
the risks of toxicity. However, now looking at the modern series of CIAC/CIAC + BBBD, we can
confidentially claim it to be safe, when performed in expert centers.
Doolittle et al. reported on the experience of the BBBD consortium, a multi-site consortium
performing CIAC with and without BBBD for malignant brain tumors [30]. These authors concluded
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that with standardized protocols, CIAC was safe across multiple centers, with a low incidence of
catheter-related complications. In their series of 221 patients treated between 1994 and 1997, they
observed a sub-intimal tear rate of 5%, whereas the rate of strokes was 1.7%.
We undertook a detailed review of our own experience in terms of complications, going into
further details. We analyzed our entire cohort of CIAC patients to brush the best possible picture in
terms of innocuity. Between January 2000 and June 2015, a total of 3583 arteriographic procedures
for CIAC/CIAC + BBBD were performed on 722 patients in the treatment of brain tumors at CHUS
(centre hospitalier universitaire de Sherbrooke, Sherbrooke, Canada). All patients were afflicted by a
malignant brain tumor (463 primary brain tumor, 158 metastasis, 101 lymphomas). To our knowledge,
this is the largest such series available in the literature [31].
As clinical data have been cumulated prospectively in the context of clinical studies, data were
extracted from all hospitalization records for care events related to a CIAC procedure in the treatment
of brain tumors (glial tumors, PCNSL, and metastatic tumors). Complications were studied and
grouped under 3 different headings: Vascular complications, per-procedural epileptic manifestations,
and hematological toxicities. The results are detailed in Table 3.
Table 3. Angiographic, seizure-related and hematologic complications in the series of CIAC/CIAC


















Dissections 5 1 0 5
Stenosis 9 2 0 9
Occusions 3 2 2 1
Hemorragic lesions 5 5 1 4
Lacunar Strokes 38 38 20 18
Strokes 6 6 4 2










65 9 23 4 12 62 12
74 seizure events (2%) 39 patients (5.4%)
Hematologic Toxicites (per NCIC
Toxicity Criteria)
Grade 1 Grade 2 Grade 3 Grade 4 Total
Neutropenia 70 (9.7%) 67 (9.3%) 22 (3.1%) 21 (2.9%) 180 (24.9%)
Thrombocytopenia 43 (5.9%) 37 (5.1%) 35 (4.9%) 21 (2.9%) 136 (18.8%)
Anemia 115 (15.9%) 78 (10.8%) 25 (3.5%) 10 (1.4%) 228 (31.6%)
Total 228 (31.6%) 182 (25.2%) 82 (11.4%) 52 (7.2%)
5.2.1. Vascular Complications
Overall, a total of 66 vascular angiographic or MRI incidents were uncovered (1.84%).
More specifically, 5 asymptomatic dissections were observed, 9 asymptomatic carotid stenosis
and 3 occlusions were identified, 2 which were symptomatic. (Table 3).
In terms of cerebral newly described lesions, the MRI identified 5 acute hemorrhagic strokes
(1 symptomatic), 38 lacunar strokes (20 symptomatic), and 6 acute ischemic lesions (4 symptomatic).
One of these strokes in the posterior fossa was a catastrophic event that led to the patient’s death.
Overall in this series, the total number of symptomatic vascular complication rate was 27 (0.75%).
5.2.2. Seizure Events
The overall per-procedural seizure incidence was 2% (74 incidents) as can be appreciated in
Table 3. Of these, 9 were generalized seizures, whereas 65 were partial seizures. Interestingly, a simple
discontinuation of the chemotherapy infusion was sufficient to halt the seizure in all patients, but one.
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Most seizure fits (84%) were observed during Methotrexate infusion for primary CNS lymphomas
(PCNSL). Only 3 partial seizures were observed in the treatment of glial tumors.
5.2.3. Hematological Complications
Hematological complications were classified according to the National Cancer Institute of Canada
(NCIC) toxicity criteria. A total of 11.4% grade 3 and 7.2% grade 4 toxicities were observed.
Hence, from the analysis of this data, we feel justified to conclude that the procedure is safe,
and its use is appropriate in this clinical context. This affirmation does imply that the treatments are
performed in expert centers, and the therapeutics used with CIAC have been screened with an adequate
methodology and are known to be devoid of neurotoxicity. While the technical details of the procedure
are beyond the scope of this publication, a few considerations need to be discussed. First, although
some might argue that a supra-selective catheter placement might be of interest, we always use a
proximal position in the treated vessel (C1-2 for the carotid, C2-C3 for the vertebral). The rationale
supporting this has to do with the infiltrative nature of most brain tumors, always lending for a more
widespread disease than the MR scans actually reveal. This is true for glial tumors, PCNSL, but also
metastasis. Because of that, we see little interest to target for a supra-selective catheterization, especially
considering that this approach would likely increase the risks of complications while limiting the
actual distribution of chemotherapy to the CNS.
Secondly, each therapeutic comes with its own set of infusion parameters based on the
concentration, density, and volume of the infusion solution. This is paramount to minimize the
risks of neurotoxicity related to concentration and streaming.
6. Clinical Results
We will focus the discussion on the results obtained for GBM (grade 4 astrocytomas) and PCNSL.
As a remainder, all patients with GBM were treated by CIAC, whereas 10% of these receive CIAC +
BBBD as a consolidation procedure for the last 2 cycles. PCNSL patients were all treated with CIAC
+ BBBD.
6.1. Glioblastoma (GBM)
In our series, 319 GBM patients were treated by CIAC. Treatment sessions were performed every
4 weeks, unless hematologic parameters prevented it. Carboplatin is the drug of choice, either alone, or
combined with either Melphalan or Etoposide phosphate, depending on the protocol used. All GBM
patients were treated at relapse. Seventeen percent were treated at first relapse, 68% at second relapse,
11% at third relapse and 4% at fourth (Figure 5).
The fact that most of our patients were treated at 2nd relapse unfortunately negatively biases
our results.
Overall, patients received a median of 4 cycles (1–22 cycles). Progression-free survival was
5 months. The whole series presented an overall median survival of 25 months, and survival
from study entry was 8 months for the entire cohort (Figure 6). This is superior to most commonly
reported treatments at relapse, which usually produces median survival from treatment initiation of
4–6 months [2,3,7].
Ten patients are still alive, with the longest survival now at 16 years. When looking exclusively at
those patients treated at 2nd relapse, median survival jumps at 11 months from the study entry for the
entire cohort.
Looking at the best radiological responses obtained according to the RANO criteria, we found the
following: 23% of patients have shown progression, 26% have presented a stabilization of their disease,
42% have shown a partial response (Figure 7), and 6% a complete response.
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Figure 5. A breakdown of the number of treatment lines to which GBM patients were exposed prior to
accrual in our series. As can be appreciated, most patients were exposed to 2 lines of treatment (68%)
prior to accrual.
 
Figure 6. Median survival from diagnosis (A) and distribution survival histogram (B) of GBM patients
exposed to CIAC. Median survival from diagnosis was 25 months, whereas it was 8 months from the
study entry. As can be appraised from the distribution histogram, most patients progress and die from
their disease in the first 12 months after accrual. This leaves around 25% of patients whose survival is
greater than 12 months.
Although these results are encouraging, comparing this data with modern series is complicated
by 2 factors. Our data on GBM is plagued by a major weakness: Heterogeneity. Indeed, in 2016,
the classification on gliomas changed, and one major overhaul has been the inclusion of molecular
markers to better stratify the patients in prognostic classes that strongly determine their evolution [32].
The IDH marker is the stronger determinant of survival, and, nowadays, most modern series stratify
patients according to this marker, which we did not. The other source of heterogeneity in this series
pertains to the fact that a majority of patients were exposed to multiple treatments prior to accrual
(Figure 5). These 2 factors are obviously now considered in the design of our studies. Recruitment and
stratification is now refined to eliminate these confounding factors.
Ideally, to avoid this heterogeneity, a randomization process should also be utilized. We tried
to launch such a study a few years back, but were faced with difficulty as to what should be the
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randomized arm. The design of the randomized study is now complete and submitted. It will compare
carboplatin/Etoposide phosphate CIAC against oral Lomustine (CCNU) in the control arm, and will
constrain accrual at 1st relapse, as well as stratify patients against molecular status. Hopefully, this
will allow us to demonstrate the superiority of this approach, once and for all.
 
Figure 7. Example of one of our best responder: A 43-year-old female glioblastome (GBM) patient
treated with intraarterial Carboplatin/melphalan in 2008, who remains in complete response in 2017.
This patient was treated at first relapse, without using any other therapy than the Stupp regimen at
the first-line.
6.2. Future Perspectives in the Treatment of Malignant Gliomas
6.2.1. Heterogeneity of Response: The Impossibility to Predict the Best Regimen for Each Patient
Carboplatin is our drug of choice, as it appears to be the most effective, producing responses in
70% of patients for a median PFS of 5 months at relapse. However, we do have an array of agents
available for intra-arterial infusion in the clinic, and we continue to expand this list: Carboplatin,
Methotrexate, Melphalan, Etoposide phosphate, and more recently, Caelyx. These agents have all been
used safely in CIAC for brain tumor treatment by our team. Interestingly, in the case of non-response
to Carboplatin, other agents can be used in subsequent cycles of treatment for patients still presenting
an adequate functional status. In these cases, we are often confronted with extremely variable results,
with some long-term responses (up to 180 months) observed with other agents than Carboplatin,
whereas some patients show no response whatsoever to any agents. Indeed, these tumors all appear to
have their own distinctive sensitivity profile to chemotherapy agents, and we believe that they should
therefore all be approached as a singular disease entity requiring a personalized treatment. Molecular
stratification has come a long way in the management of glial tumors [32], but its role is limited in
assisting pathological stratification and prognosis. It is not yet used in treatment selection. We propose
to combine data from in vitro drug sensitivity testing (DST) and molecular characterization using “The
Cancer Genome Atlas” (TCGA) stratification, in addition to a panel of chemoresistance markers, to
select the best drug candidates prior to the initiation of CIAC. Hence, in accordance with this scheme in
a proposed clinical study at 1st relapse for GBM, all patients will be re-operated prior to the beginning
of CIAC. During surgery, a tumor sample will be obtained for the DST, molecular stratification and
chemoresistance panel markers, and the treatment will be tailored specifically to each patient.
6.2.2. Radio-Chemotherapy
Another area we have started to explore is the combination of Carboplatin with radiation
therapy [33,34]. Indeed, radiotherapy is the most effective single-treatment modality for GBM tumors,
but it controls the disease only transiently. A way to improve treatment consists of coupling radiation
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with a potent radiosensitizer. Carboplatin, a platinum (Pt) drug, is ideally suited for this. Our group
has demonstrated that the addition of Carboplatin to ionizing radiation produced significantly more
DNA strand breaks [35–39]. In numerous cell lines, combining radiotherapy and Carboplatin was
found to increase cell death. In a mouse model, we observed a maximum antitumor effect with
Carboplatin administration at 4 or 48 h prior to irradiation. This timing correlated to the highest levels
of Pt bound to DNA [35,37,39]. Concurrent Carboplatin and radiation treatment represent a common
modality for treating a variety of cancers. Unfortunately, since this class of drug does not readily cross
the BBB when administered via the standard IV routes, they are not used to treat GBM. We have just
started accrual on a new phase II study in which we administer IA Carboplatin with a re-irradiation
protocol in a dose escalation scheme. We feel that this combination has the potential to improve clinical
results. We have 6 patients (of a total of 35) recruited, and enrollment is ongoing.
6.3. Primary CNS Lymphomas
PCNSL are a rare and aggressive form of central nervous system tumors. Generally confined to
the brain, eyes and/or cerebrospinal fluid compartments, these extra nodal non-Hodgkin large B cell
lymphomas typically show no evidence of systemic diffusion [40]. PCNSL is an extremely aggressive
disease, with a median survival time of 3 months without treatment [40]. It is a fairly unusual occurrence,
accounting for 1% of cases of lymphoma, whereas it represents 4% of primary brain tumors [41,42].
A current trend in the treatment of this disease has been radiation therapy avoidance, as it was
shown to be extremely neurotoxic to patients [43]. Over the years, different protocols of IV high-dose
Methotrexate have shown encouraging results. Indeed, Da Broi et al. reported the results of 57 patients
treated over 12 years with chemotherapy [44]. Overall, they found a median OS of 35.4 months, and a
PFS of 15.7 months. Using CIAC + BBBD infusion protocol of high-dose Methotrexate (combined to
Etoposide, Cyclophosphamide and/or Procarbazine), Angelov et al. reported a median overall survival
of 3.1 years. They also reported the neuropsychological outcome profile in 26 long term survivors from
the treatment (median follow up of 12 years), showing the innocuity of this approach [45]. This good
quality data shows without a doubt that repeated CIAC + BBBD infusion protocol of high-dose
Methotrexate does not impact the neurocognitive functioning of responding patients.
Using CIAC + BBBD Carboplatin (400 mg/m2) in addition to high dose IA Methotrexate (5 g), we
treated 43 newly diagnosed PCNSL patients from 1999–2018. The median age of the cohort was 63, with
a mean age of 60 years old. The cohort was comprised of 24 males and 19 females. Overall, remission
was induced in 34 patients (79%). The overall median survival was 46.5 months for the entire cohort.
Actuarial survival was 88%, 64%, 54%, 39% and 18% at 1, 2, 3, 5 and 10 years. The progression-free
survival for the entire cohort was 43.3 months. The actuarial PFS was 83%, 59%, 56%, 30%, and 9% at 1,
2, 3, 5, and 10 years. These are amongst the best results ever published in the treatment of this disease,
without the use of radiation therapy. The detailed manuscript presenting these results is in preparation.
7. Conclusions
Intra-arterial chemotherapy is a delivery vehicle allowing the increase of available therapeutics
in the treatment of brain cancers. Its initial use many decades ago has been hampered by toxicity,
a problem which is no more of concern. Angiographic refinements, combined with intra-arerial
infusion of therapeutics carefully selected for this purpose have rendered this approach safe and
sound. The addition of an osmotic permeation of the BBB further increases delivery of therapeutics to
the CNS. We need to acknowledge the extreme heterogeneity of GBM, and eventually start tailoring
treatment to each tumor for individual patients in order to improve the modest results obtained so far.
Drug selection is at the core of this process. We also need to keep expanding the pool of agents that
can safely be administered via this route. As for the treatment of PCNSL, different refinements are
considered to keep improving outcomes in the treatment of this disease. The addition of rituximab, a
CD-20 antibody, should be considered as an adjunct to the treatment protocol. In the end, the use of
intra-arterial therapeutics infusion combined to osmotic blood-brain barrier permeation answers the
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need to adequately address an issue that is commonly underestimated: The presence of the BBB, and
the complex pharmacokinetic set of compartments it imposes on CNS delivery.
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Abstract: Phytosterols are plant sterols recommended as adjuvant therapy for hypercholesterolemia
and tocopherols are well-established anti-oxidants. However, thermo-sensitivity, lipophilicity and
formulation-dependent efficacy bring challenges in the development of functional foods, enriched
with phytosterols and tocopherols. To address this, we developed liposomes containing brassicasterol,
campesterol and β-sitosterol obtained from canola oil deodorizer distillate, along with alpha,
gamma and delta tocopherol. Three approaches; thin film hydration-homogenization, thin film
hydration-ultrasonication and Mozafari method were used for formulation. Validated liquid
chromatographic tandem mass spectrometry (LC-MS/MS) was utilized to determine the entrapment
efficiency of bioactives. Stability studies of liposomal formulations were conducted before and after
pasteurization using high temperature short time (HTST) technique for a month. Vesicle size after
homogenization and ultrasonication (<200 nm) was significantly lower than by Mozafari method
(>200 nm). However, zeta potential (−9 to −14 mV) was comparable which was adequate for colloidal
stability. Entrapment efficiencies were greater than 89% for all the phytosterols and tocopherols
formulated by all three methods. Liposomes with optimum particle size and zeta potential were
incorporated in model orange juice, showing adequate stability after pasteurization (72 ◦C for 15 s)
for a month. Liposomes containing phytosterols obtained from canola waste along with tocopherols
were developed and successfully applied as a food additive using model orange juice.
Keywords: phytosterols; tocopherols; liposomes; canola oil deodorizer distillate; model orange juice
1. Introduction
Functional foods and nutraceuticals are increasing rapidly due to growing consumer preferences
towards natural bioactives rather than synthetic drugs for disease prevention and treatment [1].
Phytosterols and tocopherols are such bioactives (plant metabolites) that have numerous health
claims [2,3]. The primary health benefit of phytosterols is to lower low-density lipoprotein (LDL)
cholesterol levels in plasma [2,4,5]. Due to this health claim, the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) has recommended phytosterols as adjuvant therapy
to statins in hypercholesterolemia [6]. Phytosterols compete with cholesterol for their solubilization
in bile salt micelles, hindering the absorption of cholesterol in blood [7,8]. Tocopherols, on the other
hand, are free radical scavengers and natural anti-oxidants [9,10]. Due to their anti-oxidant properties,
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tocopherols are used in the treatment of age related macular degeneration [11], Alzheimer’s disease [12],
glaucoma [3] and heart diseases [13].
Sources of phytosterols and tocopherols include oil seeds such as canola and sesame, as well as
nuts [14–16]. Among these, canola is a major source for edible vegetable oils, and the most abundant
oilseed crop in Canada [17]. It is a rich source of four phytosterols, namely beta-sitosterol, campesterol,
stigmasterol and brassicasterol, and four tocopherols (alpha, beta, gamma and delta) [16,18]. Canola oil
loses some of its valuable components during the refining process [16]. Significant amount of
phytosterols and tocopherols are transferred to the waste stream, termed canola oil deodorizer distillate
(CODD) [16] which offers an ideal source of these components.
However, formulation of these bioactives in functional foods has always been challenging due to
their lipophilicity and light sensitivity [19]. In particular, degradation products of phytosterols,
phytosterol oxidation products (POPs), are known to have some negative impact on human
health [20,21]. Thus, the selection of suitable formulation approach is crucial during the development
of functional food that contain these bioactives. Encapsulation techniques, such as spray drying,
fluidized bed coating, microemulsification and liposomal entrapment are emerging in the food industry
to address lipophilicity related challenges [22,23]. Unfortunately, most of these techniques have
shortcomings such as usage of high temperature (can possibly degrade phytosterols and tocopherols)
and the requirement of large quantities of emulsifiers and surfactants, which are deleterious to human
health [23–27]. All of these shortcomings can be addressed by employing liposomal formulations that
require low heat and low quantities of surfactants or emulsifiers [28].
Phytosterols in both the free and esterified forms have been used in the food industry [2,4].
Solubilization of esterified phytosterols in fat containing foods, like margarine [29,30], salad dressing [31]
and yogurt [32] is prevalent in the food industry. However, this approach is not favorable to people
who are on low fat diet [33]. To overcome this, various low fat or non-fat food matrices such as
low fat milk [34,35], granola bars [36], orange juice [37] and non-fat beverages [38–40] are emerging
as food products. However, for these type of food products, lipophilic phytosterols should be well
formulated prior to their development into functional food. In addition to the choice of the food matrix,
the biological efficacy should also be carefully considered.
Various clinical trials have shown that the efficacy of phytosterols depends on different parameters,
such as solubility in the food matrix and the formulation [2,41]. Esterified phytosterols solubilized
in fat/oil are driven favorably towards the bile salt micelles in the guts than the crystalline or the
insolubilized forms [42,43]. Phytosterols ester containing food products such as milk, spread and
yogurt have showed reduction in LDL-cholesterol by 7–12% at daily dose of 1.6–2 g relative to
control research participants [44–46]. In contrast, some failed clinical trials are also prevalent [47,48].
For example, Ottestad et al. showed that phytosterol ester in the capsular formulation revealed
no significant reduction of LDL cholesterol [47]. Similarly, Denke et al. showed no significance in
cholesterol reduction by sitostanol capsule relative to control [48]. Unlike phytosterol capsule-based
trials, lecithin-based free phytosterol formulations have shown to impart efficacy as high as 14.3% at
a daily dose of only 1.9 g relative to control [39]. In sum, literature reports show that the efficacy of
phytosterols depends greatly on the formulation approach, which provides insights regarding the
possibility of further enhancing their efficacy by well formulating in suitable delivery systems.
The work of Shin at al. [38] and Spilburg at al. [39] provides a strong evidence that lecithin
(phosphatiylcholine) can be effective carrier of phytosterols to increase cholesterol-lowering efficacy.
Both of these studies used lecithin micelles to formulate sterol/stanol which have shown promising
cholesterol-lowering efficacy [38,39]. Liposomes, which have same building blocks as micelles that
is lecithin (i.e., phosphatidylcholine) but different architecture are another formulation strategy in
which lecithin can be utilized, thus have potential of further enhancing its cholesterol-lowering efficacy.
In addition, liposomes can prevent oxidation of thermo-sensitive bioactives and are biocompatible
and biodegradable [49]. Further, co-formulation of tocopherols along with phytosterols can enhance
oxidative stability of phytosterols [50].
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Thus, in this work, with the aim of enhancing phytosterols’ oxidative stability and increasing its
efficacy, we formulated phytosterols (obtained from CODD) and commercially available tocopherols
into liposomes employing three different approaches, namely thin film hydration homogenization,
thin film hydration ultra-sonication and Mozafari method. The liposomal formulation showing
the highest entrapment efficiency, adequate size and zeta potential was incorporated into model
orange juice (acidified solution). Thus, functional orange juice containing liposomal phytosterols and
tocopherols was developed and its stability was assessed.
2. Materials
Chemicals and Reagents
Phytosterols were extracted from CODD obtained from LDM foods (Yorkton, SK, Canada). Briefly,
5 g of CODD was saponified with 1 M potassium hydroxide in 95% ethanol for 1 h at 65 ◦C after
which water was added and the mixture was chilled at 9.5 ◦C for 1 h. After the crystallization of
phytosterols, vacuum filtration was performed and the residue was washed before being dried under
high vacuum. Tocopherols, chloroform, ethyl acetate and potassium hydroxide were purchased from
Sigma Aldrich (Oakville, ON, Canada), and phosphatidylcholine (PC) was purchased from Avanti
Polar Lipids (Alabaster, AL, USA). Purified water was obtained from Millipore (Bedford, MA, USA).
3. Methods
3.1. Formulation of Liposomes
Three different formulation techniques namely thin film hydration homogenization; thin film
hydration ultrasonication and Mozafari method were used for formulation in order to evaluate the
formulation technique that can produce liposomes with optimum physicochemical properties for both
oral delivery and industrial scale up.
3.1.1. Method I. Thin Film Hydration–Homogenization
This method was adopted from Chung et al. [51] with some modifications. In brief, tocopherols
(alpha, gamma and delta tocopherol), phytosterols mixture (brassicasterol, campesterol and
beta-sitosterol) and PC were dissolved in 5 mL ethyl acetate (food grade) in 0.1:0.9:2, 0.1:0.9:3,
0.1:0.9:4 and 0.1:0.9:5 ratio of tocopherol: phytosterol: PC. Ethylacetate was evaporated using rotary
evaporator at pressure of 90 mmHg. The thin lipid film containing bioactives and PC formed on the
wall of the flask was lyophilized for 10 h to remove traces of ethylacetate and was hydrated with 20 mL
of purified water for 3 h at 55◦C with occasional vortexing in the presence of glass beads. The lipid
dispersion was homogenized using recirculating high fluid pressure homogenizer (Microfluidics
Corporation, Westwood, MA, USA) at 60 psi for 20 min. The prepared liposomes were left overnight at
4 ◦C prior to size analysis.
3.1.2. Method II: Thin Film Hydration Ultrasonication
This method was adopted from Akbarzadeh et al. [52]. Similar to thin film hydration
homogenization; tocopherols (alpha, gamma and delta tocopherol), phytosterols mixture (brassicasterol,
campesterol and beta-sitosterol) were dissolved, along with PC in 5 mL ethyl acetate, in 0.1:0.9:2 ratio
of tocopherols: phytosterols: PC. Ethylacetate was evaporated using rotary evaporator at pressure
of 90 mmHg. Thin lipid film containing bioactives and PC was formed at the bottom of the flask.
Lipid film was lyophilized for 10 h to remove traces of ethylacetate and was hydrated with 20 mL of
purified water maintained at 55◦C. Lipid dispersion was ultrasonicated using bath sonicator (ELMA
Corp.,Singen, Germany) for 30 min maintained at 55 ◦C then was allowed to cool at room temperature.
The prepared liposomes were left overnight at 4 ◦C prior to size analysis.
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3.1.3. Method III: Mozafari Method
This method was adopted from Colas et al. [53]. 50 mg of PC was hydrated with 20 mL of purified
water for 1 h and was heated to 55 ◦C. Nine mg of the phytosterol mixture and 1 mg of the tocopherol
mixture were heated with 3% v/v glycerol at 110 ◦C and 55 ◦C temperature, respectively for 15 min
on a hot plate stirrer at approximately 1000 RPM (Corning Corporation, Midland, ON, Canada) and
then was cooled down to 55 ◦C. PC dispersion, phytosterols and tocopherols were mixed together
with stirring on a hot plate for 30 min at approximately 1000 RPM. The formed liposomes were cooled
down to room temperature and kept overnight at 4 ◦C prior to size analysis.
3.2. Characterization of Particle Size, Size Distribution and Zeta Potential
Particle size and zeta potential measurement of the liposomes were performed using Zeta sizer,
Nano ZS instrument, Malvern instruments Ltd. (Worcestershire, England). All measurements were
conducted in triplicates at 25 ◦C and reported as mean ± SD.
3.3. Transmission Electron Microscopy (TEM) Analysis
TEM analysis was performed by negative staining. Briefly, a drop of liposomal sample was placed
on copper- formvar coated TEM grid and was allowed to settle on grid surface for 1 min. Excess of the
liquid was removed using absorbent tissue. Staining of grid was done using 0.5% phosphotungstic
acid for 30 s and excess of stain is removed. Imaging was done using aHT 7700 TEM (Hitachi, Japan)
at 80 kV.
3.4. LC-MS/MS Method Development and Validation
LC-MS/MS method was developed and was validated as per International Council for
Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidance
for bioanalytical method validation guideline [54]. Briefly, chromatographic separation of the analytes
was carried out on an Agilent Acquity UPLC (Agilent Technologies, Mississauga, ON, Canada) with an
Agilent Poroshell C18 column (2.1 mm× 150 mm, 5μm) protected by a guard column (2.1 mm × 4.7 mm,
2.7 μm) of the same packing material. The column temperature was set at 30 ◦C and the injection
volume was 2.5 μL. An isocratic elution consisting of acetonitrile: methanol (99:1 v/v) with 0.1% acetic
acid was used at a flow rate of 0.8 mL/min. The detection and quantification were performed using
an API 6500 QTRAP® quadruple-linear ion trap (QqQ-LIT) mass spectrometer equipped with an
atmospheric pressure chemical ionization (APCI) source obtained from AB Sciex(Mississauga, ON,
Canada). The instrument was operated in the positive ion mode and tandem mass spectrometric
analysis (MS/MS) was employed using the following interface parameters: source temperature 380 ◦C,
curtain gas 30 psi (gas), nebulizer current 2.5 μA, declustering potential 30 V and an ion source gas1
30 psi (gas) [55].
The parameters, selectivity, accuracy, precision, reproducibility, sensitivity, matrix effects, dilution
integrity, stability were assessed [55]
3.5. Entrapment Efficiency (EE)
In order to determine entrapment efficiency, free and entrapped bioactives were separated using
ultracentrifugation. Ultracentrifuge (Beckman coulter, Inc., Indianapolis, IN, USA) with rotor SW 60Ti
was used for ultracentrifugation. Briefly, 5 mL of liposomes was ultracentrifuged at 30, 60, 90 and 120 min
at constant RPM 32,000 (G-force of 138000). The sediment at each time were analyzed using a validated
LC-MS/MS method to optimize ultracentrifugation parameters. The liposomes (present in sediment)
separated by ultracentrifugation were lyophilized using freeze dryer for 24 h. Similar lyophilization
process was employed with 5 mL of unseparated liposomes for 24 h. Dried unseparated and separated
liposomes were dissolved in 2 mL of chloroform separately. Aliquot of each were spiked with internal
standard and diluted with acetonitrile. Samples were injected in LC-MS along with freshly prepared
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calibration and quality control standards, as described [55]. The entrapment efficiency was calculated
by measuring the ratio of entrapped bioactives in the formulation to the total bioactives present in the





where, E bioactives = Entrapped bioactives in liposomes (present in sediment of separated liposomes);
T bioactives = Total bioactives in liposomes (present in unseparated liposomes).
3.6. Development of Functional Juice Using Model Orange Juice
In order to preserve particle size during freeze drying, sucrose was added to liposomes as a
cryoprotectant by adopting the procedure of Shaikh et al. [56]. Briefly, 5% w/v of sucrose was added to
liposomes of well-defined size and was vortexed. Lyophilization then was employed for 24 h.
Freeze dried liposomes were re-suspended in model orange juice which is an orange juice mimic
at 3.2 pH. A mimic was used instead of real orange juice to enable particle size analysis without the
interference of particulate components existing in the orange juice. In fact, the acidified solution is
considered a model juice and was prepared by using acetic acid as per the protocol of Marsansco
et al. [57]. This protocol can be applied for fruit juice with a pH less than 5.0, such as orange juice
and pineapple juice. Finally, liposomes with optimum entrapment efficiency in a dried form were
incorporated into the model orange juice by vortexing for 5 min.
3.7. Pasteurization
High temperature short time (HTST) pasteurization technique was employed as described [58].
HTST is a commonly used strategy for the pasteurization of juice [59]. The liposomes containing model
orange juice was pasteurized at 72 ◦C for 15 s. Unpasteurized formulation was used as a control.
Both pasteurized and unpasteurized model juice were stored at 4 ◦C for stability evaluation.
3.8. Chemical Stability Studies
Both pasteurized and non-pasteurized model juice containing liposomal bioactives were analyzed
using LC-MS/MS to assess the degradation of bioactive upon exposure to pasteurization temperature.
Briefly, 5 mL each of pasteurized and non-pasteurized liposomal model juice were lyophilized.
Dried sample were dissolved in chloroform and were diluted with acetonitrile for LC-MS/MS analysis.
The LC-MS/MS response was compared to obtain relative quantification data.
3.9. Physical Stability Studies
Physical stability evaluation was conducted at the interval of 7 days for a month. Particle size of
pasteurized and non-pasteurized liposomes incorporated both in model orange juice were analyzed.
4. Statistical Analysis
The statistical analysis of the samples was conducted with SPSS statistical software version 24
(SPSS Inc., Chicago, IL, USA) using student t-test, and p-values < 0.05 were considered statistically
significant. All data are reported as means ± standard deviations.
5. Results and Discussions
5.1. Physicochemical Characterization
Size is an important parameter to assess the stability, the biological fate and the efficacy of
formulated bioactives [60,61]. Optimization of bioactive to lipid weight ratio (B/L ratio) was performed
at ratio of 1:5, 1:4. 1:3, 1:2, 1:1 using liposomes prepared by thin film hydration- homogenization
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approach. An increase in particle size was observed at high B/L ratio (1:1) as shown in Figure 1.
At 1:5 B/L ratio, the particle size was 149.53 nm; however, when B/L ratio increased to 1:1, the particle size
increased to 258.31 nm (Figure 1). This observation is reported previously [62,63], in which incremental
vesicle size was observed when increasing the cholesterol (a sterol) concentration. While 1:1 ratio is
preferable from a commercial point of view (less PC required for formulation), smaller particle size
(less than 200 nm) attained at 1:2 ratio, is optimum for liposomal stability. This optimum vesicle size
(less than 200 nm) is consistent with several food-based liposomes [64–66]. Thus, 1:2 B/L ratio was
selected for follow-up experiments. Same optimum B/L ratio was selected for thin-layer ultrasonication
approach. However, in case of the Mozafari method, B/L higher than 1:5 led to the appearance of
visible white precipitate. Loading techniques along with the preparation procedures are found to
influence drug/lipid ratio of liposomes [67]. In both thin film hydration homogenization and thin
film hydration ultrasonication, hydrated bioactives-PC film is subjected to cavitation and shearing
forces unlike the Mozafari method where less intense magnetic stirring is used during the loading
process. This might have led to differences in the B/L ratio of the mozafari method in comparison with
ultrasonication and homogenization methods. In this way, 1:5 B/L as optimum ratio was selected for
formulations prepared by the Mozafari method.
 
Figure 1. Particle size of liposomes prepared at different B/L ratio by homogenization method expressed
as mean ± standard deviation.
The comparison of the vesicle size using the different formulation strategies is presented in Table 1.
Thin film hydration homogenization and thin film hydration ultrasonication were comparable, showing
sizes at 186.33 ± 4.38 nm and 196.2 ± 16.1 nm, respectively. On the other hand, the size was significantly
larger in the case of the Mozafari method (260 ± 22.98 nm). It is possible that the high shear force
and cavitation involved in size reduction during the homogenization and ultrasonication methods is
the reason for the obtained smaller vesicles [68]. The Mozafari method uses a less intense magnetic
stirring [69], probably yielding larger particles. Polydispersibility index (PDI) shown in Table 1 was
found to be in the range from 0.29 to 0.37, which shows the desirable narrow size distribution for
all formulations.
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Table 1. Average particle size (nm), polydispersibility index and zeta potential (mv) of
liposomes prepared by thin film hydration homogenization, thin film hydration ultrasonication
and Mozafari method expressed as mean ± standard deviation where * represents statistical significant
(*p < 0.05) in average particle size of Mozafari method in comparison with homogenization and
ultrasonication method.
Formulation Techniques Average Particle Size (nm) Polydispersibility Index (PDI) Zeta Potential (mV)
Thin film hydration
Homogenization 186.3 ± 4.4 0.370 ± 0.001 −13.0 ± 5.0
Thin film hydration
ultra-sonication 196.2 ± 16.1 0.294 ± 0.084 −14.0 ± 3.4
Mozafari method 260.0 ± 23.0* 0.348 ± 0.087 −9.8 ± 0.3
Zeta potential (surface charge) is another important parameter that determines the stability of
liposomal dispersions [70]. All the liposomes, demonstrated similar zeta potential values (Table 1),
that is in the range of -9 mV to -14 mV, indicating relatively stable systems [71]. Thus, based on
particle size and zeta potential, the developed liposomal formulations are theoretically stable that was
confirmed experimentally by conducting the stability studies.
Finally, TEM analysis of liposomes shows spherical shaped particles with a single lipid bilayer
(Figure 2), representing the expected morphology of unilamellar liposomal vesicles (ULV) [72,73].
The size of approximately 200 nm is consistent with the size range measured by dynamic light scattering
(DLS) (Table 1). Some aggregated particles were observed in ultra-sonication and Mozafari method as
shown in Figure 2.
5.2. Entrapment Efficiency (%EE)
The developed LC-MS/MS method (representative chromatogram shown in Figure 3) was able to
separate and quantify four phytosterols (brassicasterol, campesterol, stigmasterol and β-sitosterol)
and three tocopherols (alpha, gamma and delta). Both ultracentrifugation parameters and entrapment
efficiencies were determined by analyzing bioactive using LC-MS/MS. The separation of the liposomes
during ultracentrifugation was time-dependent. Relatively low amounts of liposomes sedimented after
30 min (around 80% for all bioactives) of ultracentrifugation, whereas high sedimentation of liposomes
was observed at 60, 90 and 120 min. There was no significant difference in sedimentation at 60, 90 and
120 min of ultracentrifugation. This supports the notion that after 60 min of ultracentrifugation at RPM
32,000 (G-force of 138000), a significant amount of liposomes was sedimented, leaving free bioactives
in the supernatant.
The optimum entrapment efficiencies of phytosterols and tocopherols into the liposomes obtained
by the thin film hydration homogenization, thin film hydration ultra-sonication and Mozafari method is
shown in Table 2. The results demonstrate that all three methods resulted in entrapment efficiency> 89%
for phytosterols and tocopherols. Table 2 does not show any specific pattern in entrapment efficiency
for bioactives. For example, in case of thin film hydration homogenization method, brassicasterol
showed the highest entrapment efficiency among all phytosterols; however, in the case of the Mozafari
method, brassicasterol has the lowest entrapment efficiency. Similarly, the Mozafari method showed
the highest entrapment efficiency for gamma tocopherols among all tocopherols. On the other hand,
thin film hydration ultrasonication showed the lowest entrapment efficiency for gamma tocopherol.
Thus, no concrete conclusion was obtained regarding entrapment differences between these bioactives.
The entrapment efficiency of some of lipophilic compounds were reported to be almost close to
100% [74,75]. However, Table 2 shows EE in the range of 89–97% for various bioactives, evaluated
in our work. It is possible that some of the liposomes were too small and failed to sediment during
ultracentrifugation. This will lead to decreased EE (the amount of bioactives in the sediment were
taken as a basis to calculate EE). Nevertheless, the obtained EE (shown in Table 2) is consistent with
entrapment efficiency of nutraceuticals such as vitamin E, resveratrol and retinol specified in the
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literature [57,65,76]. High entrapment efficiency, that is, greater than 85% is considered economical for
industrial application because it eliminates the cost of separating free and entrapped bioactives that
will be required in case of low entrapment efficiency.
Figure 2. Transmission electron microscopy (TEM) analysis of liposomes prepared by;
(A) homogenization method, (B) Ultrasonication and (C) Mozafari method. Sample of unilamellar
vesicles are shown with a dotted arrow while aggregates are indicated by solid arrows. Scale bar in the
figure A, B and C indicates 200nm, which represents the size of vesicle.
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Figure 3. LC-MS/MS chromatogram of tocopherols: 1-δ tocopherol, 2-γ tocopherol, 3-α tocopherol;
and phytosterols: 4-brassicasterol, 5-campesterol, 6-stigmasterol and 7-β-sitosterol. A-Rac tocol and
B-cholestanol are internal standard.
Table 2. Entrapment efficiency of bioactives (phytosterols and tocopherols) into liposomes prepared by
the thin film hydration homogenization, thin film hydration ultra-sonication and Mozafari method
expressed as mean ± standard deviation.
Methods








Thin film hydration-Homogenization 95.9 ± 1.7 94.0 ± 2.2 94.8 ± 3.0 91.6 ± 2.4 90.5 ± 2.9 91.6 ± 3.6
Thin film hydration-Ultrasonication 91.5 ± 2.4 92.3 ± 3.4 90.1 ± 1.9 91.2 ± 2.1 89.8 ± 3.1 90.1 ± 2.3
Mozafari method 89.4 ± 2.8 93.7 ± 6.0 93.1 ± 6.0 92.3 ± 7.5 97.4 ± 1.9 95.3 ± 1.4
5.3. Effect of Lyophilization on the Physicochemical Properties
Freeze-drying of liposomes resulted in the increment in particle size, reaching up to 500 nm
(Figure 4). Various food compatible cryoprotectants such as sucrose, mannitol and lactose can be
used to address this issue [77]. Thus, food compatible sucrose was tested as a cryoprotectant [56].
The addition of sucrose maintained the desired particle size (Figure 4). The lyophilized liposomes
were then incorporated into model orange juice. Lyophilization is one of the crucial steps used for
stabilization of liposomes [78]. It extends the shelf life of liposomes and can prevent thermosensitive
bioactives from degradation [78].
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Figure 4. Effect of addition of sucrose as a cryo-protectant on particle size of liposomes before and after
lyophilization expressed as mean± standard deviation where * represents statistical significant (*p< 0.05)
in particle size after lyophilization in comparison to before lyophilization and after lyophilization in
presence of sucrose.
5.4. Chemical Stability Studies
Pasteurization technique did not compromise the stability of bioactives as shown in Table 3.
There was no significant change in the LC-MS/MS response for pasteurized and non-pasteurized
formulations, ranging from 0.5 to 2.59% (Table 3). This shows that exposure to temperature of 72 ◦C
for short time of 15 s does not degrade bioactives entrapped within liposomes in the model juice
Table 3. Relative change in the concentration (represented by area under curve, AUC) of phytosterols






Percentage Relative Change in AUC (%)
of Pasteurized and Non-Pasteurized
Brassicasterol 5.63 × 106 5.60 × 106 0.53
Campesterol 2.32 × 107 2.26 × 107 2.59
β-sitosterol 3.40 × 106 3.37 × 106 0.88
α-tocopherol 2.76 × 107 2.72 × 107 1.45
γ-tocopherol 4.94 × 106 4.89 × 106 1.01
δ-tocopherol 4.84 × 106 4.73 × 106 2.27
5.5. Physical Stability Studies
Both pasteurized and non-pasteurized liposomes in model orange juice showed similar trend in
particle size (Figure 5). This implies that high temperature in HTST pasteurization process did not
compromise the stability of the liposomes. Further, particle size of vesicle did not change significantly
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during the one-month storage at 4 ◦C (Figure 5). This shows that liposomal orange juice can be stored
in 4 ◦C for a month with adequate stability. Regarding zeta potential, unlike liposomes in purified
water, liposomal model juice was found to have positive zeta potential in the range of 5.6–8.9 mV.
Even though this zeta potential value is generally considered an indicator of instability to the colloidal
system [71], liposomal model orange juice showed adequate storage stability. Probably, the optimized
smaller vesicular size maintained the stability of particles preventing its aggregation.
 
Figure 5. Particle size of pasteurized and non-pasteurized liposomes incorporated in model orange
juice during storage period of 1 month at 4 ◦C expressed as mean ± standard deviation.
6. Conclusions
To address the lipophilicity, heat and light sensitivity challenges, unilamellar liposomes containing
phytosterols obtained from CODD and tocopherols were formulated and were applied to develop
a functional juice. Three different formulation approaches were employed and were compared for
their suitability in formulating phytosterols and tocopherols. All three methods showed optimum
physicochemical properties and excellent entrapment efficiencies that were greater than 89%. Mozafari
method was found to be simple and quick for formulating liposomes; however, the use of high
temperature can possibly degrade thermosensitive bioactives. In addition, its low B/L ratio (not
economical for scaling up) makes the Mozafari method less suitable method for phytosterols
and tocopherols in comparison to thin film hydration ultrasonication and thin film hydration
homogenization method. Both ultrasonication and homogenization seemed to be equally suitable
at a laboratory scale. At an industrial scale, however, the homogenization method is more feasible
due to the availability of homogenizers of large capacity. Thus, thin film hydration-homogenization
seems to be the best method for scaling-up the liposomal formulation containing phytosterols and
tocopherols. The pasteurization technique did not affect the chemical stability of tested bioactives.
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Moreover, model orange juice containing liposomes maintained an adequate physical stability during
a period of one-month storage at 4 ◦C. In the future, liposomes containing phytosterols will be tested
for cholesterol-lowering efficacy by conducting animal and human trials.
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Abbreviations
LDL Low-density lipoprotein
CODD Canola oil deodorizer distillate
POPs Phytosterol oxidation products
LC-MS/MS Liquid Chromatography Tandem Mass Spectrometry
PC Phosphatidylcholine
TEM Transmission electron Microscopy
HTST High temperature short time
B/L Bioactive/lipid
RPM Revolution per minute
%EE percentage entrapment efficiency
DLS Dynamic light scattering
PDI Polydispersibility Index
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Abstract: Phyto-phospholipid complexes have been developed as a common way of improving the
oral bioavailability of poorly absorbable phyto-pharmaceuticals; however, the complexation with
phospholipids can induce positive or negative effects on the bioaccessibility of such plant-derived
active ingredients in different parts of the gastrointestinal tract (GIT). The purpose of this study
was to investigate the effects of phospholipid complexation on the bioaccessibility of a rosmarinic
acid-phospholipid complex (RA-PLC) using the TNO dynamic intestinal model-1 (TIM-1). Preparation
of RA-PLC was confirmed using X-ray diffraction, Fourier-transform infrared spectroscopy, partition
coefficient measurement, and Caco-2 monolayer permeation test. Bioaccessibility parameters
in different GIT compartments were investigated. Complexation by phospholipids reduced the
bioaccessibility of RA in jejunum compartment, while maintaining the ileum bioaccessibility.
The overall bioaccessibility of RA-PLC was lower than the unformulated drug, suggesting that
the improved oral absorption from a previous animal study could be considered as a net result
of decreased bioaccessibility overwhelmed by enhanced intestinal permeability. This study
provides insights into the effects of phospholipid on the bioaccessibility of hydrophilic compounds,
and analyzes them based on the relationship between bioaccessibility, membrane permeability,
and bioavailability. Additionally, TIM-1 shows promise in the evaluation of dosage forms containing
materials with complicated effects on bioaccessibility.
Keywords: phospholipid complex; rosmarinic acid; bioaccessibility; dissolution; TNO gastrointestinal
model; gastrointestinal simulator
1. Introduction
The use of phospholipid complexation has been commonplace in food and pharmaceutical
sciences since its first development in 1989, promising much in the delivery of poorly absorbed
plant actives and some synthetic compounds, with less complicated preparation methods compared
with many other formulations [1–6]. Many poorly soluble or permeable compounds have been
formulated to be more effective, systemically, by complexing with dietary phospholipids through
various types of interactions (i.e., hydrogen bonding, van der Waals forces, the hydrophobic effect) [7,8].
Of late, burgeoning interest in this technique arose due to its multi-ability to enhance dissolution of
hydrophobic compounds, improve permeability of hydrophilic compounds, reduce gastrointestinal
toxicity of non-steroidal anti-inflammatory drugs, and protect unstable phyto-pharmaceuticals [9–12].
These properties are mainly attributed to the amphiphilic and biocompatible nature of phospholipids,
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which possess a polar and a non-polar moiety in their structures and have considerable dispersing
ability in both aqueous and oil media. Phospholipids, especially those containing phosphatidylcholine,
have shown the ability to incorporate into cell membranes to replace cellular phospholipids and affect
membrane fluidity, facilitating the absorption of co-administrated payloads [13–16].
The rosmarinic acid-phospholipid complex (RA-PLC) described in this work is a PLC formulation
designed to enhance the oral bioavailability and certain therapeutic activities by improving the
intestinal permeability of hydrophilic RA [10,17]. The complexation reduces the contact between
RA and gastrointestinal fluids, increasing the possibility for these hydrophilic compounds to
simultaneously cross the membrane barrier through the uptake of phospholipids by intestinal
membrane. In a recent study, the permeability coefficient and bioavailability of RA-PLC in rats
were determined to be 3.15-fold and 1.25-fold higher than unformulated RA [10].
Systemically viewing the intestinal absorption, bioaccessibility is an important factor apart
from membrane permeability. A prerequisite for oral bioavailability is bioaccessibility, defined
as the amount of a given compound in a form that can be readily absorbed in gastrointestinal
tract (GIT) [18–20]. Phospholipid complexation exhibits two opposing effects on the bioaccessibility
according to many studies. On the one side, when RA, or similar poorly absorbable compounds,
are complexed with phospholipid, it has been observed that the aqueous solubility and dissolution rate
were reduced in both acid media and alkaline phosphate buffer, although the amphiphilic structure
of phospholipid was expected to enhance the dissolution [21–23]. Resulting from the low gel to
liquid crystal transition temperature (Tm), unsaturated phospholipids are difficult to formulate as fine
powders under room temperature as the low Tm values and amorphous nature lead to sticky powders
that are difficult to deaggregate [24–26]. Due to the cohesive or agglomerated state of phospholipids,
the wetting of these drug-phospholipid complexes can be compromised by the decrease in effective
surface area contacting digestion fluids. The poor dispersibility retards the release of payloads into
aqueous fluids, thus decreasing the drug amount to be readily bioaccessible. PLC may also positively
influence the bioaccessibility of RA through a protective effect in GIT. Many studies have described
significant content loss of plant-derived active ingredients under gastrointestinal conditions due
to instability [27–30]. RA has been reported to undergo a 0–25% intestinal degradation due to its
instability in an alkaline environment [31,32]. Through complexation with phospholipids, unstable
active ingredients may become less exposed to digestion fluid due to the described poor dispersibility
of the phospholipids, which may lead to a decrease in degradation rate [2,33]. Herein, based on
the described opposing effects, attention needs to be paid to the uncertainty in the net effect of
phospholipid complexation on RA bioaccessibility. Without such data, it would be difficult to explain
whether the improved oral absorption of RA is accredited to the sum effect of increased bioaccessibility
plus membrane permeability, or the improved permeability overwhelming decreased bioaccessibility.
Therefore, there is demand for a systemic evaluation method on the bioaccessibility of PLC dosage
forms in order to assess the net effect of phospholipid. Better understanding on the mechanism of
oral absorption is expected to be provided by the analysis of bioaccessibility parameters in different
compartments of a dynamic GIT, and in turn guide the formulation process.
The TNO intestinal model (TIM-1) is a dynamic, multi-compartmental digestion system
simulating physiological processes in the human upper GIT through the use of biorelevant media
and computer-controlled hydrodynamics [34–36]. The physical and biochemical parameters used
in the TIM-1 were determined on the basis of extensive in vivo data from both human and animal
trials. This system has been widely used in the following aspects: To assess the bioaccessibility
of natural extracts and nutritional products, to test the bioequivalence of a variety of drug
formulations, to evaluate the gastrointestinal stability of phytochemicals, and to predict the drug–food
interactions under different conditions including human fasting and fed states [37–41]. The validation
of experimental parameters used for TIM-1 can be found in previous literature and the latest
research [37,41–43]. To date, no attempt in the literature is traceable to have used the TIM-1 in
the bioaccessibility assessment of PLC formulations, and so in this study, TIM-1 was employed to test
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the bioaccessibility parameters of RA-PLC and investigate the opposing effects of phospholipid in
different GIT environments within a single continuous process. We intended to provide insights into
the bioaccessibility change by breaking up the digestion process into individual steps and analyzing
the interplay between them. This study also demonstrates a broader application of the TIM-1 system
in the assessment of PLC formulations and other phospholipid-based dosage forms loaded with
hydrophilic active compounds.
2. Materials and Methods
2.1. Materials
RA (96%, 536954), phospholipid (P3644), 2,2-diphenyl-1-picrylhydrazyl (DPPH, D9132),
and (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox, 238813) were purchased
from Sigma-Aldrich (Oakville, ON, Canada). The phospholipid used in this study contains 55%
phosphatidylcholine, 25% phosphatidylethanolamine, and other phospholipids, giving an average
molecular weight of 776 g/mol according to the product information sheet. Trace components in the
phospholipid including triglycerides and cholesterol are not routinely quantified. ReagentPlus® grade
(99.5%) 1-octanol, dimethyl sulfoxide (DMSO), high-performance liquid chromatography (HPLC)
grade methanol, and trichloromethane were purchased from Sigma-Aldrich (Oakville, ON, Canada).
Cell culture reagents and other chemicals were supplied by Fisher Scientific (Hampton, NH, USA) and
used as received. Reagents and enzymes used in the TIM-1 system including lipase, pepsin, amylase,
pancreatin, trypsin, hydroxypropylmethylcellulose (HPMC), bile salts, sodium chloride, potassium
chloride, calcium chloride di-hydrate, sodium bicarbonate, and hydrochloric acid were purchased
from Sigma-Aldrich (Oakville, ON, Canada). Fresh porcine bile was obtained from Conestoga Meats in
Breslau, ON. Water used in this study was obtained from a Millipore Milli-Q system (MilliporeSigma,
Burlington, MA, USA). The chemical structures of phospholipid and rosmarinic acid are shown in
Figure 1.
 
Figure 1. Chemical structures of phospholipid and rosmarinic acid.
2.2. Preparation of the RA-PLC and Physical Mixture of RA and Phospholipid
RA-PLC were prepared by the solvent evaporation method. Unformulated RA and phospholipid
with a molar ratio of 1:1.5 were fully dissolved (visually inspected, sonication was used as needed) in
anhydrous methanol to give a final solution with a concentration of 2.5 mg RA/mL. The methanol was
removed by rotary evaporation at 45 ◦C. The resulting mixture was solubilized with trichloromethane
to obtain a solution of RA-PLC, after which the solution was centrifuged at 5000 rpm for 10 min to
remove free RA. The collected supernatant was dried under reduced pressure at room temperature for
24 h to remove the residual solvent. The physical mixture (PM) of RA and phospholipid was prepared
by mixing two components at the above molar ratio in a glass mortar.
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2.3. Content Determination of RA in RA-PLC
Standard solutions of RA in methanol were prepared and determined spectrophotometrically
on a plate reader (SpectraMax M5, Molecular Devices, LLC., San Jose, CA, USA) at 330 nm to give
a linear Beer–Lambert calibration curve (0–15 mg/L, r2 = 0.998). A total of 15 mg RA-PLC was fully
dissolved in 10 mL methanol and analyzed. The measurements were run in triplicate and the average
concentration with standard deviation is reported.
2.4. Powder X-ray Diffraction (PXRD)
To confirm the complexation between RA and phospholipid, the physical state of RA, phospholipid,
RA-PLC, and PM were analyzed on a MiniFlex X-ray diffractometer (Rigaku Corporation, Tokyo, Japan).
Diffractograms were recorded over a 2θ angle from 5◦ to 40◦ at a scanning rate of 2◦ per minute and
a 0.02◦ step size.
2.5. Fourier-Transform Infrared (IR) Spectroscopy
IR spectra of RA-PLC, unformulated RA, phospholipid, and physical mixture (PM) were recorded
in transmission mode using a Perkin-Elmer RX I infrared spectrometer (Perkin-Elmer Inc, Waltham,
MA, USA) equipped with diamond ATR attachment, to further validate the formation of RA-PLC.
Samples were pressed into thin films without diluent and analyzed within a scan range of 4000 to
450 cm−1 with a resolution of 1 cm−1.
2.6. n-Octanol/Water Partition Coefficient (P) Determination
P values of RA-PLC and unformulated RA were determined by the shake flask method at room
temperature, to compare the lipophilicity of different samples. Different media including Milli-Q
water, hydrochloric acid solution (HCl, pH 1.2), and phosphate buffer solution (PBS, pH 6.8) were
pre-saturated with 1-octanol before tests. Different samples equivalent to 5 mg of RA were added to
sealed glass containers containing 10 mL of testing medium and stirred on a hotplate at 150 rpm for
24 h. All samples were centrifuged to obtain an aqueous phase. Afterwards, 5 mL of these aqueous
samples were added to 5 mL of 1-octanol (pre-saturated with corresponding aqueous media) and
stirred at 150 rpm for another 24 h. The liquid mixtures were left to separate for 24 h to obtain
aqueous and organic phases. The RA concentration in aqueous phase of each step was determined
spectrophotometrically at 330 nm. All measurements were run in triplicate.





where C1 represents the RA concentration in the aqueous phase in the first step, and C2 represents the
RA concentration in the aqueous phase after water-octanol phase separation.
2.7. Radical Scavenging Activity Assay
The antioxidant activities of RA and RA-PLC were assessed using an in vitro chemical model
system, DPPH, to test the possible change in the bioactivity of RA induced by the co-administration
of phospholipid. The antiradical activity was determined spectrophotometrically as described
previously [44]. DPPH working solution (350 μM) and Trolox standard solutions (1000, 750, 500,
250, 125, and 62.5 μM) were prepared by dissolving the required amounts of each in anhydrous
methanol. Samples equivalent to 5 mg of RA were dissolved in 5 mL of methanol, and 25 μL of this
sample solution was mixed with 200 μL of DPPH working solution in a 96-well plate, after which
the plate was sealed, and the mixture was allowed to incubate for 6 h at room temperature. Finally,
the absorbance was recorded at 517 nm.
89
Pharmaceutics 2019, 11, 156
The percentage DPPH quenched (%) was determined as following:
DPPH quenched (%) =
[




where Asample, Ablank, and Acontrol refer to absorbance values of the sample, methanol, and DPPH
methanol solution at 517 nm. DPPH quenched (%) was plotted against the concentrations of Trolox,
and the antioxidant capacity of samples were calculated based on the linear calibration curve.
The antioxidant activity was expressed as mM Trolox equivalent (TE) per mM RA.
2.8. Cell Culture
The Caco-2 human intestine cell line obtained from Sigma Aldrich Canada was cultured in
high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum and 1% penicillin–streptomycin. The cells were incubated under a 5% CO2 atmosphere at
37 ◦C and spent media was replaced every 2 days. After reaching 80–90% confluency in a T-75 culture
flask, cells were harvested with 0.25% trypsin–ethylenediaminetetraacetic acid (EDTA) solution and
sub-cultured to proper culture plates depending on the experiments to be conducted.
2.9. Cell Viability Assay
The cytotoxic effects of unformulated RA and RA-PLC on Caco-2 cells were determined using
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. RA and RA-PLC were
dissolved or dispersed in DMEM and then diluted to different concentrations. Caco-2 cells were
sub-cultured in a 96-well plate at a density of 1.0 × 105 cells/cm2 and allowed to attach. The cells were
incubated with sample solutions at RA concentrations of 10, 20, and 50 μg/mL for 4 h, and then the
samples were removed and the cells were rinsed with Hank’s balanced salt solution (HBSS). The cells
were treated with MTT (0.5 mg/mL) for 4 h under 5% CO2 at 37 °C, after which the medium was
aspirated and 100 μL of DMSO was added to each well to dissolve formazan crystals. The plate was
shaken for 5 min and the absorbance was recorded at 570 nm with untreated cells as control. The cell
viability (%) was calculated as following:
Cell viability (%) =
Asample − Ablank
Acontrol − Ablank × 100,
where Asample, Ablank, and Acontrol refer to absorbance values of sample, blank media, and untreated
cells, respectively.
2.10. Caco-2 Cell Transport Assay
Caco-2 cells were cultured and harvested as described in Section 2.9, followed by seeding in
trans-well inserts (Corning Costar Corporation, Tewksbury, MA, USA) in a 6-well plate with a density
of 1.0 × 105 cells per cm2. The media in both upper and lower compartments were replaced every
other day and the cells were cultivated over 21 days to achieve a confluent monolayer. RA and RA-PLC
were dissolved or dispersed in HBSS buffer to a concentration of 50 μg/mL and applied onto either
the apical (AP) side or basolateral (BL) side in an atmosphere of 5% CO2 at 37 °C, while the recipient
compartments were filled with 1 mL blank HBSS. Recipient samples were withdrawn from BL side
in AP-BL test, and AP side in BL-AP test at 1, 2, 3, and 4 h after sample treatment, and then a same
amount of blank solution was supplied to recipient compartment. RA concentrations of all samples
were determined spectrophotometrically on a plate reader at 330 nm based on a linear Beer–Lambert
calibration curve with HBSS as blank control. All experiments were run in triplicate. The apparent
permeability coefficient (Papp) was calculated as following:
Papp =
dQ/dt
A × C0 ,
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where dQ/dt (μg/s) is the rate of permeation of RA across the monolayer as described by the linear
appearance rate of RA in the recipient compartment, A is the surface area of cell monolayer (4.2 cm2 in
this study), and C0 is the initial RA concentration (49.10 μg/mL) in the donor compartment.
The net efflux ratio was calculated following the equation below:
Efflux ratio =
Papp(BL − AP)
Papp(AP − BL) ,
where Papp (BL-AP) is the Papp value from basolateral side to apical side, and Papp (AP-BL) is the Papp
value from apical side to basolateral side.
2.11. TIM-1 Study
The TNO gastrointestinal model (TIM-1) method has been described in detail [45]. Briefly,
the model consists of four compartments that model the stomach, duodenum, jejunum, and ileum,
with a fluid volume of 250 mL, 55 mL, 115 mL, and 115 mL, respectively. Each compartment has an inner
silicon tubing surrounded by water and encased in a glass exterior. Peristaltic valves determine the
transport rate of the digestate between the different compartments. Peristaltic movement is simulated
by the squeezing action of the silicon tubes as dictated by the pumping of the surrounding water.
The water is set at 37 ◦C to ensure that all compartments are kept at a physiological temperature.
The rate of secretion of digestive juices in each compartment is set in accordance to predetermined
physiological data [45]. The pH of the stomach was pre-set in system protocol as follows: 3.0 at 0 min,
2.2 at 10 min, 1.8 at 30 min, and 1.7 from 60min. The pH of duodenum, jejunum, and ileum were kept
at 6.3, 6.5, and 7.4, respectively. All parameters are computer-controlled and a protocol for fasted state
digestion of a water-soluble compound was selected for this experiment. Transit of the test formulation
between compartments is automatically controlled by system sensors that detect the volume of fluids
entering the compartments, as well as their solution properties (i.e., viscosity). The residual volume
for the stomach compartment was set at 40 mL. For simulation of absorption of potentially available
RA, the jejunal and ileal compartments are connected to semi-permeable hollow fiber membrane units
(hemodialyzer cut-off of 3–5 kD). Samples equivalent to 20 mg RA were added to 240 mL of water in
the stomach compartment containing 10 mL of a gastric enzyme and HPMC/bile mixture solution
at pH 2. Gastric enzyme solution consists of 6000 U lipase, 1,440,000 U pepsin and 42,000 U amylase.
Each experiment was terminated after 300 min. Jejunal and ileal dialyzable fractions along with the
ileal efflux were collected at 15 min intervals for the first hour, at 30 min intervals in the following
hour, and at 1 h intervals for the remainder of the run. All samples were run in triplicate. Secretions
and enzyme solutions were prepared in accordance with TNO-Triskelion protocols.
2.12. HPLC Analysis
Bioaccessible fractions from TIM-1 digestion were analyzed with an Agilent 1100 series HPLC
system equipped with an auto sampler, a degasser, a quaternary pump, a diode-array detector (DAD),
ChemStation software, and separated on a Zorbax 300SB-C18 column (150 × 4.60 mm, 5 μm, Agilent
Inc., Santa Clara, CA, USA). The binary mobile phase consisted of 0.1% trifluoroacetic acid in water
(v/v) (solvent A) and 70% methanol in water (v/v) (solvent B). The solvent gradient was as follows:
0–20 min, 0–100% B; 20–25 min, 100% B; 25.5–30 min, 0% B. Injection volume was 10 μL and the
flow rate was constantly kept at 1.0 mL/min for a total run time of 30 min. Peaks were monitored at
330 nm and identified by matching the retention time and UV absorption spectra with the standard RA.
Quantification was done using RA standard curve generated from serial dilutions (7.8125–2000 mg/L;
r2 = 0.99).
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2.13. Statistical Analysis
All samples were run in triplicate and concentrations were expressed as the means ± standard
deviation. Data were analyzed using a one factor analysis of variance (ANOVA) with the IBM SPSS
Statistics program (IBM, Armonk, NY, USA).
3. Results
3.1. RA Content in RA-PLC
The RA content was determined to be 22.6 ± 1.01% (w/w) in RA-PLC, slightly lower than the
weight percent of RA in the starting material blend, which was 23.7%. The result indicated that most
of the RA input was complexed to the phospholipids. The complexation efficiency is likely a result of
the strong molecular interactions between RA and phospholipids, as discussed below.
3.2. PXRD Pattern
PXRD patterns (Figure 2) were obtained to verify the solid state of the RA-PLC system.
The diffraction pattern of unformulated RA showed a high-degree of crystallinity characterized by
sharp peaks over the experimental 2θ range, as described in other literature [10]. The phospholipid used
in this study showed broad amorphous bands, indicative of its non-crystalline nature. RA-PLC system
appeared to be in amorphous state, as revealed by the halo bands in its spectra similar to phospholipid.
This amorphous profile suggested that RA was successfully complexed to the phospholipid. In contrast
to RA-PLC, the PM diffraction pattern showed a reduction on the intensity of the characteristic
peaks of RA, being the sum of RA and phospholipid diffraction patterns. The maintenance of
crystalline nature of RA in PM indicated that the molecular interaction between two components was
limited. In conclusion, a high-degree of complexation between RA and the phospholipids in RA-PLC
validated the successful preparation of a complex structure that differs from the physical mixture of
two components.
Figure 2. XRD diffractogram of rosmarinic acid (RA), phospholipid, physical mixture, and rosmarinic
acid-phospholipid complex (RA-PLC).
3.3. IR Spectroscopy
The IR spectra of RA, phospholipid, RA-PLC, and PM were determined to further examine the
interaction between RA and phospholipid. As shown in Figure 3, the spectrum of RA showed
characteristic peaks at 3518, 3454, 3396, and 3307 cm−1, assigned to the stretching vibration of
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the phenolic hydroxyl group in the structure of RA [10,46]. These peaks were also observed in the
spectrum of PM, indicative of limited interactions between the phenolic hydroxyl group of RA and
phospholipid structure. In contrast, these characteristic peaks were found to disappear in the spectrum
of RA-PLC, suggesting that there were strong interactions between the phenolic hydroxyl of RA and
the phospholipid induced by complexation. The changes likely result from the formation of hydrogen
bonds between the -OH group of RA and the P=O group of the phospholipids.
The spectrum of the phospholipids showed characteristic peaks at 2946, 2829, and 1737 cm−1,
assigned to the non-polar saturated long-chain fatty acids of phospholipid. Similarly, these peaks were
observed in the spectra of both RA-PLC and the physical mixture of RA and phospholipid, suggesting
that the non-polar fatty acids did not interact with RA directly. A possible aggregation behavior of
these fatty acid tails is to surround the surface of RA-PLC structure to further improve the lipophilicity
of the complex. Strong interactions between RA phenolic group and phosphatidic acid group in
phospholipid were considered as an evidence of a high-degree of complexation. IR spectroscopy
further supported the PXRD results.
Figure 3. IR spectra of RA, phospholipid, physical mixture, and RA-PLC.
3.4. 1-Octanol/Water Partition Coefficient (P) of RA, RA–PLC, and PM
The P values of RA, RA-PLC, and PM determined in different media are listed in Table 1.
Compared to unformulated RA, the P values of RA-PLC in water and phosphate buffer solution
(PBS, pH 6.8) increased significantly (p < 0.05), attributed to the increased partitioning of RA into
organic phase due to the improved lipophilicity after complexation with phospholipid. Compared
with RA-PLC, PM exhibited a smaller extent of increase in P values in water and PBS, respectively,
resulting from the slightly increased solubility of RA in 1-octanol phase induced by the in-solution
interactions between RA and phospholipids. The P value for RA in water showed a 1.07-fold increase
after physically mixing with phospholipid, and a 2.47-fold increase (p < 0.05) after forming RA-PLC.
The difference can be explained by the different extents of interaction between RA and phospholipid
as revealed by the PXRD and FTIR results. The partition of RA into the octanol phase relies on
its incorporation into the amphiphilic structure of phospholipid, in favor of the RA-phospholipid
interactions. Thus, compared with PM, RA-PLC showed a more effective increase in P value of due to
the stronger interaction. A same trend can be found for PBS, where PM and RA-PLC increased the
P value by 1.86-fold and 2.43-fold, respectively (p < 0.05 for both cases).
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Table 1. 1-Octanol/water partition coefficient of RA, physical mixture (PM), and RA–PLC in different










RA Millie Q water 488 ± 8 139 ± 3 2.50 ± 0.06
HCl (pH 1.2) 500 ± 10 4.91 ± 0.09 100 ± 4
PBS (pH 6.8) 483 ± 3 452 ± 4 0.068+0.005
PM Millie Q water 500 ± 4 136 ± 4 2.68 ± 0.09
HCl (pH 1.2) 350 ± 8 3.5 ± 0.3 100 ± 10
PBS (pH 6.8) 491 ± 8 433 ± 6 0.131 ± 0.004
RA-PLC Millie Q water 500 ± 7 70 ± 3 6.2 ± 0.4
HCl (pH 1.2) 325 ± 7 3.25 ± 0.06 99 ± 3
PBS (pH 6.8) 493 ± 6 423 ± 7 0.165 ± 0.005
In HCl solution at pH 1.2, both RA-PLC and PM presented similar P values to unformulated RA.
The concentrations of RA released into original aqueous phase (C1) were found to be lower than those in
pure water and PBS (p < 0.05 in all cases). This is likely the result of poor dispersion of the phospholipid
in acidic media due to protonation and electrostatic effects. When the pH of the environment is
close to the first pK value of a phospholipid, intermolecular acid-anion complexation could occur
through strong hydrogen bonding between the protonated phosphatidic acid (P–OH) and deprotonated
phosphatidic acid (P–O−) groups [47–49]. The aggregation of phospholipids induced by intermolecular
complexation was supposed to reduce the wetting of RA by incorporating a certain portion of free
drug molecules and making them less exposed to aqueous media. Thus, the concentrations of RA were
observed to decrease in both the first and second aqueous acid phase. As the ratio of RA concentrations
in two aqueous layers, the P values of RA, PM, and RA-PLC showed similarity in HCl solution.
Both similarities and differences were observed when comparing our data with Yang’s results
in acidic media [10]. In Yang’s study, the amount of RA in the original acidic aqueous phase was
significantly decreased when physically mixing or forming complex with phospholipid, which is in
agreement with our results, and can be explained by the intermolecular acid-anion complexation of
phospholipids in acidic environment. However, Yang’s study showed that RA-PLC was more lipophilic
than unformulated RA or the physical mixture, which is different from the results in this study.
One possible reason for this difference is the composition difference in the phospholipid materials.
Differentiating from the phospholipid containing 70–97% phosphatidylcholine used in Yang’s study,
the one for this study contains 55% phosphatidylcholine and 25% phosphatidylethanolamine.
Phosphatidylethanolamine is well characterized by its non-bulky head group with a strong tendency
to form intermolecular (N–H to P–O) hydrogen bonds between the amine and phosphate group [50].
Similar to the complexation between protonated and deprotonated phosphatidic acid group,
this intermolecular hydrogen bond may further facilitate the phospholipid aggregation in acidic
aqueous phase. Alternatively, unlike the preparation of RA-PLC using dissolved phospholipid,
the incorporation of RA into phospholipid aggregates in acidic aqueous phase can be seen
as an uncontrollable process, which may or may not be accompanied by RA incorporation.
When contacting octanol, the RA hosted by phospholipid aggregates can either enter the organic phase
with the phospholipid aggregates or release from the aggregates to undergo partitioning individually.
The experimentally determined P value is a final equilibrium of all these factors, as such could
contribute to differences between the two studies. Given the discussed observations, future researchers
are suggested to take phospholipid types and their ionization constants into consideration for the
formulation work.
The increased lipophilicity of RA in water and alkaline media is expected to provide a faster
partition of RA into the lipid cell membranes. Results will be discussed in Section 3.7.
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3.5. Radical Scavenging Activity (DPPH) Assay
The major biological effect of RA is demonstrated by its ability to reduce liver damage caused by
lipopolysaccharides and D-galactosamine through the scavenging of superoxide molecules [51–53].
As a result, the maintenance of antioxidant activity is expected to preserve the anti-inflammatory
bioactivity and other pharmacological effects which are linked to degenerative and chronic diseases
caused by oxidative stress [54,55]. The DPPH assay measures the reducing ability of a compound
and was used in this study to assess any possible difference in the antioxidant activity between
RA and RA-PLC. The TE (Trolox equivalent) values for RA and RA-PLC were calculated based on
the equivalent RA content in each sample. The results were calculated to be 3.62 ± 0.08 mM and
3.64 ± 0.09 mM, respectively, suggesting that the antioxidant activity of RA was not compromised
by the co-administration of phospholipid. Thus, the possible change in RA biological activity in
PLC formulation is considered as the result of bioaccessibility alteration, of which the importance is
emphasized in this study.
3.6. Cell Viability
RA and RA-PLC samples equivalent to 10, 20, and 50 μg/mL RA were used to incubate Caco-2
cells to assess the effects of RA and phospholipid on cell viability. It can be seen from Figure 4 that
unformulated RA did not induce obvious cell death up to a dose of 50 μg/mL. After complexation with
phospholipid, the cell viability was not compromised at these concentrations. Therefore, the Caco-2
cells were treated with an equivalent RA concentration of 50 μg/mL in the following transport assay.
 
Figure 4. Cell viability (%) of RA and RA-PLC at different concentrations. Shared letters indicate no
significant difference in cell viability between compared samples (n = 3, mean ± SD).
3.7. Caco-2 Transport Assay
As presented in Figure 5, the membrane permeability of RA was improved from both AP-BL and
BL-AP sides (p < 0.05). The permeability coefficients were increased by 3.07-fold on AP-BL side and
2.50-fold on BL-AP side. These improvements could be attributed to the enhanced lipophilicity of RA,
as revealed by the increased P value in phosphate buffer, and the increased uptake of RA through
the simultaneous incorporation of phospholipid into cell membranes. The P value of RA-PLC was
0.17 in phosphate buffer, compared with that of unformulated RA, 0.07. According to Artursson’s
correlation between drug lipophilicity and apparent permeability coefficients in the Caco-2 model,
an increase in drug lipophilicity leads to an increased Papp, as it makes the drug partition faster into
the lipid cell membranes [56]. Drugs that can be completely absorbed in humans have Papp values
over 1 × 10−6 cm/s, while those with Papp values less than 1 × 10−8 cm/s can only be absorbed to
a value of less than 1% [56]. According to the Artursson’s correlation, the absorption of unformulated
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RA in human should be within the range of 50% to 100%, while RA-PLC is expected to increase the
value to approximately 100%. The efflux ratio of RA-PLC was decreased to 0.69, compare with 0.85 of
unformulated RA, indicating the uptake of RA through caco-2 monolayer could be effectively improved
by RA-PLC. Combined with results of PXRD, FTIR, and o/w partition coefficient tests, the Caco-2
transport assay suggested a successful complexation between RA and phospholipid. RA-PLC was
demonstrated to be a complex entity possessing different structure and physiochemical properties
from a physical mixture. In this regard, prepared RA-PLC was assessed using the TIM-1 system in the
following steps.
Figure 5. Permeability coefficient of RA and RA-PLC. * p < 0.05 between RA and RA-PLC (n = 3,
mean ± SD).
3.8. In Vitro Bioaccessibility
3.8.1. Cumulative Bioaccessibility
The bioaccessibility of RA and RA-PLC were studied through the TIM-1 system operating in
a water mode, in which the bioaccessible portion was the amount of RA detected in the dialysate.
The cumulative contents of bioaccessible RA in jejunum dialysate, ileum dialysate and ileum effluent
were determined.
In general, as shown in Figure 6a, the total cumulative amounts of bioaccessible RA in the jejunum
compartment increased continuously for both unformulated material and RA-PLC within 5 h. Within
each time interval, unformulated RA showed higher bioaccessibility compared to RA-PLC, indicating
a retarded release of RA after complexing with phospholipid. At the beginning of jejunum digestion,
the slower release from RA-PLC could be explained by a gastric effect from the previous digestion
step (i.e., within the stomach compartment). The protonation of the phospholipids in gastric fluid
could induce an intermolecular acid-anion complexation as discussed in Section 3.4, resulting in poorly
dispersible state for the phospholipid. A certain portion of RA was both complexed with phospholipid
molecules and surrounded by the phospholipid aggregate, thus the contact between RA and aqueous
media was reduced. Therefore, a smaller amount of RA was released from RA-PLC into aqueous
media and transported from stomach to jejunum in a dissolved form that could be detected directly.
This observation corresponds well to the findings from the partition coefficient tests, which showed
a reduced RA concentration from RA-PLC in acidic media. With the continuous processing of jejunum
digestion, the protonation of phospholipids in the gastric environment became less of a determinant
in bioaccessibility as the phospholipids could disperse well in alkaline media. The bioaccessibility
difference between RA and RA-PLC became smaller gradually, indicative of similar release behaviors
for the two samples in alkaline environment. Finally, the maximum bioaccessibility of RA in jejunum
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compartment within 5 h was determined to be 64.9% of the input amount, slightly higher than the
60.9% of RA-PLC.
Figure 6. Cumulative bioaccessibility of RA and RA-PLC in jejunum (a), ileum (b), and the sum (c).
* p < 0.2 and ** p < 0.1 between RA and RA-PLC (n = 3, mean ± SD).
In the ileum compartment, as shown in Figure 6b, the digestion of both RA and RA-PLC showed
a monotonic increase in bioaccessibility, similar to that observed in the jejunum chamber. Within most
time intervals, no significant difference was found between the bioaccessibility of RA and RA-PLC,
indicative of similar dissolution behaviors of two samples. An interesting difference between RA
and RA-PLC was observed in the profile obtained for the ileum compartment after 4 h, where the
cumulative bioaccessibility of RA-PLC became higher than unformulated RA, which suggested the
dissolution of RA was enhanced in the presence of phospholipids. In contrast to the bioaccessibility
relation between RA and RA-PLC in previous chambers, the release rate of RA from the complex
was enhanced by the amphiphilic nature and fine dispersible state of phospholipid in the alkaline
intestinal environment, and by virtue of the long exposure time in the intestinal tract. After 5 h
digestion, the maximum bioaccessibility of RA-PLC in the ileum compartment was determined to be
approximately 28%, slightly higher than the 25% obtained for unformulated RA.
The overall bioaccessibility was defined as the sum of the amount of bioaccessible RA in both the
jejunum and ileum dialysates. As shown in Figure 6c, the total bioaccessibility of unformulated RA was
higher than RA-PLC for every time interval; however, it should be noticed that the bioaccessibility gap
between RA and RA-PLC decreased at longer times, due to the enhancement of bioaccessibility seen for
the RA-PLC in the ileum chamber at long times. At the end of the digestion process, the bioaccessibility
of unformulated RA was ~90%, essentially equivalent to the ~89% obtained for RA-PLC. A more
sustained digestion profile of RA-PLC was shown in Figure 6c.
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3.8.2. Non-Cumulative Bioaccessibility
Non-cumulative bioaccessibility of RA and RA-PLC was studied to analyze the digestion behavior
of RA in each time interval, further supporting the findings from cumulative bioaccessibility study.
Bioaccessibility rate was defined as the amount of RA becoming bioaccessible per minute and was
plotted against digestion time.
From Figure 7a, it was observed that the bioaccessibility rate of unformulated RA was higher than
for RA-PLC in the jejunum up to 120 min. Within this period, the bioaccessibility rate for unformulated
RA rose from 0.08%/min to 0.76%/min and then decreased to a value of 0.26%/min for the 90–120 min
timepoint, while the rate of RA-PLC increased from 0.08%/min to the peak of 0.64%/min and then
decreased to 0.25% for the 90–120 min timepoint. By virtue of the ready dissolution of unformulated
RA in gastric fluid, a larger amount of RA could be transported to the jejunum compartment in
a dissolved state to be instantly detected as bioaccessible, showing as a burst release profile for RA
in the initial stage of jejunum digestion. In contrast, the lower peak value of bioaccessibility rate of
RA-PLC (i.e., a slower rate of increase for bioaccessibility of RA from RA-PLC) could be explained
by the poor dispersing behavior of the phospholipids in gastric fluid as discussed above. With less
effective wetting process in the stomach, a smaller amount of free RA could be transported to jejunum
in a dissolved state to be immediately determined.
Figure 7. Bioaccessibility rate of RA and RA-PLC in jejunum (a), ileum (b), and the sum (c). * p < 0.2
and ** p < 0.1 between RA and RA-PLC (n = 3, mean ± SD).
At 90 min, the bioaccessibility rate of unformulated RA decreased significantly and the difference
in bioaccessibility rate between RA and RA-PLC became non-significant due to two reasons. First,
most of the RA had already been dissolved and was bioaccessible, and/or transported to the ileum
compartment for the next step of digestion, decreasing the following bioaccessibility rate for RA.
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Second, the dissolution of RA-PLC was maintained at a higher level in the jejunum as compared
to RA by virtue of the exposure of phospholipid to the alkaline environment (again as described
above). After 120 min timepoint, the bioaccessibility rate of RA-PLC became higher than RA. The more
sustained bioaccessibility rate profile for RA-PLC from 90 min to 300 min is attributed to the continuous
RA release from the reservoir that formed in stomach due to phospholipid complex aggregation.
The absolute value of bioaccessibility rate of RA-PLC became larger than that of RA from 120 min,
further supporting the discussion.
During ileum digestion, comparable profiles were observed in the bioaccessibility rate of RA and
RA-PLC, especially at longer times. According to Figure 7b, the bioaccessibility rate of unformulated
RA increased to peak within 60 min and started to decrease significantly thereafter. As a comparison,
the rate of RA-PLC increased to maximum in 45 min, presenting a shorter time required to reach
maximum. The results suggested that ileum environment is a dissolution-favored environment more
for RA-PLC than RA, likely resulting from the amphiphilicity of phospholipid which facilitates the
wetting of RA. Compared to unformulated RA, a more sustained bioaccessibility rate profile of RA-PLC
was observed similar to that in jejunum compartment. The continuous release of RA from RA-PLC was
likely a result of the extra time required for RA to transit from the jejunum into ileum compartment
due to the delay in release from the stomach. Another reason could be the continuous separation of
RA from the complex which still remained after a long-time digestion.
The total absorption rate was calculated in the same fashion as the total cumulative bioaccessibility,
namely by summing the rates of the jejunum and ileum compartments. The total digestion rate is
shown to be time-dependent as described above. As shown in Figure 7c, the overall bioaccessibility
rate of RA was higher than RA-PLC in the initial stages of digestion, before 90 min, followed by
a transition stage where two samples showed comparable rates (90–120 min), after which the digestion
of RA-PLC reached an approximate steady state and the bioaccessibility rate became higher than for
unformulated RA.
From the profiles of cumulative bioaccessibility, it can be concluded that the bioaccessibility
of RA decreased at each time point due to the complexing with phospholipids, or extra time was
required for RA-PLC to be bioaccessible. Not only does the analysis on the bioaccessibility rate support
the above conclusion, but it also reveals differences that are more detailed, including the starting
timepoint for RA-PLC to become more effective than RA, and the quantification of difference in
instantaneous performance (i.e., the bioaccessibility rate for a 15-min period) between RA and RA-PLC.
These details are expected to benefit the future formulation design of PLCs when modified or sustained
release is needed. Besides, with the evaluation on the dispersibility, protonation, and the change in
bioaccessibility rate of phospholipid complex in different digestive environments, controlled release of
active ingredients to specific GIT regions may be achieved by adjusting phospholipids with different
gel to liquid transition temperatures and pK values, as well as drug–phospholipid ratios.
It should be noted that for a BCS class 3 compound with high solubility and low permeability
such as RA, bioaccessibility is a necessary but insufficient parameter to determine its bioavailability
as the permeation of dissolved drug is the key determinant. Thus, the bioaccessibility data obtained
from TIM-1 cannot be quantitatively used to predict drug absorption of this type of compounds.
Even if combining with a caco-2 permeation experiment, the prediction of drug absorption may also be
inaccurate when there is no quantitative translation model. Nevertheless, TIM-1 can be effectively used
to reveal any unfavorable change in drug bioaccessibility induced by excipients, and warns formulation
scientists of how much drug loses its potential to permeate into blood circulation. Considering the
cost and ethical issues related to animal studies, TIM-1 bioaccessibility study is expected to help select
the most worthwhile formulations to move into animal pharmacokinetic studies, in the best effort to
improve the success possibility of drug product development.
At this point, it is observed that the RA-PLC dosage form increased the permeability of RA by
3.07-fold and decreased the bioaccessibility by only 1.8%, which is likely to correspond to the increased
Cmax, AUC and the shorten Tmax in the previous animal study [10]. These results suggest that the
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bioaccessibility disadvantage of RA-PLC was likely overwhelmed by its permeability enhancement.
When formulating phospholipid complexes, it is suggested to conduct a parallel comparison between
formulations using bioaccessibility change as indicator before entering animal trial, in order not
to overwhelm the permeation enhancement by the decreased bioaccessibility. Several factors were
identified as important considerations for future research, including ionization constant, intermolecular
complexation of phospholipids, intestinal transition time, and pH changes. Currently, however, there is
no way to correlate these factors with pharmacokinetic profiles in a quantitative manner. Here, we do
not suppose that the TIM-1 system is able to perfectly mimic the real in vivo situation, instead it is
an effective tool to compare formulations in parallel by breaking the digestion process into different
stages and testing the complicated effects of excipients like phospholipids.
4. Conclusions
The effect of complexing RA with phospholipids on the RA bioaccessibility was successfully
evaluated using the TIM-1 dynamic system where the net effect was shown to be a slight reduction
in bioaccessibility for RA-PLC (88.7%) compared to unformulated RA (90.4%). The bioaccessibility
profiles of RA-PLC were shown to be dependent on different digestive environments. The complexation
with phospholipids decreased the bioaccessibility of RA in the early stage of jejunum digestion,
while providing a more sustained digestion profile in the following ileum process. The reduction of
jejunum bioaccessibility was considered as a result of poor dispersion of phospholipids in the stomach.
As the prerequisite for oral bioavailability, these bioaccessibility profiles are expected to provide rational
predictions on the absorption behaviors of tested formulations. In this regard, the improved oral
bioavailability of RA in rats from previous research could be considered as a net result of significantly
increased intestinal permeability and slightly decreased bioaccessibility.
The insights into the pH-dependent effects of phospholipid materials on the bioaccessibility
of a hydrophilic compound acknowledged a potential broader application of the TIM-1 to the
characterization of PLC formulations, as well as other types of dosage forms containing components with
opposing effects on bioaccessibility. The study on both cumulative and non-cumulative bioaccessibility
is expected to benefit the design of controlled-release PLC formulations. The combination of TIM-1
dynamic system and Caco-2 transport assay is expected to provide an alternative approach to better
select formulations of low-permeable drug before moving into animal studies.
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Abstract: (1) Background: Monoclonal antibodies are used in the treatment of multiple conditions
including cancer, autoimmune disorders, and infectious diseases. One of the initial steps in
the selection of an antibody candidate for further pre-clinical development is determining its
pharmacokinetics in small animal models. The use of mass spectrometry and other techniques to
determine the fate of these antibodies is laborious and expensive. Here we describe a straightforward
and highly reproducible methodology for utilizing radiolabeled antibodies for pharmacokinetics
studies. (2) Methods: Commercially available bifunctional linker CHXA” and 111Indium radionuclide
were used. A melanin-specific chimeric antibody A1 and an isotype matching irrelevant control
A2 were conjugated with the CHXA”, and then radiolabeled with 111In. The biodistribution was
performed at 4 and 24 h time points in melanoma tumor-bearing and healthy C57BL/6 female mice.
(3) The biodistribution of the melanin-binding antibody showed the significant uptake in the tumor,
which increased with time, and very low uptake in healthy melanin-containing tissues such as the
retina of the eye and melanized skin. This biodistribution pattern in healthy tissues was very close
to that of the isotype matching control antibody. (4) Conclusions: The biodistribution experiment
allows us to assess the pharmacokinetics of both antibodies side by side and to make a conclusion
regarding the suitability of specific antibodies for further development.
Keywords: pharmacokinetics; antibodies; radiolabeling; biodistribution; mouse models
1. Introduction
The field of immunotherapy is experiencing explosive growth, with new antibodies being
approved for clinical use, or being introduced into the research pipeline on a regular basis [1–3].
Monoclonal antibodies find applications in the treatment of multiple conditions, including cancer,
autoimmune disorders, and infectious diseases. One of the initial steps in the selection of an antibody
candidate for further pre-clinical development is determining its pharmacokinetics (PK) in small
animal models. Usually PK studies are performed by administering the antibody candidate to the
healthy mice, or a mouse model of a relevant disease, followed by harvesting organs and tissues at
pre-determined time points. These samples are then digested and subjected to various downstream
analytical techniques, such as mass spectrometry and immune-PCR (Polymerase Chain Reaction),
in order to test for the presence of the candidate antibody [4,5]. These techniques are laborious and
expensive and require access to state-of-the-art equipment, such as MALDI (Matrix Assisted Laser
Desorption Ionization) mass spectrometers, as well as highly trained personnel for interpretation
of the results. An alternative technique is to attach a radiolabel to the antibody of interest before
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administering it to mice, and then to follow its fate in vivo by measuring the amount of radioactivity
present in the mouse organs and tissues at the pre-determined time points. Here we describe a
straightforward and highly reproducible method for radiolabeling antibodies using commercially
available linker and radionuclide, and performing biodistribution in a murine melanoma model.
2. Materials and Methods
2.1. Reagents, Antibodies, Radionuclides, and Cell Lines
The antibody to melanin, Ab1, was produced in our laboratories and human IgG isotype control
Ab, referred to as Ab2 in the text, was purchased (Creative Diagnostics, Shirley, NY, USA). 111Indium
was purchased as 111InCl3 from Nordion (Vancouver, BC, Canada). Bifunctional CHXA” ligand was
purchased from Macrocyclics (Plano, TX, USA). Murine melanoma cell line B16-F10 was purchased
from ATCC (Manassas, VA, USA).
2.2. Metal-Free Buffer Preparation
Stock buffers must be prepared as metal-free solutions in order to ensure contaminating metals do
not interfere with downstream radiolabeling steps. All buffers were prepared as concentrated stocks
with distilled/deionized H2O (ddH2O), using components purchased from Fisher Scientific (Ottawa,
ON, Canada). Stock buffers were run through a Chelex cation exchange resin column to scavenge
contaminating free metal ions.
The Chelex column was prepared by placing a glass wool plug in a glass chromatography column.
The wool plug was rinsed with concentration HCl, followed by water until the eluate was a neutral
pH. A slurry of Chelex-100, Na+ form, 200–400 mesh (BioRad, Hercules, CA, USA) was prepared in
ddH2O and poured into the column in order to have approximately 5 cm of packed resin. The Chelex
column was washed with ddH2O until the eluate returned to a neutral pH.
Conjugation buffer stock was prepared as 0.5 M Carbonate/Bicarbonate (0.02 M/0.48 M), 1.5 M
NaCl solution at pH 8.6–8.7 in ddH2O. A prepared Chelex column was equilibrated with 100 mL of
10× stock buffer and the eluate was discarded. The remaining 10× stock buffer was run through the
column and collected as a metal-free 10× stock. Conjugation buffer was prepared by diluting the 10×
conjugation buffer by 10 with ddH2O and adding EDTA to 5 mM.
Ammonium acetate buffer was prepared as a concentrated stock (5 M, pH 7.5) and run through a
Chelex column to scavenge free metal ions. Prior to completing Ab labeling it was diluted with ddH2O
and used at 0.15 M concentration.
2.3. Radiolabeling of Antibody-CHXA” Conjugate with 111Indium (111In)
To conjugate the bifunctional chelator CHXA” to the antibody, the Ab must first be exchanged
out of the storage buffer and into conjugation buffer. This was achieved by loading the Ab onto a
0.5 mL 30K molecular weight cutoff Amicon microconcentrator (Millipore, Burlington, MA, USA)
with conjugation buffer and then centrifuging at 4 ◦C following the microconcentrator manufacturer’s
recommended conditions. Conjugation buffer was added and centrifugation was repeated at least
10 times to ensure complete exchange of the Ab storage buffer to conjugation buffer. A 5-fold molar
excess of CHXA” (2 mg/mL in conjugation buffer, prepared immediately before use) was added to the
antibody solution. The reaction mixture was then incubated at 37 ◦C for 1.5 h. Upon completion of the
reaction the Ab-CHXA” conjugate was then exchanged into the 0.15 M ammonium acetate buffer at
4 ◦C, the same as described for the exchange into the conjugation buffer. Protein concentration was
determined by Bradford assay (BioRad, Hercules, CA, USA) prior to labeling the Ab.
The radiolabeling of the antibody-CHXA” conjugate with 111In was performed to achieve a specific
activity of approximately 5 μCi/μg of the antibody. The amount of the radiolabeled antibody to be
administered to a mouse was approximately 6 μg, therefore, the amount of radioactivity was 30 μCi.
111In chloride was diluted with 0.15 M ammonium acetate buffer and added to a microcentrifuge
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tube (MCT) containing the Ab-CHXA” conjugate in the 0.15 M ammonium acetate buffer, a minimum
volume was desired, with a typical reaction volume being ~30 μL. The reaction mixture was incubated
for 60 min at 37 ◦C. The reaction was quenched by the addition of 3 μL of 0.05 M EDTA solution to
bind any free 111In.
The percentage of radiolabeling (radiolabeling yield) was measured by instant thin layer
chromatography (iTLC) by developing 10 cm silica gel strips (Agilent Technologies, Santa Clara,
CA, USA) in 0.15 M ammonium acetate buffer. In this system the radiolabeled antibodies stay at the
point of application while free 111In, in the form of EDTA complexes, move with the solvent front.
The strips were cut in half and each half was counted on a 2470 Wizard2 Gamma counter (Perkin
Elmer, Waltham, MA, USA) that was calibrated for the 111In emission spectrum and only emissions
in this range were considered in the counts per minute (CPM). The percentage of radiolabeling was
calculated by dividing the CPM at the bottom of the strip (labeled antibody) by the sum of the CPM at
the bottom and the top of the strip (total amount of radioactivity) and multiplying the result by 100.
2.4. B16-F10 Melanoma Tumor Model
All animal studies were approved by the Animal Research Ethics Board of the University of
Saskatchewan (Animal Use Permit #20180006, approved 1 February 2017). For the biodistribution
experiment, 6 week-old C57BL/6 female mice obtained from Charles River Laboratories (Wilmington,
MA, USA) were injected subcutaneously with 5 × 106 B16-F10 murine melanoma cells in Matrigel
(Corning, Corning, NY, USA) into the right flank, or were not given tumor cells. The radioactivity was
administered on Day 8 post tumor cells injection, when the tumors reached 0.7–1.0 cm in diameter.
2.5. Biodistribution of Antibody-CHXA” Conjugate in Tumor-Bearing Mice
For the biodistribution of melanin binding antibody (Ab1) B16-F10 tumor-bearing C57BL/6 mice
were injected intravenously (IV) via the tail vein with 30 μCi antibody-CHXA”—111In in 100 μL saline.
The same activity of the radiolabeled non-specific antibody (Ab2) was injected into healthy C57BL/6
mice. At the predetermined time points of 4 and 24 h groups of 4–5 mice were humanely sacrificed,
their tumors and major organs removed, blotted from blood, weighed and counted for radioactivity
in a gamma counter. The standard was prepared by diluting 10 μL (1/10 of the injected dose) of the
respective radiolabeled antibody with 2 mL 0.15 M ammonium acetate buffer and counted in a gamma
counter at the same time as the organ/tissues were counted. Percentage of injected dose per gram
(ID/g) organ/tissue was calculated by dividing the CPM in an organ by its weight in grams and by
the CPM of the standard, followed by multiplying the resulting number by 10.
3. Results
3.1. Radiolabeling of the Antibodies
Two IgG isotype antibodies, Ab1 to melanin and irrelevant isotype matching control Ab2, were
conjugated to the bifunctional chelating agent CHXA” to enable subsequent radiolabeling with 111In.
The concentration of the conjugated antibodies was 16 mg/mL as per Bradford assay which constitutes
the 80% recovery of the antibodies after buffer exchange and subsequent purification on the Amicon
microconcentrators. The iTLC analysis of the 111In-labeled antibody conjugates revealed a radiolabeling
yield of >92%, which allowed for the use of the radiolabeled antibody conjugates in the biodistribution
experiment without further purification.
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3.2. Biodistribution of the Radiolabeled Antibodies in Melanoma Tumor Bearing Mice
The raw data and the calculated % ID/g for a 4 h time point for the 111In-Ab1 is shown in Table 1.
The complete set of data for both 111In-Ab1 and 111In-Ab2 and 4 and 24 h time points is presented in
Supplementary Table S1 in the form of an Excel file. The columns in Table 1 include the following:
rack number (for record keeping purposes), tube number, Ab name, organ/tissue, empty tube weight
into which that organ was subsequently placed, weight of the tube with the organ, calculated weight
of the organ, the CPM in the organ obtained by counting it on the gamma counter, and finally, the %
ID/g which is calculated using a formula described in the Methods section, in footnotes to Table 1 and
incorporated into the Excel file in Supplementary Table S1.
To take into consideration the radioactive decay of 111In during the experiment, the standards (in
our case 1/10 of the injected dose) were counted simultaneously with the organs. Each standard was
counted two times, at the beginning and end, and the mean of these two measurements was used in
the calculations of the % ID/g. The mean of the two readings allow us to account for the minor decay
of 111In that occurs during counting of multiple samples in a gamma counter. Table 2 shows the values
in CPM for the 111In-Ab1 and 111In-Ab2 standards for 4 and 24 h time points.
The process of biodistribution is shown in Supplementary Video S1. The biodistribution was then
used to construct biodistribution plots which are presented in Figure 1. The organs and tissues are
shown on the X axis while the % ID/g for the respective organ/tissues is shown on the Y axis. The
biodistribution patterns for both antibodies are typical for IgG biodistribution in mice. The clearance
from the blood has begun by 24 h, although antibodies are still in circulation at this time point. The
antibodies have started to clear from blood rich organs such as heart and lungs. The organs where
the antibodies are processed such as spleen, liver and kidneys show very similar uptake for both
antibodies, which starts to decrease by 24 h. No penetration of the antibodies in the brain and into the
melanized tissues such as eyes is observed. There is very insignificant uptake into stomach, small and
large intestines, femur and muscle. The melanin binding antibody Ab1 accumulates in the tumor in
B16F10 tumor bearing mice and its uptake increases with time, indicating that it is specific to melanin
present in the tumors.
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Figure 1. Biodistribution of 111In-labeled antibodies Ab1 to melanin and isotype matching irrelevant
control Ab2 in C57BL6 mice at 4 and 24 h after IV administration. (A) Ab1 antibody in B16F10
melanoma bearing mice; (B) Ab2 in healthy mice. Blue and orange bars represent 4 and 24 h time
points, respectively. The error bars represent the SEM of sample groups of 4–5 mice.
4. Discussion
With the increasing pace of drug discovery, in particular antibody-based drugs, faster and more
cost-effective methods to assess PK parameters are required. Utilizing commercially available linkers
and radioisotopes, we are able to improve upon traditional pharmacokinetic studies by reducing
time and cost investments while increasing reproducibility. Here we describe the radiolabeling and
biodistribution of two IgG isotype antibodies in tumor bearing versus healthy mice. Ab1 is specific for
the pigment melanin, while Ab2 is an isotype matching control. The radiolabeling procedure, which
involves using commercially available bifunctional chelating agent CHXA” and radionuclide 111In, is
straightforward and does not require post-labeling purification. Mice used in the biodistribution could
be either healthy if only PK data is being collected, or could be a model of a disease of interest. For this
study we used murine melanoma tumor bearing mice for the melanin-binding antibody and healthy
mice for isotype matching controls.
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In this study, we collected the data at two time points of 4 and 24 h. These time points were
chosen to obtain initial evidence of specific targeting. While these time points do not constitute a
complete PK study, they do provide sufficient evidence that this method for assessing PK parameters
is sensitive enough to detect the changes in targeting and accumulation over time. Depending on the
nature of the research, much earlier or much later time points could be collected for more extensive
longitudinal studies assessing adsorption, distribution, metabolism, and excretion. For example, when
the 111In radiolabel is used for labeling antibodies the pharmacokinetics in mice could be followed
for up to 7 days, as the physical half-life is 2.8 days. If much later time points are desirable, longer
lived radionuclides such 177Lutetium, which also forms stable complexes with CHXA” bifunctional
chelating agent [6] and has a 6.7-day physical half-life, could be used in place of 111In. Collection of
data from at least 4–5 time points would enable the modeling of blood clearance of the antibodies
using biphasic models, as well as allowing radiation dosimetry calculations if an antibody-based
imaging or radioimmunotherapeutic agent is being developed. This method is sensitive as we were
detecting 111In at the 150–1200 nCi level, which correlates to 75–600 ng amounts of Ab, based on the
2 μCi/μg specific activity. The use of metabolic cages during the biodistribution experiments would
enable collection of urine and feces, which could be counted in a gamma counter in the same way as
the organs, and would provide a wealth of information on the metabolic fate of the antibody. Finally,
if non-invasive imaging equipment such as microSPECT (micro Single Photon Emission Computed
Tomography) or microPET (micro Positron Emission Tomography) is available [7] and is equipped
with the software allowing quantification of the radiolabeled antibody uptake in the organs/tissue,
one group of 4–5 mice per antibody could be followed longitudinally without the need to sacrifice
animals at every time point, greatly reducing the number of animals used in the experiment.
5. Conclusions
In conclusion, here we describe a relatively simple and efficient way to study the pharmacokinetics
of antibodies by radiolabeling them with commercially available radionuclides and performing
biodistribution, either in healthy mice or in disease models. We, as well as other groups have
successfully used this technique for preclinical development of antibodies for therapy or for imaging
of cancer, infection, and neurodegenerative diseases [8–20].
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/262/s1,
Table S1: Raw data for biodistribution; Video S1: Evaluating Pharmacokinetics of an Antibody by Radiolabeling
and Performing Biodistribution in Mice.
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Abstract: Hypoxia can induce chemoresistance, which is a significant clinical obstacle in cancer
therapy. Here, we assessed development of hypoxia-induced chemoresistance (HICR) against
free versus polymeric cisplatin micelles in a triple negative breast cancer cell line, MDA-MB-231.
We then explored two strategies for the modulation of HICR against cisplatin micelles: a) the
development of actively targeted micelles; and b) combination therapy with modulators of HICR in
MDA-MB-231 cells. Actively targeted cisplatin micelles were prepared through surface modification
of acetal-poly(ethylene oxide)-poly(α-carboxyl-ε-caprolactone) (acetal-PEO-PCCL) micelles with
epidermal growth factor receptor (EGFR)-targeting peptide, GE11 (YHWYGYTPQNVI). Our results
showed that hypoxia induced resistance against free and cisplatin micelles in MDA-MB-231 cells.
A significant increase in micellar cisplatin uptake was observed in MDA-MB-231 cells that overexpress
EGFR, following surface modification of micelles with GE11. This did not lead to increased
cytotoxicity of micellar cisplatin, however. On the other hand, the addition of pharmacological
inhibitors of key molecules involved in HICR in MDA-MB-231 cells, i.e., inhibitors of hypoxia
inducing factor-1 (HIF-1) and signal transducer and activator of transcription 3 (STAT3), substantially
enhanced the cytotoxicity of free and cisplatin micelles. The results indicated the potential
benefit of combination therapy with HIF-1 and STAT3 inhibitors in overcoming HICR to free or
micellar cisplatin.
Keywords: hypoxia-induced chemoresistance; cisplatin; polymeric micelle; EGFR-targeted therapy;
STAT3; HIF-1; GE11 peptide; pharmacological Inhibitors of HIF-1 and STAT3; combination therapy
1. Introduction
Hypoxia is a common feature of solid tumors. Hypoxic areas in tumors are defined as regions
with lower oxygen (O2) levels than physiological oxygen concentrations [1]. Hypoxia arises when the
need for oxygen exceeds its supply. Hypoxia-induced chemoresistance (HICR) has been observed in a
number of human cancers, including triple negative breast cancer (TNBC) [2–5], the most deadly and
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therapy-resistant type of breast cancer [6]. The development of HICR in TNBC is a significant clinical
obstacle against effective cancer therapy. This necessitates the development of new strategies that can
prevent or overcome HICR in TNBC.
Cisplatin is a platinum drug used as part of a standard chemotherapy regimen in TNBC
patients [7,8]. However, its use in cancer patients leads to the emergence of severe side effects including
renal damage, deafness, and peripheral neuropathy. The use of nanocarriers has been extensively
studied in recent decades as a means to attenuate the toxic side effects of anticancer agents. Several
different nanocarriers of cisplatin have been reported in the literature, from which a few have found
their way to clinical trials [9]. The developed nano-formulations have been mostly effective in lowering
the side effects of cisplatin in preclinical models. However, they failed to potentiate the anticancer
effects of drug [10,11].
Reports on the effect of nano-delivery of anticancer drugs on HICR are limited. This is of
particular interest, as delivery of anticancer drugs by their nano-formulations may, in fact, restrict
drug access and movement to hypoxic regions of the tumor where resistant cancer cells may be
present. To circumvent the problem of nano-formulation penetration to hypoxic regions of solid
tumors, incorporation of nanoparticles in non-malignant cells that display inherent hypoxia-targeting
abilities, such as monocytes, macrophages or even neural stem cells [12,13], or modification of the
surface of nanoparticles by tumor-penetrating peptides has been tried by different research groups [14].
These strategies sought to enhance the penetration of nano-drug delivery systems at the solid tumor at
a tissue level.
This study aimed to study the effect of cisplatin delivery by a stealth nano-formulation on HICR
at a cellular level and explore strategies to circumvent HICR. For this purpose, we used a previously
reported polymeric micellar formulation for cisplatin developed by our group [15] and assessed
the cytotoxicity of cisplatin as part of this formulation versus free drug in normoxic versus hypoxic
MDA-MB-231 cells. We then explored two strategies for the modulation of hypoxia-induced cisplatin
resistance in the same cell line; first, by active targeting of cisplatin micelles to MDA-MB-231 cells, to
enhance intracellular cisplatin levels, and second, by combining cisplatin or its nano-formulations
with modulators of HICR in MDA-MB-231 cells.
For the purpose of active drug targeting, we chose modification of polymeric micellar cisplatin
with peptide ligands against epidermal growth factor receptor (EGFR), since coexistence of hypoxia
and high levels of EGFR expression is a known feature of TNBC [16,17]. We postulated the high
expression of EGFR on the hypoxic TNBC cells can be exploited to achieve enhanced delivery of cancer
therapeutics to the cells [17,18].
Targeted nanocarriers can significantly improve drug performance by delivering a high payload
of drug to cancer cells [19–22]. Previous studies have provided support for the use of EGFR
monoclonal antibody for the development of ligand guided nanocarriers for the purpose of tumor
imaging or targeted drug delivery [23–27]. The high molecular weight of the full-length antibody,
however, may compromise the penetration of antibody modified nanocarriers into tumor tissue,
particularly in hypoxic tumor regions. It may also enhance the chance of nanocarrier removal by
the reticuloendothelial system following opsonization in the blood circulation [28]. Furthermore, the
high cost of the full-length antibody and limitations on the use of organic solvents for its conjugation
to the surface of nanocarriers prohibits the wide use of antibodies as ligands for tumor-targeted
nanocarriers. In this context, use of an EGFR-specific peptide, GE11, may be a better option. GE11
is a 12-residue peptide (YHWYGYTPQNVI) which was originally developed using phage display
technique [29]. GE11 peptide shows a lower affinity for EGFR than its natural ligand, EGF, however,
it provides the advantage of lower mitogenic activity. Overall, due to its high EGFR affinity, minimum
immunogenicity, and relatively cheap method of synthesis and scale-up, GE11 has been widely
conjugated to a variety of nanocarriers, including liposomes, polymeric micelles, as well as gold and
gelatin nanoparticles [28,29].
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In this study, we developed GE11 modified polymeric micellar complexes of cisplatin and assessed
the success of this approach in enhancing cellular delivery of cisplatin and overcoming HICR to
cisplatin in a TNBC associated cell line, i.e., MDA-MB-231 cells. We then investigated the effect of
adding pharmacological inhibitors of hypoxia inducing factor-1 (HIF-1) and signal transducer and
activator of transcription 3 (STAT3), as the key modulators of HICR in this cell line [4,30], on anticancer
activity of polymeric micellar formulations of cisplatin versus free drug.
2. Materials and Methods
2.1. Materials
Cisplatin (cis-diamminedichloroplatinum(II) (CDDP) (purity 99%), #H878, was purchased from,
AK Scientific Inc., Union City, CA, USA. Methoxy-PEO 5000 (MePEO), sodium cyanoborohydride,
and Stattic were obtained from Sigma, St Louis, MO, USA. Stannous octoate was dried
and purified using anhydrous magnesium sulfate, dry toluene, and vacuum distillation [31].
α-Benzylcarboxylate-ε-caprolactone (BCL) was synthesized by Alberta Research Chemicals Inc. (ARCI,
Edmonton, AB, Canada) based on methods published previously by our group [32]. All other chemicals
and reagents used were of analytical grade.
2.1.1. Synthesis of Block Copolymers with Functionalized Poly(ethylene oxide) (PEO)
Acetal-poly(ethylene oxide) (acetal-PEO) was synthesized based on the previously published
method by Nagasaki et al. [33]. Briefly, potassium naphthalene, the catalyst, was freshly prepared
before the synthesis of acetal-PEO. To prepare the catalyst, 1.65 g (12.9 mmol) naphthalene and 0.575 g
(14.7 mmol) potassium were added into 50 mL anhydrous tetrahydrofuran (THF). The reaction was
protected under dry argon gas and kept running for 24 h, until a dark green color was obtained.
To prepare acetal-PEO, 0.3 mL (2 mmol) 3,3-diethoxy propanol, the initiator, was first added into 40 mL
anhydrous THF in a three-neck round bottom flask. The flask was purged with dry argon gas and
maintained under an argon atmosphere. The catalyst solution (7 mL, ∼2 mmol) was added dropwise
into the reaction solution to activate the initiator. After 10 min of stirring, the flask was transferred into
an ice water bath. Ethylene oxide (11.4 mL, 228 mmol) was added into the reaction solution. After 48 h,
the reaction was quenched by acidified ethanol (2 mL). Acetal-PEO was recovered by precipitation
in ethyl ether. The product was purified by dissolution in THF and precipitation in ethyl ether, and
vacuum dried for further use.
Synthesis of acetal-PEO-poly-(ε-caprolactone) (acetal-PEO-PCL) and acetal-PEO-poly(α-benzyl
carboxylate-ε-caprolactone) (acetal-PEO-PBCL) block copolymers has been described in our previous
publications in detail [34]. Acetal-PEO-PBCL was first prepared through ring opening bulk
polymerization of BCL with acetal-PEO as an initiator. This was followed by hydrogen reduction
of PBCL block catalyzed by Pd/charcoal. Briefly, 600 mg (0.1 mmol) acetal-PEO was reacted with
500 mg (2 mmol) BCL under vacuum at 145 ◦C for 6 h using stannous octoate as catalyst. Then
the benzyl groups on acetal-PEO-PBCL were removed through hydrogen reduction in anhydrous
THF catalyzed by Pd/charcoal. The produced acetal-PEO-PCCL was recovered and purified by
precipitation in hexane.
2.1.2. Synthesis of GE11 Peptide and GE11 Conjugation to Poly(ethylene
oxide)-poly(α-carboxyl-ε-caprolactone) (PEO-PCCL) Block Copolymers
The GE11 peptide (NH2-YHWYGYTPQNVI-COOH) (Figure S1a) was synthesized chemically
using standard Fmoc solid phase peptide synthesis as described previously by the laboratory of
Kaur et al. [35]. Briefly, the first amino acid, isoleucine, was coupled to a 2-chlorotrityl resin (0.1 mM)
(NovaBiochem, San Diego, CA, USA) at 5-fold excess using the N,N diisopropyl ethylamine (DIPEA) at
room temperature for 5 h. Further amino acids were added automatically using an automated peptide
synthesizer (Tribute, Protein Technology, Inc., Tucson, AZ, USA). The completed peptide was ultimately
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released from the resin with a mixture of 90% trifluoroacetic acid (TFA), 9% dichloromethane, and
1% triisopropylsilane (∼10 mL) for 90 min at room temperature. The cleaved peptide combined with
TFA was then concentrated, washed with diethyl ether, dissolved in water and purified. Purification
was done using C18 semi-preparative (1 cm × 25 cm, 5 μm) reverse-phase high-pressure liquid
chromatography (HPLC) (Varian Prostar, MD, USA) with a gradient of acetonitrile−H2O (10−70%
containing 0.05% TFA, 2 mL/min, 45 min run time). The peptide solution was freeze-dried to give
pure peptide as a white powder. Analytical (0.46 cm × 25 cm, 5 μm) HPLC revealed a purity of 97%
at 220 nm with retention time (Rt) = 13 min, and the MALDITOF (Voyager spectrometer, Applied
Biosystems, Foster City, CA, USA) mass analysis showed [M + H]+ for the peptide as 1541.6 (calculated
1540.7) (Figure S1b).
The GE11 peptide was conjugated to the micellar surface through a reaction with the functional
acetal groups on the micellar shell [34]. First, acetal-PEO6000-PCCL3000 (with 87% reduction of PBCL to
PCCL) was assembled into polymeric micelles. Briefly, a diblock copolymer of acetal-PEO6000-PCCL3000
(20 mg) was dissolved in 1 mL acetone and added dropwise to 4 mL water while stirring. The solution
was stirred for 24 h under a fume hood to remove acetone by evaporation. On the following day,
the aqueous solution of polymeric micelles was acidified to pH 2 with 0.5 M HCl and stirred for 1 h at
room temperature to produce aldehyde modified polymeric micelles. The resulting solution was then
neutralized with 0.5 M NaOH. The osmolarity of the micellar solution was adjusted by addition of an
appropriate volume of concentrated 10X P phosphate-buffered saline (PBS). An aqueous solution of
the peptide (1.95 mg peptide in 500 μL of 1% dimethyl sulfoxide (DMSO)) (1:2 peptide to polymer,
mole:mole ratio) was added and incubated with the aldehyde bearing micelles at room temperature for
2 h under moderate stirring. Subsequently, sodium cyanoborohydride (NaBH3CN) (1 mg) was added
to the polymer to reduce the Schiff’s base. After 48 h of reaction, the unreacted peptide and reducing
agent were removed by extensive dialysis using Spectrapor, MWCO 3500 (Spectrum Laboratories, Inc.,
Rancho Dominguez, CA, USA) against distilled water (24 h). The conjugation efficiency of the peptide
to polymeric micelle was assessed by gradient reversed phase HPLC method measuring unreacted
peptide concentration. A μ Bondpack (Waters Corp., Milford, MA, USA) C18 analytical column (10 μm
3.9 × 300 mm) was used. Gradient elution was performed at a flow rate of 1 mL/min using a Varian
Prostar 210 HPLC System. Detection was performed at 214 nm using a Varian 335 detector (Varian Inc.,
Mulgrave, Australia). The mobile phase consisted of 0.1% TFA in H2O (solution A) and acetonitrile
(solution B). The mobile phase was programmed as follows: (1) 100% A for 1 min, (2) linear gradient
from 100% A to 60% A in 20 min, (3) linear gradient from 60% A to 0% A in 4 min, (4) 0% A for 2 min, (5)
linear gradient from 0% A to 100% A in 4 min, and (6) 100% A for 5 min. The concentration of unreacted
peptide was calculated based on a calibration curve for the peak height of known concentrations of
GE11 peptide in aqueous solution of 1% DMSO. The amount of conjugated peptide was calculated by
subtracting the amount of unreacted peptide from the initial peptide added to the reaction. The peptide
conjugated polymer was then freeze-dried until further use. 1H NMR was performed on a Bruker,
ASENDTM 600 MHz spectrometer (Billerica, MA, USA) to confirm the conjugation of the GE11 peptide
on PEO-PCCL block polymer. Samples (GE11 peptide, acetal-PEO-PCCL, and GE11-PEO-PCCL)
were dissolved in deuterated DMSO at a concentration range of 3–5 mg/mL and 1H NMR spectra
were generated.
2.1.3. Preparation of Plain and GE11 Cisplatin Micelles
GE11-PEO-PCCL or PEO-PCCL block copolymers were assembled into cisplatin polymeric
micelles as reported previously with slight modification [15]. Briefly, either of the diblock copolymer
(20 mg) was mixed with 4 mL aqueous solution of cisplatin (20 mg) and sodium bicarbonate (4–5 mg).
The mixture was stirred for 24 h at room temperature. We couldn’t dissolve the whole amount
of cisplatin in such volume, but high cisplatin levels were identified to be required to enhance
complexation with the polymer and increase its loading levels. After micelle preparation, initially
using centrifugation, the undissolved portion of cisplatin was separated from the micellar solution.
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In the next step, the unbound cisplatin was removed by ultrafiltration (3600× g for 40 min) using
Centricon® plus centrifugal filter units (MWCO 3 KDa, Millipore, Billerica, MA, USA) and micelles
were re-suspend in 4 mL doubly distilled water. The final concertation of cisplatin was determined
using ion coupled plasma mass spectrometer (ICP-MS).
2.1.4. Measurement of the Size and Zeta Potential of Plain and GE11 Cisplatin Micelles
The average hydrodynamic diameter and size distribution of the GE11 cisplatin micelles were
estimated and compared to plain cisplatin micelles by dynamic light scattering (DLS) using Malvern
Zetasizer (Nano ZEN3600, Malvern, UK). The zeta potential of polymeric micelles was also estimated
using the same equipment.
2.1.5. Measurement of the Critical Micellar Concentration (CMC) of Plain and GE11 Cisplatin Micelles
The CMC of the GE11 cisplatin micelles were estimated and compared to plain cisplatin micelles
by DLS [36] using Malvern Zetasizer (Nano ZEN3600, Malvern, UK). For this purpose, plain and
GE11 cisplatin micelles having polymer concentrations ranging from 1000 to 3 μg/mL were prepared.
Briefly, from a stock solution of 1000 μg/mL micellar solution, different concentrations of micelles were
prepared by serial dilution. The lowest prepared concentration was 3 μg/mL. The intensity of scattered
light for each of concentrations was measured at a scattering angle of 173◦ at 25 ◦C. The average
intensity of scattered light from three measurements was plotted against polymer concentration.
The intersection of the two linear graphs in the sigmoidal curve, i.e., the onset of a rise in the intensity
of scattered light, was defined as the CMC value.
2.1.6. Measurement of Cisplatin Encapsulation
The Pt(II) content in the GE11 cisplatin micelles was determined by ion coupled plasma mass
spectrometer (ICP-MS, Agilent Technologies, Tokyo, Japan). The ICP operated at a radiofrequency
power of 1550 W, and the flow rate of argon carrier gas was 0.9–1.0 L/min. Pt(II) was monitored at
m/z 195. A standard curve in the Pt(II) concentration range of 100, 50, 20, 10, and 1 ppb was generated
using atomic absorption standard. Appropriate dilutions of the test samples were prepared in 1%
nitric acid (HNO3). Data were acquired and processed by ICP-MS ChemStation (Agilent Technologies,
Santa Clara, CA, USA). The encapsulation efficiency (EE) and drug loading (DL) were calculated using
the following equations:
EE (%) =
the amount o f encapsulated cisplatin (mg)
the total f eeding amount o f cisplatin (mg)
× 100
DL (%) =
the amount o f encapsulated cisplatin (mg)
the total amount o f polymer (mg)
× 100
2.1.7. In Vitro Release Studies
The release of free cisplatin and its micellar formulations (plain and GE11 cisplatin micelles) was
measured using equilibrium dialysis method in PBS (pH = 7) and acetate buffer saline (pH = 5). Briefly,
free cisplatin, plain or GE11 cisplatin micelles (4 mL) containing 30 μg/mL cisplatin were placed into
a dialysis bag (Spectrapor, MWCO 3500) in a beaker containing 500 mL PBS or acetate buffer saline.
The release study was performed at 37 ◦C in a Julabo SW 22 shaking water bath (Seelbach, Germany).
At selected time intervals, 100 μL samples were withdrawn from the inside of dialysis bag and replaced
with fresh medium for ICP-MS analysis. The percent cumulative amount of cisplatin released was
calculated and plotted as a function of time. The release profiles of plain and GE11 cisplatin micelles
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were compared using the similarity factor, f2, and the profiles were considered significantly different if
f2 < 50 [37]. The similarity factor, f2, was calculated using the following equation [38].












where n is the sampling number, Rj and Tj are the percents released of the reference and test
formulations at each time point j.
2.1.8. Cell Culture
MDA-MB-231 cells was obtained from ATCC (Manassas, VA, USA) and maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (Invitrogen, Karlsruhe, Germany), 100 units/mL
penicillin, and 100 μg/mL streptomycin in a humidified incubator under 95% air and 5% CO2 at 37 ◦C.
For hypoxic conditions, cells were cultured in a CO2 incubator maintained at 94% N2, 5% CO2, and
1% O2.
2.1.9. Flow Cytometric Detection of Apoptosis using Annexin V-FITC and Propidium Iodide
Annexin V-FITC (Fluorescein IsoThioCyanate) and propidium iodide (PI) from BD Biosciences
(FITC Annexin V Apoptosis Detection Kit I, #556547, BD Pharmingen™) was used to measure apoptotic
cells by flow cytometry according to the manufacturer’s instructions. Briefly, both floating and
adherent cells were harvested; adherent cells were collected by adding a warm solution of 10 mM
ethylenediaminetetraacetic acid (EDTA) in PBS. The cells were centrifuged at 500 g for 5 min, washed
with ice-cold 1 PBS twice and re-suspended in 400 μL binding buffer containing 5 μL Annexin V-FITC
and 5 μL PI for 15 min at room temperature in the dark. Fluorescence was induced on a Beckman
Coulter Cytomics Quanta SC MPL flow cytometer (10,000 events per sample). Spectral compensation
was performed using Cell Lab Quanta analysis software (Cell Lab Quanta™ SC MPL, Beckman Coulter,
Mississauga, ON, Canada). The number of viable and apoptotic cells were quantified by events in
the quadrants. The results were expressed as the percentage of apoptotic cells at the early stage
(PI negative and Annexin V positive, lower right quadrant), apoptotic cells at the late stage (PI positive
and Annexin V positive, upper right quadrant), necrotic cells (PI positive and Annexin V negative,
upper left quadrant) and viable cells (PI negative and Annexin V negative, lower left quadrant).
2.1.10. MTT Assay
MDA-MB-231 cells (9 × 103 cells/well) were seeded in 96-well plates overnight, and on the
following day, they were exposed to increasing concentration of cisplatin (free drug/cisplatin micelles)
and then incubated for 48 h under hypoxia or normoxia. For combination therapy, MDA-MB-231
cells (9 × 103 cells/well) were seeded in 96-well plates overnight. On the following day, cells were
treated with Tat-tagged form of cyclic peptide inhibitor of HIF-1 (cyclo-CLLFVY) named P1 (50 μM per
well) [39] or Stattic (2 μM per well), or combination of P1 and Stattic for 4 h under normoxia, to give a
final concentration of 2 μM and 50 μM per well, respectively. After 4 h incubation, cells were treated
with cisplatin (50 μM) (as a free drug, plain cisplatin micelles or GE11 cisplatin micelles) and then
incubated for additional 48 h under hypoxic or normoxic conditions. Cellular viability was assessed by
the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide (MTT) assay. Briefly, MTT solution
(5 mg/mL) was added to incubated cells for 4 h at 37 ◦C. Then the medium was replaced by DMSO
to dissolve the crystals. Optical density was measured spectrophotometrically using a plate reader
(Synergy H1 Hybrid Reader, Biotek, Winooski, VT, USA) at 570 nm. The cellular activity ratio was
represented relative to control (untreated group, cells with media only).
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2.1.11. Western Blot
To measure the expression level of different proteins, MDA-MB-231 cells (2 × 105 cells/well)
were seeded in 6-well plates overnight. After treatment, cells were washed with cold 1X PBS and
lysed using radioimmunoprecipitation assay buffer (RIPA lysis buffer) that was supplemented with
0.1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), a protease Inhibitor Cocktail Set III,
Animal-Free–Calbiochem (#535140, Millipore), and a phosphatase Inhibitor Cocktail Set II (#524625,
Millipore). The lysate was then incubated on ice for 30 min, which was followed by centrifugation at
17,000× g for 20 min to remove genomic DNA. Protein quantification was made by the bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL, USA), and equal amounts of protein (35–40 μg)
were loaded in 4−15% Tris-Glycine gradient gel (#456-1084, Biorad, Pleasanton, CA, USA). After gel
electrophoresis, proteins were transferred to a nitrocellulose membrane. Membranes were probed with
antibodies against phospho-STAT3 (Tyr705) (pSTAT3) (#9131, Cell Signaling Technologies, Danvers,
MA, USA), Total-STAT3 (T-STAT3) (#8768s, Cell Signaling Technologies), EGFR (#2232, Cell Signaling
Technologies), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (#sc-47724, Santa Cruz
Biotechnologies). Proteins were then detected using peroxidase-conjugated anti-mouse IgG (#7076,
Cell Signaling Technologies) or anti-rabbit IgG (#7074, Cell Signaling Technologies) and visualized
by enhanced chemiluminescence (Pierce ECL Western Blotting Substrate, #32106, Thermo Scientific,
Rockford, IL, USA). Representative results of three independent Western blot analyses are shown in
the Figures 4 and 5, Figure S4 and Figure S5.
2.1.12. Cisplatin Cellular Uptake
Cellular uptake of cisplatin was quantified by ICP-MS (Agilent Technologies, Tokyo, Japan).
MDA-MB-231 cells (65 × 104 cells/flask) were seeded in 25 cm2 flasks overnight. Cells were
exposed to free cisplatin or its micellar formulations (plain and GE11 cisplatin micelles) (166 μM)
for 24 h under normoxic and hypoxic conditions. On the following day, the medium was aspirated,
cells were rinsed with cold PBS, detached using trypsin-EDTA, aliquoted in duplicate in 1.5 mL
micro-centrifuge tubes and pelleted by centrifugation at 500× g for 5 min. One of each duplicate
cell pellet was digested with 20% (v/v) HNO3 overnight at 60 ◦C and analyzed for Pt(II) content by
ICP-MS. The other duplicate was lysed using RIPA lysis buffer that was supplemented with 0.1 mM
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA), a protease Inhibitor
Cocktail Set III, Animal-Free–Calbiochem (#535140, Millipore), and a phosphatase Inhibitor Cocktail
Set II (#524625, Millipore) and quantified for protein content using the BCA protein assay kit (Pierce,
Rockford, IL, USA). The cell uptake was expressed as cisplatin/cell protein (μg)/μg).
2.1.13. Statistical Analysis
The statistical analysis was performed by Graphpad Prism (version 5.00, Graphpad Software Inc.,
La Jolla, CA, USA). Statistical analysis was performed either using unpaired Student’s t test or one-way
ANOVA (analysis of variance) with Tukey post-test analysis. Statistical significance is denoted by
(p < 0.05). All graphs represent the average of at least three independent experiments with triplicates
unless mentioned otherwise in the text, or graphs. Results were represented as the mean ± standard
deviation (SD).
3. Results
3.1. Successful Synthesis of GE11 Conjugated Poly(ethylene
oxide)-poly(α-carboxyl-ε-caprolactone)(PEO-PCCL) Block Copolymer and Its Self-assembly
GE11 showed a conjugation efficiency reaching 70% of an added peptide as quantified by reversed
phase HPLC to the acetal-PEO-PCCL micellar surface (Figure S2). The molar conjugation percent for
GE11 conjugated PEO-PCCL block polymer was ∼35%. In other words, for 100 mole block copolymers,
there is around 35 mole conjugated peptide.
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The peptide conjugation was also confirmed by 1H NMR (Figure S3). Signals from 6.5 to 8.5 ppm
in 1H NMR spectra of GE11 peptide correspond to aromatic protons in its structure (n = 20). To calculate
the molar conjugation percent for GE11-conjugated PEO-PCCL block polymer, first, the summation
of integration of peaks from 6.5 to 8.5 ppm in acetal-PEO-PCCL spectra was subtracted from the
summation of integration of peaks from 6.5 to 8.5 ppm in GE11-PEO-PCCL spectra. The obtained
value corresponded to the integration of aromatic hydrogens of GE11 peptide (n = 20). The degree of
conjugation of GE11 was then determined by calculating the peak intensity ratio of methylene protons
of PCCL segment (OCH2CH2CH2CH2 ((COOH)CO): δ = 4.1 ppm) and the value calculated for the
integration of aromatic hydrogens of GE11 peptide. The calculated degree of conjugation was 0.45
which corresponds to 45 mole peptide per 100 mole block copolymers (Figure S3). The calculated
peptide conjugation degree by 1H NMR (0.45 mol/mol) was slightly higher than what was calculated
by HPLC (0.35 mol/mol).
As summarized in Table 1, both plain and GE11 cisplatin micelles showed similar average
diameters around 80 nm with a low polydispersity index. Critical micellar concentration (CMC),
cisplatin encapsulation efficiency and drug loading of both micelles were also comparable. Overall,
both micellar formulations showed similar characteristics, and it appeared as though the presence of
the GE11 peptide did not alter different micellar properties (p > 0.05, Student’s t test).
















Cisplatin plain micelle 84.4 ± 2.6 0.263 ± 0.11 −13.3 ± 1.2 65.1 ± 5.5 12.4 ± 0.99 12.0 ± 1.41 3.93 ± 0.31
GE11 cisplatin micelle 84.1 ± 3.2 0.235 ± 0.18 −13.6 ± 0.95 70.5 ± 7.2 13.0 ± 2.95 15.5 ± 3.53 4.01 ± 0.93
a Plain and GE11 cisplatin micelles consist of PEO6000-PCCL3000 block copolymers. The number shown in the
subscript indicates average number molecular weight of each block determined by 1H NMR spectroscopy. b Z
average measured by dynamic light scattering (DLS). c Average polydispersity index (PDI) of micellar size
distribution measured by DLS. d Measured from the onset of rise in the intensity values of scattered light as a function
of concentration of micelles by DLS. e Encapsulation efficiency (%) = the amount o f encapsulated cisplatin (mg)the total f eeding amount o f cisplatin (mg) × 100.
f Drug loading (%) = the amount o f encapsulated cisplatin (mg)the total amount o f polymer (mg) × 100.
The in-vitro release of cisplatin from both micelles was investigated in phosphate buffered saline
(PBS) (pH = 7.4), and acetate buffered saline (pH = 5.0) using a dialysis method. Both micellar
formulations showed burst release at the early time points (<1 h). The cumulative drug release
appeared to be significantly slower at the later time points (>2 h) as compared to free drug for
both micelles, however (Student’s t test, p < 0.05). As shown in Figure 1a, micellar formulations
showed ∼60% release of cisplatin within 30 min in PBS as compared to ∼80% release of free drug in
the same media. After 48 h, in PBS, ∼85% of the incorporated drug was released from micelles to
media, compared to complete 100% release for free drug. Similar results were obtained for micellar
formulations of cisplatin in acetate buffered saline (pH = 5.0) (Figure 1b) where a significant reduced
drug release was achieved at later time points (>2 h) (Student’s t test, p < 0.05) for micellar cisplatin
compared to free drug. No difference was observed between the release profiles of plain versus GE11
cisplatin micelles in either media (f 2 > 50). Of note, in acetate buffered saline (pH = 5) complete
release of drug after 48 h was seen, whereas only 80% drug was released in PBS at the same time point
(pH = 7.4) (Figure 1b), although the overall profile of drug release did not show a significant difference
between the two pHs (f2 > 50).
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Figure 1. Percent cumulative release profile of cisplatin from plain and GE11 cisplatin micelles at
different pHs in (a) PBS (pH = 7.4) and (b) acetate buffer saline (pH = 5.0). (*) denotes where the
cumulative release of free drug appeared to be significantly different from plain and GE11 cisplatin
micelles at the related time points (p < 0.05, Student’s t test). Data are represented as mean ± SD (n = 3).
3.2. Hypoxia Induces Chemoresistance to Free Cisplatin in MDA-MB-231 Cells
The MDA-MB-231 cells incubated under hypoxic conditions were shown to be less sensitive
to cytotoxic effects of cisplatin as measured by MTT assay. Cells cultured under hypoxia had a
significantly higher number of colonies surviving cisplatin treatment than cells grown under normoxic
conditions, as well (Figure 2a). Moreover, apoptosis induced by cisplatin was significantly reduced
under hypoxia, as evidenced by a significant decrease in the proportion of late apoptotic cells measured
by FITC Annexin V/propidium iodide (PI) assay (Figure 2b). The viable proportion of cells also showed
a significant increase under hypoxic conditions compared to normoxic ones, when treated with cisplatin
(Figure 2b). Interestingly, the proportion of necrotic cells following treatment with cisplatin under
hypoxic conditions increased compared to normoxia, pointing to a change in the predominant mode
of cisplatin-induced cell death under hypoxic conditions. This phenomenon was also previously
reported for prostate carcinoma [40]. Similar to observation on free cisplatin (Figure 3a), we found
less sensitivity towards polymeric micellar cisplatin in MDA-MB-231 cells cultured under hypoxic
conditions by MTT assay (Figure 3b,c). There was also no significant difference between cell responses
to micellar versus free cisplatin irrespective of the oxygen content for cell culture (one-way ANOVA
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Figure 2. Hypoxia confers chemoresistance to free cisplatin in MDA-MB-231 cells. (a) Colony formation
ability was assessed for cells treated with cisplatin (8.3 μM) after 24 h incubation under normoxic or
hypoxic conditions. Cells were then re-plated at a density of 500 cells/well in duplicate in six-well plates
under normoxia. The number of colonies formed from 500 cells after 7 days was graphed. (b) Cisplatin
induced-apoptosis under normoxic and hypoxic conditions was measured by flow cytometric analysis
of Fluorescein IsoThioCyanate (FITC) Annexin V staining in a buffer containing propidium iodide.
MDA-MB 231 cells were left untreated or treated with increasing concentrations of cisplatin for 48 h.
Flow cytometry analysis showed different populations of (Q1) necrotic or already dead cells (PI
positive), (Q2) cells in end-stage apoptosis (FITC Annexin V and PI positive), (Q3) viable cells (FITC
Annexin V and PI negative), and (Q4) cells in early stage of apoptosis (FITC Annexin V positive and
PI negative). 2D plot is representative of cells treated with cisplatin (33 μM) under normoxia for 48 h.
Data are represented as mean ± SD (n = 3). (*) denotes a significant difference between hypoxic and
































































Figure 3. Hypoxia confers chemoresistance to free and micellar formulations of cisplatin in
MDA-MB-231 cells. Viability of MDA-MB-231 cells was measured by MTT assay for cells treated
with increasing concentrations of (a) free cisplatin; (b) plain cisplatin micelles and (c) GE11 cisplatin
micelles under hypoxic or normoxic conditions for 48 h. (*) denotes a significant difference between
groups at each individual concentration (Student’s t test, p < 0.05).
3.3. Modification of Cisplatin Micelles with GE11 Peptide Enhances the Cellular Uptake of Cisplatin, but Does
Not Affect its Cytotoxicity in MDA-MB-231 Cells
Modification of polymeric micelles with EGFR targeting peptide, GE11, was not able to increase
the cytotoxicity of incorporated cisplatin towards MDA-MB-231 cells under normoxic or hypoxic
conditions (Figure 3c versus 3b).
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This was despite high levels of EGFR expression by MDA-MB-231 cells under normoxic or hypoxic
conditions (Figure 4a) [17], that led to significantly higher cisplatin uptake following modification of
polymeric micelles with GE11 peptide compared to plain micelles under both conditions (Figure 4b).
As shown in Figure 4a, the levels of EGFR expression under hypoxia were time-dependent. At the
24-h time point, there was no significant difference between the expression of EGFR under hypoxia
and normoxia. However, the expression of EGFR was reduced under hypoxia for longer incubation
times. Thus, for the purpose of comparability, we chose the 24-h time point for performing the cell
uptake studies. When we treated the cells with the low concentration of cisplatin, due to multiple
steps of digestion and washing for a sample preparation, we could not quantify the (low) amount
of intracellular cisplatin. To compensate for the limitation of the measurement method, we chose to
treat the cells with a high concentration of cisplatin (166 μM). As shown in Figure 4b, intracellular
levels of cisplatin were found to be significantly reduced under hypoxia for the free drug (∼1.6-fold
decrease) as well as plain cisplatin micelles (∼1.4-fold decrease). Nonetheless, the presence of the
GE11 peptide on micelles appeared to compensate for the hypoxia-mediated reduction in cellular




































































































































Figure 4. Modification of cisplatin micelles with GE11 peptide enhances the cellular uptake of cisplatin
in MDA-MB-231 cells. (a) High levels of epidermal growth factor receptor (EGFR) expression under
normoxia and hypoxia in MDA-MB-231 cells; (b) The GE11-peptide decoration of cisplatin micelles
enhanced cellular uptake of cisplatin under hypoxia in MDA-MB-231 cells and bridged the gap of its
cellular uptake under hypoxia and normoxia. Cisplatin content was measured by ion coupled plasma
mass spectrometer (ICP-MS) after 24 h treatment of cells with cisplatin (166 μM) under hypoxia or
normoxia. (*) denotes a significant difference between compared groups (Student’s t test, p < 0.05).
3.4. Co-Treatment with Pharmacological Inhibitors of HIF-1 and STAT3 Potentiates the Anticancer Activity of
Free Cisplatin, as well as Its Micellar Formulations in Hypoxic MDA-MB-231 Cells
We have previously reported on the role of STAT3 up-regulation under hypoxia as a mediator
of hypoxia-induced resistance to cisplatin in MDA-MB-231 cells [30,41]. Here, we assessed the
chemo-sensitizing effect of pharmacological inhibitors of STAT3 and/or HIF-1 (a known mediator
of hypoxia- induced chemoresistance) in MDA-MB-231 cells treated with different formulations of
cisplatin. For this purpose, a cyclic peptide that inhibits the assembly and function of the HIF-1
transcription factor (cyclo-CLLFVY) [39], as well as a known inhibitor of STAT3, i.e., Stattic, [42] were
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used in combination with free, plain and GE11 cisplatin micelles and the cytotoxicity of cisplatin
against MDA-MB-231 cells was measured using MTT assay under normoxic and hypoxic conditions.
The tat-tagged form of cyclo-CLLFVY (named P1), a cyclic peptide which has shown to prevent
the dimerization of HIF-1α/HIF-1β complex by binding to HIF-1α and subsequently inhibit HIF-1
mediated hypoxia response [39,43], was used as a HIF-1 inhibitor. Stattic, a small molecule shown to
inhibit the dimerization and activation of STAT3 mainly through prevention of its phosphorylation [42],
was used as a STAT3 inhibitor. As shown in Figure 5a and Figure S4, successful inhibition of
phosphorylation of STAT3 was achieved in MDA-MB-231 cells using Stattic (2 μM). Both P1 and
Stattic showed minimal non-specific cytotoxicity at their respective effective dose for the inhibition of
HIF-1 and STAT3 (50 and 2 μM, respectively) as shown by MTT assay (Figure 5b).
Under normoxic conditions, co-treatment of MDA-MB-231 cells with P1 and cisplatin formulations
showed a trend towards potentiating the anticancer effect of cisplatin, plain cisplatin micelles or
GE11 cisplatin micelles, as measured by MTT assay, although the difference was not statistically
significant (Figure 5c–e, white bars). However, under hypoxic conditions, combination of P1 with free
cisplatin (Figure 5c, black bars), plain cisplatin micelles (Figure 5d, black bars) and GE11 cisplatin
micelles (Figure 5e, black bars) significantly enhanced the cytotoxicity of cisplatin as part of each
formulation (one-way ANOVA with Tukey post-test, p < 0.05). This was not observed when different
formulations of cisplatin were combined with the inhibitor of STAT3, Stattic, under normoxic conditions
(Figure 5c–e, white bars). Under hypoxia, a combination of Stattic with free cisplatin (Figure 5c, black
bars), plain cisplatin micelles (Figure 5d, black bars) and GE11 cisplatin micelles (Figure 5e, black

































































































































































































































































Figure 5. Dual pharmacological inhibition of signal transducer and activator of transcription 3
(STAT3) and hypoxia inducing factor-1 (HIF-1) in combination with free cisplatin or its micellar
formulations successfully reversed hypoxia-induced chemoresistance. (a) Lower expression of pSTAT3
in MDA-MB-231 cells after treatment with STAT3 inhibitor (Stattic). Phosphorylation of STAT3 Tyr705
was analyzed by Western blot. (b–d) Viability of MDA-MB-231 cells was measured by MTT assay
for cells which first pre-incubated with the HIF-1 inhibitor (named P1) (50 μM), the STAT3 inhibitor
(Stattic) (2 μM) or both under normoxia for 4 h and then incubated under hypoxia for additional 48 h
(b) in the absence of cisplatin or in the presence of 50 μM (c) free drug; (d) plain cisplatin micelles and
(e) GE11 cisplatin micelles. (*) denotes a significant difference between compared groups (one-way
ANOVA with Tukey post-test, p < 0.05).
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Simultaneous co-treatment of cells with inhibitors of HIF-1 and STAT3 enhanced the cytotoxic
effects of free cisplatin (Figure 5c), plain cisplatin micelles (Figure 5d) and GE11 cisplatin micelles
(Figure 5e) in both normoxic and hypoxic MDA-MB-231 cells (one-way ANOVA with Tukey post-test,
p < 0.05). Simultaneous co-treatment of cells with inhibitors of HIF-1 and STAT3 was the most
effective approach in the reversal of HICR for free cisplatin as well its nano-formulations in this
study. Co-treatment of cells with inhibitors of HIF-1 and STAT3 increased cisplatin toxicity under
both conditions for all different drug formulations; the enhancement was more noticeable under
hypoxia. For example, there was a ∼3.51-fold increase of cytotoxicity under hypoxia versus ∼1.93
under normoxia for free drug, ∼2.42-fold increase of cytotoxicity under hypoxia versus ∼2.27 under
normoxia for plain cisplatin micelles, and ∼2.46-fold increase of cytotoxicity under hypoxia versus
∼1.97 under normoxia for GE11 cisplatin micelles. All the comparisons were made to cells treated
with the related formulation in the absence of the inhibitors. Overall, free drug showed the highest
cytotoxicity enhancement (∼3.51-fold increase) after co-treatment of cells with the inhibitor of HIF-1
and STAT3, following by GE11 cisplatin micelles (∼2.46-fold increase) and plain cisplatin micelles
(∼2.42-fold increase) under hypoxia; whereas the cytotoxicity enhancement was similar for all the
formulations under normoxia (∼2.05-fold increase).
In all of the above experiments, irrespective of the oxygen pressure under which the cells were
cultured, no significant difference between the cytotoxicity of free drug and micellar formulations was
observed. In addition, GE11 cisplatin micelles showed a similar profile of toxicity as compared to plain
cisplatin micelles in MDA-MB-231 cells.
4. Discussion
Hypoxia is widely known to be associated with chemoresistance in different types of solid
tumors [2,3] including TNBC [4,5]. The increase in the expression of HIF-1α has long been associated
with the development of chemoresistance [4]. More recently, an increase in the activation of STAT3
following hypoxia is shown to be at least partly responsible for mediating chemoresistance in the
human ovarian cancer (i.e., A270 cells) and TNBC (i.e., MDA-MB-231 cells) [3,30]. Overexpression of
epidermal growth factor receptor (EGFR) and tumor hypoxia have also been shown to correlate with
worse outcomes in several types of cancers including breast cancer [16,44]. This coexistence of hypoxia
and EGFR may implicate a survival advantage of hypoxic cells that also express EGFR.
Design and development of nanotechnology products as a means to enhance the therapeutic
index of anticancer drugs has been explored intensely in the past few decades. In successful cases,
nano-formulations of anticancer drugs have shown to extend their blood circulation time leading to
improved accumulation of the drug in solid tumors mostly by the enhanced permeability and retention
(EPR) effect and/or decrease drug exposure and toxicity to normal tissues [9,45]. However, owing
to their nanoscopic size and slow drug release, nano-formulations of the anticancer drugs are also
speculated to provide limited access of the drug to hypoxic cancer cells that are located in areas of
tumor away from blood vessels [46].
The objective of this study was first to evaluate the cytotoxic behavior of a newly developed
nano-formulations of cisplatin on hypoxia-induced chemoresistant (HICR) MDA-MB-231 cells, a
TNBC cell line; and secondly to explore feasible approaches for overcoming HICR against free and
nano-formulations of cisplatin. For the latter purpose, we developed EGFR-targeted cisplatin micelles
using an EGFR-ligand, GE11 peptide and investigated the effect of combination therapy with inhibitors
of HIF-1 and STAT3 as the key mediators of HICR in this cell line.
Similar to plain cisplatin micelles, the GE11 cisplatin micelles showed slightly accelerated drug
release in an acidic environment (Figure 1b). The ability of acid-triggered release of these micelles
is important; tumors, particularly those with hypoxic regions, usually have lower extracellular pH
than that of normal tissues [47]. In this case, the acid-triggered release of cisplatin from the micellar
formulations may encourage drug release from the nano-formulation in the hypoxic tumor. This may
compensate for the restrictions faced by these nano-formulations for penetrating the tumor core. It is
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of note that this feature, i.e., the acid-triggered release of cisplatin from its micellar formulations, was
not investigated in our cell cytotoxicity studies as the pH of the cell culture media was maintained
at 7.4.
In concert with our previous study [30], we found that hypoxia significantly induced resistance
against free cisplatin in MDA-MB-231 cells (Figures 2 and 3a). MDA-MB-231 cells also showed
similar resistance against nano-formulations of cisplatin under hypoxia (Figure 3b,c). GE11 cisplatin
micelles showed increased intra-cellular levels of cisplatin compared to free and plain cisplatin micelles
under hypoxia, reaching intracellular cisplatin levels similar to that of the free drug under normoxic
conditions (Figure 4b). EGF receptors (EGFR) are internalizing receptors [48] with GE11 peptide as
their ligand [29]. Thus, surface modification of cisplatin micelles with the GE11 peptide in this study
was made to compensate for lower uptake of cisplatin under hypoxic conditions in MDA-MB-231 cells
expressing high levels of EGFR. The upregulation of ATP-binding cassette (ABC) drug transporters,
particularly ABCC2 and ABCC6, has been shown as one of the possible mechanisms responsible for
active efflux of free cisplatin under hypoxia in MDA-MB-231 cells, which subsequently contributes to
a decrease in the cellular levels of free cisplatin in this cell line [30]. Thus, the GE11 modified micelles
have a potential to bypass ABC-transporter mediated drug efflux.
In spite of enhanced intracellular cisplatin levels by the GE11 modified micelles, cytotoxicity of
cisplatin as part of GE11 micelles was not improved over plain cisplatin micelles, and both formulations
showed similar cytotoxicity in MDA-MB-231 cells under normoxic and hypoxic conditions. In addition,
irrespective of the oxygen pressure under which the cells were cultured, no significant difference
between the cytotoxicity of free drug and micellar formulations was observed. We are speculating two
reasons for this observation: (a) release of cisplatin from micelles at > 24 h incubation of micelles with
the cells have contributed to the similar profile of toxicity between free drug and micellar formulations;
(b) the increased level of cell uptake for cisplatin by GE11 cisplatin micelles is not enough to pass the
threshold required for bypassing the mechanisms of cisplatin resistance. More thorough studies are
required to elucidate the reason, which will be the subject of our future investigations.
The master regulator of cellular adaptation under hypoxia is believed to be the hypoxia-inducible
factor (HIF) protein [47,49]. HIF is a heterodimeric transcription factor comprised of an
oxygen-regulated unit, HIF-1α, as well as a constitutively expressed beta unit, HIF-1β. In the presence
of oxygen, once HIF-1α is produced; it will be hydroxylated, ubiquitinated, and degraded. In contrast,
in the absence of oxygen, HIF-1α is stabilized, dimerizes with HIF-1β, and the HIF heterodimers
translocate to the nucleus where it activates the transcription of various downstream targets, many of
which are known to be involved in cancer aggressiveness and chemoresistance [47,49,50]. The HIF-1
inhibitor used in our study (P1) specifically inhibits HIF-1α dimerization with HIF-1β and subsequently
inhibits HIF-1 transcription factor activity [39]. Our results showed that the combination of P1 with
cisplatin significantly enhanced cisplatin toxicity under hypoxia; however, it was not effective under
normoxic conditions. Co-treatment of cells with the HIF-1 inhibitor resulted in similarly enhanced
cytotoxicity for all cisplatin formulations under hypoxia as compared to cells treated with the related
formulation in the absence of inhibitor. The effectiveness of combination therapy under hypoxia is
likely due to the higher expression of HIF-1α under hypoxia as compared to normoxic conditions.
When combining a STAT3 inhibitor (Stattic) with cisplatin treatment, we did not observe any
significant changes in the profile of cytotoxicity of cisplatin in MDA-MB-231 cells. This was unexpected
given the results of previous studies supporting a role for activation of STAT3 in conferring HICR to
cisplatin [3,30], and the effectiveness of STAT3 siRNA in sensitization of MDA-MB-231 cells to cisplatin.
The exact reason behind the discrepancy is not clear and warrants further investigation. The efficiency
of inhibition of STAT3 activation may be varied following siRNA transfection versus Stattic treatment
at applied doses. The difference in the expression levels of pSTAT3 and its downstream targets involved
in aggressiveness and chemoresistance of cancer cells (e.g., c-Myc [51]) following STAT3 siRNA versus
Stattic treatment is speculated to have a role in this observation (Figure S5).
125
Pharmaceutics 2018, 10, 196
It should be noted that some cancer cells, including MDA-MB-231 cells, constitutively express
high levels of HIF-1α [52] and pSTAT3 [53] under normal oxygen conditions, although their levels of
expression are significantly lower as compared to hypoxia. The inhibition of HIF-1 or STAT3, alone,
was not effective in enhancing the cytotoxic effect of cisplatin in our study under normoxic conditions.
However, when HIF-1 and STAT3 both were inhibited, the cytotoxic effects of cisplatin increased under
both normoxic and hypoxic conditions.
Previous studies have also provided support for the combined targeting of HIF-1 and STAT3 under
hypoxia for enhancing anti-tumor activity. For instance, administration of a series of dual inhibitors
of HIF-1α and STAT3 (in the absence of anticancer agent) resulted in significant anti-proliferative
activity across a panel of various cancer cell lines [54]. Furthermore, it has been shown that the
combination of other pharmacological inhibitors of HIF-1α and STAT3 enhanced prostate tumor
growth suppression [55]. The results of our study, however, provide proof-of-principle for the use of
HIF-1 and STAT3 inhibitors (individually or in combination) for sensitization of resistant cells under
hypoxia to cisplatin and its micellar formulations in TNBC. Our present efforts for combination therapy
are made by separate addition of inhibitors and cisplatin micelles in-vitro. Addition of inhibitors
to the cell culture medium was done a few hours before the treatment with cisplatin or its micellar
formulations. This approach was expected to provide enough time for the inhibitors to execute their
inhibitory effect and sensitize the cells to the treatment. However, moving forward to in-vivo studies,
delivery of both inhibitors and cisplatin within the same or separate micellar formulation can be
explored. The use of nanodelivery systems for drugs is expected to provide a control over the time
and extent of their delivery in solid tumors, maximizing their benefit
5. Conclusions
In summary, we have shown that the modification of cisplatin micelles with EGFR ligand
(i.e., GE11 peptide) compensated for the hypoxia-mediated reduced cisplatin uptake, although this
approach was not successful in increasing the levels of cytotoxicity of the drug. Importantly, our
findings suggest that the potency of conventional (i.e., cisplatin) and nano-formulations (i.e., cisplatin
micelles) can be enhanced under hypoxia once inhibitors of major cellular and molecular players of
hypoxia-induced chemoresistance (i.e., HIF-1 and STAT3) were used in combination. To conclude, we
have provided evidence to support that the rational therapeutic drug combination of sensitizing drugs
with other therapies should be used to overcome drug resistance.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/196/s1,
Figure S1. (a) GE11 peptide structure and (b) MALDI-MS spectrum of GE11 peptide, Figure S2. Monitoring
GE11 peptide conjugation to acetal-PEO-PCCL polymers using HPLC with UV detection at 214 nm, Figure S3.
The conjugation of GE11 peptide onto acetal-PEO-PCCL was confirmed by 1H-NMR spectra of block copolymer
before and after peptide conjugation. Samples (3–5 mg/mL) of acetal-PEO-PCCL and GE11-PEO-PCC were
prepared in DMSO for 1H NMR analysis, Figure S4. Bar graph illustrating quantification of the Western blot
densitometry analysis for Figure 5A. Densitometry data are expressed as fold changes compared to untreated
normoxic group, normalized to GAPDH band intensity, Figure S5. The chosen experimental model for inhibition
of STAT3 activation, STAT3 siRNA transfection versus pharmacological inhibition by Stattic, may result in different
levels of expression of STAT3 and/or its downstream targets such as c-Myc protein. The differential levels of
protein expression in MDA-MB-231 cells after transfection with STAT3 siRNA or treatment with Stattic (2μM) for
24 to 48 hours under hypoxia is depicted by Western blot.
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Abstract: Doxorubicin (DOX) is a very potent and effective anticancer agent. However, the effectiveness
of DOX in osteosarcoma is usually limited by the acquired drug resistance. Recently, Vitamin D (Vit-D)
was shown to suppress the growth of many human cancer cells. Taken together, we synthesized DOX-Vit
D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate
the chemoresistance associated with DOX. For this purpose, MG63 cells were treated with 10 μM DOX
or DOX-Vit D for 24 h. Thereafter, MTT, real-time PCR and western blot analysis were used to determine
cell proliferation, genes and proteins expression, respectively. Our results showed that DOX-Vit D,
but not DOX, significantly elicited an apoptotic signal in MG63 cells as evidenced by induction of
death receptor, Caspase-3 and BCLxs genes. Mechanistically, the DOX-Vit D-induced apoptogens were
credited to the activation of p-JNK and p-p38 signaling pathway and the inhibition of proliferative
proteins, p-Akt and p-mTOR. Our findings propose that DOX-Vit D suppressed the growth of MG63
cells by inducing apoptosis while inhibiting cell survival and proliferative signaling pathways. DOX-Vit
D may serve as a novel drug delivery approach to potentiate the delivery of DOX into cancer cells.
Keywords: doxorubicin; MG63; Vitamin D; DOX-Vit D
1. Introduction
Osteosarcoma (OS) is one of the most widespread and lethal forms of childhood primary bone
cancer [1]. In Canada, OS accounts for about 5% of all tumors in pediatric patients with an incidence
rate of 8 cases per million each year especially in adolescents [2,3]. Despite the substantial progress in
chemotherapies against OS, the mortality rate of OS patients has not been changed significantly due to
chemoresistance and other factors [4].
One of those standard therapies for OS is doxorubicin (DOX), an effective anthracycline
antibiotic [5]. The combination of DOX with other chemotherapeutic agents such as cisplatin, ifosfamide
and methotrexate cured 60–76% of newly diagnosed non-metastatic OS [6]. Although DOX has
improved survival rates in cancer patients, the effectiveness of DOX in OS is usually limited by
the acquired drug resistance. This resistance is dose-dependent and may develop gradually within
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a month or years after the treatment initiation. Though the specific mechanism of chemoresistance
associated with DOX is still unclear, several reports have demonstrated that drug inactivation, increased
DNA damage repair, disturbances in intracellular drug transport and evasion of apoptosis could play a
role in the chemoresistance [7].
Numerous epidemiological reports have suggested a strong association between Vitamin D (Vit-D)
and cancer risk [8,9]. The deficiency of Vit-D has been reported to contribute to the development of
tumors whereas, higher intake of Vit-D was accompanied by a lower incidence of cancer disease [10,11].
Experimental studies using cancer cells or tumors in mice have shown that Vit-D exhibited antitumor
activities through the induction apoptosis in addition to the inhibition of cell proliferation and
differentiation [12,13].
Vit-D can be classified naturally into animal-based Vit-D3 and plant-based Vitamin D2. Vit-D3,
cholecalciferol, is synthesized by the mammalian skin after exposure to sunlight then metabolized into
its active form, calcitriol, in the liver and kidneys [14]. Upon binding to its receptor, calcitriol activates
several signaling pathways that regulate bone metabolism and calcium homeostasis. Of interest,
calcitriol was shown to inhibit the growth, proliferation and differentiation of many cancer cell lines
such as breast, prostate and colon cancers [15,16]. However, the anticancer activity of calcitriol
was associated with significant hypercalcemia that limits its clinical utility [17]. In contrast to
Vit-D3, ergocalciferol, Vit-D2, has been reported to exert a low calcemic effect and potent antitumor
activity [14,18]. Ergocalciferol, Vit-D2, occurs naturally in plants and it is synthesized from proVit-D2,
ergosterol, upon exposure to sunlight [14]. Of particular interest, it has been reported that Vit-D2
enhanced the cytotoxic effect of DOX on human breast and prostate cancer cell lines [19].
In light of the information described above, we hypothesized that by synthesis of DOX-Vit D, a novel
DOX derivative, through conjugating Vit-D2 to DOX, the chemoresistance associated with DOX could
be mitigated. For this purpose, the current study was designed to (1) investigate the antiproliferative
and apoptogenic effects of DOX-Vit D in the human OS cell line, MG63 cells, and (2) explore the possible
mechanism(s) involved. Our study provides substantial evidence that DOX-Vit D suppressed the growth
of MG63 cells by inducing apoptosis while inhibiting cell survival and proliferative signaling pathways.
Our DOX-Vit D conjugate may be of particular importance in drug delivery and may serve as a novel
drug delivery approach to potentiate the delivery of DOX into the bone cancer cells.
2. Materials and Methods
2.1. Materials
Total Akt (t-Akt) rabbit polyclonal, phosphorylated-Akt (P-Akt) rabbit polyclonal, mammalian
target of rapamycin C (t-mTOR) goat polyclonal and p-mTOR rabbit polyclonal were bought from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Any other materials used in the current study
has been described previously [20].
2.2. Chemistry
2.2.1. Calciferol-Succinate
In a round bottom flask, 200 mg of calciferol (0.5 mmol) was dissolved in 20 mL of anhydrous
dichloromethane (DCM), followed by the addition of 360 mg of succinic anhydride (3.6 mmol, 7.2 eq.)
and 500 μL of triethylamine (TEA, 3.6 mmol, 7.2 eq.). The reaction mixture was stirred at ambient
temperature under N2 for 24 h in the dark. The solution was washed with water three times, and
the organic layer was concentrated under reduced pressure. The compound was purified with a
Combiflash RF system (hexane/ethyl acetate, 30/70) to obtain a yellowish solid with a yield of 93%.
1H NMR (400 MHz, Acetone-d6) δ 6.30 (d, J = 11.2 Hz, 1H), 6.10 (dt, J = 11.3, 1.6 Hz, 1H), 5.35–5.18 (m,
2H), 5.12 (dt, J = 2.6, 1.2 Hz, 1H), 4.94 (tt, J = 7.8, 3.8 Hz, 1H), 4.84 (d, J = 2.6 Hz, 1H), 4.07 (q, J = 7.1 Hz,
1H), 2.90 (dd, J = 11.9, 4.0 Hz, 1H), 2.69–2.50 (m, 5H), 2.49–2.32 (m, 2H), 2.27–2.16 (m, 1H), 2.16–1.94 (m,
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6H), 1.89 (qd, J = 6.9, 5.9 Hz, 1H), 1.83–1.65 (m, 4H), 1.66–1.27 (m, 7H), 1.22 (t, J = 7.1 Hz, 1H), 1.07 (d,
J = 6.7 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H), 0.87 (t, J = 6.6 Hz, 6H) (Figures 1 and 2).
Figure 1. Chemical synthesis of DOX-Vit D.
 
Figure 2. Schematic 1HNMR diagram of DOX-Vit D.
2.2.2. Calciferol-Succinate-DOX
Calciferol-succinate (230 mg, 0.463 mmol), HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) (211 mg, 1.2 eq.), and Dox-HCl (295 mg.
1.1 eq.) were dissolved in 10 mL of anhydrous N,N-Dimethylformamide (DMF). To the he mixture was
added 400 μL of N,N-Diisopropylethylamine (DIPEA). The solution was stirred at ambient temperature
under N2 for 24 h in the dark. The crude mixture was dried under reduced pressure, and purified with
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a Combiflash RF system (hexane/ethyl acetate, 50/50) to afford product as an orange solid with a yield
of 60%. 1H NMR (400 MHz, Acetone-d6) δ 8.68 (dd, J = 4.4, 1.4 Hz, 1H), 8.50–8.37 (m, 1H), 7.56–7.38
(m, 1H), 6.14 (d, J = 11.2 Hz, 1H), 5.94 (dd, J = 11.2, 1.8 Hz, 1H), 5.23–5.05 (m, 2H), 4.97 (dq, J = 3.6,
2.2, 1.8 Hz, 1H), 4.86 (tt, J = 7.7, 3.8 Hz, 1H), 4.69 (d, J = 2.7 Hz, 1H), 3.22–3.09 (m, 2H), 2.84–2.71 (m,
2H), 2.71–2.63 (m, 1H), 2.54–2.39 (m, 2H), 2.37–2.24 (m, 2H), 2.08 (dddd, J = 12.3, 5.9, 4.7, 3.5 Hz, 2H),
1.98–1.79 (m, 8H), 1.78–1.55 (m, 4H), 1.55–1.42 (m, 3H), 1.42–1.10 (m, 9H), 0.95–0.86 (m, 4H), 0.80 (d,
J = 6.8 Hz, 4H), 0.72 (t, J = 6.7 Hz, 7H). ESI (m/z); calculated for C59H79N2O14 [M + NH4]+: 1039.5531;
found: 1039.7386 (Figures 1 and 2).
2.3. Cell Culture and Treatments
The human osteosarcoma cancer cell line, MG63 cells, (ATCC, Manassas, VA, USA) was
maintained according to the ATCC’s instructions.
2.4. Effect of DOX and DOX-Vit D on MG63 Cell Proliferation
The effect of DOX and DOX-Vit D on MG63 cell proliferation was determined by measuring the
capacity of reducing enzymes to convert 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide
(MTT) to colored formazan crystals as described previously [21,22]. The percentage of cell proliferation
was calculated relative to control wells designated as 100% viable cells using the following formula:
cell proliferation = (Atreated)/(Acontrol)× 100% (1)
2.5. RNA Extraction and cDNA Synthesis
Total RNA was extracted using TRIzol reagent (Invitrogen®, Carlsbad, CA, USA) as described
previously [20].
2.6. Quantification of mRNA Expression by Quantitative Real-Time Polymerase Chain Reaction (Real
Time-PCR)
Quantification of specific gene expression was performed by real time-PCR using ABI Prism 7500
System (Applied Biosystems, Foster City, CA, USA) as previously described [23]. Human primers
sequences and probes for Caspase-3, p53, BCLxs, death receptor-4 (DR-4), heme oxygenase-1 (HO-1),
NAD(P)H:quinone oxidoreductase-1 (NQO-1)and β-actin are illustrated in Table 1. These primers
were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA).
Table 1. Primers sequences used for RT-PCR reactions.








2.7. Determination of Reactive Oxygen Species (ROS) Production
ROS was measured fluorometrically using 2,7-dichlorofluorescein diacetate (DCF-DA) assay as
described previously [24]. Briefly, MG63 cells were treated for 24 h with 10 μM DOX-Vit D. Thereafter,
cells were washed with PBS before incubated for 30 min in fresh media containing 10μM DCF-DA.
The fluorescence was directly measured using excitation and emission wavelengths of 485 and 535 nm,
respectively, the Bio-Tek Synergy H1Hybrid Multi-Mode Microplate Readers (Bio-Tek Instruments,
Winooski, VT, USA).
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2.8. Protein Extraction from MG63 Cells
MG63 cells were treated for 24 h with 10 μM DOX-Vit D or DOX, then the total cellular protein
was extracted from the cells as described previously [20].
2.9. Immuno Blot Analysis
Cell lysates were analyzed by SDS-PAGE and immunoblotting were performed as described
previously [20].
2.10. Determination of MAPKs Signaling Pathway
The protein phosphorylation of MAPKs was measured using the PhosphoTracer MAPK ELISA Kit
(Abcam, Cambridge, UK) according to manufacturer’s instructions and as described previously [20].
2.11. Extration of Nuclear Protein
MG63 cells were treated for 2 h with 10 μM DOX-Vit D or DOX, then the nuclear protein was
extracted from the cells as described previously [20,25].
2.12. Determination of NF-κB Binding Activity
The NF-κB binding activity was determined using NF-κB Assay Chemiluminescent Kit
(Millipore, Schwalbach/Ts., Germany, #70-660) according to the manufacturer’s protocol as described
previously [26].
2.13. Statistical Analysis
Results are shown as mean ± SEM. Statistical analysis was carried out using SigmaPlot® for
Windows (Systat Software, Inc., San Jose, CA, USA). One-way analysis of variance (ANOVA) followed
by Tukey-Kramer multiple comparison tests or unpaired two-sided student t-test was carried out.
A probability value obtained less than 0.05 is considered significant.
3. Results
3.1. Physiochemical Properities of DOX-Vit D in Comaprison to DOX
Given that the main purpose of the current study is to improve the lipopilicity of DOX, we
investigated the physiochemical properties of DOX-Vit D in comparison to DOX using ACD iLab
and VCCLAB software (https://www.acdlabs.com/resources/ilab/) as described previously [27].
Perhaps the better predictor of lipophilicity is the distribution coefficient at pH 7.4 (LogD7.4) since it
considers the ionizable group at certain pH in addition to the estimated partition coefficient (LogP).
Of interest, Table 2 shows that DOX-Vit D has clear higher predicted values of LogP and LogD7.4
in comparison to DOX. This was consistent with a low predicted water solubility of DOX-Vit D
(0.0029 μg/mL) in comparison to DOX (0.49 mg/mL) and a higher LogS value for DOX-Vit D.
Together, it is reasonable to assume that our novel DOX derivative, DOX-Vit D, is more lipophilic
than DOX.
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Table 2. Physicochemical properties of DoxVD vs. Dox and Vitamin D2.
Compound Doxorubicin (Free Base) Vitamin D2 DoxVD
Structure
 
Chemical Formula C27H29NO11 C28H44O C59H75NO14
Molecular Weight
(g/mol) 543.53 396.65 1022.22
LogP (ACD Chemsketch) 2.82 ± 1.30 9.56 ± 0.27 12.83 ± 1.32
LogP (VCCLAB) 1.41 7.59 5.95
LogP (experimental,
Pubchem) 1.27 7.3 NA
Log D7.4 (ACD iLab) −0.29 7.5 8.68
Solubility H2O (ACD
iLab) 0.49 mg/mL 0.0018 mg/mL 0.0029 μg/mL
LogS (VCCLAB) −2.67 −5.96 −5.81
Solubility (experimental,
drug bank) 2% 0.05 mg/mL NA
3.2. Effect of DOX and DOX-Vit D on MG63 Cells Proliferation
To determine the cytotoxic effect of DOX and DOX-Vit D on OS, MG63 cells were exposed to
10 μM DOX and DOX-Vit D for 24 h. Thereafter, the cell proliferation was determined using MTT assay.
Our results showed that a 10 μM DOX did not significantly affect cell proliferation at 24 h (Figure 3).
However, 10 μM DOX-Vit D significantly decreased the cell proliferation by approximately 50% in
comparison to control (Figure 3).
Figure 3. Effect of DOX and DOX-Vit D on MG63 cells proliferation. MG63 cells were exposed to
10 μM DOX and DOX-Vit D for 24 h. Thereafter, the cell proliferation was determined using MTT assay.
The results are presented as the mean ± SEM (n = 6). + p < 0.05 compared to control.
3.3. Effect of DOX and DOX-Vit D on Proapoptotic Genes
To investigate whether the inhibitory effect of DOX-Vit D on MG63 cell proliferation and growth
is an apoptosis-dependent mechanism, MG63 cells were treated for 24 h with 10 μM DOX and DOX-Vit
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D. Thereafter, the mRNA levels of proapoptotic genes, Caspase-3, p53 and BCLxs, were determined by
real time-PCR. Figure 4 shows that DOX-Vit D caused a significant induction of Caspase-3 and BCLxs
genes expression by approximately 250% and 400%, respectively, in comparison to control. On the
other hand, DOX significantly decreased the expression of Caspase-3, BCLxs and P53 by about 50%,
20% and 30%, respectively, in comparison to control.
In light of our findings, DOX-Vit D seems to inhibit the growth of MG63 cells through an
apoptosis-dependent mechanism. Next, we questioned whether the DOX-Vit D elicited an apoptotic
signal in MG63 cells is mediated extrinsically through the activation of death receptor and/or
intrinsically by the induction of oxidative stress. Therefore, a series of independent experiments




Figure 4. Effect of DOX and DOX-Vit D on proapoptotic genes. MG63 cells were treated for 24 h with
10 μM DOX and DOX-Vit D. Thereafter, total RNA was isolated using TRIzol reagent, and the mRNA
levels of (A) Caspase-3, (B) p53 and (C) BCLxs were quantified using real time-PCR and normalized to
a β-actin housekeeping gene. The results are presented as the mean ± SEM (n = 6). + p < 0.05 compared
to control. * p < 0.05 compared to DOX.
3.4. Effect of DOX and DOX-Vit D on the Expression of DR-4
In order to determine the capacity of DOX and DOX-Vit D to modulate the expression of DR-4
mRNA, MG63 cells were treated for 24 h with 10 μM DOX and DOX-Vit D. Thereafter, the mRNA
levels of DR-4 was determined by real time-PCR. Figure 5 shows that treatment of MG63 cell with
DOX-Vit D caused a significant induction of DR-4 by about 170% in comparison to control. On the
other hand, DOX significantly inhibit the expression of DR-4 by approximately 60% in comparison
to control.
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Figure 5. Effect of DOX and DOX-Vit D on the expression of DR-4. MG63 cells were treated for 24 h
with 10 μM DOX and DOX-Vit D. Thereafter, total RNA was isolated using TRIzol reagent, and the
mRNA level of DR-4 was quantified using real time-PCR and normalized to a β-actin housekeeping
gene. The results are presented as the mean ± SEM (n = 6). + p < 0.05 compared to control. * p < 0.05
compared to DOX.
3.5. Effect of DOX and DOX-Vit D on the Oxidative Stress
The involvement of intrinsic apoptotic pathway was addressed by two approaches. Firstly, we
determined the effect of DOX-Vit D and DOX on the mRNA expression of oxidative stress markers.
Figure 6 shows that treatment of cells with 10 μM DOX-Vit D caused a significant induction of NQO-1
and HO-1 by approximately 250% and 6000%, respectively, in comparison to control. In contrast, DOX
significantly inhibited the expression of HO-1 by about 70%, whereas no significant changes were
observed with NQO-1 (Figure 6A,B).
The second approach was to investigate the effect of DOX and DOX-Vit D on the generation of
ROS using DCF assay. The incubation of MG63 cells with DOX and DOX-Vit D for 24 h caused a
significant increase in the formation of ROS by about 400% and 350%, respectively, in comparison to
control (Figure 6C).
Our findings suggest an involvement of both extrinsic and intrinsic pathways in the induction
of proapoptotic genes by DOX-Vit D. The induction of the aforementioned pathways are known to
trigger apoptosis through the activation of MAPK signaling pathway. Thus, we have investigated
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(B) 
(C) 
Figure 6. Effect of DOX and DOX-Vit D on the oxidative stress. MG63 cells were treated for 24 h with
10 μM DOX and DOX-Vit D. Thereafter, total RNA was isolated using TRIzol reagent, and the mRNA
levels of (A) NQO-1 and (B) HO-1 were quantified using real time-PCR and normalized to a β-actin
housekeeping gene. (C) MG63 cells were treated for 24 h with 10 μM DOX and DOX-Vit D then, cells
were incubated with DCF-DA (10μM) for 1 h. DCF formation was measured fluorometrically using
excitation/emission wavelengths of 484/535 nm. The results are presented as the mean ± SEM (n = 6).
+ p < 0.05 compared to control.
3.6. Effect of DOX and DOX-Vit D on MAPK Signaling Pathway
To assess the role of MAPK signaling pathway on the DOX-Vit D mediated induction of proapoptotic
genes, MG63 cells were treated with 10 μM DOX-Vit D and DOX. Thereafter, phosphorylated MAPK
levels were determined using a commercially available kit. Figure 7 shows that incubation of the cells with
10 μM of DOX-Vit D but not DOX significantly induced phosphorylation of p38 and JNK by approximately
250% and 160%, respectively, in comparison to control.
To further confirm whether activation of the MAPK pathways is required for the apoptotic cell
death mediated by DOX-Vit D, MG63 cells were treated with 10 μM p38 inhibitor, SB203580, and
JNK inhibitor, SP600125, in the presence and absence of DOX-Vit D. Thereafter, the cells proliferation
were measured using MTT assay. Figure 8 shows that DOX-Vit D alone caused a significant inhibition
of MG63 cell proliferation by about 50% in comparison to control. Importantly, treatment of cells
with SB203580 and SP600125 partially but significantly protects the cells against the cytotoxic effect of
DOX-Vit D. Our findings suggest that the activation of MAPK is essential for the cytotoxic effect of
DOX-Vit D.
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Figure 7. Effect of DOX and DOX-Vit D on MAPK signaling pathway. MG63 cells were treated for
24 h with 10 μM DOX and DOX-Vit D. Thereafter, MAPKs protein phosphorylation was determined
in cytoplasmic protein extracts using the PhosphoTracer (A) p38 MAPK (pT180/Y182) (B) JNK1/2/3
(pT183/Y185) (C) ERK1/2 (pT202/Y204) Elisa Kit (Abcam, Cambridge, UK). The results are presented
as the mean ± SEM (n = 6). + p < 0.05 compared to control. * p < 0.05 compared to DOX.
(A) 
(B) 
Figure 8. Effect of MAPK inhibitors on DOX-Vit D-induced cytotoxicity. MG63 cells were treated with
p38 inhibitor, SB203580, and JNK inhibitor, SP600125, in the presence and absence of 10 μM DOX-Vit D.
Thereafter, the cell proliferation was determined using MTT assay. The results are presented as the
mean ± SEM (n = 6). + p < 0.05 compared to control. * p < 0.05 compared to DOX-Vit D.
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In order to examine whether the inhibitory effect of DOX-Vit D on MG63 cell proliferation and
growth is also attributed to the suppression of cell survival and proliferation pathways, we have
determined the effect of DOX-Vit D on NF-κB, Akt and mTOR signaling pathways.
3.7. Effect of DOX and DOX-Vit D on NF-κB Signaling Pathway
The basal activity of the NF-κB transcription factor in OS seems to be crucial for their growth or
resistance to chemotherapy. Therefore, we have investigated whether DOX-Vit D suppresses MG63 cell
growth through the inhibition of NF-κB. For this purpose, MG63 cells were treated with 10 μM DOX
and DOX-Vit D. Thereafter, NF-κB binding activity was determined using a commercially available kit.
Figure 9 shows that neither DOX nor DOX-Vit D significantly affects the binding activity of NF-κB
suggesting an NF-κB-independent mechanism.
(A) 
(B) 
Figure 9. Effect of Effect of DOX and DOX-Vit D on NF-κB signaling pathway. MG63 cells were treated
for 24 h with 10 μM DOX and DOX-Vit D. Thereafter, NF-κB binding activity was determined in nuclear
extracts using a commercially available kit. The results are presented as the mean ± SEM (n = 6).
3.8. Effect of DOX and DOX-Vit D on Akt and mTOR Signaling Pathway
Since Akt and mTOR pathway promotes cell growth, proliferation and survival, we examined
the effect of DOX-Vit D on Akt and mTOR signaling pathway. For this purpose, MG63 cells were
treated with 10 μM DOX and DOX-Vit D. Thereafter, Akt and mTOR protein expression levels were
determined using Western blot analysis. Figure 10 shows that DOX-Vit D caused a significant inhibition
of p-Akt and p-mTOR protein expression by approximately 40% and 50%, respectively, in comparison
to control suggesting an Akt/mTOR-dependent inhibition of cell growth by DOX-Vit D. In contrast,
DOX did not significantly alter the expression of p-Akt and p-mTOR protein expression.
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Figure 10. Effect of DOX and DOX-Vit D on Akt and mTOR signaling pathway. MG63 cells were
treated for 24 h with 10 μM DOX and DOX-Vit D. Thereafter, total and phosphorylated Akt and mTOR
protein expression levels were determined by Western blot analysis and detected using the enhanced
chemiluminescence method. The intensity of protein bands was normalized to the signals obtained for
GAPDH protein and quantified using ImageJ®. The results are presented as the mean ± SEM (n = 6).
+ p < 0.05 compared to control. * p < 0.05 compared to DOX.
4. Discussion
These investigations provide strong evidence that DOX-Vit D suppresses the growth of human OS,
MG63 cell line, through the induction of apoptosis and the inhibition of cell survival and proliferative
signaling pathways.
One of the strategies for treating OS and minimizing the development of chemoresistance
associated with chemotherapeutic agents includes the induction of apoptosis and/or the attenuation
of cell survival and proliferative signaling pathways. Studies using transgenic mice provide direct
evidence that overexpression of cell survival pathways and/or disruption of apoptosis promote
tumorigenesis, metastasis and contribute to chemoresistance [28,29]. Therefore, the development of a
new chemotherapeutic agent that is able to attenuate the proliferation of OS while inducing apoptosis
is an urgently needed to overcome chemoresistance.
DOX, a broad-spectrum anthracycline antibiotic, is one of those standard therapies for the
treatment of OS [5]. Unfortunately, the effectiveness of DOX in OS is usually limited by the
acquired drug resistance that leads to poor prognosis and suboptimal outcomes [30]. Recently, Vit-D
has been shown to suppress the growth of many human cancer cells and reverse chemotherapy
drug-resistant [30,31]. Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX
in order to mitigate the chemoresistance associated with DOX. The current study was conducted
to investigate the antiproliferative and apoptogenic effects of 10 μM DOX-Vit D in comparison to
10 μM DOX and the possible mechanism(s) involved using the human OS cell line, MG63 cells.
The concentration of DOX used in the current study was maintained within the therapeutic range of
plasma concentration reported in human. For example, human subjects given a dose of 60–75 mg/m2
DOX for the treatment of metastatic cancer had mean plasma concentrations range from 5 and 15 μM
and an average half-life of ∼25 h [32,33]. In addition, several in vitro studies on human cancer cells to
explore the cytotoxicity of DOX used concentrations range from 1 to 10 μM [32,33].
Initially, we have demonstrated that DOX-Vit D, but not DOX, was able to significantly suppress
the MG63 cell proliferation and growth. Notably, the anticancer effect of DOX-Vit D is attributed to the
induction of proapoptotic genes Caspase-3 and BCLxs. Activation of the proapoptotic genes plays a
crucial role in the initiation of apoptosis through the cleavage of the key cellular proteins resulting in
the irreversible commitment to cell death [29,34]. Similar to our observation, it has been reported that
calciferol and its chemical derivative, MT19c, induce apoptosis and inhibit the growth and proliferation
of many cancer cell lines through the activation of the Caspase-3 enzyme [35,36]. The inhibitory effect
of DOX on proapoptotic genes might be attributed to the fact that our MG-63 cells are resistant to
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DOX. In agreement with our results, it has been shown that 10 μM DOX was neither elicit Caspase-3
activation or apoptosis in DOX resistant MG63 cells [37]. Importantly, promoting apoptosis has been
shown to overcome the chemoresistance associated with DOX during the treatment of OS [38].
Apoptosis is known to be elicited by the activation of extrinsic and/or intrinsic signals.
These signals are instructing the cells to undergo programmed cell death through the activation of
proapoptotic genes [29,34]. Accordingly, we investigated whether the DOX-Vit D-induced apoptosis in
MG63 cells is mediated through the extrinsic and/or intrinsic apoptotic pathway. The extrinsic signals
induce apoptosis through binding of cell surface death receptors such as TNF/Fas-receptor with its
ligand and subsequently activates proapoptotic enzymes [39]. Hence, we have tested whether DOX-Vit
D triggers extrinsic apoptotic pathway by measuring the expression of DR-4. In this current study,
we found that the induction of DR-4 mRNA in response to DOX-Vit D significantly contributes to the
activation of proapoptotic genes. These findings are in agreement with the observation that calciferol
increases the activity of proapoptotic genes through the induction of DR [36]. On the other hand, DOX
seems to decrease the expression of proapoptotic genes through the downregulation of DR-4.
The intrinsic signal is another pivotal pathway that could initiate apoptosis through the oxidative
stress and ROS-dependent mechanism [40]. Oxidative stress and ROS have been considered as a potent
inducer of apoptosis [41]. In this context, the involvement of the intrinsic apoptotic pathway in the
cytotoxic effect of DOX-Vit D was evidenced by the induction of the oxidative stress markers, NQO-1
and HO-1, in addition to the generation of ROS. In a manner similar to our observations, it has been
reported that calciferol treatment results in the accumulation of ROS and subsequently coordinates
proapoptotic genes activation [36].
Our findings suggest that DOX-Vit D upregulated the expression of proapoptotic genes through
the activation of both extrinsic and intrinsic apoptotic pathways. The induction of the aforementioned
pathways are known to trigger apoptosis through the activation of the MAPK signaling pathway.
A wealth of information suggests the involvement of MAPK cascades in cell death and survival
signaling [42,43]. In particular, it has demonstrated that persistent activation of p38 and JNK promotes
apoptosis and cell death [42,43]. Taken together, the possibility that DOX-Vit D would induce apoptosis
through the activation of MAPKs could not be ruled out. Thus, the third objective of the current study
was to explore the role of DOX-Vit D on the MAPKs signaling pathway. Our results demonstrate
that DOX-Vit D, but not DOX, significantly increased the protein expression level of p-p38 and p-JNK
whereas no significant changes were observed on p-ERK1/2. The direct evidence for the involvement of
p-p38 and p-JNK in the DOX-Vit D-induced cytotoxicity was supported by the observation that p-p38
inhibitor, SB203580, and JNK inhibitor, SP600125, significantly protect against DOX-Vit D-induced
cell death suggesting a MAPK-dependent mechanism. The premise of this observation emerges
from the finding that calciferol chemical derivative, MT19c, induces apoptosis through a p38 and
JNK-dependent mechanism [35].
Apoptosis-mediated cell death might induce the turn off of survival pathways, such as NF-κB
and Akt/mTOR pathways, that could otherwise interfere with the apoptotic response. The aberrant
activation of those proliferating proteins in OS seems to be crucial for their growth or resistance
to chemotherapy [44,45]. Thus, it is imperative to investigate the effect of DOX-Vit D on the
aforementioned cell survival and proliferating pathways. Although DOX-Vit D did not significantly
affect the binding activity level of NF-κB in MG63 cells, DOX-Vit D significantly downregulated
the protein expression level of p-Akt and p-mTOR. In addition, DOX did not significantly alter
the p-Akt/p-mTOR proteins expression. These results are in agreement with previous reports
on OS showing that high Akt/mTOR activity was associated with poor clinical outcome and
chemoresistence associated with DOX [46,47]. On the other hand, everolimus, an mTOR inhibitor,
has been shown to decrease drug-induced resistance in OS [48,49]. Our findings not only suggest an
Akt/mTOR-dependent inhibition of MG63 cell growth by DOX-Vit D but also support DOX-Vit D as a
promising developmental strategy for the treatment of OS resistant to chemotherapy [50].
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To reiterate, our results clearly demonstrated that DOX-Vit D, a novel DOX derivative, suppresses
MG63 cell growth through the induction of apoptosis and the inhibition of Akt/mTOR signaling
pathways. Such observation will raise the potential of developing DOX-Vit D analogues for the
treatment of OS resistant to chemotherapy. Given that DOX-VitD has a higher lipophilicity compared
to DOX, it is reasonable to assume that DOX-VitD may serve as a novel drug delivery approach to
minimize the first-pass effect while increasing lymphatic exposure and ultimately improving overall
systemic drug exposure. Additional studies are going to test the toxicity and the kinetic of DOX-VitD
in rats. Our preliminary data have shown that DOX-VitD is tolerable upon oral and intravenous
administration in rats. Given that our new derivative has a stoichiometry of 1 to 1 ratio (Dox-VitD), it
might not necessarily be the most active one. Therefore, we will compare our new derivative with a
combination of the free drugs at different ratios in order to confirm the mechanism(s) of action and
discriminate additive effects vs synergistic effects.
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Abstract: A large proportion of pharmaceutical compounds exhibit poor water solubility, impacting their
delivery. These compounds can be passively encapsulated in the lipid bilayer of liposomes to
improve their water solubility, but the loading capacity and stability are poor, leading to burst drug
leakage. The solvent-assisted active loading technology (SALT) was developed to promote active
loading of poorly soluble drugs in the liposomal core to improve the encapsulation efficiency and
formulation stability. By adding a small volume (~5 vol%) of a water miscible solvent to the liposomal
loading mixture, we achieved complete, rapid loading of a range of poorly soluble compounds
and attained a high drug-to-lipid ratio with stable drug retention. This led to improvements in the
circulation half-life, tolerability, and efficacy profiles. In this mini-review, we summarize our results
from three studies demonstrating that SALT is a robust and versatile platform to improve active
loading of poorly water-soluble compounds. We have validated SALT as a tool for improving drug
solubility, liposomal loading efficiency and retention, stability, palatability, and pharmacokinetics
(PK), while retaining the ability of the compounds to exert pharmacological effects.
Keywords: liposome; water miscible solvents; remote loading; staurosporine; cancer; gambogic acid;
loading gradients; mefloquine; child friendly formulation
1. Introduction
1.1. Challenges in Delivery of Poorly Water-Soluble Drugs
Clinical translation of pharmaceutical compounds is often hindered by poor solubility. Over 40%
of new chemical entities are not appreciably soluble in water, often resulting in limited therapeutic
use, or abandonment as drug candidates [1,2]. Methods for improving apparent solubility include salt
formulations, excipients, amorphous solid dispersions, pH adjustment, co-solvents, and nanocarriers [1,2].
There has been interest in the development of systematic approaches to overcoming low soluble
compounds, as outlined in the developability classification system which describes a categorization of
compounds based on permeability and solubility [3]. There has also been growing interest in the use
of nanocarriers as a vehicle to overcome issues of solubility, as they serve as a platform technology
and provide cell targeting [4]. Lipid-based nanocarriers (LNCs) represent a class of lipid particles,
including solid lipid nanoparticles, micro- or nano-emulsions, polymer-lipid hybrid nanoparticles,
and liposomes.
1.1.1. Liposomes and Drug Loading
Liposomes are among the most studied class of LNCs for improving drug delivery [5].
Liposomes are nano-scale spheroid vesicles composed of one or multiple lipid bilayer(s) enclosing
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an aqueous core [5]. Liposomes can be manufactured using several methods, including thin-film
hydration [6], reverse phase evaporation [7], and microfluidic mixing [8]. The process used to generate
the liposome will impact its size and lamellarity [9–11]. Likewise, various lipids can be used to
formulate liposomes with different properties, such as size, drug release kinetics, biocompatibility,
surface charge, and cell targeting [12,13]. To encapsulate drugs into liposomes, two methods have
been implemented; passive and active loading, both of which are briefly reviewed below.
1.1.2. Passive Loading
Passive loading describes the procedure in which liposomes are formed concurrently with drug
loading (Figure 1A). In general, hydrophilic compounds are distributed homogenously in the aqueous
phase (both inside and outside the liposomes), whereas hydrophobic drugs are retained inside the
lipid bilayer of liposomes, respectively. Specifically, when working with poorly water-soluble drugs,
the drugs are first dissolved with lipids in an organic solvent, followed by solvent evaporation to
prepare a drug containing thin film, which is later hydrated with an aqueous phase to prepare liposomes.
When loading water-soluble drugs, the lipid film is dispersed in a drug-containing aqueous phase.
A) 
B) 
Figure 1. The two major methods for liposomal drug loading. (A) Passive loading involves co-current
loading and liposomal formation. (B) In active loading, liposomes are formed containing a gradient
used to load drugs.
1.1.3. Limitations of Passive Loading
The trapping efficiency of passive loading varies due to several factors, including drug solubility,
vesicle size, lipid concentration, and preparation procedure. In most cases, the typical drug-to-lipid
ratio (D/L) achieved by this passive loading technique is less than 0.05 (w/w) [14,15]. In addition,
the entrapped drugs often cannot be retained stably due to weak association between the drugs and the
liposomes, resulting in poor drug retention and storage stability. Passive loading often also results in a
“burst release” phenomenon, whereby a large percentage of the entrapped drug is released quickly.
1.1.4. Active Loading
In active loading, liposomes are first generated containing a transmembrane gradient, i.e.,
the aqueous phases inside and outside the liposomes are different. Subsequently, an amphipathic drug
dissolved in the exterior aqueous phase can permeate across the phospholipid bilayer(s), followed by
interactions with a trapping agent in the core to lock-in the drug (Figure 1). In 1976, Deamer and
Nicols [16–18] demonstrated that a pH gradient could be utilized to load catecholamine into liposomes,
leading to stable retention in vitro. They formed liposomes in a low pH (pH 5) solution and then
147
Pharmaceutics 2019, 11, 465
bathed the liposomes in an alkaline solution (pH 8) to create a 1000-fold difference in H3O+ ions
across the bilayer. As the catecholamine molecules remained as the free form in the basic exterior,
they freely permeated through the bilayer into the low pH core, where they were subsequently
protonated. The charged catecholamine molecules were no longer membrane permeable and thus
locked in. An accumulation of catecholamine molecules in the core of the liposomes was observed.
Subsequent to the work of Dreamer et al. [18], Haran et al. [19] demonstrated that active loading
can be achieved using an ammonium sulfate gradient. They produced liposomes with an interior
containing ammonium sulfate. A concentrated solution of anthracycline was added to the liposomes
and loading was then achieved after incubation at an elevated temperature. Anthracycline molecules
formed aggregates in the core of the liposomes through precipitation with sulfate ions, and a high
drug loading efficiency of >90% was achieved without burst drug leakage. Several other pH gradients
have been established, including phosphate and calcium acetate [20]. Similar to the calcium acetate
gradient, basified copper acetate gradients have also been employed for liposomal loading.
1.1.5. Limitations of Standard Active Loading
Active loading remains a powerful tool that can be used to effectively and stably retain drugs
in the core of liposomes. However, traditional active loading is predicated on compounds having
high solubility and membrane permeability (i.e., amphipathic), so that they can be solubilized in the
exterior aqueous phase and permeable through the lipid bilayer into the liposomal core. These selection
criteria exclude a large number of hydrophobic drugs currently on the market or in the development
pipeline. Excipients such as ß-cyclodextrin and super saturated solutions have been also used to
increase the active loading efficiency of liposomes. These techniques have helped somewhat in
overcome issues of poor solubility [21]. In addition, recent approaches have focused on examining
the role of nanocrystillazaion inside liposomes to improve drug retention [22]. Although discussion
of these techniques is beyond the scope of this paper, these methods have significant limitations,
and consequently there is a need for an improved loading technology.
2. Solvent-Assisted Active Loading Technology (SALT)
2.1. Introduction
Our laboratory has developed an innovative technology for liposomal loading of poorly water-soluble
drugs. Solvent-assisted active loading technology (SALT) allows for stable and efficient loading of
poorly water-soluble drugs into the aqueous core of liposomes. SALT has demonstrated efficacy across
a range of poorly soluble compounds and is a versatile method for drug loading. We hypothesized
that including a small volume of water-miscible solvent in the loading mixture of liposomes and a
hydrophobic drug could help solubilize the drug in the aqueous phase, increase the drug penetration
through the liposomal bilayer and boost active loading encapsulation efficiency. pH adjustment
is among the most commonly-used methods to increase drug solubility. When compared to pH
adjustment, the SALT/liposome technique enhanced the solubility of our model drugs Staurosporine,
Gambogic Acid and Mefloquine from 120 μg/mL to 1 mg/mL, 5 μg/mL to 1 mg/mL, and 0.6 mg/mL to
8 mg/mL, respectively [13,23,24].
2.2. Applications and Mechanism
A drug needs to be solubilized in the free form in the exterior phase of liposomes in order to
effectively penetrate the lipid bilayer. Therefore, a small amount of solvent is included in the liposomal
suspension for complete solubilisation of the compound. After penetration into the liposomal core,
the drug can then interact with a trapping agent inside the liposomes to form insoluble precipitates
for stable a “lock-in” effect. Finally, the solvent can be removed by dialysis or gel filtration (Figure 2).
To test the feasibility of this idea, we performed proof-of-principle studies [13,23,24] with a range of
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poorly soluble drugs. We further characterized SALT through the use of various solvents, liposomal
formulations and trapping agents to demonstrate its versatility.
 
Figure 2. Solvent-assisted active loading technology (SALT) mechanism overview for liposomal loading
of a poorly water-soluble drug.
2.3. Proof-of-Principle with a Weak Base Drug
Staurosporine and Liposomal Loading
Staurosporine (STS) is a broadly acting alkaloid protein kinase inhibitor with demonstrated
efficacy as an antitumor agent against several cancer types [25]. STS contains a secondary amine
group, but its solubility remains negligible even at a low pH [26]. Despite promising in vitro results,
STS development was hindered due to poor solubility and non-specificity [26]. We hypothesized that
liposomal delivery of STS would minimize its systemic toxicity through enhanced tumor targeting
while also overcoming issues surrounding poor solubility. Liposomal loading of STS was previously
reported by Mukthavaram et al. [27]. They utilized an active loading strategy employing a reverse pH
gradient [27]. However, they were only able to achieve 70% drug encapsulation and a low drug-to-lipid
ratio (D/L) of 0.09 mol/mol [27]. We hypothesized that introducing a limited amount of dimethyl
sulfoxide (DMSO) to the liposomal suspension could keep STS soluble during the active loading process
and would also facilitate the permeation of the drug into the inner core of liposomes. We employed
an ammonium sulfate gradient to effectively trap STS via sulfate-STS nano-aggregates inside the
liposomal core and achieve 100% drug encapsulation at a high D/L of 0.31/1 (mol/mol). Subsequently,
gel filtration facilitated the removal of DMSO generating a final liposomal product. In the following
section, we report the SALT method optimization and results of PK and efficacy studies.
Liposomal Formulation: A thin lipid film composed of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), cholesterol and PEGylated 1,2-distearoyl-sn-glycero-3-phosphoetholamine (DSPE-PEG2000)
(55/40/5 mole ratio) (100 mg total lipids) was hydrated with 1 mL of 350 mM ammonium sulfate at
60 ◦C, followed by membrane extrusion to control the size ~100 nm with a polydispersity index (PDI)
of <0.06. The liposomes were then dialyzed against an acetate buffer (100 mM, pH 5) to create a
transmembrane gradient of ammonium sulfate.
Liposomal STS Loading Using SALT: We dissolved STS in DMSO and added into the liposomal
suspension at a range of D/L with a final DMSO content of 5–60% and incubated the mixture at room
temperature or 60 ◦C. We found that at least 5% DMSO was required to achieve complete drug loading,
and that complete drug loading was maintained over a range of DMSO concentrations between
5% and 60%. Loading kinetics was impacted by the temperature. In the presence of 5% DMSO,
complete loading was achieved more rapidly (5 min) with incubation at 60 ◦C compared to room
temperature (15 min). The highest D/L achieved for complete drug loading was 0.31 w/w. The size
(~100 nm) and the PDI (<0.06) of the final STS-Lipo produced with various amounts of DMSO were
comparable and remained unchanged compared to the empty liposomes. We also determined that STS
leakage from the liposomes was minimal (<5%) after seven days incubation in 50% fetal bovine serum
(FBS) at 37 ◦C. Finally, the cryo-transmission electron microscopy revealed that STS molecules form
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spherical precipitates inside the liposomal core (Figure 3). The data support the contention that STS
was actively and stably loaded into the liposomal core by the SALT.
Figure 3. Cryo-TEM images of the drug free liposomes (a) and the staurosporine (STS)-Lipo loaded
using 5% dimethyl sulfoxide (DMSO) (b) 60% DMSO (c). Scale bar represents 100 nm. Reprinted with
permission from Tang et al., Pharmaceutical Research, published by Springer Nature, 2016 [24].
Safety and Efficacy Studies: It was found that the accumulated maximum tolerated dose (MTD)
of STS-Lipo was 9 mg/kg relative to 3 mg/kg for free STS (dissolved in acetate buffer and 1% DMSO).
STS-Lipo exhibited significantly improved efficacy against multidrug resistant EMT6-AR1 murine
breast tumor in mice compared with free STS and docetaxel (DTX). The tumor growth was effectively
impeded by STS-Lipo therapy and the average tumor volume was controlled by 150 mm3 in comparison
to ~800 mm3 in the free STS group by day 18, while all tumors in the DTX and buffer treated mice all
exceeded the endpoint size (1000 mm3) before day 14. The STS-Lipo treatment did not cause significant
body weight loss. On the other hand, 3 out of 3 mice in the free STS group reached humane endpoints
on day 9 due to the drug toxicity, and there was ~5% body weight loss in the mice treated with DTX.
The data indicate that SALT enabled liposomal delivery of STS, leading to enhanced safety and efficacy
compared to free STS and the standard taxane chemotherapy.
2.4. Proof-of-Principle with a Weak Acid Drug
2.4.1. Introduction
After our initial discovery that SALT could promote loading of an insoluble weak base compound
into the liposomal aqueous core to improve the drug delivery, we sought to further explore applications
for SALT. We investigated whether SALT could efficiently load other drug classes. In addition,
we examined whether solvents other than DMSO could be used in this technology and the role these
solvents played in drug loading. To achieve this, we investigated the ability of SALT to improve
loading of gambogic acid (GA). GA was selected as a model drug as it is water insoluble yet dissolvable
in a range of water miscible solvents (>20 mg/mL). As such, we could investigate both the use of SALT
on a different drug class (weak acid) and how SALT performs with solvents other than DMSO.
2.4.2. Gambogic Acid (GA)
GA is a naturally-derived compound found in traditional Asian medicines. GA has been reported to
have anti-cancer and anti-inflammatory properties by acting through a number of cell processes [28–30].
Despite its promising results as an anti-cancer compound, its clinical development has been hindered
by its poor water solubility (<5 μg/mL). Several methods have been attempted to overcome its issues of
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poor solubility, yet parameters relating to PK were only marginally improved [31–35]. We hypothesized
that SALT could facilitate stable and efficient loading of GA into liposomes, leading to prolonged PK
and tumor-targeted delivery.
SALT Promotes GA Loading into Liposomes: We began the GA study by seeking to find answers
to three questions. Primarily, we were interested in determining whether SALT could be applied to
load other drugs besides weak bases. Second, we sought to determine if other water miscible solvents
were compatible with the SALT system. Third, we wanted to elucidate the mechanism behind the SALT
system, specifically, to investigate the functions of solvents in promoting drug loading. GA is freely
soluble in eight different water-miscible solvents; DMSO, DMF, EtOH, MeOH, acetonitrile, acetone,
1,4-dioxane, and NMP. We examined whether these solvents could be used to promote GA loading into
liposomes. We prepared liposomes containing a gradient of basified copper acetate where [Cu2+]interior
> [Cu2+]exterior. We rationalized that after drug solubilization and loading into the liposomal core,
GA would bind cooper via coordination complex. This drug-copper conjugate forms stable complexes
and effectively traps GA in the liposome. This mechanism, which parallels other trapping strategies
using compounds such as calcium acetate, helps boost drug retention and minimize leakage during
storage. Our results showed that all 8 solvents could facilitate GA loading and the optimal solvent
content was unique to the solvent. The data suggests the solvent function is twofold. Primarily,
the solvent is used to completely dissolve the drug in the liposomal exterior water phase. This is
required as large drug precipitates are impermeable to the lipid bilayer. However, we discovered that
just complete solubilisation did not promote complete drug loading. After the solvent has dissolved
the drug, additional solvent added serves to increase the permeability of the liposomal membrane
(Figure 4). However, additional solvent must not exceed the limit that induces lipid membrane
instability. In these studies, we have demonstrated that SALT is capable of loading both poorly soluble
weak acid and base model drugs with high efficiency and retention. SALT is a versatile platform which
could be used to load an array of compounds that may have been previously non-deliverable with
liposomes. In addition to STS and GA, we further demonstrated that this method could be applied for
loading other drugs, including artesunate, prednisolone hemisuccinate, and quercetin [13].
 
Figure 4. The solvent effect on drug loading in the SALT system. The figure is reprinted with permission
from Tang et al., Biomaterials; published by Elsevier, 2018 [13].
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Formulation Optimization: After confirming that SALT could facilitate active loading of
GA, we next sought to optimize the formulation by modifying the loading gradient and lipid
composition to improve the D/L and drug retention. We studied GA loading efficiency in 1,2-distearoyl-
sn-glycero-3-phosphocholine/cholesterol/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino
(polyethyleneglycol)-2000 (DSPC/Chol/DSPE-PEG2K) liposomes with a range of transmembrane
gradients, including magnesium gluconate, calcium formate, and copper acetate. All gradients
achieved complete drug loading in the presence of 5 vol% DMSO at a D/L of 1/5 w/w. However,
the basified copper acetate gradient (pH 9) demonstrated the highest drug retention in 50% serum:
~45% GA retained in the liposomes after 4 h incubation. We then modified the lipid composition to
further enhance GA retention. Our results show that decreasing the cholesterol content from 45%
to 0% increased GA retention from 40% to 68% after 2.5 h incubation in serum. We then compared
formulations prepared with an unsaturated lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
or a saturated lipid (DSPC): the DOPC-liposomes retained >95% of the drug after 24 h incubation
in serum without significant size change. This finding was unanticipated as saturated liposomes
containing lipids with a high transition temperature have been shown to increase doxorubicin retention
relative to unsaturated lipids [36]. However, it has been discovered that unsaturated lipids, such as
DOPC, may form flexible liposomes which trap hydrophobic molecules more effectively [37].
Characterization of optimized Lipo-GA: Transmission electron cryomicroscopy (CryoTEM)
imaging revealed that liposomes displayed bi-lamellar structure with an electron dense core (Figure 5).
Both these features have been previously reported with liposomes containing a copper gradient for
drug loading [38,39], indicative of bilayer rearrangement and copper-GA complex formation in the
core. The formation of copper-GA complexes, in addition to the optimized lipid composition resulted
in stable retention of GA.
 
Figure 5. Cryo-TEM images of empty liposomes (DOPC/Chol/DSPE-PEG2K, 85/10/5 by mol%) (A)
and Lipo-GA (B). The figure is reprinted with permission from Tang et al., Biomaterials; published by
Elsevier, 2018 [13].
Safety, PK and Efficacy: GA is known to induce apoptosis of red blood cells, leading to potential
toxicity in vivo [40]. While free GA was highly hemolytic, the equivalent concentration of Lipo-GA
showed no activity in inducing hemolysis. Compared to free GA, the Lipo-GA formulation resulted in
an 18-fold increase in plasma half-life, a 20-fold higher mean residence time, a 7.5-fold higher area
under the curve (AUC0–∞), and 10-fold decreased clearance, confirming its prolonged circulation
relative to free GA. In two murine tumor models, we observed a significant dose-dependent reduction
in tumour volume after Lipo-GA therapy. In particular, in the EMT6-AR1 multidrug resistant breast
tumor model, one dose of Lipo-GA completely suppressed the tumor growth, while free GA only
moderately inhibited 65% tumor growth. Mice treated with Lipo-GA showed no body weight loss,
suggesting good safety.
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3. Pediatric Formulation
We next explored a unique application for SALT. Malaria is the world’s leading parasitic disease [41],
with over 200 million cases reported in 2015. Children under 5 years old are the most vulnerable
population and account for over 70% of malaria associated deaths [42]. Treatment or prophylaxis
of malaria often relies on the first line drug mefloquine (Mef) [43]. Despite its effectiveness as an
antimalarial agent, Mef is difficult to accurately dose in children and neonates [44]. This is due to
the lack of a pediatric formulation and Mef is typically administered by crushing up a portion of
an adult tablet and administering with milk or food, in an effort to mask the extremely bitter taste.
However, children often spit out the medicine, leading to subtherapeutic levels. Microemulsions of
Mef have been developed to overcome poor solubility and increase bioavailability [45,46], yet their
use in newborns is contradicted by risk of renal and liver damage caused by high concentrations of
surfactants [47]. A pediatric pill of Mef is available (Artequin pediatric), yet this pill remains too
large for neonatal dosing. We hypothesized that liposomal delivery of Mef could overcome many of
these issues. Liposomal suspension of Mef could increase the solubility and subsequent absorption
leading to higher bioavailability [48]. In addition, dosing the liquid suspension to children is easy
and accurate. We hypothesized liposomes could also mask the taste of the bitter drug by shielding
it from the taste buds. Liposomes can be lyophilized to prepare a powder formulation that is stable
upon room temperature storage and orally dispersible for pediatric use. Lastly, liposomal formulations
using only the neutral lipid DSPC and cholesterol can be considered very safe for oral administration
in young children. The remaining challenge was how to prepare a stable Mef-Lipo formulation.
Liposomal Loading of Mef Using SALT: We first prepared liposomes (DSPC and cholesterol)
containing an ammonium gradient, and then incubated the liposomes with Mef in the presence of 10%
DMSO at a D/L concentration of 0.1 w/w at room temperature for 30 min to achieve complete loading.
The liposomes were then purified by dialysis to remove DMSO and a formulation containing 8 mg/mL
of Mef was obtained.
Lyophilizaition: The Mef-Lipo suspension was subjected to freeze drying, aiming to prepare a
solid powder formulation to facilitate longer storage time and produce a rapidly dissolvable formulation.
To protect the integrity of the liposomes during lyophilization we buffered the exterior with 300 mM
sucrose and 20 mM phosphate. Sucrose is a known lyoprotectant and phosphate was shown to increase
the stability of liposomes [49]. The lyophilization process only increased the liposome size from
110 nm to 130 nm and the PDI remained <0.1. Importantly, we observed no significant drug leakage.
The lyophilized liposomes containing Mef remained stable under the storage at room temperature
for >3 months. In addition, they were rapidly dissolvable in water within 10 s, indicating an orally
dispersible formulation.
Drug Release: Both the liquid suspension and the lyophilized Mef-Lipo exhibited similar drug
release profiles in simulated saliva, gastric, and intestinal fluids. In simulated saliva, both liquid
and lyophilized Mef-Lipo demonstrated no observable drug release. Drug release was highest in the
simulated stomach fluid for both formulations. There was no drug release in the simulated intestinal
fluid in the absence of a bile salt for both preparations, while Mef was effectively released from the
liposomes in simulated intestinal fluid supplemented with a bile salt. Our data indicate that Mef
release from the liposomes was triggered by acid- or surfactant-induced destabilization of liposomes.
The results also suggest that the liposomal formulation would effectively mask the drug taste in the
oral cavity but rapidly release the drug in the gastrointestinal fluids.
Bitterness Masking: To determine the bitterness masking effect of the liposomal technology,
we employed the Astree e-tongue technology and compared the bitterness of Mef-Lipo to 10% sucrose,
Mef suspension and Infant Tylenol®. As shown in Figure 6, the bitterness of the Mef-Lipo was similar
to 10% sucrose indicating a palatable formulation, while the standard Mef suspension displayed
high bitterness.
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Figure 6. Quantification of bitterness of various drug formulations using the e-tongue. Data =mean ±
Standard Deviation (SD) (n = 3). The figure is adapted with permission from Tang et al., Molecular
Pharmaceutics; published by American Chemical Society, 2017 [23].
Pharmacokinetics and Bioavailability: In PK and bioavailability (BA) studies in mice, our data
confirmed that the liquid and lyophilized Mef-Lipo were comparable formulations with similar Cmax,
Tmax, area under the curve (AUC), and BA (81−86%). Mef suspension, however, displayed ~20%
decreased Cmax, AUC, and BA compared to the liposomal formulation. There was no difference in Tmax
and t1/2 among these three formulations, suggesting that the formulations did not alter the metabolism
or elimination of the drug, and the difference in BA was due to the absorption. Liposomes might
improve the absorption by preventing aggregation of Mef in the gastrointestinal tract, protectiing from
degradation, and promoting direct uptake by enteric cells.
4. Perspectives and Future Directions
We have demonstrated that SALT is a versatile loading technology for promoting the active
loading of poorly water-soluble drugs into the liposomal core. We performed proof-of-principle studies
with multiple drugs to characterize the versatility and robustness of SALT. Our studies show that SALT
could improve drug solubility, liposomal loading efficiency, liposomal retention, stability, palatability,
PK, and efficacy. SALT has the potential to overcome barriers currently impeding delivery of many
compounds. We have also demonstrated applications of SALT in cancer therapy and child-friendly
oral formulations. The application of SALT could extend beyond therapeutic drug loading and also
be employed in the imaging and theranostic fields. Specifically, SALT could be useful in loading
poorly soluble imaging probes into the core of liposomes. A frequent barrier to effective image-guided
drug targeting is the weak association between the probe and the delivery vehicle [50]. SALT could
help retain imaging probes inside the core of liposomes to improve their delivery to target tissues.
Despite the high performance of SALT as a loading platform, there remain parameters that can be further
optimized. As demonstrated in these specific studies, a limitation of SALT when implemented across
different compounds is the requirement for optimization of the loading gradient, trapping method,
and lipid composition for maximal loading efficiency and retention. However, trapping agents can
be rationalized based on the drug structure and lipid composition can be empirically determined.
In addition, a limitation of SALT is found in the need to find a water miscible solvent that can be used
to load certain drugs, which may not always be possible. Moreover, some drugs may require large
volumes of solvent that may result in degradation on the liposome itself prior to efficient drug loading
although this was not found in our studies. The drugs themselves must almost possess an ionizable
functional group, limiting potential candidates for this technology. Despite these limitations we
anticipate that future innovations of SALT could help overcome loading of other species of drugs such
as the poorly membrane-permeable yet water-soluble biomolecules such as proteins and nucleotides,
both of which may benefit from liposomal delivery. SALT, however, is not limited to liposomes and
will be implemented for drug loading in other bilayer-based delivery systems, further expanding the
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impact of this exciting technology. In addition, SALT can be used to improve current formulations
that are prepared using passive loading. There exist several drugs on the market that are prepared
using passive loading due to their hydrophobicity. SALT could be employed to re-formulate these
existing liposomal products to improve the loading efficiency, stability and drug retention. SALT is a
promising platform which may propel the field of lipid-based drug delivery to novel areas.
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Abstract: Oral squamous cell carcinoma (OSCC), which encompasses the oral cavity-derived
malignancies, is a devastating disease causing substantial morbidity and mortality in both men and
women. It is the most common subtype of the head and neck squamous cell carcinoma (HNSCC),
which is ranked the sixth most common malignancy worldwide. Despite promising advancements
in the conventional therapeutic approaches currently available for patients with oral cancer, many
drawbacks are still to be addressed; surgical resection leads to permanent disfigurement, altered
sense of self and debilitating physiological consequences, while chemo- and radio-therapies result
in significant toxicities, all affecting patient wellbeing and quality of life. Thus, the development
of novel therapeutic approaches or modifications of current strategies is paramount to improve
individual health outcomes and survival, while early tumour detection remains a priority and
significant challenge. In recent years, drug delivery systems and chronotherapy have been developed
as alternative methods aiming to enhance the benefits of the current anticancer therapies, while
minimizing their undesirable toxic effects on the healthy non-cancerous cells. Targeted drug delivery
systems have the potential to increase drug bioavailability and bio-distribution at the site of the
primary tumour. This review confers current knowledge on the diverse drug delivery methods,
potential carriers (e.g., polymeric, inorganic, and combinational nanoparticles; nanolipids; hydrogels;
exosomes) and anticancer targeted approaches for oral squamous cell carcinoma treatment, with an
emphasis on their clinical relevance in the era of precision medicine, circadian chronobiology and
patient-centred health care.
Keywords: oral, head and neck squamous cell carcinoma; targeted therapies; drug delivery systems;
nanoparticles; controlled drug delivery; circadian clock; chronotherapy; precision medicine
1. Introduction
Oral cancer refers to tumors developed in the lips, hard palate, upper and lower alveolar ridges,
anterior two-thirds of the tongue, sublingual area, buccal mucosa, retromolar trigons, and floor of the
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mouth [1]. The majority (>90%) of oral cancer are carcinomas with squamous differentiation arising
from the mucosal epithelium, thus called oral squamous cell carcinomas (OSCCs) [2,3]. In 2018, 354,864
new cases of lip and oral cavity cancer were identified, and 177,384 people died from these types of
cancer worldwide [4]. According to the Canadian Cancer Society and the Canadian Dental Association,
the incidence of OSCC has increased in Canada in both males and females since mid-1990s; 4700 new
cases of oral cancer and 1250 oral cancer-related deaths were reported in Canada in 2017 alone [5,6].
Most often diagnosed at late stages (approximately 60% of patients present with advanced stage disease
at the initial diagnosis, OSCC remains one of the most difficult challenges in head and neck oncology,
and continues to be a disfiguring and deadly disease with dismal 50% to 60% five-year disease specific
survival rate [7,8]. Due to its anatomic location, OSCC progression and treatment significantly impact
patient quality of life, involving impairment of most vital functions (e.g., speech, swallowing, taste.),
appearance and sense of self; they are associated with profound functional morbidity even when the
cancer is cured [3,9].
New trends have recently emerged in the OSCC patient profile including younger patients
(younger than 50 years), particularly those with human papillomavirus (HPV)-positive tumors [10,11];
a steady change in the OSCC sex ratio with a worrisome increase in OSCC incidence and mortality
in females [12]; and the implications of novel, previously unrecognized factors, such as the circadian
clock disruption in the initiation and progression of the OSCC [13–16].
OSCC has traditionally been associated with risk factors such as tobacco and alcohol consumption;
however, HPV, a well-known cause of cervical cancer, has emerged in recent years as an etiological
cause for a subset of head and neck squamous cell carcinoma (HNSCC), particularly in patients who
lack the traditional risk factors [17,18]. The majority (60–80%) of HPV-driven cancers of the head and
neck are oropharyngeal squamous cell carcinomas (comprising the tonsils and the base of the tongue).
Recent studies have identified various types of HPV associated with both benign and malignant lesions
in the oral cavity [19–22].
The HPV diagnosis is critical in planning treatment for oropharyngeal cancer (OPC) patients [23–25].
Within OPC, there is a marked difference between clinical behaviors and outcomes for patients who
test positive versus negative for HPV infection. For high/late-stage patients, HPV positivity has
become a significant prognostic factor that is critical for guiding the choice of treatment, with an HPV
positive diagnosis resulting in lower toxicities and improved outcomes [26]. In contrast, a significant
subset of early-stage OPC patients are HPV negative, their cancer rapidly progresses into advanced
metastatic tumors and fails to respond to the standard of care with poor outcomes and survival.
Patients with chronic exposure of the entire mucosa of the upper digestive tract (cancerization field)
to carcinogenic factors (e.g., from tobacco, alcohol, and betel quid chewing) are at a higher risk for
multiple primary tumors.
Oral squamous cell carcinoma is the second most common cancer in transplant patients (e.g.,
treated for leukemia, lymphoma, multiple myeloma, etc) [27]. The conventional approaches for
oral cancer treatment involve surgery, which is the treatment of choice, ionizing radiation which
is the prevalent non-surgical therapeutic approach, or a combination of radio-, chemotherapy, and
surgery [28]; surgical resection leads to permanent disfigurement, altered sense of self and debilitating
physiological consequences, substantial functional impairment, and morbidity, while chemo- and
radio-therapies result in significant toxicities, all affecting patient wellbeing and quality of life. These
treatments are efficient for the treatment of the primary tumor but are used with palliative intent in
advanced cases with metastatic disease, with significant side and adverse effects [29]. Despite the
advances in surgery, chemotherapy, and radiotherapy for HNSCC treatment, the prognosis for this
disease has not been significantly improved over the last 50 years [8]. Thus, the development of novel
therapeutic approaches or modifications of current strategies is paramount to improve individual
health outcomes and survival, while early tumor detection remains a priority and significant challenge.
The oral, head, and neck cancer is an immunosuppressive disease (characterized by a lower
absolute lymphocyte count and poor antigen-presenting function) that interferes with the patient’s
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natural immune response, preventing tumor cell recognition and immune-mediated clearance [30].
Immunotherapy, a recently developed cancer treatment modality, has shown promise as an additional
therapeutic option in patients having failed multiple prior therapeutic modalities, due to the success of
immune-modulating agents in patients with refractory solid tumors [31,32]. The goal of immunotherapy
as an anticancer approach is to either block the pathways cancer cells use to escape the immune system or
to enhance the patient’s immune reactions directed against tumor cells [33]. Anti-cancer immunotherapy
includes: (1) systemic therapy, which is a systemic immune activation including administration
of systemic cytokine, cancer vaccines, or adoptive cell transfer; (2) local-based therapy, which is
based on changes in local immune status including modulation of the immunosuppressive tumor
microenvironment, with immune checkpoint or small molecular inhibitors [34]. Immune-modulating
approaches available for the treatment of head and neck cancer target a variety of immune processes
and critical checkpoints, including cytotoxic T-lymphocyte associated antigen-4 (CTLA4), and program
death (PD-1) and its ligand (PD-L1); other methods using immune modulating molecules as well as
combinatorial trials evaluating these agents in the first-line setting and early-stage disease are under
development [35,36].
Because HNSCC tumors have been shown to poorly present tumor antigen (TA) on the cell surface,
monoclonal antibodies facilitating better TA presentation are one avenue for targeted therapeutics [37].
Nivolumab and pembrolizumab, two anti-PD-1 agents, recently approved for use as monotherapy in
the second-line setting for patients with platinum-refractory recurrent/metastatic HNSCC, have shown
efficacy in clinical trials [30,38]. Other targeted therapies using epidermal growth factor receptors
(EGFR, highly overexpressed in 80–90% of HNSCC) inhibitors, such as cetuximab, bevacizumab,
and erlotinib, have shown improvement of OSCC patient survival [39]. Despite the promise of
immunotherapies, new therapeutic approaches or improvements to clinical trials design that are
tailored on the tumor/patient profile are much needed in order to overcome the innate and acquired
tumor resistance, as well as to address/prevent their side and adverse effects [40]. Developing novel
immunotherapeutic approaches can be promising in providing long-term control of the disease in
the response population, although the low efficacy and high toxicity in some patients can be a severe
issue [33,34,38]. Generally, using immunotherapy can be challenging due to auto-immune side effects,
variability in tumor responses rate, and financial cost [36]. A solution to enhance the efficacy of immune
agents is using nano-based drug delivery systems (DDSs) through direct targeting of the cancer cells,
facilitating intracellular penetration, and boosting the immunogenicity of antigens [41]. To date, there
are limited studies on the utilization of DDS combined with immunotherapy for the treatment of
HNSCC or OSCC. Hirabayashi et al. and Maeda et al. developed anti-EGFR antibody-conjugated
microbubbles for the treatment of HNSCC and OSCC, respectively [42,43]. These studies showed
promising results for future applications of combined immunotherapy with DDSs.
DDS have been developed as an alternative method aiming to enhance the benefits of the current
anticancer therapies, while minimizing their undesirable toxic effects on the healthy cells. For instance,
the chemotherapeutic agents have several limitations in terms of oral bioavailability, stability in natural
conditions, and non-specific bio-distribution, that decrease their therapeutic efficiency [44,45]; their
side effects can be severe particularly in older patients with debilitating comorbidities. For instance, the
parenteral administration of chemotherapeutic drugs allows for the drug control via the bloodstream,
thus affecting other non-cancerous organs/tissues in the body, besides the tumor itself; the extent
and clinical consequences of these non-specific effects are hard to predict. Adverse effects such as
nausea, vomiting, hair loss, infections, and diarrhea are common in patients receiving chemotherapy.
Radiotherapy can be used alone or in combination with the chemotherapy to treat the primary tumor;
shrink the tumor prior to surgery (neoadjuvant therapy; note: chemotherapy also can be administered
in the neoadjuvant setting); as adjuvant therapy to maximize the effectiveness of the primary treatment
in hopes of extending survival and reducing the risk for recurrence; or to relieve pain or control
symptoms of advanced oral cancer (palliative therapy). A patient’s response to neoadjuvant therapy
can determine which adjuvant therapy is selected. Side effects of radiation therapy due to transient
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or permanent damage to healthy tissues are fatigue, sore or dry mouth and difficulty swallowing,
dental problems (tooth decay), taste change, loss of appetite, nausea and vomiting, nerve damage, pain,
infection, osteoradionecrosis, trismus, lymphedema, and hair loss [29]. These can affect the ability
to eat and speak and can lead to other complications such as dehydration and malnutrition, social
withdrawal, anxiety and depression, impacting the patient’s quality of life.
Conventional therapeutic approaches need improvement in bioavailability and targeted delivery
to the tumor site (for a pre-determined period) to overcome and prevent the adverse side effects of the
drugs [46]. Our group has investigated the potential anticancer benefits of antacid medications, such
as proton pump inhibitors and histamine 2 blockers that are commonly used in HNSCC patients to
manage acid reflux, a condition that contributes to complications after surgery or during radiotherapy.
Our findings in a large cohort study indicated that routine clinical usage of these two classes of
antacids in HNSCC patients was correlated with enhanced survival; remarkably our analysis identified
histamine 2 receptor antagonist class usage as a significant prognostic factor for recurrence-free survival
in patients with oropharyngeal tumors HPV-positive [47]. Ongoing studies in our laboratory are
investigating the abilities of these medications to improve the efficacy of conventional therapies,
particularly in advanced HNSCC [48,49].
An innovative approach to improve the efficacy of chemotherapeutic agents is the administration
of drugs in a time-specific manner (chrono-chemotherapy). It is becoming evident that administration
timing is as vital as the dosing amount of chemotherapy [50]. The time of administration (morning vs.
evening) influences drug toxicity and therapeutic efficacy because human body physiology is affected
by the circadian clock rhythms [51]. Anticancer chemotherapeutic agents docetaxel, doxorubicin,
fluorouracil, and paclitaxel have been recently recognized by the World Health Organization as
drugs which target circadian clock genes (Bcl2, Top2a, Tyms, and Bcl2 respectively). Hence, they
can be employed in chrono-chemotherapy for oral cancer treatment [52]. A recent study showed
that chrono-chemotherapy of a combination of Docetaxel, Cisplatin, and Fluorouracil (DCF) helped
to decrease the severity of the side effects of each of these drugs [53]; patients with OSCC had less
vomiting, nausea, and neutropenia when treated with evening DCF dosing rather than with morning
administration [53]. Thus, it seems promising that chrono-chemotherapy has the ability to reduce the
severity/extent of the side effects of some chemotherapeutic drugs, which can be exploited as a novel
therapeutic strategy in oral, head and neck cancer patients and beyond.
Another approach that showed promise in overcoming the complications of conventional
anticancer agents while enhancing their therapeutic efficacy is the targeted drug delivery system
consisting of natural and/or synthetic polymers for delivery of chemotherapeutic agents to the tumor site.
Targeted drug delivery systems have the potential to increase drug bioavailability and bio-distribution
at the site of the primary tumor. DDS is capable of releasing a bioactive molecule at a specific site with
a specific delivery rate. Targeted DDS for oral cancer could thus improve patient compliance, enhance
drug efficiency while reducing treatment duration, and consequently decrease healthcare expenses.
In vivo studies have shown that targeted DDS can also improve the half-time of otherwise rapidly
degradable drugs such as peptides and proteins, thus prolonging their local effects [54].
Our review of the most promising anticancer drug delivery approaches is structured in three
sections as follows: first, the conventional anticancer drugs are reviewed in regard to their oral
administration and potential for DDS formulation; second, a brief background of commonly used
carriers in DDS for oral cancer treatment is provided; and third, the potential of different drug delivery
methods for OSCC is discussed.
2. Anticancer Agents for Oral Cancer Treatment Formulated in Drug Delivery Systems
While most of the oncological treatments are traditionally administered intravenously, several
anticancer drugs have recently been developed and approved by the USA Federal Drug Administration
(FDA) for oral administration [55].
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Administration of chemotherapeutic drugs in the form of pill or gel is an attractive approach to
enhance patient compliance. This method of delivery is also desirable when the treatment requires drug
exposure for prolonged periods [46]. Unfortunately, oral administration of most anticancer drugs is
hindered due to the drug’s physicochemical characteristics, particularly poor aqueous solubility [56,57].
However, most of the chemotherapeutic agents delivered intravenously can also be administered via
other routes of delivery when incorporated in suitable carrier (bio)materials [58]. Carefully designed
DDS can be used to formulate chemotherapeutic agents for local (e.g., applied to the tumor site) or
intravenous delivery with higher efficacy than the standard intravenous administration. Following is
an overview of the most common anticancer drugs used for the treatment of oral cavity and oropharynx
cancer patients [59], which have already been investigated for their administration using controlled
and/or targeted DDS with promising results.
2.1. Paclitaxel (PTX)
Paclitaxel (Taxol) is an antineoplastic agent which functions by cellular growth inhibition. Oral
administration of PTX is challenging because of its low solubility and reduced permeability across
the intestinal epithelium/mucosa that limit its absorption. When PTX is administered intravenously,
which is the most common delivery method in the clinic, its distribution throughout the body is very
extensive, causing severe side effects such as liver dysfunction [60]. To increase its absorption, Lee et al.
designed a platform based on the chemical conjugation of PTX to the low molecular weight chitosan,
which increased PTX’s water solubility due to the presence of chitosan and its increased retention time
in the gastrointestinal (GI) tract [61]. Tiwari and Amiji reported nano-emulsion formulations of PTX to
improve its oral bioavailability; the nano-emulsion delivery of PTX resulted in a significant increase of
the PTX concentration in systemic circulation versus control (aqueous solution of PTX), suggesting
that this formulation can enhance the oral bioavailability of hydrophobic drugs such as PTX [62].
In another study, Dong and Feng added montmorillonite to poly(lactic-co-glycolic acid) (PLGA) in
order to synthesize nanoparticles for PTX delivery; the montmorillonite-PLGA nanoparticles allowed
for an enhanced cellular uptake and efficiency of PTX as compared to the PLGA nanoparticles alone,
suggesting that the montmorillonite-PLGA nanoparticle formulation can extend the residence time of
PTX in the GI tract [63].
2.2. Cisplatin (DDP)
Cisplatin is a chemotherapeutic agent with a recognized benefit in the treatment of various human
cancers, including oral, head and neck squamous cell carcinoma, bladder, lung, ovarian, breast, and
testicular cancers. Cisplatin causes apoptosis (cell death) of cancer cells due to its ability to crosslink
with purine bases on DNA, interfering with DNA repair mechanism, and causing DNA damage [64,65].
Because its administration has been associated with severe side effects such as renal failure, there
have been several attempts to formulate this drug in an oral sustained release system [64]. Cheng
et al. exploited the ability of the low pH-responsive porous hollow nanoparticles of Fe3O4 to be
used as a vehicle for site-specific cisplatin delivery; their system, based on the encapsulated cisplatin
into porous hollow nanoparticles of Fe3O4, not only protected cisplatin from deactivation by plasma
proteins and other biomolecules before reaching the target site, but also provided control of the release
rate of cisplatin by varying the nanoparticle’s pore size and pH [66]. Yan and Gemeinhart generated
encapsulated cisplatin poly(acrylic acid-co-methyl methacrylate) micro-particles for controlled release
of cisplatin, and their system enabled cisplatin to maintain its activity for prolonged periods [67].
A cisplatin analog with similar chemotherapeutic profile, Carboplatin, has also been investigated alone
or as part of nanoparticle formulations in order to minimize its undesired side effects [68].
2.3. Doxorubicin
Doxorubicin (DOX) is one of the most potent anticancer agents used for the treatment of numerous
cancer types, because of its ability to target rapidly dividing cells, both cancerous and non-cancerous.
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Its toxicity on non-cancerous cells limits its application because it can result in cell death in major organs
such as heart, brain, liver, and kidney [69–71]. Drug delivery strategies sought to minimize DOX side
effects while exploiting its anticancer properties with higher therapeutic efficiency. For instance, Li et al.
encapsulated DOX in dextran nanoparticles to specifically target tumor cells with the expectation that
these smart nanoparticles would increase drug loading efficiency and release the drug at a particular
site directly into the cancer cell’s nucleus [72]. She et al. used dendronized heparin nanoparticles
conjugated to DOX as a pH-responsive drug delivery vehicle for cancer treatment. These nanoparticles
showed significant anti-tumor activity on a 4T1 breast tumor model without toxicity to healthy
organs [73]. Collectively, this evidence showed that incorporating DOX into nanoparticles held promise
for reducing toxicity on healthy cells while increasing its antitumor activity.
2.4. Docetaxel
Docetaxel (DTX), an effective anticancer drug, is most commonly administered intravenously in
cancer patients because of its highly hydrophobic property, but it has low oral bioavailability due to the
P-glycoprotein (P-gp)-mediated efflux and first passes effect. To address these drawbacks, Sohail et al.
synthesized a chitosan scaffold in which folic acid and thiol groups were grafted to chitosan to target
cancer cells and improve permeation through the gastrointestinal tract [74]. They also synthesized
silver nanoclusters in situ, which allowed for the generation of core-shell nano-capsules with the
hydrophobic DTX as the core and the silver nanocluster embedded chitosan as the shell; this strategy
resulted in a DTX carrier system suitable for the oral delivery of DTX to cancerous tissues [30].
2.5. Methotrexate
Methotrexate (MTX), an antimetabolite agent used in anticancer chemotherapy, is a folate
antagonist which inhibits the synthesis of purines and pyrimidines, thereby causing inhibition of the
malignant cells’ proliferation. MTX is used for the treatment of a variety of cancers, including oral,
head, and neck cancer, acute lymphocytic leukemia, non-Hodgkin’s lymphoma, choriocarcinoma,
osteosarcoma, and breast cancer [75,76]. When administered orally, MTX systemic bioavailability
is approximately 35%, which is significantly lower than when administered parenterally [77]. Oral
administration of MTX is associated with significant side effects (diarrhea, ulcerative stomatitis,
hemorrhagic enteritis, gastrointestinal perforation) due to inhibition of cellular proliferation. Kumar
and Rao formulated MTX in proteinoid microspheres to enhance its bioavailability and targetability,
with the expectation that these microspheres could deliver MTX and other pharmaceutical compounds
that are prone to degradation, under gastric condition [78]. Paliwal R et al. encapsulated MTX into solid
lipid nanoparticles (SLNs) consisting of stearic acid, glycerol monostearate, tristearin, and Compritol
888 ATO; the MTX loaded SLNs significantly improved the bioavailability of MTX by protecting MTX
from degradation in the harsh gastric conditions [79].
2.6. Fluoropyrimidine 5-Fluorouracil
Fluoropyrimidine 5-fluorouracil (5-FU), another FDA approved anticancer drug, inhibits essential
biosynthesis processes or interferes with DNA or RNA, limiting their normal function. This drug
has been effective in treating various types of cancer, including oral, head and neck cancer, colorectal,
and breast cancer [80]. Li et al. designed a biodegradable controlled release system composed of
PLGA nanoparticles, which maintained a prolonged continuous release of 5-FU. Their results showed
that these nanoparticles could enhance the oral bioavailability of 5-FU while decreasing its local
gastrointestinal side effects [81]. Minhas et al. developed a pH-responsive controlled release system
for 5-FU delivery, by preparing a chemically cross-linked polyvinyl alcohol-co-poly(methacrylic acid)
hydrogel loaded with 5-FU, which enabled the release of 5-FU at pH 7.4, with the potential for being
used as an oral drug delivery vehicle for 5-FU in cancer treatment, particularly colorectal cancer [38].
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3. Carriers for OSCC Drug Delivery Systems
Carrier-based drug delivery systems are used for controlled release of drugs while providing
improved selectivity and effectiveness, and reduced side effects compared to the chemotherapeutic
agents alone. Different carrier systems based on nanoparticles, nanolipids, and hydrogels are discussed
here, each with unique advantages and disadvantages (Figure 1). Additionally, exosomes have been
recently introduced as potential carriers of chemotherapeutic agents for oral cancer treatment. The
benefits and drawbacks of each carrier system are summarized in Table 1.
Figure 1. Different carriers used for oral cancer: (A) polymeric nanoparticles; (B) nanolipids;
(C) inorganic nanoparticles; (D) hydrogels.
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3.1. Nanoparticles for Drug Delivery
The use of nanotechnology in drug delivery has allowed for selective and safe methodologies for
OSCC treatment [87,92]. Nanoparticles provide enhanced bioactivity due to their large surface to volume
ratio [84,96]. The most common nanoparticles investigated in oral cancer treatments include gold
nanoparticles, liposomes, magnetic nanoparticles, and polymeric micelles [88,97]. These nanoparticles
are capable of killing cancer cells by delivering the drugs entrapped or encapsulated in them [92,97].
Utilizing nanoparticles as drug carriers have also resulted in stabilization of chemotherapeutic
compounds that can be released in a controlled and sustained manner. This targeted delivery facilitates
the prolonged release of a drug at a specific site, thus reducing its systemic toxicity [98].
3.1.1. Polymeric Nanoparticles for Drug Delivery System
For targeted drug delivery with improved biocompatibility and drug controlled release,
nanoparticles fabricated from natural and synthetic polymer have received much attention [84].
Polymers consisting of polysaccharides, poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and their
copolymers, are biodegradable and thus slowly eliminated from the body after the delivery of cargo [99].
There has been substantial research into intraoral, site-specific chemoprevention using a polymeric
drug delivery system. These chemopreventive agents are delivered directly to various affected sites
within the oral cavity, thereby preventing the malignant conversion of oral epithelial dysplasia to frank
carcinoma. Several techniques are currently employed to synthesize such nanoparticles, including
nanoprecipitation, emulsifications, and self-assembly [100]. Selecting a particular method depends on
the physicochemical properties of the polymer, drug solubility, and drug release behavior [100].
Endo et al. have used polymeric nanoparticles based on poly(ethylene glycol)-poly(glutamic acid)
block copolymer to increase the anti-tumor effects and reduce the toxicity of cisplatin [101], the most
commonly used chemotherapeutic drug in OSCC patients [102]. Cisplatin was integrated into polymeric
micelles through the polymer-metal complex formation between poly(ethylene glycol)-poly(glutamic
acid) block copolymers and CDDP (NC-6004). The mean particle size of polymeric micelles (NC-6004)
was 30 nm. Also, static light scattering (SLS) measurement exhibited that there is no dissociation of
cisplatin-loaded micelles upon dilution and the critical micelles concentration (CMC) was less than
5 × 10−7 [100,103].
The treatment of oral cancer cells with cisplatin-loaded nanoparticles (NC-6004) leads to the
activation of the caspase-3 and caspase-7 pathways, which induce apoptosis [101]. In vivo results
showed that the antitumor activity of NC-6004 against tumor growth in oral carcinoma-bearing
mice was 4.4–6.6-fold higher compared to the control group. Additionally, the controlled release of
cisplatin from these nanoparticles resulted in decreased nephrotoxicity and neurotoxicity compared
with administration of cisplatin in solution [101].
Additional agents (e.g., curcumin) have been investigated for their therapeutic benefit in oral
cancer based on their ability to induce apoptosis and inhibit tumor cell proliferation [91,104]. To
enhance the clinical benefits of these therapeutic agents by improving their bioavailability and
stability, Mazzarino et al. used a nanoprecipitation technique to generate polycaprolactone (PCL)
nanoparticles coated with the polysaccharide chitosan for curcumin delivery into the oral cavity [104].
The chitosan coating on the nanoparticles was confirmed by the changes in particles size and zeta
potential measurements. With the increase in concentration of chitosan, the hydrodynamic radius of
nanoparticles increased for unloaded and curcumin-loaded nanoparticles (104 to 125 nm; polydispersity
index (PDI) < 0.2) [101]. Additionaly, chitosan-coated nanoparticles showed increased zeta potential
values (positive surface charge) compared to uncoated nanoparticles due to the presence of positively
charged amino groups of chitosan molecules on the surface of the particles, thus proving that the
nanoparticles were successfully coated [105]. Also, due to a strong interaction between curcumin and
PCL, the core of the curcumin-loaded nanoparticles was compacted, which leads to the decrease in
their size compared to the unloaded nanoparticles [101,105].
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Adsorption of chitosan on PCL formed a muco-adhesive nanoemulsion, which showed an
interaction between glycoprotein mucin and PCL nanoparticles. This system was evaluated by surface
plasmon resonance. Better muco-adhesive properties lead to an increase in the residence time of
the drug. The cytotoxic effect of these nanoparticles was evaluated in an in vitro study using an
OSCC-derived cell line, SCC-9 that showed induction of apoptosis in tumoral cells. Furthermore, these
polymeric nanoparticles encapsulating curcumin showed improved bioavailability [104] and improved
curcumin stability by preventing its degradation in neutral solutions and upon exposure to light [106].
Interestingly, dietary substances containing bioactive compounds may also have some ability
to suppress cancer. Studies indicated that ellagic acid (a polyphenolic chemopreventive agent) has
anti-cancerous, antioxidant, and antiviral properties. However, its usage is limited due to low
oral bioavailability and water solubility [107]. Bio-polymeric nanoparticles may overcome these
drawbacks, increasing the drug efficiency by preventing the degradation of unstable chemotherapeutic
biomolecules. Arulmozhi et al. developed chitosan nanoparticles encapsulating ellagic acid using the
ionotropic gelation technique, which enhanced the anticancer properties of ellagic acid, thus, making
this formulation a promising platform for oral cancer treatment [100,108].
3.1.2. Inorganic Nanoparticles for Drug Delivery System
Inorganic nanoparticles have been extensively used in treatments due to their lower toxicity,
higher tolerance towards organic solvents, and better bioavailability compared with the free drug [88].
Inorganic nanoparticles based on noble metals (e.g., gold) have been used in diagnostic and imaging
processes and received much attention due to their highly controlled optical properties [109,110]. Such
nanoparticles are potential photo-thermal agents with high efficacy in therapeutic applications. Sayed et
al. prepared anti-epithelial growth factor receptor (EGFR) antibody-conjugated gold (Au) nanoparticles
(with an average particle size of 40 nm characterized by transmission electron microscopy (TEM) and
incubated them with OSCC cell lines and a control benign epithelial cell line [110]. Continuous wave
(CW) argon ion laser was used to produce photothermal destruction. These in vitro results showed
that the malignant cells with anti-EGFR/Au conjugates required less energy to produce photothermal
destruction due to the targeting of the Au nanoparticles on the surface of EGFR-overexpressing
malignant cells but not on benign cells. In clinical applications, near-infrared (NIR) laser light with
deep penetration allowed for effective delivery of anti-EGFR/Au conjugates to the cells. Furthermore,
the surface plasmon absorption of Au nanoparticles can be finely tuned by modifying the nanoparticles’
size to allow for better absorption of this NIR laser light, thus maximizing their therapeutic benefit [110].
Recently, other therapeutic techniques, including photodynamic therapy (PDT), have been
employed to increase the penetration of drugs deeper into tissues, required for the treatment of
advanced and recurrent oral cancer [111]. Lucky et al. developed up-conversion nanoparticles
(UCN) loaded with PEGylated titanium dioxide (TiO2) to increase tissue penetration using NIR; these
nanoparticles were used for targeting EGFRs on the surface of cancer cells using anti-EGFR-antibody
conjugated with PEGylated TiO2-UCNs to inhibit tumor proliferation, invasion, angiogenesis, and
metastasis. Anti-EGFR-PEG-TiO2-UCNs nanoparticles were characterized by TEM and a well-defined
core-shell structure was observed with approximately 50 nm in diameter. Further, the composition of
nanoparticles was confirmed by Energy-dispersive X-ray (EDX) spectroscopy showing formation of
Na (Sodium), Y (Yttrium), F (Fluorine), Yb (Ytterbium), and Tm (Thulium) from the core nanocrystals
and Ti (Titanium), Si (Silicon) and O (Oxygen) from the shell [107]. In vivo studies investigating
anti-EGFR-PEG-TiO2-UCNs showed no toxic side effects, whereas in vitro studies showed enhanced
apoptosis and tumor growth inhibition [111,112].
Drug delivery using nanoparticles allowed for increased concentration of therapeutic agents
at the tumor site, which resulted in cancer cell inhibition with reduced toxicity on the surrounding
non-cancerous healthy cells. Nevertheless, there are still challenges linked to carriers stability and fate
in the human body, and their limited effective delivery remains problematic. To overcome some of these
drawbacks, Eguchi et al. prepared innovative magnetic nanoparticles consisting of μ-oxo N,N′-bis
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(salicylidene) ethylenediamine iron (Fe(Salen)) for targeted delivery of anticancer agents. Since these
particles were difficult to solubilize, they were suspended in water or saline after sonication. Iron–salen
particles were characterized using DLS and TEM, showing size ranged 1.2–3 μm for unsonicated
particles and 60–800 nm for sonicated particles. The sonication for approximately 6 hours reduced
particle size (confirmed by TEM) with smooth edges of the particles as compared to the unsonicated
particles. The sonicated Fe(Salen) particles showed zeta potential value of −24.1 mV, thus confirming
the stability of the colloidal dispersion [113].
Sato et al. used Fe(Salen) nanoparticles with average size of 200 nm for targeted delivery of
anticancer agents. These nanoparticles were sonicated for 30 min and were suspended in normal
saline. Alternating magnetic field (AMF) combining chemotherapy and hyperthermia was used to
heat Fe(Salen) nanoparticles and resulted in increased induction of cancer cell apoptosis and better
carrier stability, as compared to individual chemotherapy or magnetic guided delivery. Fe(Salen)
nanoparticles were useful for controlled drug delivery and hyperthermia therapy, with an increase in
anti-cancer therapeutic efficacy and reduced toxicity [89].
Other inorganic nanoparticles systems, such as mesoporous silica nanoparticles (MSNP), showed
promise for cancer therapy. These nanoparticles’ advantages include high porosity, biocompatibility,
and amenability for surface functionalization [114]. The porous nature of MSNPs provides much free
space for antitumor drugs to be incorporated. These nanoparticles, combined with polymers, can carry
drugs with high efficiency in targeting OSCC cells [114,115], but additional investigations are required
for the routine implementation of these systems into clinical practice.
3.1.3. Combinational (Polymeric-Inorganic) Nanoparticles
Combinational drug treatment is recognized for its increased therapeutic benefits. Targeted drug
delivery offers improved therapeutic efficacy with reduced toxicity. Quinacrine (QC) is an anticancer
agent that is also used as an antimalarial drug; it has shown therapeutic benefits in breast, lung,
colon, and renal cell carcinoma. Despite these positive outcomes, QC clinical applications are limited
due to its poor bioavailability and various side effects, including skin rash and pigmentation, and
immunological complications [116]. Inorganic silver-based nanoparticles (AgNPs) also have potential
as anticancer agents due to their ability to induce tumor cell apoptosis. Combinational approaches
have been employed to address AgNP’s limitation of toxicity to healthy cells at higher doses, which
resulted in the enhanced anticancer activity of AgNPs [100,116]. Satapathy et al. prepared highly stable
PLGA based quinacrine (QC)–silver hybrid nanoparticles (QAgNP) using an oil-in-water emulsion
solvent evaporation technique. The TEM analysis determined the size and morphology of QAgNP
with size ranging 50–100 nm. Average particle size of 382.4 ± 0.11 nm was obtained by DLS with
a positive zeta potential of 0.523 ± 0.09 mV [111]. These nanoparticles were allowed to interact
with various oral cancer cell lines and OSCC-derived stem cells and evaluated for their antitumor
activity. PLGA/quinacrine/silver nanoparticles showed high cytotoxicity against cancer cells with
improved ability to destroy specifically the OSCC-derived stem cells. The study also confirmed
that PLGA/quinacrine/silver nanoparticles not only inhibited proliferation of OSCC but also reduced
neo-angiogenesis, suggesting that this hybrid nanoparticle drug delivery system can be a promising
platform for the treatment of OSCC [100,116].
3.2. Nanolipids
Polymeric nanoparticles’ cytotoxicity, due to low internalization into the tumor cells, restricts
their therapeutic efficiency [85,86]. Solid lipid-based nanoparticles (SLNs) have overcome this problem
because they can penetrate cancer cells. Furthermore, their high stability provides controlled drug
release, drug protection from chemical degradation, and they can serve as carriers for drugs with low
aqueous solubility [92,117]. Therefore, these nanoparticles seem suitable for local delivery of drugs
and chemopreventive agents [118,119].
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One limitation of nanoparticles prepared from solid lipids is their crystalline structure, which
allows for only limited space to accommodate drugs. Nanostructured lipid carriers (NLCs) have been
designed and tested in cancer therapy to overcome this limitation. These NLCs consist of both solid
and liquid lipids in a core matrix, thereby distorting the crystal structure and providing space for drugs
to be encapsulated in amorphous clusters [120,121]. Thus, NLCs addressed the issues of poor solubility,
low bioavailability, and instability of anticancer drugs and therapeutic agents [93,121]. A recent study
by Fang et al. reported the enhanced bioavailability of curcumin loaded into nanostructured lipid
particles, an emerging method for treating OSCC [122]. Other studies reported the fabrication of
nanostructured lipids with other therapeutic agents, such as docetaxel and etoposide, which have
shown promise in treating oral cancer [123–125].
3.3. Hydrogel-Based Drug Delivery Systems
Hydrogels are three-dimensional (3D) mesh structures of hydrophilic fibers that contain a large
amount of water or biological fluids. Hydrogels resemble the soft body tissues and are capable of
encapsulating drugs and biomolecules such as proteins and genetic materials [126]. Depending on the
mechanism used for their gelation, there are two types of hydrogels, physical and chemical. Physical
gelation is not inherently permanent, but reversible whereas chemical gelation is reversible because it
involves chemical bonds, and thus results in permanent or very stable hydrogels [127–129].
Hydrogels act as localized, targeted drug delivery systems and offer some advantages when
juxtaposed with active and passive targeting by using nanocarriers [130]. For instance, a limitation
of nanoparticle-based systems is the swift elimination from blood circulation due to their small
size and renal clearance. Also, the tumor microvascular morphology, characterized by increased
interstitial fluid pressure, results in low intra-tumoral penetration of the drug-loaded nanocarriers,
which in turn results in decreased therapeutic efficiency [130–133]. In contrast, hydrogels can provide
sustained administration of both hydrophilic and hydrophobic drugs, proteins and other biomolecules
independently of the microvascular system of the tumor, allowing for high drug loading capacity,
as high as the drug’s solubility in water [134,135]. Hydrogels can also control the release of the
drug for short or long periods (up to several months) by altering the density of the nanofibers in the
hydrogel [136].
Moreover, hydrogels allow for co-administration of multiple drugs with synergistic anti-cancer
effects and decreased drug resistance [46,130]. In one study, a thermosensitive physical hydrogel
composed of poly(ethylene glycol)-poly(ε-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE)
showed great potential as an in situ controlled delivery system for suberoylanilide hydroxamic acid
(SAHA), a histone deacetylase (HDAC) inhibitor in combination with cisplatin (DDP). When injected
intratumorally in a OSCC mouse model, the PECE hydrogel provided sustained release of the loaded
SAHA and DDP for more than 14 days, enhanced therapeutic effects, and reduced side effects [137].
3.4. Exosomes
Exosomes are membranous vesicles with sizes between 40–120 nm that are secreted by different
cells, such as dendritic cells, macrophages, mesenchymal stem cells, endothelial, and epithelial cells, into
the extracellular space [138–141]. Due to their nanosized dimensions and natural formation, exosomes
have received much attention and are involved in many biological and pathological processes. Exosomes
are secreted when the multivesicular body (MVB) fuses with the plasma membrane. Exosomes can
contain many types of biomolecules and play an essential role in inter-cellular communication [142].
Their ability to bind to the cell membrane through adhesion proteins and ligands has made them a
sound carrier system for targeted drug delivery applications [139,141]. They have been used as a
vehicle for chemotherapeutic agents such as curcumin, DOX, and PTX, helping to reduce their side
effects while increasing their therapeutic efficiency [139,143,144]. Tian et al. used targeted exosomes
as a targeted delivery system for DOX to treat breast cancer cells; when injected intravenously in
mice, these exosomes delivered DOX targeted to tumor tissues, which resulted in inhibition of tumor
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growth without overt toxicity [144]. Despite their promising preclinical evidence for cancer therapy,
several limitations prevent exosomes utilization as an efficient drug delivery system in the clinical
practice, mainly due to their limited capacity to deliver high doses of therapeutic agents. Also, the
separation of exosomes with high purity is a long and demanding process that usually generate low
amounts. Finally, studies showed that exosome administration in patients might lead to adverse
immune reactions [140]. Conclusively, exosomes can be a useful tool for the treatment of oral cancer,
but their purification, analysis, and administration are still challenging [145].
4. Controlled Drug Delivery Approaches for Oral Cancer
The treatment options for advanced OSCC are limited and suboptimal. Conventional therapeutic
approaches (i.e., surgery, chemotherapy, and radiotherapy) significantly impact patient’ wellbeing
and quality of life. Thus, there is an imperative requirement for new therapeutic methods with
reduced side effects and systemic toxicity. Several controlled drug delivery and release strategies
have been developed to overcome the current challenges associated with the parenteral (intravenous,
IV) administration of chemotherapeutic agents. These strategies include: the administration of
chemotherapeutics via intra-tumoral injection; local delivery; photo-thermal administration using
drug-loaded nanoparticles; and ultra-sonoporation using microbubbles (Figure 2). These approaches
are reviewed and discussed herein regarding oral cancer.
Figure 2. Different controlled drug delivery approaches: (A) Intra-tumoral drug delivery;
(B) local drug delivery; (C) photo-thermal therapies combined to drug delivery systems;
(D) ultrasound-mediated microbubble.
4.1. Intra-Tumoral Drug Delivery in Oral Cancer
One approach is local intra-tumoral administration [146,147]. Li et al. developed a controlled
release system that optimized the combined therapeutic benefits of two anticancer drugs while
minimizing their side effects, by using suberoylanilide hydroxamic acid (SAHA) and cisplatin (DDP)
loaded into PECE hydrogel for the OSCC treatment. Six mice groups were comparatively analyzed
(1st group was injected with normal saline (NS); the 2nd was injected with blank hydrogel; the 3rd with
SAHA; the 4th with DDP; the 5th with SAHA-DDP; and the 6th with SAHA-DDP/PECE; the mice in the
sixth group had the smallest tumor volume with no noticeable systemic cytotoxicity compared to other
groups at the end of the study [137]. Intra-tumoral delivery of chemotherapeutic drugs incorporated
in a hydrogel is considered as a promising approach for further exploration of OSCC treatment [137].
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4.2. Local Drug Delivery in Oral Cancer
Local drug delivery is a tumor-targeted approach that delivers the drug to the proximity of the
tumor. With this approach, the drugs enter the systemic circulation to a lesser extent compared with
other administration routes, thus limiting the adverse side effects of the drugs on healthy cells [148].
For example, locally delivered drugs formulated inside nanoparticles can reach cancer cells passively
or through active targeting. In the case of passive targeting, the nanoparticles reach cancer cells by
diffusion and enter the cytoplasm by endocytosis, while in the case of active targeting the nanoparticles
are functionalized to identify specific receptors on the cancer cell surface resulting in increased drug
delivery inside the cancer cell, leaving the majority of the healthy cells unaffected (Figure 3) [149].
Figure 3. Tumor targeting approaches in oral drug delivery.
Local delivery of anticancer drugs to the oral cavity provides a convenient and safe local
administration, with benefit of rapid turnover of the oral mucosa; this allows for a rapid self-repair
after given damage and is a significant advantage that helps alleviate the adverse effects caused by
long-term local drug delivery [150]. The majority of studies that employed local drug delivery for
OSCC treatment used chitosan as a mucoadhesive polymer. To highlight the promise of local delivery
in oral cancer treatment, a remarkable study authored by Arulmozhi et al. reported the encapsulation of
ellagic acid (EA, an anticancer drug with poor water solubility and oral bioavailability) inside chitosan
nanoparticles, which were then evaluated for their therapeutic efficacy in a human oral cancer-derived
cell line (i.e., KB cells). The significant cytotoxicity exhibited by the EA nanoparticles suggested that
this system has the potential to overcome the limitations of any drug with poor oral bioavailability via
targeted local delivery to cancer cells by enhancing its local therapeutic benefits while reducing its
systemic side effects [108].
4.3. Phototherapy Approaches in Drug Delivery
Phototherapy is a minimally invasive method that is commonly used in the treatment of
neoplastic disease. The first phototherapeutic technique is photodynamic therapy (PDT), consisting of
administration of a photosensitizing agent followed by irradiation, which is absorbed by the agent
at a specific wavelength. The photosensitizer generates reactive oxygen species (ROS) following the
utilization of near-infrared (NIR) light, which results in the apoptosis of cancer cells. This process
has proven to be efficient in killing the cancer cells, with the limitation that accumulation of the
photosensitizer in the tumor is relatively low [151,152]. Photo-thermal therapy (PTT) is another method
of phototherapy, which employs light absorbing agents to generate heat, that damages cancer cells
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and consequently eliminates the tumor [153]. However, PTT is not considered for clinical applications
because the laser power density is high and can also damage the surrounding normal tissue [152].
Drug delivery systems (DDS) can improve the phototherapy techniques and address
their limitations. Recent studies have focused on incorporating chemotherapeutic agents and
photosensitizers or light absorbing agents into nanocarriers. After delivery of these agents at the tumor
site, local irradiation has resulted in the killing of the cancerous cells and tumor shrinkage. Current
research studies are focused on the use of magnetic nanoparticles for targeting or tracking cancer cells
by magnetic resonance imaging (MRI) [154–157].
He et al. combined photodynamic therapy (PDT) with chemotherapy to simultaneously release
anticancer and photosensitizer drugs at the tumor site for the treatment of resistant head and neck
cancer. Coordination polymer (NCP)-based core-shell nanoparticles were prepared and loaded with
cisplatin and the photosensitizer pyrolipid. They performed in vivo studies, where mice were treated
with a combination of nanoparticles loaded with cisplatin and pyrolipid; a remarkable tumor reduction
(83%) occurred in cisplatin-resistant SQ20B subcutaneous xenograft murine HNSCC model after the
combined treatment of loaded nanoparticles and irradiation. This system of delivery allowed for
high loadings of cisplatin and pyrolipid to be locally released after irradiation at the tumor site, with
increased anticancer effects as compared to monotherapy [158].
4.4. Microbubbles Mediated Ultrasound in Drug Delivery
Microbubbles are micrometer-sized (1–2 μm) gas bubbles that are used as ultrasound contrast
agents. The injection of microbubbles into blood circulation improves the contrast of ultrasound
images. In addition to their diagnostic usage, the combination of microbubbles and ultrasound can be
used in local drug delivery for the treatment of cancer. Microbubbles can be targeted to specific tumor
sites by incorporation of ligands or monoclonal antibodies binding to receptors expressed on cancer
cell membranes. The combination of chemotherapeutic agents with microbubble-mediated ultrasound
therapy increases drug uptake in targeted tissues through so-called ‘sonoporation’, improves the
drugs’ biodistribution and decreases their systemic toxicity [159–161]. Sonoporation is defined as a
drug delivery system that uses ultrasound for intracellular delivery of agents that cannot move into
cancerous cells under normal conditions [42].
One crucial strategy for the treatment of HNSCC is the inhibition of EGFR signaling, but
current methods cannot suppress this signaling completely. EGFR inhibition can occur through RNA
interference by using microbubbles as nucleic acid delivery vectors. Microbubbles delivered to the site
get ruptured by ultrasound-targeted microbubble destruction (UTMD) resulting in drug release from
the microbubbles’ shell to the insonified area [162].
Recently, Hirabayashi et al. developed anti-EGFR antibody-conjugated microbubbles for colon
squamous cell carcinoma treatment. In in vivo studies, anti-EGFR-microbubbles were injected directly
into the tumor, while the anticancer drug bleomycin (BLM) was injected via the tail vein. The findings
of this study showed that anti-EGFR-microbubbles bound to EGFR on Ca9-22 cells, and the BLM
uptake was increased following anti-EGFR-microbubbles binding to cancerous cells. This system is
promising to enable effective targeted delivery of anticancer drugs into oral cancer cells [42].
Carson et al. highlighted the potential use of microbubbles as carriers of anti-EGFR siRNA along
with ultrasound-targeted microbubble destruction (UTMD) in SCC-VII-induced murine squamous cell
carcinoma model. Delivery of microbubbles to the tumor site, where they were ruptured by UTMD and
resulted in drug release from the microbubbles to the insonified area, led to tumor growth suppression
in mice with OSCC [162]. Recent studies on drug delivery for oral cancer are summarized in Table 2.
A novel immunotherapy strategy involves using small molecules as monotherapy or combined
with other anticancer therapies [163]. The main advantages of these small molecules are good oral
bioavailability, ability to penetrate the physiological barriers, precise formulations and dosing options,
and lower cost to produce and administer [163,164]. A summary of the small molecules designed for
HNSCC and/or OSCC treatment are provided in Table 3.
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Table 3. Monoclonal antibodies-based therapies for the treatment of head and neck cancer.
Drugs Mechanism of Action Reference
Cetuximab, panitumumab, zalutumumab
and nimotuzumab EGFR inhibitors [171]
Gefitinib, erlotinib, lapatinib, afatinib and
dacomitinib EGFR tyrosine kinase inhibitors [171]
Bevacizumab VEGF inhibitors [171]
Sorafenib, sunitinib and vandetanib VEGFR inhibitors [171]
Rapamycin, temsirolimus, everolimus,
torin1, PP242 and PP30, BYL719 PI3K/AKT/mTOR pathway inhibitors [171,172]
Pembrolizumab and nivolumab Anti-PD-1 antibodies [171]
Motolimond ( VTX-2337) TLR8 agonist [173]
AZD1775 (Adavosertib)




Abemaciclib ( LY2835219) Cyclin-dependent kinase inhibitor [175]
TPST-1120 Selective antagonist of PPARα [176]
Sitravatinib (MGCD516) RTK inhibitor [177]
Nintedanib (BIBF1120) Triple receptor tyrosine kinase inhibitor(PDGFR/FGFR and VEGFR) [178]
Durvalumab (Imfinzi, MEDI4736) (IgG1κ) monoclonal antibody [179,180]
Tremelimumab Anti-CTLA4 antibody [170,181]
Abbreviations: EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, VEGF
receptor; PI3K, phosphatidylinositol 3-kinase; AKT, serine/threonine-specific protein kinase; mTOR, mammalian
target of rapamycin; PD-1, program death receptor 1; TLR8, a selective toll-like receptor 8; PPARα, peroxisome
proliferator-activated receptor alpha; RTK, receptor tyrosine kinase; PDGF-R, Platelet-derived growth factor receptor;
CTLA4, cytotoxic T-lymphocyte associated antigen-4; IgG1κ, human immunoglobulin G1 kappa; WEE1, Wee1-like
protein kinase.
There is also promising burgeoning research on immunotherapy and gene therapy for oral cancer
treatment, and these therapies can also benefit from DDS [162,182,183]. A significant advantage of DDS
is their clinical potential for oral cancer diagnostics and treatment simultaneously. Therefore, designing
theranostic systems containing both imaging and anticancer agents will significantly improve the
diagnosis and treatment of OSCC at early stages.
5. Conclusions and Future Perspective
The major challenge in the management of HNSCC patients today is the development of the
evasive cancer cell resistance to conventional therapies. Drug delivery systems employed for the
administration of chemotherapeutic agents have shown promise in the abilities to overcome the
limitations of the conventional anticancer therapeutic approaches. Drug delivery systems for oral
cancer consist of three major components: the anticancer agents (single or multiple); carriers to
encapsulate the agents; and the methods of delivering the agents to the tumor site. The carriers can be
chosen among natural, synthetic, or a combination of materials. They can be prepared in the form of
hydrogels or nanocarriers, including nanoparticles and nanolipids. New drug delivery approaches in
oral cancer focused on intratumoral or local drug delivery, photothermal therapies combined with
DDS, and delivery using ultrasound-mediated microbubbles. Even though controlled drug delivery
systems have been around for more than 30 years, improving clinical efficiency and release profiles of
anti-cancer drugs as well as lowering their side effects remains a challenge. One of the main hindrances
for the commercialization of these systems is the low production reproducibility. Currently, most
research investigations are still focused on in vitro or in vivo studies, whereas only a few systems
have been implemented into the clinic (Table 2). A nano-formulation of DOX (liposomal-encapsulated
formulation of DOX, DOXIL®) was approved by the USA Food and Drug Administration (FDA) in
1995 [184] and is used for breast and ovarian cancer treatment [185]. Similar or novel formulations and
delivery methods are required to address unmet needs for the treatment of oral cancer. A personalized,
reliable drug delivery system explicitly tailored on the unique genetic, molecular, histological, and
circadian profile of a given tumor and a given patient seems the ideal approach in treating patients
with oral cancer and beyond.
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Abstract: The minimally- or non-invasive delivery of therapeutic agents through the skin has several
advantages compared to other delivery routes and plays an important role in medical care routines.
The development and refinement of new technologies is leading to a drastic expansion of the arsenal
of drugs that can benefit from this delivery strategy and is further intensifying its impact in medicine.
Within Canada, as well, a few research groups have worked on the development of state-of-the-art
transdermal delivery technologies. Within this short review, we aim to provide a critical overview of
the development of these technologies in the Canadian environment.
Keywords: transdermal drug delivery; Canada; skin; permeation enhancers
1. Introduction
The skin is the most accessible organ of the body, stretching over a surface area of 1.7 m2 and
making up roughly 10–16% of the total mass of the body [1,2]. Its primary function is to act as a
protective layer against environmental hazards such as chemicals, heat, and toxins, as well as to defend
the body against invading microorganisms and allergens. Moreover, the skin plays a key role in
homeostasis and body temperature regulation, and acts as a sensory organ exposed to the environment,
detecting external stimuli such as temperature, pressure, and pain [2].
While the skin might appear to be an ideal route of administration for local and systemic
therapeutics, it actually represents a challenging barrier against the penetration of most compounds [3].
It is composed of three main layers—the epidermis, the dermis, and the hypodermis—with a total
thickness ranging from 0.5 to 4 mm, dictated by various factors such as body region, age, and
sex [1,3]. The epidermis is a non-vascularized, multilayered stratum whose cells receive nutrients
via diffusion from the lower layers, with the outermost portion, the stratum corneum, acting as
the main barrier against the passage of drugs [4]. The stratum corneum has a wall-like structure
with corneocytes—non-nucleated keratinocytes composed of 70–80% keratin and 20% lipids—acting
as “bricks” in a network of intercellular lipids, while desmosomes act as structural links between
the “bricks” [5]. Beneath the epidermis is the dermis, which contains a network of blood vessels,
which provide nutrients, regulate body temperature, and remove waste products; as well as a
network of lymphatic vessels, which are important in regulating interstitial pressure and clearing large
molecules [5]. These networks are critical for the distribution of molecules crossing the epidermis into
the systemic circulation. When a skin-permeable chemical is applied to the surface of the skin, this
process creates a concentration gradient between the surface and the dermis which helps to drive the
drug into the skin over time. Thus, the capillary network embedded in the dermis is the main target for
transdermal delivery strategies. Finally, the innermost layer, the hypodermis, is mostly composed of
adipose tissue and its primary roles are to provide thermal insulation, protect against physical shock,
and serve as an energy reserve.
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Though transdermal and topical drug delivery has important advantages, including bypassing
the harsh conditions of the gastrointestinal tract, as well as the pain and requirement for trained
personnel associated with parenteral administration, the skin represents a significant physical barrier
and only a very limited number of drugs are compatible with this route of administration without
the use of permeation promoters. An important effort has thus been focused on the design of more
efficient strategies to facilitate the permeation of drugs across the skin, while avoiding tissue damage.
These strategies have drastically improved small molecule delivery for cosmetic, dermatological, and
other localized applications, and have allowed the delivery of macromolecules and vaccines in clinical
trials, along with a few other systemic applications [6–8].
The industrial sector for topical and transdermal drug delivery has grown as the global market
continues to prosper. In addition to established transdermal formulations developed by larger
manufacturing companies, there are a number of initiatives focusing on new systems, and numerous
start-ups have been successfully seeded in this expanding market [9]. The general acceptance of
transdermal products by patients is very high, which is also evident in their increasing market share,
worth $20.5 billion in 2010 and currently estimated at over $32 billion [9,10]. Canada is the world’s
10th largest pharmaceutical market with a 1.9% share of the global market, and annual domestic
pharmaceutical manufacturing was valued at $9.6 billion in 2017 [11]. Hence, research on topical
and transdermal drug delivery systems is of great importance in Canada. In this brief review, we
present and discuss the works of Canadian research groups in the field, critically comparing them
to similar research performed outside the country, as well as highlighting instances where research
has translated to the private sector. We categorized the proposed systems based on their nominal
nature and/or performance mechanisms, namely: chemically enhanced, physically enhanced, and
nanoparticle-based delivery systems (Table 1). We believe that this short review suitably fits the overall
topic of this Special Issue, entitled “Drug Delivery Technology Development in Canada”, and will be
useful for the community in positioning Canada within this important research field.
2. Chemical Permeation Enhancer-Based Systems
Chemical permeation enhancers (CPEs)—generally defined as molecular compounds able to
destabilize the stratum corneum and facilitate the passage of drugs while, ideally, limiting or avoiding
deeper tissue damage—have long been used in transdermal and topical formulations [12]. In the
past, several compounds, such as alcohols, surfactants, terpenes, and fatty acids, have been shown
to enhance the permeation of therapeutics, however, only a few have been adopted in commercial
transdermal and topical products [13,14].
A remarkable example of the use of CPEs to help deliver larger molecules across the stratum
corneum has been proposed by a group at the University of Waterloo. The system, initially described
in a patent in 1998 [15], consists of multilamellar biphasic lipid vesicles (BPVs) ranging in size from
0.1–10 μm. These vesicles were proposed to contain a lipophilic dispersion within an aqueous core,
surrounded by over 15 concentric phospholipid bilayers separated by additional aqueous phases. This
allows molecules of interest (otherwise too large to cross the stratum corneum) to be loaded throughout
the vesicle, enabling local or systemic delivery, with permeation enhanced by the incorporation of
solvents and surfactants within the vesicle structure. Importantly, the works demonstrated that
the relative proportions of lipids and permeation enhancers used in these formulations can vary
significantly, possibly as a function of the molecule being delivered. Two of the most abundant
enhancers, namely propylene glycol and oleic acid, were included in a study of the mechanisms
of permeation enhancement by CPEs [16]. Though both were defined as solvents, oleic acid was
demonstrated to increase fluidity and disorder in the structural lipids of the stratum corneum,
whereas propylene glycol was speculated to primarily enhance permeation through solubilization
of the molecule being delivered. Early uses of this technology were described in the context of the
transdermal delivery of insulin and vaccines [17,18], highlighting the initial promise of the delivery
method, though neither application has thus far led to clinical or commercial translation. Nonetheless,
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research into this topic appears to be ongoing, with more recent articles describing mechanistic
studies of vesicle delivery and the use of BPVs for the topical (rather than transdermal) delivery of
interferon (IFN)-α in the context of human papilloma virus (HPV) treatment. It was demonstrated
in a guinea pig model that, when applied topically, the treatment effectively delivered IFN-α to the
dermis, reaching a maximum local concentration of ~100,000 IU/100 cm2 within 6 h, and remaining at a
therapeutically effective level for up to 72 h [19]. However, more comprehensive studies of the half-life
of IFN-α in the skin were not conducted. Additionally, when compared to an intradermal injection (the
standard delivery method for IFN-α), the vesicle-based topical application never generated elevated
systemic concentrations (<100 IU/mL), while the intradermal administration resulted in rapid systemic
absorption of the drug and consequently an increased likelihood of adverse side-effects. Overall,
dermal application of BPV-IFN-α led to a sustained local release of IFN-α with minimal systemic
exposure [19]. The authors reported that the topical IFN-α was generally well tolerated by animals, as
no significant difference in body weight, apparent pain, or visual appearance of the skin was observed
between animals treated with the vesicle-based IFN-α, those treated with a placebo formulation,
and animals that did not receive treatment. In cases where irritation or redness did occur (3.5%),
it was minor and resolved itself within 2 h of application. The transdermal delivery mechanism of
IFN-α was investigated using confocal microscopy, differential scanning calorimetry (DSC), and small-
and wide-angle X-ray scattering (SAXS/WAXS) [20]. Confocal microscopy analysis indicated that
encapsulated IFN-α was delivered across the stratum corneum to the viable epidermis and dermis,
at a depth of roughly 70 μm. Data extracted from DSC and SAXS/WAXS analyses suggest that a
three-dimensional cubic Pn3m polymeric phase rearrangement of intercellular lipids is induced by
the interaction between stratum corneum lipids and the biphasic vesicles, possibly explaining the
improved delivery of IFN-α. More importantly, in another work, the authors investigated the delivery
of BPV-IFN-α in humans [21]. The particles were demonstrated to be between 1000 and 1100 nm in
size and their zeta potentials were measured between 70 and 78 mV. Following the application of 5, 15,
and 40 MIU/g formulations of encapsulated IFN-α to the upper, inner arm of healthy volunteers as
a topical patch, dermal levels of IFN-α were measured to be 120 ± 30, 380 ± 60, and 400 ± 80 IU/mg
respectively, suggesting a limit to the local concentration deliverable through this system. These local
concentrations indicated a delivery of between 3% and 5% of the dose contained in the patch to the
skin, comparable to many topical formulations of small molecules [22]. In a pilot study of 12 patients
with external Condylomata acuminata warts (a topical manifestation of HPV infection in the genitals)
the application of a significantly lower dose of encapsulated IFN-α (1 MIU/g) twice daily for two weeks
resulted in a decrease in lesion size and 2’,5’-oligoadenylate synthetase activity (a marker for viral
infection), as well as a significant decrease in systemic HPV viral load [21]. In light of this demonstrated
potential for IFN-α delivery, multilamellar BPVs could be envisioned as suitable candidates for the
non-invasive topical delivery of other therapeutic macromolecules to the skin. Despite these promising
initial results, the most recent publication concerning these biphasic vesicles was released in 2013, likely
owing to the acquisition of the technology by the Vancouver-based company Altum Pharmaceuticals
Inc. Branded as BiPhasix™, Altum appears to have further developed the technology in the context of
IFN-α delivery, and has conducted clinical trials of a vesicle-containing cream for treatment of HPV
in females, with Phase III trials slated to begin in Q2 2019, according to their website [23,24]. While
the specific use of multilamellar BPVs for topical or transdermal delivery was quite unique (likely
owing to the proprietary nature of the technology), no other examples of work on similar lipid-based
transdermal delivery systems were found in Canada. For the simplest forms of lipid-based carriers
(namely single-layer liposomes), this can be attributed to their limited success at breaching the stratum
corneum without additional permeation enhancers, and ambiguity regarding their mechanism of
transdermal delivery [25]. Despite this, over the past few years there has been a growing interest in
the concept of nanostructured lipid carriers (NLCs) as a means of overcoming some of the difficulties
associated with traditional liposomes [26]. Similar to some of the principles used in the design of
multilamellar biphasic vesicles, NLCs consist of a solid lipid nanoparticle with a variable percentage of
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liquid lipids and surfactants included within, resulting in a disordered internal structure, and allowing
increased drug loading and improved skin permeation. While many groups have been studying this
delivery route [27–29], none are based in Canada, highlighting a potential topic of interest for groups
studying topical or transdermal delivery. In particular, since the systemic delivery of insulin, vaccines,
and other larger therapeutic compounds through BPVs never reached clinical stages, NLCs could
present another avenue for investigation, especially as they have been primarily studied in the context
of small molecule delivery.
Another important class of CPEs is ionic liquids (ILs); low melting point salts that have drawn
interest for their uses in green chemistry, but are also being investigated based on their potential
for transdermal drug delivery [30–32]. Indeed, ILs have shown the ability to facilitate transdermal
transport, bypassing the physical barrier of the stratum corneum through disruption of cellular
structure, lipid bilayer fluidization, and generation of permeation routes, all of which facilitate the
diffusion of drugs to the dermis [33–36]. For instance, Zakrewsky et al. have demonstrated that
choline-based ILs can enhance the transdermal delivery of mannitol, a small hydrophilic molecule
with low skin permeability [35]. Importantly, this interest in ILs has also extended to the design of
ILs based on active pharmaceutical ingredients (API-ILs); the combination of an API with an optimal
counterion results in a new chemical entity with improved pharmaceutical properties, including better
solubility and ADME characteristics [37]. Although ionized forms of a drug typically cross biological
membranes to a lesser extent (owing to their charged nature), limiting their transport through lipid
membranes, recent reports have demonstrated that additional interactions (e.g., hydrogen bonding)
with a counterion can promote their co-transport to a greater extent than the free ionic drug [38–42].
However, despite the advantages they offer, research into the transdermal applications of API-ILs
remains in early stages. Recently, a group at McGill University described the development of ILs to
improve the delivery of poorly soluble drugs through the skin. Zavgorodnya et al. studied the effects
of various counterions on the membrane permeability of salicylate-based APIs-ILs [43]. Specifically,
they paired three counterions (choline, tributylammonium, and triethylene glycol monomethyl ether
tributylammonium) with a salicylate anion to generate three different API-ILs and assessed their
impact on transdermal diffusion using a silicone membrane as a skin mimic. Remarkably, each of the
ILs showed increased transmembrane diffusion relative to sodium salicylate dissolved in triethylene
glycol monomethyl ether, suggesting that the counterions play an important role in the permeation of
salicylate, beyond simple solubilization. In particular, the polyethylene glycol (PEG)-functionalized
counterion (triethylene glycol monomethyl ether tributylammonium) enhanced transdermal transport
up to 2.5-fold relative to the non-PEGylated tributylammonium. The improved permeation observed
with the PEGylated counterion was potentially due to capacity of triethylene glycol to act as a CPE
while also improving the dissolution of the whole IL complex [44,45]. Although further evaluations,
both ex vivo and in vivo, are needed to confirm the actual potentials of these salicylate formulations,
the same group proceeded to evaluate the in vivo transdermal delivery of lidocaine—a common local
anesthetic often selected as a model compound due to its limited transdermal permeability—using a
similar strategy [46,47]. For this study, the authors prepared two API-IL pairs: lidocainium docusate
([Lid][Doc]) and Lidocaine·Ibuprofen (Lid·Ibu)—which have previously been reported to generate
strong hydrogen bonds, promoting transport across a synthetic membrane [39]—and compared them
to lidocainium chloride ([Lid]Cl). To perform in the in vivo tests, each form was dissolved in a
commercially-available moisturizing vehicle cream (LUBRIDERM®), topically applied to shaved rats,
and the plasma profile of concentration vs. time was assessed by ELISA assay. Among the different
forms, Lid·Ibu demonstrated the greatest and most rapid systemic exposure of lidocaine (4 h AUC
of 12, 602, and 1763 μM·h for [Lid][Doc], [Lid]Cl, and Lid·Ibu). Interestingly, the [Lid][Doc] API-IL
displayed a drastically lower plasma concentration compared to the salt API ([Lid]Cl), which could be
due to the strong hydrophobicity of the ionic salt and the high molecular weight of the counterion.
Importantly, after application of Lid·Ibu, the authors also measured the plasma profile of ibuprofen and
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observed a higher plasma concentration relative to lidocaine, in contrast with previous observations in
synthetic membranes, where the two drugs showed the same kinetics [47].
This phenomenon requires more investigation; a possible explanation could be that the two
compounds permeate the stratum corneum in paired form, and become dissociated within the complex
skin matrix, leading to different plasma absorption kinetics. Despite the relative novelty of the API-IL
strategy for transdermal and topical delivery, early works appear to indicate that it is a promising
method for the enhancement of transdermal and topical delivery, which could be applied to a vast
range of low molecular-weight drugs [47,48]. Nonetheless, more systematic studies are needed, to
investigate different counterions and their effects on drug absorption, cytotoxicity, and skin irritation
in order to better understand their mechanism of action, and to compare them with other transdermal
and topical delivery systems.
3. Physical Permeation Enhancer-Based Systems
Physical permeation enhancers use a physical process to promote the passage of drugs through the
superficial layers of the skin, avoiding damage to the deeper layers. While some of these methods permit
the delivery of drugs across the stratum corneum without damage—for instance iontophoresis, which
uses an electrical field to promote the electrophoretic mobility of a drug—others cause only superficial
physical disruption to the skin. Indeed, one conceptually simple and effective way to bypass the
stratum corneum without the use of chemical compounds is to physically pierce the superficial layers
of the skin and inject the active compound. However, classical hypodermic needles are usually too
large to do this without damaging the deeper layers, potentially causing pain and tissue damage. Thus,
microneedles (MNs), pointed microstructures with a submillimeter length, have been developed as an
alternative technique to deliver vaccines and drugs. Their potential clinical use presents the substantial
advantage of being painless (as the MNs are not long enough to reach skin nociceptors) and could
potentially be self-administered, similar to other topical formulations [49]. Designs for transdermal
drug delivery include solid, dissolving, and hollow MNs, which can be arranged as in-plane or
out-of-plane arrays. Among these, hollow MNs have the primary advantage of being able to deliver
large doses (comparable to hypodermic needles) directly to the dermis and can be used with any drug
without the need for optimization of the formulation, or post-manufacturing sterilization. Although
different methods have been proposed for the manufacture of hollow MNs, including femtosecond
laser two-photon polymerization [50] and microinjection molding [51], their commercial use has been
curbed by their high costs of fabrication [52]. One important player in this field is the Stoeber group,
located at the University of British Columbia in Vancouver. They introduced a new, allegedly more
cost-effective process based on solvent casting, to manufacture hollow out-of-plane clay-reinforced
polyimide MNs with lengths up to 250 μm [53]. To do so, they used photolithography to manufacture
re-usable micromolds containing pillar-shaped MNs using an epoxy-based photoresist. The mold was
then spin-coated with polydimethylsiloxane and treated with O2 plasma to improve its surface wetting.
Using these molds, they optimized the manufacture of hollow MNs by casting a montmorillonite
nanoclay powder mixed with N-methyl-2-pyrrolidone (NMP) dispersed in a solution of polyimide
PI-2611 (85–95% N-methyl-2-pyrrolidone, 10–20% S-biphenyldianhydride/p-phenylendiamine) onto
the mold structures. Following a 2 h evaporation of NMP at 65 ◦C, 250 μm MNs were formed and
removed from the molds. The tips of the MNs were then opened at an aperture of 50 μm using 3
μm aluminium oxide polishing film. Mechanical tests indicated that the MNs were robust enough to
penetrate rabbit skin (an in vivo model generally recognized as a suitable mimic of the thicknesses
and elasticity of human skin) and efficiently deliver a 0.0025 wt % suspension of 0.21 μm fluorescent
polystyrene beads when attached to a standard syringe. The same group adjusted the manufacturing
process to allow the preparation of metallic MNs with the same hollow, out-of-plane geometry [54].
To do so, they used a MN mold coated with a layer of poly(methyl methacrylate) seeded with carbon
black (a conductive polymer) as a cathode, and a pure nickel anode, both immersed in an electroplating
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solution consisting of nickel sulfate, nickel chloride, and boric acid. After the application of a 2 mA
current for 150 min, a 70 μm thick nickel backing layer was obtained.
Following this electroplating process, the tips of the MNs were opened using O2/CF4 plasma
etching. Subsequently, the outer surface of the MNs was covered with a 20 nm thick gold layer to
avoid any dermal allergic reaction that could be caused by the nickel. Mechanical compression tests
indicated that the MNs were strong enough to pierce human skin without breaking, with a measured
fracture force of 4.2 ± 0.61 N. Moreover, the delivery of 2.28 μm fluorescent beads into pig skin was
demonstrated, using 500 μm hollow metallic MNs with a tip lumen diameter of 40 μm. The significant
advantage of this new hollow out-of-plane MN preparation process is that MNs with a wide range of
heights, spacing, and lumen sizes could be prepared. Importantly, this group has funded the start-up
company Microdermics®, and has begun clinical testing, with the primary goal of evaluating the safety
of these MNs in humans [55]. Their aim was to evaluate the biocompatibility and inertness of gold-
and silver-coated MNs, relative to uncoated MNs when applied to the skin, as nickel is known to cause
skin irritation. Though this clinical trial was completed in 2015, no results have yet been disclosed.
4. Nanoparticle-Based Systems
The last decade has witnessed a remarkable rise of nanomaterials in drug delivery research, which
has also translated into promising results in the field of transdermal delivery [56]. Indeed, micro- and
nano-carriers are among the most sought-after methods that have been extensively studied as potential
delivery systems for the transport of non-permeable molecules across the stratum corneum [57].
Specifically, microemulsions are thermodynamically stable colloidal systems containing oil and water,
stabilized by a combination of surfactants and co-surfactants, that have attracted significant attention
for topical and transdermal delivery purposes [58]. These systems have been studied and developed
for the delivery of a vast range of compounds to and across the skin for dermatological, cosmetic,
and systemic applications. In comparison with conventional emulsions, microemulsions have been
claimed to enhance skin delivery primarily by virtue of their reduced droplet size and the disruption
of the stratum corneum by their constituents [58]. For instance, microemulsion-based formulations
for lidocaine delivery generally have a longer-lasting effect than emulsion-based ones and result in
1.5–2 times greater permeation of lidocaine than the emulsion-based EMLA® cream [59,60].
At the University of Toronto, the Acosta group has investigated the design and optimization of
microemulsion-based systems for transdermal drug delivery applications [61]. To do this, they used a
donor-skin-receiver mass balance model to study the effects of the concentration of surfactant used
to generate the microemulsions on the transdermal delivery of lidocaine. Among different classes of
components, lecithin-based microemulsions have attracted attention thanks to the generally recognized
as safe status of their main constituent [62]. However, lecithin (a mixture of amphiphilic substances)
tends to form lamellar and other liquid-crystal phases, and the addition of co-surfactants—generally
medium-chain alcohols (e.g., butanol and pentanol)—is thus necessary for the formation of stable
microemulsions [63].
While presence of these co-surfactants results in the low interfacial tension and small particle
size observed in the emulsions [63], they are known to have skin-irritation properties [64]. To solve
this problem, the group investigated other classes of additives as co-surfactants, which led to the
selection of sorbitan monooleate (Span 80) as a lipophilic linker, and a mixture of caprylic acid (CA)
and sodium caprylate (SC) as a hydrophilic linker for the fabrication of stable oil-in-water (type I),
water-in-oil (type II), and bicontinuous (type III or IV) microemulsions (classified by studying their
phase behavior), based on an isopropyl myristate oil phase [64,65]. The ratio of Span 80 to lecithin was
kept constant at 3:1, while the ratio of CA to lecithin was maintained at 0.75:1. Using these emulsions,
transdermal delivery performance was assessed as a function of lecithin concentration. The droplet size
(radius) was measured by dynamic light scattering and was found to be constant at 6 nm regardless of
surfactant concentration. It was shown that in lecithin-linker microemulsions, an increase in surfactant
concentration was associated with an increased quantity of lidocaine delivered across porcine ear
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skin using a MatTek permeation device [61,66]. In addition, the authors demonstrated the superior
lidocaine delivery of their lecithin-linker-based formulations relative to a pentanol-based formulation,
with the type II microemulsions being the most effective, with a flux of up to 0.4 mg/(cm2·h) compared
to the maximum of 0.12 mg/(cm2·h) for type I microemulsions.
In vitro cytotoxicity studies using a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) tetrazolium cell viability assay on human reconstructed skin showed that these
lecithin-linker microemulsions had a reduced toxicity profile compared to medium-chain alcohol-based
microemulsions [64]. Despite having been extensively explored, the actual mechanism by which
nano- and micro-formulations can promote the delivery of compounds through the epidermis remains
controversial [57]. To explain the observed permeation results with their optimized formulations, the
group proposed a dominant transport mechanism: due to their small size, the microemulsion droplets
migrate to the lower epidermis and upper dermis, creating a depot-like effect and release the drug into
the deeper layers of the skin. However, the observed increase in permeation as a function of surfactant
concentration might suggest a combined mechanism in which the surfactants destabilize the lipid
structure within the stratum corneum (acting in a CPE-like manner), leading to the diffusion of the
nano-droplets into the deeper layers. Given this possible mechanism of action, this technology could
also be considered as a CPE-based system.
It should be noted that the proposed system is likely to require further investigation. Indeed, it
has been shown that when a lecithin-related, naturally-derived monoacyl phosphatidycholine (MAPL)
surfactant was used, crystal-like structures formed at the surface of the skin, acting as an additional
barrier and further limiting drug diffusion. This observation, combined with the limited permeation
enhancement of lecithin surfactants, might raise concerns regarding the overall efficacy of this strategy
for the topical or transdermal delivery of drugs [67].
Regardless of the mechanism, after establishing the transdermal delivery potential of their
lecithin-based microemulsion system, the same group went on to tackle a classical problem associated
with topical formulations, namely that the low viscosity of microemulsions makes them challenging
to apply and localize on a designated area of skin [65–68]. As a result, a longer-releasing formula
using gelatin was developed to enhance the viscosity of the system. The selected formulation
containing 20% gelatin had a zero-shear viscosity close to 3 Pa·s, an order of magnitude higher than
the original microemulsions and within the range of commercial topical creams (1–10 Pa·s) [69]. The
authors reported that their microemulsion-based gels (MBGs) performed similarly to their lecithin
microemulsions, though with a slightly lower loading and release of lidocaine.
To make these lecithin-linker microemulsions, the authors modified their previous formulation,
replacing the hydrophilic linkers sodium octanoate and octanoic acid with a milder combination of
PEG-6-caprylic/capric glycerides and decaglycerol monocaprylate/caprate, less irritating to human
skin [70]. Permeability experiments studying passage through a synthetic membrane made of silicone,
as well as transdermal delivery to and through pig ear skin, showed a comparable efficiency for these
newly-formulated MBGs and the parent microemulsions (permeability coefficients = 6 ± 1 × 10−3 and
6.3 ± 0.4 × 10−3 cm/h, respectively). Though the addition of a gelling agent improves the rheological
behavior of the formulation for clinical use, previous studies by other groups have suggested that
the addition of a gelling agent reduces transdermal delivery (by roughly 1.5-fold) for hydrophobic
nonsteroidal anti-inflammatory drugs, highlighting a potential limitation of the formulation which
would need more evaluation [71]. Compared to commercial microemulsion-based formulations such
as Topicaine® (ESBA Laboratories Inc., Jupiter, FL, USA, 30–60 mg/(cm2·h)), these lecithin-based
formulations, with the same loading of 4% w/w, presented a much slower release profile (3 mg/cm2 in
18 h) for the local delivery of lidocaine, potentially beneficial for a longer-release formulation [72,73].
In addition to the reported works, studies of transdermal delivery in vivo and biocompatibility will be
necessary to determine the clinical potential of this system.
Recently, the use of archaeosomes, liposome-like structures composed of archaeal lipids, have
generated interest in drug delivery applications, with the Krishnan group at the National Research
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Council of Canada being a very active player in the field. Although most of their research is focused on
the design of archaeosomes as immune adjuvants and delivery systems for parenteral administration,
in 2017, Jia et al. investigated the transdermal permeability potentials of these structures. The authors
screened the capacity of a pool of archaeosomes composed of archaeal total polar lipids, as well
as semi-synthetic glycosylarchaeol, to diffuse through the skin and deliver ovalbumin (a common
reference protein for vaccination experiments) and compared it to a standard DPPC/DPPG liposome
formulation with similar size (100–300 nm) and comparable ovalbumin loading capacities. Using pig
ear skin, the authors showed that all the tested particles generated from the total archaeal lipids had
remarkably improved (up to 5 times) their capacity to cross the SC and deliver ovalbumin to the dermal
layer compared to the liposomes composed of standard lipids or semi-synthetic glycosylarchaeol.
While the authors observed that this improved permeability at least partially correlated with the fluid
character of these archaeal vesicles, as well as with their negative surface charge, no other insights
on the actual mechanism behind these activities has yet been provided [74]. While the small particle
size is self-explanatory when it comes to permeation-enhancing properties of this system, a few
previous works investigated similar systems for transdermal drug delivery applications and showed
that their physical deformability is an important factor behind their significant SC permeability [75].
Nevertheless, further systematic structure-activity investigations will be needed to fully understand by
which mechanism these compounds are able to cross the SC and promote the transdermal delivery
of large hydrophilic molecules, which might lead to the design of ideal synthetic delivery methods.
Aside from the mechanistic investigation, in vivo studies will be necessary to confirm the observed
results and to assess the safety of such archaea-derived compounds.
During the last decade, carbon nanotubes (CNTs) have gained popularity as potential drug and gene
delivery vehicles for two main reasons: (1) their large inner volume, which allows the loading of either
large pharmaceutical molecules, or larger quantities of smaller drugs, and (2) their observed capacity to
operate as “nano-needles” which are able to effectively cross biological membranes, via a diffusion-like
mechanism [76,77]. CNTs have thus been described for the delivery of several chemotherapeutic and
antifungal agents such as cisplatin, doxorubicin, methotrexate, taxol, and amphotericin B, by parenteral
administration [78]. However, their intrinsic hydrophobicity strongly limits their medical applications
and consequently, different strategies have been described to overcome this limitation. Among them,
surface decoration with polar or charged groups (such as the cationic polymer polyethylenimine)
has been widely used to functionalize CNTs, leading to increased solubility and permitting the
effective delivery of therapeutically active compounds [79]. Moreover, this functionalization with
cationic residues has been shown to drastically improve the loading of nucleic acid-based therapeutics
such as siRNA [80]. By virtue of their ability to cross biological membranes, a work from Western
University in London, Ontario in 2014, investigated for the first time the use of single-walled carbon
nanotubes (swCNTs) non-covalently functionalized with succinated polyethylenimine to topically
deliver pharmaceutically active siRNA for the management of melanoma [81]. Functionalized swCNTs
were loaded with an siRNA targeting Braf (a kinase involved in tumor growth via the MAPK pathway)
at a remarkable w/w ratio of 2:1. These swCNTs demonstrated the selective downregulation of the
targeted gene in melanoma cells (B16-F10), although no comparison with standard transfecting agents
(i.e., cationic liposomes) was performed by the authors. Following these promising in vitro results, and
based on a previous work demonstrating the ability of swCNTs to deliver low molecular-weight drugs
transdermally, in association with an iontophoresis system [82]; the authors investigated the capacity of
the particles to deliver siRNA across the epidermal layer, and to transfect melanoma cells in vivo after
topical administration. Fluorescent microscopy of frozen sections of skin following the administration
of swCNTs loaded with Cy3-labelled siRNA demonstrated the capacity of the nucleic acid sequence
to cross the epidermis and reach the dermal layer (Figure 1a), while the same formulation without
swCNTs did not cross the stratum corneum. Though these experiments highlighted the key role
played by swCNTs in helping the siRNA to cross the epidermis, is should be noted that 10% DMSO,
a well-known permeation enhancer, was added to the formulation. The authors then investigated the
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actual pharmaceutical potential of the swCNTs loaded with an anti-Braf siRNA in a mouse model of
melanoma (intradermal inoculation of B16-F10 cells). Down-regulation experiments in the tumor cells
indicated a remarkable 70% knockdown of Braf when delivering siRNA loaded in the functionalized
swCNTs, 24 h after a single topical administration. Moreover, multiple administrations every 2 days
for 25 days resulted in drastic inhibition of tumor growth (Figure 1b). Overall, these experiments by
Siu et al. highlighted for the first time the potential of swCNTs to deliver pharmaceutics, even relatively
large and hydrophilic molecules, across the epidermis, though the actual role of DMSO should be
clarified. Nevertheless, prior to any actual clinical translation, the reported experiments will need to be
validated in a more quantitative manner and in a more relevant animal model for transdermal studies,
such as newborn pigs. Above all, while the described protocol used a functionalization step to increase
the solubility of the CNTs, which has been reported to reduce their toxic accumulation and retention
within the body, the actual fate of the CNTs as well as the non-degradable functionalization polymer
will have to be carefully investigated [83,84].













































































Figure 1. Carbon nanotube (CNT)-mediated delivery of siRNA in mice. (a) Representative images of
tumor-bearing mouse skin treated with Cy3-labeled siRNA loaded CNTs; (b) tumor size evolution after
topical administration of siRNA-loaded CNTs. Three days after the mice were injected with tumor
cells, siRNA-loaded CNT solution was applied every 2 days for 25 days. Adapted with permission
from [81]; published by Elsevier, 2014.
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5. Conclusions
In this brief review, we summarized and discussed the main topical and transdermal drug delivery
technologies that have been developed in recent years in Canada. Overall, although the number of
works describing new technologies appears limited at first glance, it is interesting to note that they
cover a wide range of strategies, from nanotechnology to CPEs, to hollow MNs. Furthermore, the
research spans from the development of innovative technologies based on new materials that have
shown a remarkable capacity to enhance the transdermal delivery of high molecular weight drugs
(e.g., functionalized CNTs), but require intensive and more quantitative studies to better identify their
clinical potentials and biocompatibility profiles; to more fundamental studies with the broader goal
of identifying superior enhancement compounds based on well-known materials. Finally, advanced
strategies have been developed over the past decade, and are currently being further studied by private
companies in clinical settings (e.g., the BiPhasixTM technology) and could ideally soon reach the market,
highlighting the favorable environment for the development of new medical and pharmaceutical
technologies in the country.
Nonetheless, it should be noted that some transdermal drug delivery technologies undergoing
rapid development are not currently represented in Canada. A notable example of this can be seen
in polymeric MNs, two varieties of which have seen increasing use for drug delivery. The first of
these are dissolving MNs made of soluble polymers, where a drug is loaded within the soluble
polymeric matrix of the MNs, allowing release across the skin upon dissolution of the tips following
application [85]. The Prausnitz group at Georgia Tech helped pioneer this technology in the context of
non-invasive vaccination and drug delivery [86–88] and continue to work on this topic [89]. While
research is also active globally, particularly in the context of delivering peptide-based drugs and
macromolecules [90–92], no Canadian groups are currently investigating this class of MNs.
The other class of polymeric MNs being studied for transdermal drug delivery is swellable
hydrogel MNs, typically made of crosslinked hydrophilic polymers able to swell by absorbing fluid
from the skin. While these have also been used for sampling biological fluids from the skin [93], the
Donnelly group at Queen’s University Belfast have primarily studied them for drug delivery purposes,
as their swelling properties also allow drug molecules contained within the MNs to flow into the
skin after application [94,95]. This research appears to have progressed significantly, with recent
studies focusing on optimizing the system for clinical applications [96–98]. Iontophoresis is another
transdermal drug delivery strategy currently experiencing worldwide growth [99]. By passing an
electrical current through the skin, this technique serves to enhance skin permeability, as well as allow
positively charged compounds to be transported into the skin by the resulting electric field. Though
various groups are developing iontophoresis-based transdermal delivery methods for both small
molecule- and peptide-based drugs [100,101], the topic is seemingly not undergoing active research
within Canada.
These methods, alongside the ones discussed previously, serve to reveal the current state of
transdermal drug delivery technology worldwide. Though Canada has generated meaningful
contributions within the past decade, it remains clear that many opportunities for further work exist, if
groups within Canada wish to further the progression of this field.
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Abstract: Viruses have recently emerged as promising nanomaterials for biotechnological applications.
One of the most important applications of viruses is phage display, which has already been
employed to identify a broad range of potential therapeutic peptides and antibodies, as well
as other biotechnologically relevant polypeptides (including protease inhibitors, minimizing proteins,
and cell/organ targeting peptides). Additionally, their high stability, easily modifiable surface, and
enormous diversity in shape and size, distinguish viruses from synthetic nanocarriers used for drug
delivery. Indeed, several plant and bacterial viruses (e.g., phages) have been investigated and applied
as drug carriers. The ability to remove the genetic material within the capsids of some plant viruses
and phages produces empty viral-like particles that are replication-deficient and can be loaded with
therapeutic agents. This review summarizes the current applications of plant viruses and phages
in drug discovery and as drug delivery systems and includes a discussion of the present status of
virus-based materials in clinical research, alongside the observed challenges and opportunities.
Keywords: virus; plant; bacteriophage; phage display; drug discovery; encapsulation; drug delivery
1. Introduction
In the 18th century, the term “virus” was defined as a morbid principle or poisonous substance
produced in the body as the result of some disease [1]. This was due to the initial identification of
viruses as infectious agents that could be transferred to other humans or animals, similarly to bacteria
but of different size. Since the discovery of the first virus by Ivanovsky in 1892, our understanding of
the properties of viruses has changed significantly [2]. Owing to advances in virology, their definition
was changed to small, non-cellular obligate parasites carrying non-host genetic information [3]. In fact,
these advances not only improved our knowledge about the nature of viruses, but also contributed to
change their negative connotation. After the discovery of bacterial viruses (bacteriophages; phages), the
French Canadian Felix d’Herelle recognized their ability to replicate exponentially and kill bacteria [4].
These observations suggested potential clinical applications for bacteriophages such as their use as
antibacterial agents for the treatment of infectious disease. Although many large pharmaceutical
companies marketed phage products in the 1920s and 1930s, clinical failures and theoretical concerns
led to their abandonment [5]. In parallel, the discovery of antibiotics equally contributed to the loss
of interest in phage therapy around this time [6]. Nonetheless, in the 1940s bacteriophages regained
attention in the field of molecular biology. They were notably used as model organisms to understand
the genetic basis of virus–host interactions in addition to enabling the discovery of several genetic
processes such as transcription, translation, recombination, and regulation of gene expression [7].
While these discoveries reshaped the paradigm of virology, in 1985 the invention of the so-called
“phage display” technique greatly broadened the field to new areas of application including drug
discovery, vaccine development, antibody engineering, enzyme evolution, and gene therapy [8,9].
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Thirty-three years after its development, the contribution of phage display technology to the selection
of peptides and antibodies was recognized by a Nobel Prize in Chemistry in 2018 [10]. Another
milestone was reached around the year 2000, when viruses were recognized as nanomaterials with
the ability to encapsulate molecules within their capsids, to template biomineralization of inorganic
materials, and to form self-assembled 2D/3D nanostructures. In this regard, viruses have become
promising materials for several applications ranging from biosensing, imaging, and targeted drug/gene
delivery to energy/electronic applications (memory devices, batteries, and light-harvesting systems).
This review summarizes the current applications of plant and bacterial viruses in medicine, with a
focus on virus-based drug discovery approaches and drug delivery systems. Human/animal viruses
used e.g., for gene delivery, have been reviewed elsewhere and will not be discussed herein [11,12]. The
review begins with an overview of the structure and chemistry of the most common plant and bacterial
viruses used in nanomedicine and is concluded by a discussion of the present status of virus-based
materials in clinical research, alongside current existing challenges and opportunities.
2. Viruses as Nanomedicine
From a material point of view, viruses can be considered as protein-based supramolecular
assemblies composed of multiple copies of coat proteins assembled into shell structures of different
shapes/sizes ranging from tens to hundreds of nanometers. The protein outer shell (i.e., the so-called
capsid) encapsulates the genomic material that contains all essential genes to replicate within a host [13].
The primary function of the capsid is to protect the genomic material and this feature makes viruses
stable under conditions such as extreme temperature and pH [14]. Although animal viruses are
widely recognized as a delivery vehicle, or ‘vector’, for gene therapy, their use as a nanocarrier has
remained relatively limited due to safety concerns. Indeed, while it has been demonstrated that
the administration of 1011 plant viruses or phage to mice showed no sign of toxicity, the same dose
of animal viruses caused severe hepatotoxicity [15–18]. Therefore, plant and bacteria viruses have
received considerably more attention than animal viruses in nanomedicine for applications other than
gene delivery. The most studied bacterial virus is M13 phage, whereas the tobacco mosaic virus (TMV),
cowpea chlorotic mottle virus (CCMV), and cowpea mosaic virus (CMV) are the most extensively
studied plant viruses [19]. Viruses possess precise, nanoscale structures and dimensions that are
difficult replicate using chemical synthesis or top-down fabrication methods [20]. The diversity in
shape and size of viruses provides a wealth of possibilities to researchers, who can choose the most
appropriate system for a given application. For instance, while viruses with higher aspect ratios are
more suitable to target diseased vessel walls, viruses with flexible rod shapes have been shown to
penetrate better into tumor tissue [21,22]. In addition, the surface properties of viruses can be controlled
using chemical and genetic approaches without destroying their structural integrity. This feature
enables spatial control on the position of functional moieties, such as targeting ligands, drug molecules,
and contrast agents on the virus surface and allows for the design of multifunctional systems bearing
combinations of the above [23]. One of the most interesting properties of viruses, in terms of material
synthesis, is that they can be produced in large quantities by infecting host cells, and can be purified
inexpensively on a large scale. Therefore, virus-based materials are a niche nanomaterial with several
unique features compared to synthetic nanomaterials.
2.1. Bacterial Viruses (Bacteriophages)
2.1.1. Filamentous Bacteriophages (M13 and fd)
M13 and fd phages belong to a group of filamentous phages (Ff) that specifically infect
Escherichia coli bacteria. As their genomes are more than 98% identical and their gene products
are interchangeable, they are usually collectively referred to as Ff phage [24]. Thus, only the properties
of M13 phage are discussed herein as a representative example of filamentous phages. The relatively
simple structure of the M13 virion has been extensively studied and is very well known. M13 is 65 Å
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in diameter and its length depends on the size of enclosed genome (9300 Å in the case of the wild-type
M13) (Figure 1A). The flexible filamentous structure contains a circular, 6407 base-pair single-stranded
DNA genome coated with 2700 copies of the major coat protein p8 (Figure 2A). The major coat proteins
form a tube around the DNA, in an overlapping helical array. The N-terminus of the p8 protein
extends towards the exterior of the capsid while the C-terminus interacts with the DNA inside. The
hydrophobic domain located in the central part of p8 protein stabilizes the viral particle by interlocking
the coat proteins with their neighbors. Additionally, four other minor coat proteins are present, at
five copies per particle. p7 and p9 are located at one end of the capsid, while p3 and p6 are located
at the other end. p3 is the largest and most complex coat protein and is responsible for the host cell
recognition and infection [25–27].
M13 phage engages in a chronic infection life cycle where the propagated phage particles are
slowly released from the host cell by secretion through the outer membrane, a process that does not lead
to bacteria lysis. Phage infection starts with the attachment of p3 protein to the F pilus of bacteria. The
phage genome enters the cell and is converted into double-stranded DNA. Afterwards, the synthesis
of all M13 phage proteins starts, and the double-stranded DNA is amplified in a process involving p2
and p10 proteins to produce plus-strand copies of the phage DNA. Protein p5 is employed in coating
the amplified DNA molecules while the coat proteins p8, p7, p9, p6, and p3 are inserted into the inner
bacterial membrane. A small uncovered hairpin of single-stranded DNA is captured by a complex of
integral membrane proteins p1, p4, and p9. This complex is described as a membrane pore where the
phage is assembled and extruded from the bacterium. As the release of mature M13 virions occurs
right after phage assembly, they do not accumulate inside the bacteria and the infected cell continue to
grow, albeit at a reduced rate [26,28–31].
2.1.2. T4 Bacteriophage
The T4 phage is a double-stranded DNA virus that is known as one of the largest viruses to infect
bacteria. It belongs to the Myoviridae family and infects Escherichia coli and the closely related Shigella.
Like other members of Myoviridae family, T4 has a prolate icosahedral head, a collar with whiskers, and
a contractile tail terminating in a baseplate that is attached to six long tail fibers (Figure 1B). While the
fibers recognize the host cell surface and attach to the bacterium during infection, the baseplate binds
to specific surface receptors and degrades the bacterial wall with its enzymes. This process enables the
introduction of DNA into the cell. The virion consists of several components including DNA, proteins,
and a few non-protein constituents such as polyamines associated with DNA (putrescine, spermidine,
cadaverine), ATP and Ca2+ associated with the tail sheath, and dihydropteroylhexaglutamate associated
with the baseplate [32].
The DNA of T4 phage is tightly packed inside the protein capsid, which has a length of 120 nm
and a width of 86 nm. The capsid is built from three essential proteins: the major capsid protein
gp23* (49 kDa, *: final form within capsid, following enzymatic processing) present at 930 copies, the
vertex protein gp24* (47 kDa) present at 55 copies, and the portal protein gp20 (61 kDa) present at
12 copies (Figure 2C). Additionally, there are two outer capsid proteins that are nonessential and bind
to the capsid after assembly. The highly antigenic outer capsid protein (Hoc, 39.1 kDa) occupies the
center of the gp23 capsomers and is present in up to 155 copies per capsid particle. The rod-like small
outer capsid protein (Soc, 9.7 kDa) binds to the capsid surface between the gp23* capsomers (up to
810 copies per capsid) and form a nearly continuous mesh on the surface encircling the gp23* hexamers.
Interaction of a Soc protein with two gp23* proteins of adjacent capsomers, as well as trimerization of
Soc proteins through C-terminal interactions, stabilize the gp23* hexameric capsomers. Although Soc
protein is not essential, the assembly of Soc proteins on the surface of T4 improves stability towards pH
(up to pH 11), temperature (<60 ◦C), osmotic shock, and denaturants. Nevertheless, deletion of either
one or both Hoc and Soc genes does not affect phage viability or infectivity under standard laboratory
conditions [33–35].
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Figure 1. Structures of the viruses discussed in this review. Transmission electron microscopy (TEM)
images of (A) M13 phage, (B) T4 phage, (C) T7 phage, (D) λ (lambda) phage, and (E) MS2 phage.
(TEM Images were acquired by the authors, except for λ phage (reprinted with permission from [36],
Copyright Elsevier, 1968) and TEM image of MS2 phage (reprinted with permission from [37], Copyright
The Royal Society of Chemistry, conveyed through Copyright Clearance Center, Inc., 2011). Structures
of plant viruses (F) brome mosaic virus (BMV), (G) cowpea chlorotic mottle virus (CCMV), (H) cowpea
mosaic virus (CPMV), (I) cucumber mosaic virus (CMV), (J) red clover necrotic mosaic virus (RCNMV),
(K) turnip yellow mosaic virus (TYMV), (L) hibiscus chlorotic ringspot virus (HCRSV), (M) tobacco
mosaic virus (TMV), and (N) PVX. (Images of the following viruses were obtained from the VIPERdb
(http://viperdb.scripps.edu/) [38]: BMV, CCMV, CPMV, CMV, RCNMV, TYMV. The image of HCRSV
was reprinted with permission from [39], Copyright Elsevier, 2003. The image of TMV was reprinted
with permission from [40], Copyright Elsevier, 2007. The image of PVX was reprinted with permission
from [41], Copyright Elsevier, 2017).
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2.1.3. T7 Bacteriophage
T7 bacteriophage belongs to the genus of T7-like bacteriophages, which are characterized by
their isometric capsid and non-contractile tail (Figure 1C). T7 phage contains a short tail and a 60 nm
symmetrical polyhedral capsid with a conspicuous core (composed of proteins gp14, 15, and 16)
containing a 40,000 base-pair double-stranded DNA. Phage assembly begins with the formation of
a prohead composed of the major head protein gp10A (36.4 kDa), the minor head protein gp10B
(41.7 kDa, derived from a read-through of gp10A), and the scaffolding gp9 protein (Figure 2B). During
the process of DNA packaging, the prohead interacts with DNA through the terminase proteins (gp18
and 19) and loses the scaffolding protein once the encapsidation of DNA is complete. Afterwards,
the connector protein (gp8) that attaches the core to the tail is incorporated into the capsid structure.
The function of core structure is believed to be essential for infectivity, but not for the stability of the
prohead structure [42,43].
2.1.4. λ (lambda) Phage
λ phage is a temperate Escherichia coli virus composed of a flexible helical tail and a 62 nm diameter
icosahedral capsid containing a 48,500 base-pair double-stranded DNA genome (Figure 1D) [44]. As a
part of its temperate life cycle, λ phage initially integrates its DNA into the bacterial genome where
it is replicated with bacterial chromosomes and transmitted to new cells. Thereafter, the lytic cycle
begins and phage proteins are synthesized to form the phage particles. The lytic cycle takes ~40 min
and produces ~100 phage, and the ends with cell lysis, which releases the phages. The generation of
empty procapsids is the first step of phage assembly. Four hundred and five copies of protein E (gpE),
one of the major capsid proteins, are organized into hexameric and pentameric capsomers (Figure 2D).
The phage DNA is then packed into the procapsid, which provokes a reconfiguration of gpE as well
as the expansion of the procapsid. The expansion is followed by the attachment of protein gpD, the
head decoration protein, to form mature capsid. Four hundred and twenty copies of protein gpD are
present within the capsid and stabilize the expanded capsid structure to prevent DNA release [44,45].
2.1.5. MS2
MS2 is an RNA-containing Escherichia coli bacteriophage with a 27 nm diameter icosahedral capsid
(Figure 1E). The phage capsid is composed of 180 copies of coat protein and a single copy of maturation
protein (A protein) that is responsible for attachment to the host bacterial cell during infection [46].
During the assembly of phage particles, coat proteins initially form dimers and attachment of the
dimer to an RNA hairpin produces a complex initiating the growth of the capsid [47]. As the complete
RNA sequence is not necessary for initiation of the capsid formation, the self-assembly of purified coat
proteins can be achieved with only the RNA hairpin loop to form empty virus-like particles [46,48].
Empty capsids can be also produced by removing the RNA genome in alkaline conditions (pH ~11.8),
conditions that are suspected to degrade the RNA molecule through phosphate hydrolysis and reduce
its affinity for the capsid proteins. In addition to the ability to produce phage capsids without genetic
material, the presence of 32 pores, each with a 1.8 nm diameter, on the capsid surface enables the use
this virus as a nanocarrier [49].
2.2. Plant Viruses
Like bacteriophages, plant viruses also possess many shapes, sizes, and surface properties, which
offer a great diversity of possibilities for medical applications. Plant viruses can be conveniently
produced from infected leaves, where infection is achieved by exposure to purified virus particles,
infected leaf samples, or simple genomic products of the virus such as cDNA and RNA transcripts [50].
Moreover, plant viruses demonstrate remarkable stability over a wide pH range (3.5–9), temperatures
up to 90 ◦C, and towards a variety of organic solvents (e.g., ethanol, dimethyl sulfoxide) [51–54]. As
the shape of the viruses can significantly affect their performance in a given biomedical application, in
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the following sections they are categorized based on their shape. There are two main groups of plant
viruses: icosahedral viruses with spherical shapes and rod-shaped viruses with high aspect ratios
(Table 1).
Table 1. Plant viruses used in drug delivery systems.
Virus Size Symmetry Family Genome
Locations on Coat Proteins for
Genetic Modification
Ref
BMV 30 nm Icosahedral BromoViridae ssRNA Valine 168 [55,56]
CCMV 28 nm Icosahedral BromoViridae ssRNA Lysine 42Serine 102/130 [57,58]
CPMV 30 nm Icosahedral Comoviridae ssRNA βB-βC loop of the small subunit/
βE-βF loop of the large subunit [53,59]
CMV 29 nm Icosahedral Bromoviridae ssRNA [60]
HCRSV 30 nm Icosahedral Tombusviridae ssRNA [61]
RCNMV 36 nm Icosahedral Tombusviridae ssRNA [62]
TYMV 28 nm Icosahedral Tymoviridae ssRNA Threonine 44Lysine 45 [63]




N/C-terminal of coat protein
[64–66]
PVX 515 × 13 nm Rod-like Potexviridae ssRNA N-terminal of coat protein [67]
2.2.1. Icosahedral Plant Viruses
The icosahedral structure is the most common shape for plant viruses. The members of this group
most commonly used in medicine are cowpea mosaic virus (CPMV, Figure 1H), cowpea chlorotic
mottle virus (CCMV, Figure 1G), brome mosaic virus (BMV, Figure 1F), cucumber mosaic virus (CMV,
Figure 1I), hibiscus chlorotic ringspot virus (HCRSV, Figure 1L), red clover necrotic mosaic virus
(RCNMV, Figure 1J), and turnip yellow mosaic virus (TYMV, Figure 1K). They are composed of
180 copies of coat protein that form capsid structures with sizes ranging from 28–36 nm (Table 1),
each containing a single-stranded RNA genome [51,55,60–62,68]. In addition, RNA-free capsids can
be generated artificially using pressure, basic/acidic environments, denaturing agents (ca. urea),
ribonucleases, or repeated freeze–thaw cycles [51,60,61,68]. In the case of CPMV particles, empty
capsids are efficiently produced by co-expressing the fused small/large subunits of coat protein (VP60)
along with the 24K proteinase in insect cells and plants [69].
2.2.2. Rod-Shaped Plant Viruses
Tobacco mosaic virus (TMV, Figure 1M) and potato virus x (PVX, Figure 1N) are the rod shaped
plant viruses that have been most widely used for drug delivery systems. While both viruses contain
single stranded RNA genetic material, they are formed of different coat proteins with different copy
numbers, resulting in different lengths. TMV consists of 2130 copies of coat proteins, helically arranged
around RNA and forming a hollow nanorod with a 4 nm wide interior channel that is 300 nm in length.
It is also possible to produce them as disks in the absence of RNA, which is another nanostructure
consisting of 34 coat proteins. The most interesting feature of TMV particles is their ability to form
RNA-free spherical nanoparticles from the rod-shaped virus due to thermal processing. The size of
the spherical particles can be tuned between 100–800 nm [70–72]. On their side, PVX particles have a
rod-like shape with sizes similar to that of TMV, and are 515 × 13 nm in size [67,73].
3. Virus-Based Drug Discovery
3.1. Phage Display Platforms
Various types of phage have been employed to create phage display platforms and have been
used for the purpose of drug discovery. This section will present the properties of the most popular of
these, with emphasis on their relative advantages and shortcomings.
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3.1.1. M13 Phage Display Platform
M13 has been the most widely used phage for phage display since the invention of this technology
in 1985 by George P. Smith [74,75]. Combinatorial libraries of polypeptides fused to coat proteins have
been used to screen interaction partners towards several targets as well as to study structure–function
relations in proteins [25]. In phage display, the genome of M13 phage is manipulated by inserting
a DNA sequence into the gene encoding a coat protein. Generally, diverse combinatorial libraries
of short peptide sequences (8–12 amino acids) are displayed as fusions to these. Any modification
of the phage genome is reflected in a corresponding modification in the coat proteins of the phage,
which provides a link between the phenotype and genotype. Selection of the best peptide binding
sequence for a given target material is performed through an enrichment process called “biopanning”.
Initially, the phage are allowed to bind to the target then, after washing away the non-bound phage,
the bound phage are eluted and amplified through host bacterial infection. This artificial evolutionary
process to select the best binding peptide sequence is repeated several times for enrichment of the best
binding partners. Finally, the selected binding peptides are identified by DNA sequencing of the phage
genome [76–78]. Phage display technology has been extensively used to identify specific binding
peptides for many biological molecules including toxins, bacteria, organs, and tumor-associated
antigens [79–82]. Although all five coat proteins have been used to display foreign proteins, the most
common approach is to fuse foreign sequences to the N-terminus of p3 and p8 coat proteins [83–85].
There are three different strategies to display proteins as fusions to p3 and p8 coat proteins, which
are categorized as phage, phagemid, and hybrid systems. In the phage system, the gene encoding the
foreign protein is directly inserted into the phage genome and results in fusion proteins displayed on
every copy of chosen coat protein. As a general rule, larger proteins are more efficiently displayed on
p3, and the p8 protein is limited to displaying short peptides (~6–10 amino acids). Nonetheless, p3
remains limited in what it can display, and proteins larger than 50 amino acids cannot be displayed on
all five copies. Thus, it can be necessary to decrease the copy number of fusion proteins to efficiently
display them on the desired coat protein. The phagemid system is used to overcome this limitation.
A phagemid is a plasmid carrying the viral gene encoding the fusion coat protein, phage origin of
replication, and a phage-packaging signal. The genes required for phage assembly, including the wild
type coat protein, are provided by packaging-defective ‘helper’ phage. Upon coinfection of bacteria
by phagemid and helper phage, wild type proteins and fusion coat proteins are synthesized and
preferentially-assembled around the phagemid DNA. This results in hybrid phages displaying only a
few copies of the fusion coat protein. The hybrid system was also invented with a similar motivation
to the phagemid system: to enable the display of large protein sequences on the phage’s surface.
However, unlike the phagemid system, it only employs the phage genome, which carries both the
gene encoding wild type coat protein and the gene encoding fusion protein. Smith defined these three
systems using the terms“3”, “3+3”, and “33” respectively (Figure 2F). Number “3” indicates p3 coat
protein whereas formats “8”, “8+8”, and “88” are used for phage display on p8 coat protein [26,86–88].
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Figure 2. Assembly of coat proteins on bacteriophage (A) M13, (B) T7, (C) T4, (D) λ (lambda), and
(E) MS2 (Images of M13, T7, T4, and λ (lambda) phages were adapted with permission from [89],
Copyright American Chemical Society, 2015. The image of MS2 phage was adapted with permission
from [90], Copyright the PCCP Owner Societies, 2010). (F) Schematic of M13 phage display systems;
phage system (type 3/8), phagemid system (type 3+3/8+8), and hybrid system (type 33/88) (The image
was adapted with permission from [88], Copyright Elsevier, 1993).
3.1.2. T4 Phage Display Platform
The display of fusion peptides/proteins on T4 phage has emerged as a promising tool to overcome
the limitations of phage display platforms employing filamentous phages. For instance, one of the
drawbacks of filamentous phage display is the small size of the peptides displayed on the major
coat protein (6–10 amino acid residues). Larger polypeptides can only be displayed on minor coat
proteins but at very low copy numbers. Moreover, during phage amplification, synthesized coat
proteins are inserted into the inner cell membrane where virion assembly and export occur. Due to the
membrane-mediated nature of this process, fusion proteins that cannot cross the cell membrane will
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not be displayed on the phage surface. The secretion system of E. coli may also prevent the display of
some peptides that are toxic to bacteria and may also create the problem of achieving correct folding
of the displayed protein [91–94]. However, T4 phage uses a lytic life cycle for reproduction in which
phage assembly takes place inside the infected cell and, afterwards, progeny phages are released by
cell lysis. This feature of T4 enables the display of a broader range of proteins with different size,
structure, and biological functions that may not be possible with filamentous phage display [32,95].
In T4 phage display, Soc and Hoc are used for the fusion of foreign proteins (Figure 2C). Because
both Soc and Hoc sites can be used simultaneously if desired, it has been shown that higher copy
numbers of fusions on the phage surface can be achieved by display on both sites (Soc and Hoc) [96,97].
Foreign proteins can be displayed on T4 phage by in vivo and in vitro approaches. The in vivo
approach can be performed in different ways, one of which is based on the integration of a modified
soc gene into a soc-deleted T4 genome through a modified positive selection plasmid. In this type of
plasmid, the soc gene is flanked on its 5′ side by a 3′ portion of the T4 lysozyme gene (e’), and on its 3′
side by a 5′ part of another T4 gene (denV’), which allows homologous recombination between the
phage and the plasmid. Integration of the soc fusion gene into the T4 genome allows the expression
and in vivo binding of fusion proteins to the phage capsid [93]. Alternatively, Soc and Hoc fusion
proteins can be incorporated to the phage capsid through a natural assembly process in host bacteria
expressing the fusion proteins from a designed expression vector. Upon infection of bacteria with T4
phage strains having defective soc or hoc genes, fusion proteins are expressed and assembled onto the
phage capsid [98,99].
Although in vivo approaches have been widely used to display different proteins on the surface
of T4 phage, they are limited to the display of single components, such as a peptide, a domain, or a
protein. Limitations in displaying multiple components and large domains arise from the fact that
the expression and assembly of the foreign proteins occur during phage infection. This lytic phage
cycle leads to problems such as the loss of critical epitopes due to nonspecific proteolysis, low and
variable copy number of displayed proteins due to the variations in intracellular expression, structural
heterogeneity due to aggregation of the expressed proteins, insolubility, and improper folding [93,100].
Thus an in vitro approach has been developed to overcome these drawbacks for efficient and controlled
display of large proteins on the phage surface. In this approach, foreign proteins fused to Soc and Hoc
proteins are overexpressed in bacteria and purified. The high affinity interactions between Hoc/Soc
proteins and the phage capsid enable in vitro assembly of purified proteins on Hoc- and Soc-defective
phage, which is performed by simply mixing the components. Therefore, the in vitro approach results
in a phenotype no longer connected to the genotype of the engineered phage, which contrasts to
the in vivo approach. An attractive feature of the in vitro approach is that the expression of Hoc/Soc
fusion proteins is not restricted to E.coli or another specific host, thus any expression system can be
used for production of fusions. Consequently, functionally well-characterized and conformationally
homogenous fusion proteins are produced and displayed on phage capsids. Additionally, the copy
number of displayed proteins can be controlled by changing the ratio of protein to capsid binding
sites. It is worthy to note that the in vitro approach also allows customized engineering of T4 phage to
display multiple proteins on the same capsid [101–103].
3.1.3. T7 Phage Display Platform
The T7 phage capsid is composed of gp10A and gp10B, which have been employed to display
peptide moieties (Figure 2B). While high display numbers can be achieved for peptide sequences
shorter than 50 amino acids, only a few copies of larger proteins (<1,200 amino acids) are displayed
per capsid [95]. Therefore, the T7 phage display platform becomes favorable for the display of large
proteins. As for T4, T7 phage display vectors also overcome certain limitations of filamentous phage
display platforms. The lytic nature of T7 phage eliminates the need for protein export and enables
the display of a broad diversity of proteins on the phage’s surface [104,105]. Moreover, the lytic life
cycle shortens the time required for biopanning steps and thus accelerates the selection from the phage
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library [106]. Unlike many other phage display systems, the coat proteins of T7 phage are anchored
to the phage through their N-termini, which makes their C-termini available to display the peptide
moieties. This feature makes T7 phage attractive to develop recognition moieties for targeting protein
domains that preferentially interact at their N-termini [107].
3.1.4. λ (lambda) Phage Display Platform
Lambda phage libraries are used as another lytic phage display platform to overcome the
limitations of filamentous phage display systems, and employ either the gpV tail protein or the gpD
decorative capsid protein (Figure 2D). The tail tube consists of 32 disks, each containing six subunits
of gpV protein. The small C-terminal domain of gpV protein is exposed and allows the expression
of protein moieties as fusions, however, the fusion proteins are only displayed at low levels (ca. one
molecule per phage particle) [108]. On the other hand, the gpD protein enables the display of fusions
on both its N- and C-termini [109]. While the level of display depends on the size of the fusion, large
tetrameric proteins can be displayed at lower levels compared to the small protein domains [110]. In
order to overcome low display levels of lambda phage, two different approaches have been investigated.
The first approach uses a two-gene system, where both wild type gpD protein and gpD fusion coat
proteins are co-packaged into the lambda’s head and generate mosaic phage particles expressing both
proteins [111,112]. In the second approach, nonsense suppression is used to control the level of the
fusion protein. A stop codon is introduced between the gene of gpD protein and its fusion partner. As
the gene of gpD protein cannot be fully suppressed, some wild type protein will be also expressed and
displayed on phage surface [110,113].
3.1.5. MS2 Phage Display Platform
The major coat protein of MS2 can be used to display foreign proteins/peptides on its surface with
high copy number. While the insertion of peptide sequences can be accomplished at different regions
of the coat protein, the short hairpin loop between two β-strands (βA and βB) of the protein subunits
has been the most commonly used part, as it allows the display of the peptide sequences on the outer
surface of the phage (Figure 2E) [114–119]. Small peptide sequences can be displayed as N-terminal
extensions of the coat protein subunits, which protrude from the phage surface as well. However,
some deletions and base-substitutions can be observed due to the lack of genetic stability. The genetic
stability of the insert highly depends on the structure of the RNA hairpin loop encoding the insert and
it is determined by the choice of the nucleic acid sequence [120].
3.2. Phage Display-Derived Therapeutics
Phage display is one of today’s most important drug discovery technologies. It allows the
identification of a broad range of potential therapeutic peptides and antibodies, as well as polypeptides
with a variety of functions (protease inhibitors [121,122], minimizing proteins [123], novel scaffolds [124],
and DNA binding proteins [125]). Amongst all of these, monoclonal antibodies (mAb) have received
considerable attention. The generation of mAbs started with the discovery of the hybridoma technology
by Köhler and Milstein in 1975, in which hybrid cells were developed by the fusion of B-cells from
immunized animals with myeloma cells to produce antibodies [126]. 10 years later, the first approved
mAb, muromonab- CD (Orthoclone OKT3®) [127], was produced using this technology. However,
due to the non-human origin of this mAb, a significant percentage of patients developed immune
responses, which called into question the safety and efficacy of the non-human mAb therapy [128]. In
the late 1980s, recombinant DNA technologies allowed the humanization of non-human mAbs to make
them more similar to antibodies within the human body [128]. Starting in the 1990s, human antibodies
were produced by in vivo immunization and hybridoma technology using transgenic mice or rats
containing the human antibody gene repertoire, or parts of it [129–131]. However, the immunization of
transgenic animals could not be used for the production of in vivo antibodies for all types of antigens
(e.g., unstable, conserved, and toxic antigens). These limitations impose the use of other alternatives
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such as in vitro selection technologies, which can be used to discover antibodies towards almost every
type of antigen, as they do not depend on immunization.
As such, in vitro display technologies such as phage display, yeast display, ribosome display,
bacterial display, mammalian cell-surface display, mRNA display, and DNA display have been used
for antibody discovery [132]. Among these, phage display is the most widely used for antibody
selection [133]. Its use has resulted in the discovery of over 80 mAbs that have entered clinical
trials [134]. In 2002, adalimumab became the first phage display-derived mAb to have been granted
market approval, and was also the first approved human mAb [131]. Small recombinant antibody
fragments (e.g., scFv) [135,136] or fragment antigen-binding (Fab) [137,138] are also commonly
selected by phage display, in addition to full antibodies [139]. A selection of FDA-approved phage
display-derived antibody therapeutics are summarized in Table 2. Four exceptions in this table are the
non-antibody peptides ecallantide (Kalbitor®), Romiplostim (Nplate®), albigutide (Tanzeum®), and
Xyntha purification peptide. Antibody libraries are huge collections (>1010) of antibody genes encoding
antibodies with unknown properties. These are an essential resource for antibody discovery by phage
display and other in vitro selection technologies [133]. Depending on their source of origin, antibody
libraries are classified as immune libraries and universal libraries. Immune libraries containing
affinity-matured antibodies [133] are constructed using donors (humans or animals) who have received
immunization, have been infected or a chronically-diseased, or those suffering from cancer [140].
Affinity maturation is achieved by mutation and clonal selection in which mutated antibodies with
higher antigen-binding affinity are enriched [141]. However, extensive or hypermutation may increase
the risk of immunogenicity [133]. Of course, it is not possible to construct immune libraries for each
disease due to ethical issues, high cost, and laborious procedures. One solution to this problem is
to use universal libraries that are generated by a source for which the immune system had not been
activated to recognize a specific antigen (naïve) [132]. Moreover, due to the lack of affinity maturation,
these universal libraries have low risk of immunogenicity [133]. In principle, a universal library
can be applicable to mAb selection of any type of antigen. This is because the library comprises a
high variability of antibody genes and comprises antibody genes from many donors [132]. Universal
libraries are further sub-classified as naïve, semi-synthetic, or fully-synthetic. Naïve antibody libraries
are constructed from the natural human IgM repertoire (i.e., from not intentionally immunized
donors) [132,133]. Examples of naïve universal libraries are the human Fab library constructed by
de Haard and colleagues at Dyax (now Shire) [137], the scFv libraries from Cambridge Antibody
Technology (CAT) [142,143], scFv and Fab libraries from XOMA59, and the HAL scFv libraries [135,144].
Fully synthetic libraries are constructed to include synthetic genes derived from known (human)
antibody frameworks with the capacity to generate a large diversity in appropriate regions [145].
Semi-synthetic libraries are a combination of natural (i.e., donor-derived antibody) and synthetic
antibody sequences [138]. A combination of naïve and synthetic repertoires was used for the Dyax
FAB310 library. Fully-synthetic libraries were developed by MorphoSys [133]. In addition, a particular
type of antibody library is generated during guided phage display selection of human antibody using
a non-human original antibody sequence. This strategy has been used for humanization and the
discovery of fully human antibodies with similar properties to the murine antibody template, such as
adalimumab [146].
Overall, the identification of mAbs and mAb derivatives by phage display technology was a
breakthrough that has enabled the isolation of human antibodies towards many types of antigen
without immunization. Since then, it is one of the main platforms for generation of human therapeutic
antibodies together with transgenic immunized mice, antibody humanization techniques, and single
B-cell expression cloning [169].
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3.3. Phage Display Selection of Peptide Binders for Biomineralization/Self-Assembly of Inorganic Materials
Reports showing that peptides sequences displayed on the outer surface of E.coli could recognize
and specifically-bind to metal/metal oxide surfaces (e.g., gold, iron oxide, and chromium) inspired
research to extend this concept to phage display [170,171]. The first application of phage display
libraries to evolve peptide sequences binding to inorganic substrates was performed for a range
of semiconductor surfaces with the motivation of directing nanoparticles to specific locations on
semiconductor structures for the fabrication of complex, sophisticated electronic materials [172]. This
achievement led to research in phage display selection of material-binding peptides. Several peptide
sequences with affinity to different materials (e.g., platinum, palladium, titanium, silicon, silver,
gold, zinc sulfide, cadmium sulfide, graphite, calcite, indium phosphide, chlorine-doped polypyrrole
(PPyCl), and carbon nanotubes) have been identified [78,173–187].
Peptides selected by phage display have not only been used to achieve binding, but have also
been employed to direct the mineralization of nanomaterials. This approach is inspired by the process
of biomineralization of materials in Nature by living organisms. Several biominerals are formed in a
biologically-controlled manner under mild conditions and include calcium phosphate minerals in teeth
and bone, silica in sponges, and magnetic particles of magnetite (Fe3O4) or greigite (Fe3S4). Recent
interest in biomineralization has grown as it offers a greener and cheaper alternative to inorganic
synthesis of materials, which usually requires high temperatures and harsh chemical reagents [188].
Peptide sequences that can facilitate biomineralization have been identified by phage display selection
against target materials, considering that some selected peptides with binding affinity to the target
material can nucleate or promote the formation of these materials. M13 phage was used to select
several peptide sequences capable of recognition and nucleation of different materials like zinc sulfide
(ZnS), cadmium sulfide (CdS) nanocrystals, iridium oxide (IrO2), cobalt platinum (CoPt), and iron
platinum (FePt) materials [189–193]. Although the specific interactions between the peptide sequences
and the ions are crucial for the nucleation and growth of these materials, the uniform conformation of
the displayed peptides on phage surface is also mentioned to be important for controlled crystallization
of the materials with single-crystal nature. While not directly used as therapeutics per se, the ability of
phage display technology to identify peptides that bind with affinity to inorganic substrates has led to
the use of viruses as building blocks of functional structures for drug delivery applications. In the
following section, the techniques used for fabrication of virus-based drug carriers and the approaches
to design virus-based drug delivery systems are presented.
4. Virus-Based Drug Delivery Systems
4.1. Encapsulation/Decoration with External Cargos
One of the most attractive features of plant viruses is that the coat proteins can self-assemble around
synthetic materials, offering a stable and biodegradable delivery platform for various compounds. The
self-assembly of virus coat proteins around cargo molecules can be achieved in different manners,
depending on the virus. The interaction of coat proteins with a specific sequence of viral RNA
(RCNMV) or a negatively charged material (BMV, CCMV, HCRSV) to replace the negatively charged
RNA is crucial for some viral platforms to encapsulate foreign materials [61,194–196]. However, some
virus particles can form empty capsids in the absence of any genetic/external material (CPMV) by
simple co-expression of essential viral proteins in plant cells [197]. Moreover, the pores present on
the viral capsids can be employed to encapsulate small molecules [60]. However, the size of capsid
pores may not be sufficiently large for diffusion of small molecules in all virus platforms. In this case,
pore formation can be induced by depletion of capsid-integrated divalent ions for some viral particles
(e.g., RCNMV) [198]. Like many plant viruses, the relatively large interior volume of MS2 phage
capsid provides an interesting platform to load molecules or materials. Spontaneous assembly of MS2
coat proteins in the presence of RNA sequences enables the loading of RNA-conjugated functional
materials inside the phage capsid. Encapsulation of phage RNA is mediated by a 19-nucleotide RNA
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stem-loop, the so-called pac site, which specifically interacts with coat proteins. Inspired by this
mechanism, molecules of interest, such as antisense oligodeoxynucleotides, antisense RNAs, quantum
dots, drugs, and toxins, have been conjugated with a pac site to initiate the assembly of coat proteins
and to achieve packaging within the capsid [199–201]. The reassembly of coat protein dimers around
functional moieties is another strategy employed to encapsulate external cargos within the MS2 capsid.
In this approach, phage capsids are first disassembled into dimers with acetic acid. Then, reassembly
is initiated with negatively charged DNA/polymer/amino acid tags conjugated to a cargo molecule,
due to their electrostatic interactions with the interior positively-charged capsid dimers. While the
presence of highly-negatively charged cargo (ca. DNA-coated gold nanoparticles) is sufficient to
initiate the reassembly, it might be necessary to add protein stabilizing osmolytes to increase the yield
of reassembly around protein cargos, such as enzymes [202,203].
The ability to empty the T7 phage capsid of its genetic material opens up the opportunity to use
these hollow phage heads as cages for encapsulation of foreign materials. It has been demonstrated that
the phage DNA can be released from the capsid by applying osmotic pressure, and the empty capsids
then filled with precursor ions for mineralization [204]. The self-assembly of nanoparticles on the capsid
of T7 has also been reported in the literature. This was accomplished by introducing functional moieties
(biotinylation peptide, gold binding peptide) onto the coat protein through genetic engineering, and
were used to assemble quantum dots and gold nanoparticles [205,206]. M13 and MS2 phage capsids
have also been used as templates to assemble a variety of materials (e.g., 64Cu, Gd3+, drugs, single wall
carbon nanotubes, iron oxide nanoparticles and fluorophores) with high copy number by means of
genetic/chemical modification of the coat proteins for site-specific material conjugation [84,207–211].
The capsid of T4 phage has also used as a bio-scaffold to fabricate functional materials. The
fabrication of such nanostructures typically relies on the reduction of metal nanoparticles on the
capsid surface, and is generally performed in two steps. T4 phage are initially incubated in a
solution of metal salts and then the metal ions that interact with phage coat proteins are reduced
by dimethylaminoborane [212]. Although this approach has been applied to synthesize different
phage-templated metal nanostructures (e.g., gold, platinum, rhodium, cobalt, iron, palladium, and
nickel), the mechanism of metal nanoparticle formation on phage coat protein remains unknown [213].
It has been suggested that the side-chains of the surface-exposed amino acids on coat proteins interact
with the metal ions and mediate the nucleation and organization of the nanoparticles on T4 capsid [214].
4.2. Drug Delivery Systems
The extensive use of phage in drug discovery and for the identification of binding partners to
various targets have also led researchers to consider using the virus itself as a targeting probe/nanocarrier
in medicine. Genetically/chemically-modified viruses that display targeting peptides or synthetic
functional molecules have been used as building blocks to design self-assembled nanostructures for
drug delivery and the treatment of diseases. In particular, the reported ability of filamentous phages to
penetrate to the central nervous system, which is difficult for most of the drug molecules and drug
delivery systems due to the relative impermeability of blood-brain barrier, may contribute to making
viruses promising drug delivery platforms [215].
4.2.1. Anti-Cancer Drugs
The most common virus-based drug delivery platforms are based on chemotherapeutics, and
the viral particles are employed as carriers for small drug molecules. In this manner, doxorubicin,
which is a clinically approved anticancer agent, has been extensively studied. Viral particles have been
employed to improve the drug efficacy and reduce systemic toxicity. In order to create a linker with
high serum stability and sensitivity to enzymatic hydrolysis by cysteine protease (cathepsin-B; present
within the lysosomes of target cells), cathepsin-B cleavable DFK peptides were displayed on the p8
coat proteins of filamentous phage and employed to attach doxorubicin with a high copy number
(~3500) via carbodiimide coupling chemistry. Although, direct conjugation of the drug to the coat
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proteins yielded higher numbers of drug molecules per phage (~10,000), the engineered drug-release
mechanism significantly improved the potency of the carrier as a result of release of the drug at the
targeted cells [216]. Considering that all five coat proteins of M13 can be used for phage display, it
is possible to introduce more than one functionality onto the surface of the phage to achieve new
properties. By using three different coat proteins of M13, a phage-based therapeutic platform was
designed for simultaneous prostate cancer imaging and targeted drug delivery [84]. In this system,
doxorubicin was conjugated to the major coat protein while other coat proteins (p3 and p9) were used
to display cancer-targeting peptides and fluorophores (imaging agent), respectively (Figure 3). The
phage-based therapeutic enabled cancer cell targeting, imaging, and drug delivery.
 
Figure 3. (A) Schematic of M13-983 Phage. The red dots along the phage coat represent doxorubicin
(DOX) attached to p8. p3 displays a peptide with affinity for SPARC (Secreted Protein, Acidic and Rich
in Cysteine), and p9 can be enzymatically biotinylated and loaded with streptavidin-functionalized
fluorophores AlexaFluor 488 nm. (B) Overlay of brightfield and fluorescent images of SPARC positive
C42B cells (first and second column) and less expressing SPARC DU145 cells (third and fourth column)
incubated with M13-983-Alexa-DOX at 0 h (top row) and 9 h post-treatment (bottom row). FITC channel
represents fluorescence from Alexa Fluor 488, and DOX is designated by red fluorescence from DOX
uptake. C42B samples showed increased fluorescence of phage uptake, indicated by green fluorescence
(bottom row, first column) and DOX uptake (bottom row, second column) as compared to DU145 cells
after 9 h. (C) Targeted uptake measured by quantifying fluorescence intensity (** p < 0.001; * p < 0.01).
C42B consistently shows higher fluorescence intensity than DU145, confirming the observations in
panel B. Higher phage concentrations report larger differences between C42B and DU145 fluorescence.
(D) Cell viability of C42B and DU145 as a function of free DOX. (E) Cell viability of C42B and DU145 cell
lines as a function of increasing M13-983-Alexa-DOX. All samples were run in triplicate and error bars
represent standard deviations. (F) IC50 values for C42B and DU145 are given with the 95% confidence
interval given in parenthesis. * Based on 257 DOX particles per phage (Adapted with permission
from [84], Copyright American Chemical Society, 2012).
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As an alternative approach, rather than loading drug molecules onto viral particles, drug-loaded
materials can be modified with viruses for targeting purposes. For instance, M13 phage
modified with folic acid to target cancer cells, was attached onto a biodegradable polymer
(poly(caprolactone-b-2-vinylpyridine, PCL–P2VP) particles that were loaded with doxorubicin [217].
By providing a large surface area with control over the spacing and orientation, phage particles enabled
multivalent target-receptor interaction and improved targeting. Indeed, in vitro studies with human
nasopharyngeal cells showed that doxorubicin-loaded phage coated polymer particles had significantly
higher cellular uptake and selectivity in comparison to free drug.
Encapsulation of doxorubicin within the cavity at the center of MS2 has been an alternative
strategy to improve the delivery of the drugs to target cells. It has been demonstrated that reduced
intracellular accumulation of doxorubicin in human hepatocellular carcinoma cells (Hep3B) due
to the moderate P-glycoprotein levels can be overcome by loading empty MS2 virus capsids with
drug molecules [199]. As targeted drug-loaded viral particles are internalized via receptor-mediated
endocytosis, they can circumvent efflux mechanisms of P-glycoproteins and can kill cancer cells at
lower drug concentrations (20-fold improvement) compared to free drugs. Moreover, encapsulation
of doxorubicin inside the MS2 viral capsid demonstrated significantly different time-dependent
cytotoxicity. Indeed, while the free drug was highly toxic to all studied cell types exposed to the
drug for 24 h, encapsulation of the drugs within the targeted viral particles showed a high degree of
specificity towards Hep3B cells, with an >80% reduction in cell viability. In contrast, the viability of
non-targeted cells after a 7 days exposure to the encapsulated drug remained relatively unaffected.
Similar results were observed for doxorubicin-loaded cancer targeted RCNMV, CMV, and HCRSV
particles, which reduced the cytotoxicity of the drug in non-targeted cells, due to the specific cell
uptake in target cells [60,62,218]. CMV drug carriers exhibited a sustained in vitro drug release profile
over 5 days. The efficacy of doxorubicin-loaded viral particles in tumor-bearing animal models have
been studied, as well. Regarding doxorubicin-loaded TMV particles, treatment showed significant
delay in tumor growth and increased survival due to the efficient tumor accumulation of the drug
carrier platform while free doxorubicin had no effect on tumor burden or survival [219]. PEGylated
doxorubicin-loaded PVX particles also showed similar efficacy in animal models. Tumor growth rates
were significantly lower compared to free doxorubicin [220]. Cardiotoxicity of doxorubicin was also
studied in viral drug delivery systems in order to demonstrate the efficiency of targeted drug delivery
along with the prevented drug release within the heart. Johnson grass chlorotic stripe mosaic virus
(JgCSMV, a member of the family Tombusviridae), another plant virus recently gained attention as an
alternative viral platform, was loaded with doxorubicin and drug delivery efficiency of doxorubicin
loaded JgCSMV has been investigated in MCF-7 tumor-bearing athymic mouse models [221,222]. The
study showed that tumor volume of the mice treated with doxorubicin loaded JgCSMV was 2.22 times
smaller than the control group which was not treated with any drug. More interestingly, hearts of
the mice treated with doxorubicin loaded JgCSMV and untreated negative control mice showed no
significant pathological changes while thrombi were observed in hearts of the mice treated with free
doxorubicin. In addition to rod-like filamentous structures, TMV coat proteins can be self-assembled
into stable disk-shaped particles, which expands the shape library of the protein-based nanomaterials
for drug delivery. Delivery of doxorubicin molecules to glioblastoma cells in vitro demonstrated that
TMV disks could provide a promising nanocarrier platform resulting in significant cell death after 72 h
of incubation while the cells incubated with TMV disks alone showed ~100% viability [64].
The formation of hollow mesoporous silica nanocapsules around CPMV viral templates has
been another approach to control drug delivery from a viral scaffold. APTES ((3-aminopropyl)
triethoxysilane) and TEOS (tetraethyl-orthosilicate) were used to form a silicate network around
viral capsids due to electrostatic interactions between the carboxyl/carbonyl groups of CPMV and
amine groups of silicates (Figure 4A) [223]. In order to create a hollow cavity, the capsid proteins of
viruses were denatured by increasing the temperature to 40 ºC for a period of 24 h, which enabled
their diffusion out from the core. The pores within the silica nanocapsules enabled the loading of
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doxorubicin into its cavity and their release by diffusion (Figure 4B). The fabrication of surfactant free,
hollow mesoporous silica nanocapsules provided high drug stability as a result of slow decomposition
of the drug molecules, which were protected inside the capsules and their regulated sustained release
from the pores. The in vitro efficacy of the virus-templated mesoporous silica nanocapsules were
investigated by utilizing Hek293 and HepG2 cell lines, where the raise in drug dosage resulted in an
increase in the cell survival (Figure 4C–D) and showed the efficiency of the platform.
Figure 4. (A) Schematic representing the proposed synthesis mechanism of the CPMV-templated
mesoporous silica nanocapsules in three steps (Step I, Step II and Step III). (B) (a) SEM image of single hollow
capsules formed through the self-assembly of hollow SiO2 nanocapsules synthesized in the presence of
CPMV, (b) surface textures of the same formed by the self-assembly of nanoparticles. (Scale bar 10.0 μm and
1.0 μm, respectively), (c) TEM of hollow SiO2 nanocapsules (shown in (b), scale bar 0.2 μm), and (d) confocal
microscopy image of hollow SiO2 nanocapsules loaded with Rh6G (a small fluorescent molecule) (scale
bar 2 μm). Cytotoxicity assay of Hek293 (Human embryonic kidney cell line) and HepG2 cells (Human
carcinoma cell line) (C) with mesoporous SiO2 nanocapsules free from drugs and (D) nanoformulated
hollow SiO2 nanocapsules (doxorubicin (DOX)-loaded hollow SiO2 nanocapsules) of different doses
(Adapted with permission from [223], Copyright The Royal Society of Chemistry, 2015).
In addition to doxorubicin, other anticancer pro-drug/drug molecules have also been successfully
loaded inside the viral nanoparticles and their drug delivery efficiencies in cancer cells have been
evaluated. Proflavine, mostly known as a bacteriostatic, is one such compound that has shown
antiproliferative activity in cancer cells and tumors due to its intercalation into DNA [224]. Loading of
proflavin within the CPMV particles has been achieved through the diffusion of drug molecules into
the viral capsids. The loading mechanism of the drug within the capsid was explained by the genetic
material inside the capsid acting as a sponge that absorbs the drug molecules. Drug delivery studies
have shown that the interaction of proflavine with viral RNA was reversible and enabled the release of
the drug molecules in several cancer cell lines (HeLa (cervical cancer cells), HT-29 (colon cancer cells),
and PC-3 (prostate cancer cells)) while no cargo release was observed in cell-free medium.
Cisplatin (cis-[Pt(NH3)2Cl2]) is another anticancer drug that has been efficiently delivered to
cancer cells via viral particles. TMV particles have been decorated with mannose and lactose moieties to
specifically target the galectin-rich human breast cancer cell line MCF-7 and asialoglycoprotein receptor
(ASGPR) over-expressing hepatocellular carcinoma cell line HepG2, respectively. For this purpose,
alkyne modified TMV particles were modified with azido sugar derivatives via the copper(I)-catalyzed
azide–alkyne cycloaddition. The interior capsid surface of the TMV particles was covalently modified
with cisplatin molecules through a stable chelate structure with the carboxyl groups of glutamate
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residues, and the drug later slowly released and resulted in enhanced apoptosis efficiency in specific
targeted cell lines [225]. A similar drug delivery approach has also been employed for the treatment of
ovarian cancer cells with platinum resistance, which may appear at the onset of disease or develop
in response to platinum-based chemotherapy. As cisplatin offers greater efficacy than its analogue
carboplatin, it is crucial to develop alternative drug delivery platforms employing cisplatin with reduced
toxicity. It has been reported that the delivery of drug molecules conjugated to the interior surface of
TMV provided a platform capable of circumventing the resistance mechanisms in platinum resistant
ovarian cancer cells and restoring efficacy of cisplatin treatment at low concentrations. Loading of
TMV particles with cisplatin was achieved through electrostatic interactions between the deprotonated
interior glutamic acid residues of the capsid proteins with positively-charged cisplatin molecules,
which were produced via a reaction with silver nitrate. The enhanced efficacy of cisplatin-loaded TMV
particles in ovarian cancer cells suggests that encapsulation of cisplatin in viral particles increased the
rate of drug uptake/retention as well as DNA damage inside the cells [226].
4.2.2. Protein Therapeutics
The plant hormone indole-3-acetic acid (IAA) is a prodrug used in a virus-based drug carrier
to treat human prostate cancer cells. IAA generates a radical upon reaction with horseradish
peroxidase and produces radical-dependent cytotoxicity as well as cell death. The viral drug carrier
was designed by engineering M13 phage to display a short peptide to enhance prostate cancer cell
recognition/penetration. Moreover, a NeutrAvidin–horseradish peroxidase conjugate was attached
to the p9 phage coat protein of M13 fused with a biotinylated peptide [227]. The treatment of cancer
cells with this system led to a significant reduction in cell viability due to intracellular delivery. This
virus-based prodrug activation approach has also been investigated for tamoxifen, which is one of the
most widely used prodrug in the treatment of hormone-dependent breast cancer [228,229]. Tamoxifen
is mainly metabolised in the liver by cytochrome P450 (CYPs) enzymes, resulting in the active drug.
Encapsulation of CYPs inside cancer-targeting CCMV particles was suggested as a pro-drug activation
strategy to increase the drug efficiency as well as to reduce the severe side-effects of the drug in normal
cells. In order to encapsulate the CYPs, viral particles were disassembled and then reassembled in the
presence of the enzyme molecules. The electrostatic interactions between the negatively charged CYPs
and the positively charged interior of the viral capsid was used as a driving force to internalize the
enzyme molecules within the viruses. Preliminary studies have shown that CYPs encapsulated within
the viral particles maintained their activity, though the catalytic activity was one order of magnitude
lower compared to the activity of the free CYPs. The decrease in enzyme activity was attributed to
deleterious effects of crowding inside the capsid cavity, diffusion of the substrate into the virus capsid,
and improper orientation of the active site of the enzyme.
4.2.3. Antibiotics
Antibiotics are another group of drugs that have been loaded in viral-based drug carriers. It has
been reported that the conjugation of many copies of the drug molecule onto the phage’s major coat
proteins increased potency by creating a microenvironment around bacterial cell with a locally high
drug concentration. Treatment of gram positive pathogenic bacteria Staphylococcus aureus with the low
potency antibiotic chloramphenicol, well-known for its toxicity to blood cells, conjugated to the fd
phage retarded the growth of bacterial cells ~20-fold more efficiently than free chloramphenicol [230].
4.2.4. Photodynamic and Photothermal Therapy
Efficient delivery of drug molecules to targeted cells is also important for photodynamic therapy
(PDT) and photothermal therapy (PTT). PDT relies on the activation of a photosensitizer by light in
the presence of oxygen, which produces reactive oxygen species (ROS). As cell damage occurs due to
the reaction of ROS with cellular components, it is important to deliver the photosensitizers to the
targeted cells and avoid their nonspecific delivery to the healthy cells. The nonspecific dispersal of
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the photosensitizer throughout the body creates sensitivity in patients. For instance, sunlight must be
avoided for several weeks following treatment. Moreover, the insolubility of many photosensitizers in
physiological solutions is another problem encountered in PDT-related drug delivery systems and
it is necessary to develop new platforms to address this challenge. For this purpose, icosahedral
CCMV particles have been explored for PDT by dual labelling with both cell-targeting moieties and
photosensitizers. The surface coat protein of the virus was genetically-modified to display a cysteine
residue, used to attach the photosensitizer Ru(bpy2)-5-iodoacetoamino-1,10-phenathroline(phen-IA).
An antibody specific for Staphylococcus aureus, was chemically conjugated to the lysine residues of
the coat proteins [57]. PDT studies using this system showed that the photosensitizer-labelled
CCMV particles were more efficient in killing S. aureus cells compared to free photosensitizer
due to the enhanced cell targeting ability. On the other hand, the cell killing efficiency of the
photosensitizer-labelled CCMV particles was approximately the same as that achieved using and
anti-S.aureus antibody-photosensitizer conjugate. While the number of photosensitizers per binding
event for the CCMV platform (~70) was significantly higher than the antibody-photosensitizer conjugate
(~2), it was suggested that the large size of the CCMV particles significantly reduced the proximity
of photosensitizer to the cell surface, which is an important factor in efficacy due to the very short
diffusion length of singlet oxygen. The encapsulation of photosensitizers within the capsid cavity of
CCMV particles has been another approach for PDT. Water-soluble zinc phthalocyanine (ZnPc) was
encapsulated inside CCMV by two different routes: i) self-assembly of coat proteins dimers around
aggregated ZnPc molecules at neutral pH; and ii) diffusion of ZnPc molecules into empty CCMV
particles through capsid pores at acidic pH [231]. Although the potential use of ZnPc-loaded CCMV
particles as PDT delivery system was tested on macrophages and resulted in cell death, further studies
are required to evaluate the efficiency of this platform as targeted PDT delivery system for cancer therapy.
Zn-EpPor (5-(4-ethynylphenyl)-10,15,20-tris(4-methylpyridin-4-ium-1-yl)porphyrin-zinc(II) triiodide)
is another photosensitizer used in viral PDT systems. The interior channel of TMV particles were
loaded with the photosensitizer by exploiting electrostatic interactions between the negatively-charged
amino acid residues of virus and the positive charge of Zn-EpPor [232]. Zn-EpPor-loaded TMV
particles were stable and possessed a good shelf-life (drug release was not observed during one-month
storage at 4◦C in 0.01 M potassium phosphate buffer, pH 7.0). Cellular uptake and drug efficacy studies
were performed with melanoma cancer cells. The release of the photosensitizer was suggested to
occur inside the acidic endolysosomal compartment, which caused protonation of TMV’s interior
carboxylic acid groups resulting in drug release. Zn-EpPor-loaded TMV particles showed enhanced
cell killing efficacy compared to free Zn-EpPor molecules, which was attributed to the increased
cellular uptake of photosensitizer as a result of their delivery within the TMV particles. Recently, the
effect of photosensitizer’s charge on drug loading efficiency of TMV particles was investigated in
a study where different zinc porphyrin (Zn-Por) formulations (monocationic (Zn-Por1+), dicationic
(Zn-Por2+), tricationic (Zn-Por3+), and tetracationic (Zn-Por4+)) were employed [233]. While the
tricationic formulation demonstrated the highest loading efficiency (~600 molecules/TMV), the results
were attributed to the combined effect of electrostatic and hydrophobic/hydrophilic interactions; higher
positive charge was suggested to result in better stabilization of the photosensitizers inside TMV
particles due to the electrostatic interactions with the deprotonated carboxylate residue of glutamic
acid at pH 7.8. Moreover, the increased hydrophobic nature of the monocationic and dicationic
Zn-Por formulations with their electrostatic properties resulted in aggregation and reduced the loading
efficiency. In order to develop a targeted drug delivery system, F3 peptide was conjugated to the surface
proteins of TMV particles to target a shuttle protein, nucleolin, overexpressed on HeLa cells. Zn-Por+3
loaded TMV-F3 particles accumulated on the cell membrane and showed a fivefold increase in cell
killing efficacy compared to the free drug. The results are explained with some possible mechanisms
which are the cell toxicity through cell membrane disruption by light activation, the release of the
photosensitizers at the cell surface and favored cell uptake of the Zn-Por molecules due to their positive
charge. The self-assembly of drug-loaded liposomes on M13 phage has been another PDT delivery
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approach using phage as a nanocarrier [234]. Cationic liposomes were loaded with zinc phthalocyanine
(ZnPc) and were assembled on M13 phage displaying eight glutamic acid residues on the p8 major
coat protein, via electrostatic interactions. Phage-templated drug-loaded liposomes had enhanced
excited singlet oxygen generation efficiency and were able to internalize in breast cancer cells. These
two properties make phage-liposome complexes a promising tool for targeted drug delivery given that
this property can be introduced by displaying targeting peptides on the minor coat proteins of phage.
Moreover, the phage template can stabilize the liposomes in biological media against flocculation and
can help the delivery of the content loaded inside the liposome to specific targets.
Photothermal therapy (PTT), so-called hyperthermal therapy, employs gold nanoparticles as a heat
source for inducing cell damage as a result of a light-to-heat conversion process. As gold nanoparticles
generate local heating under light illumination, efficient delivery of gold nanoparticles to targeted
cells is desirable for selective cell killing. Clusters of gold nanoparticles on T7 phage particles have
been fabricated as a PTT delivery platform to treat prostate cancer cells in vitro [206]. The assembly
of gold nanoparticles on the capsid surface was achieved via the display of a gold-binding peptide
and a prostate cancer cell-binding peptide, in tandem (Figure 5A). Phage-templated gold clusters
maintained their cell-targeting functionality and promoted delivery of the system to the cancer cells.
Clusters were localized within vesicular organelles (e.g., endosomes), generating even larger clusters
with a diameter of up to few hundred nanometers, which suggested receptor-mediated endocytosis as
a possible internalization mechanism (Figure 5C,D). Irradiation of the prostate cancer cells resulted in
cell death in a very selective manner, whereas no remarkable cell death was observed in both healthy
cells and non-targeted cancer cells (Figure 5B).
 
Figure 5. (A) Schematic illustration of cancer-selective photothermal therapy via prostate cancer-targeted
intracellular delivery of T7-templated AuNP nanoclusters, where T7 phages are genetically modified to
display gold-binding and prostate cancer cell-targeting peptides on the viral surface. (B) The viability of
each cell line (prostate cancer cell (PC3), human colorectal carcinoma cells (HCT116), and normal cells
(HaCat)) by photothermal effects of T7-templated AuNP nanoclusters. (C,D) TEM images of T7-templated
AuNP nanoclusters internalized within PC3 cells in ultrathin section specimens. The cells were treated
with T7-templated AuNP nanoclusters for 5 h, followed by medium replacement and additional incubation
for 20 h (Adapted with permission from [206], Copyright American Chemical Society, 2015).
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4.2.5. Incorporation into Polymer Matrices
Polymeric materials are widely used as drug delivery systems because of their ability to be use
as a matrix that protects drug molecules and controls drug release via e.g., its rate of degradation
or swelling profile. Moreover, in some cases, the high water content and soft structures of polymer
matrices make them similar to natural extracellular matrices, which contributes to minimizing tissue
irritation and cell adhesion and makes them promising drug delivery systems. However, an initial
burst, or very fast release of drug molecules remains a challenge that can limit their use to certain types
of drugs. The incorporation of viruses into polymeric matrices has been proposed as a solution to
overcome this limitation and to better control the release of the drugs molecules. The affinity-based
polymeric drug release system is one such platforms in which M13 phage are embedded inside a
polymer matrix to suppress the release of drug proteins due to their specific interactions with phage
particles. For this purpose, the p3 coat protein of M13 phage was genetically modified to display
peptides that bind to antibodies and mixed with a gelatin solution containing antibodies to form hybrid
hydrogels [235]. While the antibodies were gradually released from M13-free gelatin hydrogels within
48 h, their release from the M13-gelatin hybrid hydrogels was ~1% after 144 h, indicating suppression
of the release due to phage-antibody interactions.
Stimuli-responsive polymers are another group of material where M13 phage has been introduced
to create polymer–protein bioconjugates combining both bioactivities of the protein molecules and
the responsive properties of the polymers. A polymer–M13 bioconjugate was produced by grafting a
boronic acid containing polymer (poly(NIPAMco- phenylboronic acid (PBA)) onto M13 surface through
amino groups of the coat proteins [236]. By doing so, around 400 poly(NIPAMco-PBA) chains were
conjugated per phage particle. Due to the temperature-responsive gelation behavior of the polymer,
the polymer–M13 phage bioconjugate was mixed with insulin at 4 ºC and could then be converted
into hydrogels by injecting into PBS buffer at 37 ºC. The insulin-encapsulated hydrogels demonstrated
glucose-responsive release behavior, which can be an interesting strategy in the regulation of diabetes.
During hydrogel formation, the virus particles interact with poly(NIPAMco-PBA) polymer, which
is in a collapsed hydrophobic state. However, in the presence of glucose, the boronic acid moieties
of poly(NIPAMco-PBA) couple to glucose to yield hydrophilic boronates that are substantially more
hydrophilic. This changes the structure of hydrogel matrix and enables faster release of encapsulated
insulin molecules. While 70% of insulin was released over 24 h, the release rate of insulin increased in
the presence of glucose with a peak value of 90% at 10 h. Similar carbohydrate-responsive polymers
have also been prepared by cross-linking phenylboronic acid (PBA)–M13 bioconjugates with poly(vinyl
alcohol), resulting in hydrogels with excellent injectability and self-healing behavior (Figure 6A) [237].
The self-healing nature of the hydrogels was investigated by placing two pieces of hydrogels adjacent
to each other (Figure 6B). It was observed that the interface became smeared after 15 min and then
completely disappeared after 1 h. Additionally, insulin molecules could be introduced into both
the PBA–M13 bioconjugate suspension and the PVA solution, resulting in insulin-loaded hydrogels.
Glucose-responsive insulin release studies showed that an initial burst release, which was observed
in less than 15 h, was similar in the presence and absence of glucose (Figure 6C). At a later stage of
release, the hydrogel in the presence of glucose released most of the insulin with a speed faster than
that without glucose as a result of swelling of the gel matrix caused by the diffusion of glucose into
the hydrogel, which partially disrupts the physical crosslinking between the diols of PVA and the
boronic acids.
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Figure 6. Schematic representing (A) the preparation of viral bioconjugates of M13 viruses with low-pKa
phenylboronic acid derivative (PBA-M13) and (B) fabrication of dynamic hydrogels via binding of
PBA-M13 with multiple diol-containing polymers and demonstration of self-healing behavior. (C)
Glucose responsiveness-regulated insulin release behaviors. FITC-insulin was loaded into the hydrogel
and then placed into PBS buffer with or without glucose. The released FITC-insulin was monitored
by fluorescent measurements. The asterisks represent the statistical significance, which is calculated
by multiple t tests-one per row: * p < 0.05, ** p < 0.01, *** p < 0.001. The hydrogels consist of 1 wt %
PBA-M13 and 0.15 wt % PVA (Adapted with permission from [237], Copyright American Chemical
Society, 2018).
RCNMV particles has been another virus incorporated into polymeric drug delivery systems.
The ability to trigger the opening and closing of RCNMV capsid pores by changing divalent ion
(Ca2+ and Mg2+) concentrations and pH enables their use as an additional release mechanism in drug
delivery systems. Doxorubicin-loaded RCNMV particles could be incorporated into two different
polymeric matrices (poly(lactic acid)(PLA) and poly(lactic acid):polyethylene oxide (PLA:PEO)) by
electrospinning into fibers [238]. Two approaches were employed to incorporate viral particles in these
matrices; i) the direct mixing of viral particles and polymer solution before fiber formation; and ii)
physisorption of the viral particles onto the pre-formed fibers by immersion (Figure 7A). It has been
demonstrated that electrospinning of drug-loaded viral particles with polymer solutions resulted in
nanofibers with significantly lower release profiles (Figure 7B). A slightly lower release profile was
also observed for PLA polymer compared to PLA–PEO polymer, which was attributed to the more
hydrophilic nature of PEO. Upon appropriate stimuli (reducing divalent ion concentrations or making
pH more basic), the release of the drug molecules from virus-polymer matrix, produced via direct
processing followed a two-phase kinetic profile. While the first phase included the diffusion of the
mobile phase through the polymer to trigger the opening of the virus capsid pores, which enables the
release of the drug, in the second phase the drug molecules diffuse through the polymer matrix.
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Figure 7. (A) Schematic of processes for incorporating plant viral nanoparticles (PVN) in nanofiber
matrices. In the direct processing method (I), the PVN active are electrospun in situ with the polymer
solution. In the immersion process (II), the nanofiber matrices are dipped into a specific volume and
concentration of PVN active particles. (Scale bars of the images from left to right 50.0 μm and 2.0 μm,
respectively) (B) Cumulative doxorubicin release over time of PLA nanofiber matrices combined with
PVN Dox () or free doxorubicin () where PLA was combined with the active either a) post mat
fabrication (dipping method) or b) prior to electrospinning (co-spinning method) and of 70:30 PLA:PEO
nanofiber matrices with PVN dox (o) or free doxorubicin () where PLA:PEO was combined with
the active either c) post mat fabrication (dipping method) or d) prior to electrospinning (co-spinning
method) (Adapted with permission from [238], Copyright WILEY-VCH Verlag GmbH & Co., 2013).
5. Challenges to Clinical Applications
Pharmacokinetics and toxicity are critical factors that determine the viability of materials intended
to be used as drug delivery system for medical applications. Therefore, several studies investigating
the circulation, clearance, blood half-life, stability, immunogenicity, and organ biodistribution of
viral platforms have been performed and have provide useful information. While not numerous,
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some fundamental studies on the interaction of plant viruses and phage with mammalian cells and
pathways that they used to enter into cells have been performed. For instance, while M13 phage
tends to only bind to the cell membrane of epithelial cells, it shows cell-type dependent interactions
and internalization mechanism: clathrin-mediated endocytosis and macropinocytosis for HeLa cells;
vesicular transport; clathrin-mediated endocytosis, and macropinocytosis for a human breast cancer
cell line (MCF-7); and caveolae-mediated endocytosis for human dermal microvascular endothelial
cell (HDMEC) [239]. On the other hand, CPMV particles naturally interact with mammalian cells,
including endothelial cells and particularly tumor neovascular endothelium in vivo, via a surface
exposed cell protein, vimentin [240].
After their administration into the body, viral particles, like many other nanoparticles, are
recognized as foreign agents by the cells of the host immune system and are eliminated from the blood.
B-cells are one type of these immune cells and B-cell dependent immunoglubins have been shown
to play an important role in rapid neutralization of T7 phage in murine blood, resulting in a short
half-life (<5 min) [241]. The reticuloendothelial system (RES) is another component of the immune
system that is highly involved in the clearance of viral particles. Indeed, clearance by macrophages
and accumulation in organs such as the liver and spleen have been reported for many viruses (ca. M13,
MS2, CPMV, PVX, and TMV) [22,242–245]. Nevertheless, there are significant differences between the
efficiency of the viral particles in avoiding clearance by phagocytosis, which results in different blood
circulation times. For instance, filamentous M13 phage can effectively avoid rapid clearance from the
RES with a plasma half-time of 3.6 h [246]. In contrast, another rod-like virus TMV has much shorter
blood clearance time (~3 min) [243]. Different plasma clearance half-lives have also been observed for
spherical viruses. For instance, while CPMV and CCMV particles are rapidly cleared from the blood
with short circulation times (CPMV, 4–7 min), MS2 viral particles show longer plasma half-life [16,208].
It has been demonstrated that certain rod-like particles can effectively evade phagocytosis since the
larger contact angles with macrophages do not favor engulfment and internalization. The surface
charge of the viral capsid is another parameter that influences their fate in tissues. Due to the negative
charge of the surface of mammalian cells resulting from abundant proteoglycans, positively-charged
viral particles are expected to interact electrostatically with cells, which has been reported to increase
their intracellular delivery and tumor penetration. The short blood circulation of CPMV particles is
attributed to their negative surface charge, hence their cellular uptake in HeLa cells could be improved
by conjugation of cationic peptide sequences [247].
The studies above suggest that the fast blood clearance of viral particles are at least partially due to
the host immune response and highlight a need for a coating to tailor the properties of the viral particles
for enhanced blood circulation times. For this, the modification of the viral capsid with passivating
agents, such as polymers or proteins, has been investigated. For instance, the modification of the CPMV
capsid with poly(ethylene glycol) (PEG) effectively blocked CPMV–cell interactions and shielded the
viral particles from inducing a primary antibody response [248,249]. The effect of PEGylation has been
also observed on plasma circulation times. The half-lives of PEGylated CPMV and TMV particles were
20.8 min and 6.6 min, respectively, which were longer than the half-lives mentioned above [22,250]. In
addition to PEG, poly(2-oxazoline) (POx) and serum albumin have also been employed as alternative
coatings agents [251]. In comparison to PEGylated TMV, POx-coated viruses showed lower cellular
uptake rates indicating less favored TMV–cell interactions due to the higher polymer grafting density
of Pox relative to PEG for the tested samples. High polymer density was associated with a reduction in
cellular recognition as well as protein adhesion to the polymer-coated particles. On the other hand,
pharmacokinetic studies showed a two-phase decay for the polymer-coated TMV particles. During the
initial clearance period, POxylated TMV particles had longer plasma half-life (11.3 min) than PEGylated
TMV particles (0.01 min) indicating better screening capability of POx polymer. Serum albumin (SA)
has been another coating material investigated to shield TMV particles from the immune system.
Similar to POx, in cellular uptake and pharmacokinetic studies of the SA coating also outperformed
the PEG [252]. While the rates of macrophage uptake of PEG- and SA-coated TMV particles were
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comparable, showing a 4-fold reduction in macrophage-particle interactions relative to uncoated TMV
particles (Figure 8A), their circulation half-lives in Balb/C mice were 10 min and 100 min, respectively
(Figure 8B). According to the authors, the enhanced pharmacokinetics of SA coating was associated
with its relatively high molecular weight. It was suggested that compared to flexible PEG chains with
low molecular weight, the globular and rigid structure of SA provided enhanced steric hindrance,
resulting in better stealth properties.
Figure 8. (A) In vitro recognition of SA- and PEG-coated TMV vs. ‘naked’ TMV by RAW264.7
macrophages. Quantitative flow cytometry analysis of the interactions between ‘naked’ and ‘stealth’
TMV formulations and RAW264.7 cells. (B) Pharmacokinetics of the TMV-PEG24 and TMV-PEG8-SA
particles in Balb/C mouse model. The particles were administered intravenously at the amount of
400 mg/mouse. Blood was collected before injection at t = 0 and after injection at t = 10 min, t = 30 min,
t = 60 min, t = 120 min, and t = 360 min (the experiments were completed at an n = 3 per group)
(Adapted with permission from [252], Copyright Elsevier, 2016).
6. Conclusions
Overall, a unique feature of viruses highlighted in this review is that they are perfectly-defined
nanomaterials that can be conveniently modified, either at the genetic level or using bioconjugate
chemistry, to yield interesting tools for drug discovery or drug delivery. Indeed, the structural
diversity of viruses as well as the connection between genotype and phenotype has provided several
complementary platforms for the discovery of different classes of therapeutic polypeptides by phage
display, some of which have made it to the clinic. While in vitro selection procedures by phage display
are the most commonplace, a better understanding of the health risks posed by plant viruses and
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bacteriophages to Humans may unbridle more complex in vivo selection procedures towards targets
that cannot be emulated in vitro. Indeed, the available yet limited number of studies examining the
application of in vivo phage screening in human patients have shown promising results [253,254]. In
contrast to the use of viruses for drug discovery, most studies employing viruses or virus-like particles
as drug delivery systems are limited to in vitro proof-of-concepts. Little information is available
regarding in vivo toxicity or biodistribution. While some immunohistochemistry studies suggest
that virus-like particles do not induce adverse effects in animal tissues, in terms of no overt signs
toxicity (tissue degeneration, cell apoptosis, and necrosis), it is necessary to support these results
with organ–function studies in the future. This information will be important for guiding future
developments of plant and bacterial viruses as drug delivery systems or components thereof. On the
other hand, some studies on bacterial viruses has shown that food-ingested phage DNA, like any
foreign DNA, can get inside the cells of mouse and, even on rare occasions, can covalently link to
mouse DNA [255]. While this information speculates some medically-relevant implications in terms of
mutagenesis and carcinogenesis, it has been one of the major concerns preventing the implementation
of viral particles in medicine. In this manner, viruses, which enable the removal of genetic material
and form empty capsids, could reduce DNA-related concerns and become more interesting as drug
carrier platform.
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Abstract: Routes of drug administration and the corresponding physicochemical characteristics of a
given route play significant roles in therapeutic efficacy and short term/long term biological effects.
Each delivery method has favorable aspects and limitations, each requiring a specific delivery vehicles
design. Among various routes, oral delivery has been recognized as the most attractive method,
mainly due to its potential for solid formulations with long shelf life, sustained delivery, ease of
administration and intensified immune response. At the same time, a few challenges exist in oral
delivery, which have been the main research focus in the field in the past few years. The present work
concisely reviews different administration routes as well as the advantages and disadvantages of
each method, highlighting why oral delivery is currently the most promising approach. Subsequently,
the present work discusses the main obstacles for oral systems and explains the most recent solutions
proposed to deal with each issue.
Keywords: oral delivery; biological barriers; co-delivery; throughput; sustained delivery
1. Introduction
Intravenous (IV), intramuscular (IM), intranasal (IN), intradermal (ID)/transdermal and oral
administration are the main drug delivery routes. Other routes, such as ocular delivery, have also been
developed for localized, site-specific drug administration without unwanted systemic side effects [1].
Each administration method faces specific barriers against the delivery of the drugs. In addition,
drugs can be incorporated into delivery devices, which considerably contribute to preservation of the
drug, targeting and therapeutic efficacy. In this review, we first present an overview of the various
administration routes, then focus on oral delivery systems as the most attractive route. We explain
the main challenges associated with such methods and review the most recent solutions developed to
address them.
The absorption mechanism as well as the nature of the drug are the fundamental factors that
determine the appropriate delivery systems for achieving the highest bioavailability and effectivity.
For instance, IM and ID administration are usually the preferred vaccination routes, depending upon
the desired immune response mechanisms. On the other hand, researchers from both academia
and industry have shown great interest in IN and oral vaccination systems, since these routes can
induce both systemic and mucosal immune responses. In IV administration, the drug is rapidly
injected into blood vessels through needles, and a high concentration of the drug is able to bypass the
physiological barriers against drug absorption, providing the highest bioavailability and the fastest
effect among all delivery routes. Therefore, such a parenteral administration is the preferred route for
acute and emergency responses, while non-invasive methods are more suitable for sustained therapy
and chronic delivery [2]. The abundance of blood vessels in muscles paves the way for the absorption
of drugs injected via needles through IM administration. IM delivery bypasses the body’s first defense
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barrier (skin) [3]. In comparison with oral administration, drugs administered through the IM route
avoid the gastrointestinal (GI) environment. However, the injection can cause significant problems,
including needle-associated phobia and pain, unsafe needle use and improper disposal, the need
for trained healthcare personnel, muscle atrophy, and injuries to bones and nerves [4]. Additionally,
there is concern over the direct injection of drugs into the bloodstream through IM administration,
necessitating constant close observation to minimize adverse effects [5,6].
Biopharmaceuticals such as vaccines are of particular interest in drug delivery because of their
specific challenges. The majority of the available vaccines are administered through IM injection [7].
This is mainly due to the poor permeability of macromolecular biopharmaceuticals across the
mucosal layer in the non-parenteral route and the destructive effects of proteases in the GI tract [8].
Silica and polymer mesoporous structures can also be successfully used to preserve drugs in various
biological surroundings and accurately control their release behavior in topical injections [9–11].
However, it should be noted that IM administration is not the ideal delivery route for peptides and
proteins, compared to subcutaneous or IV injection, mainly because of the low immunogenicity
and bioavailability achieved in IM administration [12]. Although IM vaccination is widely used
commercially and the immune response in this system can be easily induced by the local depot at the
injection site, this route is not the best choice for the delivery of peptides/proteins due to the possible
aggregation of the drug [13].
The transdermal route concerns the delivery of drugs across skin layers to the blood circulatory
system [14]. Drug absorption in this case mainly occurs through the intercellular, transcellular and
transappendageal pathways. Intercellular and transcellular transports enable the permeation through
the stratum corneum [15]. In the transappendageal pathway, the drug penetrates via the sweat ducts
or the hair follicles with their associated sebaceous glands [14]. The transdermal route also avoids
the challenges that the oral route faces, including the metabolism and the difficulties associated
with the GI environment. Moreover, it can provide a sustained drug plasma level, and convenience
of discontinuation of the drug in case adverse reactions occur. Recently, nanoparticles (NPs) were
successfully employed on nano/micro-engineered needle patches to minimize the bacterial risks
associated with transdermal delivery techniques [16]. Nanoimprint lithography has also been proposed
as a fabrication technique for these structures to address the commercial requirements. Kim et al. also
proposed a new deposition-etching protocol for the fabrication of flexible silicon nanoneedles to solve
the structural mismatch and optical inconsistency between the Si needle wafers and soft tissues [17].
The patches fabricated by this technique exhibited successful injection of biomolecules into living
tissues. Nonetheless, the most significant challenge associated with transdermal administration is the
restriction over the size of the drug molecules that can be successfully delivered. Penetration of large
molecules (>500 Da) through the stratum corneum is difficult. Additionally, the drugs are required
to be soluble, so they can cross the outermost skin barrier [18]. Chemical enhancers (concerning the
delivery of small-sized molecules) and physical approaches (for the delivery of macromolecules) have
been developed to improve drug absorption levels in the transdermal delivery route. Physical skin
permeability enhancement regards electrically-assisted methods such as electroporation, iontophoresis
and sonophoresis. Chemical enhancers include fatty acids, surfactants, terpenes and solvents,
which improve skin permeability by disrupting the highly ordered lipids and modifying the stratum
corneum microstructure [19,20]. However, toxicity and skin irritation are the major concerns to
consider when developing chemical enhancer formulations. Karande et al. used a library of more than
4000 binary formulations to systematically investigate the synergistic effects of different enhancers,
and found some fundamental rules in terms of developing new formulations [21]. While these rules
are well-known and widely accepted, the mechanisms behind such potential synergistic effects and
the interactions each individual chemical enhancer may have with other enhancers or the stratum
corneum still remain unclear.
Medications can sometimes be injected directly into veins. This is known as intravenous
administration. In this scheme, the drug directly enters the circulatory system without facing
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any physical, chemical or biological barriers. Since the absorption of the drug is guaranteed and
immediate, IV administration is the best route for emergency situations. Additionally, this method
uniquely provides a very precise control over the dosage and speed of administration, making it the
best approach for drugs requiring a stringent dosage [22]. On the other hand, the IV route entails
risks of injury, infection by the needle at the site of injection, circulatory overload, phlebitis and
thrombosis [23,24]. IV administration is commonly used for the delivery of biopharmaceuticals.
The bioavailability of the drug injected through IV route is theoretically 100%, making this system
outperform other delivery routes. However, it should be noted that IV administration is not the
ideal route for the delivery of vaccines. This is due to the difficulties associated with inducing
effective immune responses via IV administration, since the IV route does not provide an adequate
local depot of antigens to stimulate/activate the innate immune response and induce the long-term
secretion of antibodies [25]. In addition, it is not applicable to implement a mass administration
(such as nation-wide vaccinations), due to the skills required for the practitioner, safety issues and
patients’ compliance.
Intranasal drug delivery entails the infusion of the drug into the highly vascularized mucosal layer
of the nose to subsequently reach systemic circulation [26]. IN drug delivery is crucially significant
for neurological diseases, where drugs are required to reach the central nervous system (CNS) by
bypassing the blood-brain barrier (BBB). In general, the IN route is preferred for local diseases due
to its limited systemic effects compared to the other methods. The IN route also has its own specific
physiological and physicochemical barriers. The physiological barriers include capillary barriers,
nasal mucus, mucus clearance and nasal metabolism. Other factors such as pH, possible drug-mucus
interactions and the viscosity of the mucus may also influence drug diffusion and absorption in IN
administration. Mucoadhesive microencapsulation systems have been developed to deal with the
mucus-associated barriers of IN delivery and improve the bioavailability of nasally-administered
drugs. For example, Nanaki et al. coated nasal microcapsules with thiolated chitosan to aid the
mucoadhesion of the system, both physically (electrostatic attractions) and chemically (disulfide
bonds) [27]. However, it should be noted that mucociliary clearance and discharge considerably limits
the drug residence time, even if the carriers develop a strong bonding/binding with the mucus [28].
Physicochemical barriers concern the molecular weight of the drug, and its lipophilicity and degree of
ionization, which also define the absorption mechanisms [29]. Despite multiple challenges, IN is an
advantageous route for the delivery of a variety of the drugs. It avoids first-pass metabolism and GI
complications. Due to its considerable absorption rate, IN is an applicable method for emergency cases
and rapid drug action. Neurological drugs especially can be transported directly to the CNS through
the IN route.
The nasal-associated lymphoid tissue (NALT) is the principal target for inducing mucosal
immunity in nasal vaccination. The innate immunity is achieved by macrophages and dendritic cells,
and the adaptive immunity at the mucosal layer is induced by IgA [30]. Hence, IN vaccination can
induce both mucosal and systemic immunity. However, physiological barriers, especially mucociliary
clearance, need to be adequately addressed for the effective delivery of antigens to the target site.
Furthermore, due to the limitations of the nasal cavity, as well as the narrow passages beneath
the thick mucus, nasal vaccination is only permitted for small dosage and low molecular weight
compounds. In order to pass biosafety requirements, IN delivery devices need to be suitable for
narrow nasal entrances and the complex geometry of the nasal passage. On top of that, lung exposure
should be properly addressed in these systems. Among the various physical states of drugs (gels,
droplets, powders, or aerosol sprays), aerosol sprays are usually preferred for IN administration.
New technologies are constantly under development to improve the dispersion of the drugs and
modify the deposition and clearance behavior through combining solid and liquid phases. However,
human anatomy as well as the physiology of the nasal cavity and passage still limit clinical applications
and delivery efficiency. Low bioavailability (<5%) causes another major challenge for IN administration
systems [31].
242
Pharmaceutics 2019, 11, 129
2. Oral Route
Among the various drug delivery routes, the oral pathway has attracted the most attention
due to its unique advantages, including sustained and controllable delivery, ease of administration,
feasibility for solid formulations, patient compliance and an intensified immune response in the case
of vaccines [32–36]. In addition, a large surface area (>300 m2) lined with a viscous mucosal layer
paves the way for drug attachment and subsequent absorption [37,38]. Furthermore, drug molecules
trapped within mucus are protected against the shear stresses caused by flowing gastric juices [39].
The epithelium of the human intestine is very absorptive due to the abundance of enterocytes in
different parts of the intestine, especially microfold cells (M cells) covering the Peyer’s patches,
the lymphoid segment of the small intestine [40–44]. However, in comparison with other routes,
the absorption mechanism of oral drugs is more complex. Oral drugs need to be soluble in gastric fluid
so they can be absorbed in the stomach, the small intestine or the colon (Table 1). Orally administered
drugs can be absorbed in four types of pathways: Transcellular, paracellular, carrier-mediated
transcellular and facilitated transport. Among these pathways, the transcellular pathway is the
main mechanism. The challenges of drug absorption/efficacy do not limit the barriers met in the gut,
but they include the hepatic barriers after they enter the vessels under the intestinal epithelium as well.
In summary, oral drugs are not applicable for emergencies due to their slow absorption as well as the
multiple levels of barriers they need to deal with.
Table 1. Characteristics of different segments of the human gastrointestinal (GI) tract.






Stomach 0.8–5 [45] 20 [45] NA 245 ± 200 [38] 24–48 [46]
Duodenum ~7 [38] 17–56 [47] 4 [48] 15.5 [45]
24–48 [46]Jejunum ≥ 7 [38]
280–1000 [47]
2–2.5 [48] 15.5 [45]
Ileum ≥ 7 [38] 3 [48] 15.5 [45]
Colon 7–8 [38] 80–313 [47] 4–4.8 [48] 135 ± 25 [38] 24–48 [46]
Although the oral route is the most desirable administration method for small therapeutic
molecules, there are not so many oral vaccines on the market due to the harsh conditions along
the GI tract (Table 1), which can degrade/denature active antigens.
However, the attraction of the mucosal immunity, which appears to be induced by oral and nasal
routes, promotes the study of oral vaccines [49]. Besides, the convenience and other advantages of
oral delivery make it a very promising strategy for mass vaccination programs. The inductive sites
in the GI tract consist of Peyer’s patches, lymphoid follicles in lymph nodes and antigen presenting
cells (APCs). Intestine mucosal immunity is similar to that of nasal mucosal immunity. The main
barrier for vaccine delivery is the change of pH in different sites in the GI tract and various enzymes,
making it hard to permeate the mucus and reach the inductive site in gut-associated lymphoid tissue
(GALT) [50]. Additionally, the mucosa may lead to the structural change of proteins and peptides due
to various possible interactions [38]. Hence, delivery vehicles and formulations should be developed
to gain a stronger immunogenicity to meet the required therapeutic efficacy. Currently, seven live oral
vaccines have already been approved by FDA.
To meet the increasing demand for biopharmaceutical oral products, research has been focused on
developing devices for oral delivery. While still at an early stage, recent devices include intestinal patch
systems, microneedle capsules and particulate systems [51]. The intestinal patch systems are based on
a unidirectional drug release depot, which is similar to a microdevice adhered to the intestinal wall [52].
The microneedle capsule increases the penetration rate of drug molecules by piercing the mucosa
directly with microneedles. A recent study developed a method to inflate a microneedle into the
mucosa by responding to the change in pH [53]. Particulate devices are the most common oral vehicles,
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which have been investigated for the encapsulation and targeting of a vast variety of therapeutics.
In general, the current technologies are still at the preclinical stage. Therefore, more research efforts
should be directed to solve the existing technical challenges of oral drug delivery systems and prove
the feasibility in clinical use.
3. Challenges Associated with Oral Delivery
Oral drugs are transported and absorbed in the GI tract, which is in the shape of a conduit.
Some drugs have local effects in the gut, while most of them are sent to the bloodstream in the systemic
circulation to act in other parts of the body. The GI tract can be divided into upper and lower parts.
The upper GI tract includes the oral cavity, pharynx, esophagus, stomach and the initial part of the
small intestine, known as the duodenum. The lower GI tract includes the rest of the small intestine
(jejunum and ileum), as well as the large intestine segments: The cecum, colon and rectum [54,55].
The structure of the GI tract is similar in all segments. The lumen is enveloped by smooth muscle
cells, covered by mucus, submucosa and several muscle layers [56]. The mucosal layer which lines the
inner part of the GI tract consists of a layer of epithelial cells, lamina propria and muscularis mucosae,
which play significant roles in food/drug molecule transport and gastrointestinal immunity [54,55].
A large absorption area and long residence time provides greater opportunities for drug absorption,
which is one of the reasons why drug absorption mostly occurs in the small intestine. Further, between
the three main parts of the small intestine (duodenum, jejunum and ileum), the jejunum and ileum
have a higher absorption capability compared to the duodenum [57,58].
The environmental factors that influence drug integrity and absorption include the average
length of the segment, pH, thickness of the mucus, residence time of the drug and the bacterial
diversity/population in different segments [38,59,60]. The obstacles against oral administration may
be broadly classified into biological barriers and technical challenges. Biological barriers include any
biological factors that denature the orally administered drugs or prevent their successful absorption in
the target. On the other hand, technical challenges relate to any difficulty in the fabrication process of
the oral delivery devices. The technical challenges may either be issues with creating specific properties
for addressing the biological barriers or complications with scaling up and commercializing a system.
The details of each category will be discussed in the following sections.
3.1. Biological Barriers
Any digested ingredient will be dealing with three main biological environments along the
gastrointestinal (GI) tract, regardless of its absorption mechanism or target. These environments are
the lumen (i.e., the interior space), mucus and tissue. Each of these three environments may have
interactions with the drug molecules.
3.1.1. Lumen
The first biological barrier against any orally administered drug is the harsh acidic conditions
inside the stomach (pH 1–2.5), denaturing/depurinating most of the administered molecules,
drastically lowering their effectivity [61–64]. In addition to stomach acid, gastric enzymes such
as pepsin and gelatinase can degrade biopharmaceuticals. pH-responsive hydrogels can encapsulate
the drugs and protect them not only against the harsh acidic environment, but against gastric enzymes
as well. These materials can remain intact in unfavorable surrounding conditions to protect the loaded
drug (promptly reacting to environmental stimuli such as the pH in the target) and release the cargo.
For instance, Yamagata et al. confirmed that pH-sensitive hydrogel microparticles (MPs) can efficiently
preserve sensitive drugs such as insulin against gastric/intestinal enzyme fluids [65]. In another study,
Cerchiara et al. also developed an oral pH-responsive microencapsulation system and demonstrated
its capability for protection against both gastric acidic and gastric enzymatic environments [66].
Notably, in addition to the gastric enzymes, there are also pancreatic enzymes synthesized inside
the pancreas and secreted into the intestinal lumen. These enzymes include lipase (degrading fats),
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trypsin (decomposing proteins), amylase (degrading starch) and peptidases (disintegrating peptides),
and are especially abundant at the main entrance of the small intestine (duodenum). They can
readily decompose nucleic acids and reduce the gastric residential stability of biomolecules [67,68].
Although pancreatic enzymes are also introduced as biological barriers against oral delivery, they are
not considered as a major challenge due to three principal reasons. First, these enzymes are mainly
abundant in the duodenum, and their concentrations considerably decrease in the jejunum and later
parts [69]. In addition, Layer et al. attempted to deliberately deliver pancreatic enzymes to the
intestine and noticed that even the concentration of the delivered enzymes substantially decreases in
the midjejunum compared to that in the duodenum (they reported up to a 90% drop in enzymatic
activities) [70]. The second aspect is the short transit time of the digested food inside the duodenum
(Table 1), which is not enough for the enzymes to degrade the drugs. Fallingborg et al. reported that
duodenal residence comprises only 10% of the whole small intestine average residence time [71]. Lastly,
the pH of the duodenum is lower than that of the later parts of the lower small intestine (Table 1),
meaning that unwanted release of the drugs inside the duodenum can be successfully avoided by
controlling (increasing) the pKa of the delivery carriers. For example, Lozoya-Agullo et al. employed
poly(lactic-co-glycolic)acid (PLGA) nanoparticles for colon delivery and confirmed that duodenal
release may be significantly avoided due to the insufficient environmental pH [72].
In addition to the acidic and enzymatic degradation, the lumen can cause other damages to
drug molecules. Osmotic stresses along the GI tract, peristalsis of the GI muscles, as well as the
shear stresses by the flow rate of the gastric juice inside the lumen are other factors that decrease
drug efficiency due to mechanical degradation inside the lumen [32,38]. Flowing gastric juice may
also decrease the contact time between the drug molecules and the epithelial layer, thus impeding
their absorption [67]. Enveloped biologics such as viruses, vaccines and cells are usually the main
components sensitive to mechanical destruction. Valon et al. studied the possible effects of mechanical
stresses on various types of cells, and reported that shear stresses and compaction may lead to
apoptosis and cell death [73]. Choi et al. also found that hyperosmotic pressure can destroy virus
integrity in an acidic environment [32]. Although mechanical stresses by the lumen can destroy
biological agents, microencapsulation can properly address these problems as well. Indeed, MPs are
hardly studied for mechanical testing, and mechanical strength is usually discussed in regard to
hydrogel properties, which in turn is a function of the molecular weight of the monomers as well as
the degree of crosslinking of the matrix. Nanoparticles may also be added to hydrogels as reinforcing
components. For instance, France et al. recently employed cellulose nanocrystals (CNCs) to create
physical crosslinking in a hydrogel matrix, proving their significant impact on mechanical behavior (up
to a 35-fold increase in the shear storage modulus of the final composite) [74]. Yang et al. also reported
up to a 3.5-fold improvement in the Young’s modulus of poly(ethylene glycol) (PEG) hydrogels
through the addition of 1.2 vol % CNCs [75]. As an instance of ceramic-polymer composite systems,
Gaharwar et al. used hydroxyapatite as the reinforcing agent in a ceramic-polymer composite and
reported up to a 1.7-fold improvement in the compressive strength of the matrix. It should be noted
that the addition of secondary components to form a composite will not only affect the mechanical
properties, but may also affect the swelling behavior, gelation rate and degradation rate of the hydrogels
as well [74,75]. Furthermore, the distribution mechanisms of CNCs throughout the polymer matrix
are poorly understood, and there are underwhelming (sometimes contradictory) reports about the
improvements in mechanical properties of composites. However, the greatest and most effective
improvement reported by the formation of a hydrogel composite to date concerns the addition of
CNCs to hydrogels, without the need for any surface or other secondary modification of the particles.
3.1.2. Mucus
Mucus is the second compartment of the GI tract, which any digested moiety interacts with.
The entire GI tract is lined by mucus (a sticky, elastic and viscous layer), responsible for the capture
of foreign moieties, especially hydrophobic molecules, impeding their contact with the underlying
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epithelial layer. The mucus then discards such foreign moieties, acting as one of the main compartments
of the immune system, known as mucosal immunity [76–79]. The mucus itself is mainly composed of
water and mucin protein molecules coated with proteoglycans, giving the mucus a negative charge [80].
Carbohydrates, salts, bacteria, antibodies and cellular remnants are the other compounds found in
mucus [81]. The thickness of this layer is reported to vary along the GI tract, as summarized in
Table 1 [38].
Mucins are large macromolecules (0.5–40 MDa) made of monomers connected through disulfide
bonding, and these macromolecules are subsequently crosslinked to build up the mucosal layer [82,83].
The mucosal layer itself is usually composed of two separate overlaying layers: An outer loosely
adherent layer and an inner firmly adherent layer (Figure 1) [84]. The inner layer is composed of
glycoproteins, glycolipids and cell-bound mucin [85,86]. It has been claimed that the thicker outer
mucus acts as a barrier against the transition of released drugs to the submucosal tissue. For instance,
Marie Boegh and Hanne Mørck Nielsen studied the diffusion of peptides and proteins through mucus
and found that mucus is the main obstacle against the bioavailability of oral drugs [87]. On the
other hand, the narrower inner mucus is known to help the absorption/enhance the uptake efficiency
of drugs, justifying the dual role of mucus in the absorption/desorption of orally delivered drugs
(Figure 1) [88,89]. There is an equilibrium between mucin secretion, degradation and clearance in each
segment of the GI tract to protect the epithelium and control the nutrition absorption rate, which in
turn defines the final thickness of the regional mucosal layer (Table 1) [38,90].
Figure 1. The structure and function of the mucus. The schematic shows the gastric mucus layer,
the attachment of particles to the outer and inner mucus, and the drug delivery vehicle on the
outer mucus.
The approaches taken regarding mucus in the field of oral delivery can be generally classified
into two opposite mainstreams: Mucopenetration and mucoadhesion. Mucopenetrating oral vehicles
may be made through controlling the hydrophobicity/hydrophilicity nature of the carriers’ matrix.
In other words, due to the hydrophobic nature of the outer mucus, it tends to have significantly
less interactions with hydrophilic materials. Additionally, regulating the electrostatic interactions
between the carriers and the mucus can dramatically facilitate the transition of particles through mucus.
Li et al. incorporated Pluronic F127 (PF127) into the matrix of liposomes to induce hydrophilicity
and nullify the electrostatic charge of the particles, demonstrating considerable improvements in the
mucopenetration and uptake efficiency of the liposomes [91]. Cu et al. reported similar improvements
in terms of the mucopenetration of poly(lactic-co-glycolic)acid (PLGA) nanoparticles by coating them
using PEG, which neutralized the surface charge of the nanoparticles [92].
The other platform employed for penetrating through mucus is the application of mucolytic
enzymes. Muller et al. fabricated nanoparticles made of complexes of poly(acrylic acid) (PAA)
and papain (a mucolytic enzyme) through physical adsorption [93]. They showed that the
enzyme-conjugated particles can reduce the viscosity of fresh mucus by up to 5 times, reflecting the
potential of the system for improved oral bioavailability. Pereira de Sousa implemented a similar study
comparing bromelain (another mucolytic enzyme) with papain for the same purpose [94]. They showed
that the bromelain-modified particles exhibited a significantly enhanced mucopenetration behavior
compared to the papain-conjugated particles (up to a 4-fold increase in mucopenetration compared to
the papain-conjugated particles, and up to a 10-fold increase compared to the blank samples).
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On the other hand, the protective and sticky properties of mucus can be exploited to protect the
digested ingredients and extend their transition time along the GI tract. As a result, mucoadhesive
drug carriers have attracted significant attention [95,96]. For this purpose, cationic hydrogels such
as chitosan have been extensively investigated [97–99]. Recently, Kim et al. derived catechols
from mussels and conjugated it with chitosan to develop a new complex with significantly
better mucoadhesive properties and negligible cytotoxicity compared to chitosan alone [100].
Lectin functionalization has been another strategy employed for the same purpose. The study
implemented by Ertl et al. is one of the first works with this approach, in which they conjugated wheat
germ agglutinin with PLGA MPs and increased their mucoadhesion [101]. The advantage of this new
system is that lectin-conjugated MPs exhibited improved adhesion not only to the mucus but also to
the enterocyte (cell) surfaces, minimizing the problems associated with the short turnover period of
mucus. Additionally, in specific parts of the GI tract where the mucus is not thick enough, this system
can still show improved absorption efficiency.
In the case of anionic MPs, their surfaces have been functionalized with thiol functional
groups to exhibit mucoadhesive properties by forming disulfide bonds with thiol groups existing
in mucins [102–107]. Several studies have confirmed that such chemically-modified MPs show a
significantly longer residence time in the target, acting as potential candidates for the sustained
oral delivery of specific drugs, such as insulin and losartan [96,108]. For instance, Zhang et al.
functionalized Eudragit L100 with thiol groups and confirmed improvement in the absorption and
bioavailability of orally administered insulin compared to the unmodified polymer by monitoring
the blood glucose concentration [108]. However, it should be noted that mucus is constantly secreted
by goblet cells along the GI tract and is subsequently shed and cleared from tissues due to the rapid
turnover of cells. This leads to a very short residence time for the attached agents to reach the
epithelium for absorption (50–270 min) [109,110]. Mucus, with around a two day turnover period,
plays the most significant role as a barrier [111,112]. Hence, sustained delivery using mucoadhesive
particles may not represent the ideal strategy in this regard. In addition to this, it is difficult to model
the real effects of mucus on delivery carriers in vitro due to its changing thickness along the GI tract
and the constant effects of flowing gastric juice [38,67,112]. Since sustained oral delivery itself is a
major challenge, it will be discussed under a separate subsection later in this review.
3.1.3. Tissue (Extracellular Barriers)
The characteristics of the drug molecule will determine its absorption sites and its pathway to
cross through the intestinal epithelial cells in the GI tract. There are two main pathways for the
absorption of oral MPs or drugs: Transcytosis by cells (transcellular route) and diffusion through
the spaces between epithelial cells (paracellular route). Figure 2 schematically represents all the
possible absorption scenarios that a digested molecule may encounter in the intestinal lumen. In the
transcellular pathway, the drug molecules enter the enterocytes by crossing the membrane of the
epithelial cells. The paracellular pathway permits only small hydrophilic molecules to be absorbed,
playing a minor role in drug absorption as it is narrow and only occupies a small area fraction
of the whole epithelium [87]. The principal extracellular biological barrier against oral delivery is
known as tight junctions, which concern the paracellular absorption route for orally administered
agents [113,114].
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Figure 2. Absorption mechanisms through the mucosal layer. Paracellular route to lamina propia and
transcellular route (enterocytes, M-cells, transfection of the epithelial cells, direct absorption through
dendritic cells and active transport).
The transport of MPs or drug molecules through tissue depends on both their chemistry and
their size. Generally, hydrophobic drug molecules, nanoparticles, vesicles and micelles prefer to be
absorbed through transcellular routes due to their large size and chemistry, while hydrophilic small
drug molecules prefer paracellular routes [67,115]. There are also barriers due to the structure of
the cells. At the outer regions of the membrane bilayers, the high molecular density of the polar
head groups of the lipid membranes makes it difficult for the drug molecules to pass through the cell
membranes. Furthermore, after entering the cell membrane, cellular components such as enzymes
may degrade/decompose the drug molecules in the cytosol, decreasing the therapeutic efficiency [89].
Passive diffusion of MPs through intercellular routes is only possible for agents with sizes of up
to a few nanometers (0.5–3 nm), which is too small for the delivery of most drug molecules [116,117].
A notable example of this problem is the poor bioavailability of doxorubicin (DOX), which is attributed
to its limited paracellular absorption in the intestine. Kim et al. developed a medium-sized chain
glyceride-based water-in-oil (W/O) microemulsion system to overcome the paracellular barrier against
DOX intestinal absorption [118]. The improvements in the absorption level of the drug were ascribed
to the lipidic components of the carriers, inducing the paracellular enhancing effects. In addition to the
chemistry of the carriers, there are few absorption enhancing agents that have been used in oral delivery
systems. Sodium N-[8 (2-hydroxylbenzoyl) amino] caprylate (SNAC) is a paracellular permeability
enhancer which has been recently used for clinical trials by Davies et al. [69]. The problem with this
agent is that there is no distinct mechanism identified for its function. Recently, Taverner et al. identified
other peptides (PIP peptides: 250 and 640), which could enhance the paracellular permeability of
insulin through intestinal tissue [119]. They claimed that these peptides can dynamically adjust
endogenous mechanisms, inducing myosin light chains (MLCs), opening the tight junctions and
facilitating paracellular transition, especially for peptide therapeutics. Almansour et al. (in the
same group) studied PIP 640 further and confirmed its stability in the intestinal lumen environment
and explained its functioning mechanism: PIP 640 selectively enhances the MLC-pS19 levels of the
cytoplasm of enterocytes in the epithelial layer [120]. Apart from the recent studies and the progress
made, tight junctions are still one of the main challenges against the absorption of biopharmaceuticals.
The lack of a fundamental understanding of the mechanisms controlling tissue permeability and the
effects of various agents may be one of the principal reasons for this problem.
3.2. Technical Challenges
In addition to biological barriers, oral delivery systems face technical difficulties as well, in terms
of deciding whether to induce new properties addressing biological barriers or to scale up existing
systems for commercial purposes. In this section, most common oral delivery devices, sustained
delivery strategies, solvent-free microencapsulation techniques, co-delivery systems and the challenges
associated with the scaling-up of systems are analyzed.
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3.2.1. Oral Delivery Devices and Materials
The devices developed for oral drug administration may be classified as intestinal patches,
gastrointestinal microneedles and particulate carriers (including micro/nanoparticles, micelles and
liposomes), as illustrated in Figure 3. Intestinal patches are millimeter-sized mucoadhesive blankets
that attach to the inner walls of the GI tract, providing a drug reservoir at the target. These patches
can protect the drug against the harsh environment and luminal loss, improving the bioavailability
of the drug by providing a unidirectional diffusion regime towards the intestinal tissue. They have
been especially attractive for improving the oral bioavailability of drugs and sustained delivery.
Insulin, interferon-α and calcitonin are examples of drugs investigated for delivery using such
devices [121]. As far as intestinal patches are concerned, the mucosal adhesion properties, loading
capacity, release rate and release direction are the main factors to be considered. Mitragotri et al. have
used mucoadhesive polymers, such as Eudragit copolymers or pectin, to prolong the gastric residence
time of devices [122]. They also used impermeable ethyl cellulose sheets to create a unidirectional
release pattern and seal the opposite side of the patches. Shen et al. also showed that incorporation
of drug-loaded microspheres into the patches, instead of direct loading of the drugs, can provide
significantly enhanced control over the release behavior of the drug [123]. Toorisaka et al. developed
a lipophilic formulation (drug-in-oil formulation) to improve the compatibility of the system with
intestinal cell lines and enhance the absorption of insulin [124]. However, their formulation lacked
enough retention time at the target. They later solved this issue by designing a bilayer patch consisting
of a drug-impermeable layer to guarantee a unidirectional drug release regime and a mucoadhesive
layer to prolong the gastro-residence time [125]. The drug-in-oil formulation was also impregnated into
the porous mucoadhesive layer. Although it has been more than two decades since the development
of these oral devices, they have not attracted as much research attention as other designs, such as MPs.
Oral patches are mainly applicable in the initial segments of the duodenum, since solid boluses of
digested food can detach the patch from the lumen wall in later parts of the GI tract, significantly
decreasing the transient time. Even in the duodenal part, the device needs strong bonding/binding
with the mucus to avoid being washed away by gastric juice. Furthermore, the mucus turnover cycle
limits the real application of these devices for sustained delivery.
Figure 3. Schematic illustration of the principle oral vehicles designs.
Intestinal microneedles are the newest design developed as an oral delivery device. Microneedles
were first developed for transdermal delivery (transdermal patches), and their application was
subsequently extended to other administration routes including the vagina, anus and scalp [126].
In 2014, Ma et al. employed microneedles for oral vaccine delivery to the mouth cavity, which was the
first time microneedles were used for oral administration [127]. They investigated the system for the
delivery of two HIV antigens (DNA vaccines and virus-like particles), comparing the induced immune
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response with the response generated by the intramuscular injection of the drugs. They reported
that only orally administered agents showed a stimulated antigen-specific IgA response in saliva.
The limitation of this design is that it could only be employed for delivery to the oral cavity rather than
the GI tract. Traverso et al. in 2015 tried to overcome the biological barriers of the GI tract using orally
ingested microneedles and improved drug bioavailability [128]. They claimed that their device can be
safely excreted from the GI tract. This design is especially promising for the delivery and successful
absorption of large-size biomolecules. Their system demonstrated significant improvements in insulin
bioavailability compared to the subcutaneous administration route. As a newly developed system,
oral microneedles need to be studied considerably more, especially through clinical trials. There are
currently not many investigations on this system.
Spherical carrier designs, including micelles, liposomes and MPs, are the most commonly
studied oral delivery vehicles. Micelles are colloidal carriers (5–100 nm) developed to improve
the aqueous solubility of hydrophobic pharmaceuticals and facilitate their oral delivery. They are
made of amphiphilic molecules, enfolding the hydrophilic ingredients inside their hydrophobic core,
with hydrophilic segments oriented on the outer walls. For instance, Dabholkar et al. developed a
polymeric composition (polyethylene glycol-phosphatidylethanolamine conjugate) and increased the
water solubility of paclitaxel (an anticancer drug) up to 5000 times [129]. Due to their very small average
size (20–80 nm), micelles show spontaneous penetration through the interstitium of various tissues,
improving their permeation efficiency and retention time. Yu et al. developed dual-responsive (pH
and light) micelles to improve the passive tumor targeting of doxorubicin and address tumor resistance
against the drug [130]. The micelles could trigger both deep tumor penetration and cytoplasm drug
release, which in turn considerably improved treatment efficiency. Additionally, they found that the
micelles could prolong the blood circulation cycle of the drug.
In addition to passive penetration, micelles can also help the active penetration of drugs.
Suzuki et al. used cationic micelles (PLGA-b-bPEI-b-PLGA; Mw(PLGA): 36 kDa, Mw(bPEI): 25 kDa) for
the encapsulation of doxorubicin and confirmed up to a 40-fold increase for in vitro drug penetration
into multilayer cell cultures [131]. They claimed that iterative transcytosis via macropinocytosis and
exocytosis are the main mechanisms for the penetration of the cationic micelles into cells. Although
micelles are constantly proving their potential for improving therapeutic efficacy in bench-scale studies,
they have hardly been commercialized. The clinical trials for these delivery devices are limited to
a few cases for parenteral cancer therapies: Doxorubicin and its derivatives. A possible reason for
this may be the safety of the materials, in terms of the physicochemical interactions between the
carriers and mucus in real conditions [132]. On the other hand, liposomes are phospholipid vesicles
(>200 nm) which can encapsulate both hydrophobic drugs in their hydrophobic compartment and
hydrophilic drugs in their inner hydrophilic core. These carriers can be chemically modified through
the immobilization of antibodies on their surfaces for improved target specificity. It should be noted
that antibody-decorated liposomes may suffer from a short life cycle in blood circulation due to their
accumulation in the liver, especially in the absence of sufficient target antigens [133].
MPs are the other common oral delivery architecture. The materials used in oral
microencapsulation systems can be broadly classified into polymers and ceramics. Ceramics are
usually safe materials for delivery applications due to their bio-inert nature. There are various ceramic
materials used for delivery applications, including silica, alumina and calcium phosphate. For instance,
cisplatin, methotrexate and hydrocortisone acetate have been successfully delivered using calcium
phosphate carriers, and silica nanoparticles are dominantly used for chemotherapy [134]. Regarding
the polymers employed for oral delivery, hydrogels are the most attractive structural materials, mainly
due to their controllable chemical composition, tunable mechanical properties, water absorption,
ability for internal material flow, and, above all, their capacity for stimuli-responsivity [135–139].
One of the primary features to control in hydrogels is porosity, since pore size can significantly affect
the mechanical properties, uptake efficiency of extrinsic occupants, water/material flow through the
polymer matrix and swelling ratio of the gel. The larger the mesh size, the easier the transport of
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materials through the structure is, and the higher the swelling ratio. For instance, Torres-Lugo et al.
could regulate the release rate of salmon calcitonin from poly-(methacrylic acid) (PMAA) acid MPs by
up to 50% by controlling the swelling ratio and mesh size of the hydrogel [140].
There are other strategies to increase the porosity of the hydrogel structure to a larger scale
(micron scale) [141–143]. For instance, leaching out the template materials from the structure network
is a common method for making porous materials [144]. Also, the number of crosslinking sites can
be decreased through selective removal of one phase from the gel. Similarly, the aqueous/organic
liquid absorbed inside the gel may be lyophilized, and the volume increase through the freezing
process can create pores inside the polymer matrix [145–147]. The size of the pores created through
this process depends upon the size of the ice crystals formed in the solid state and may range from
nanoscale, by freezing the remaining molecular water contents inside the structure, to microscale
macropores by concentrating the liquid at specific spots [148]. It should be noted that although
removing crosslinking sites considerably affects the mechanical properties and the swelling ratio of
the polymer, the porosity created by the frozen liquid does not change the hydrogel mesh size and
consequently its properties/behavior [143].
In addition to achieving the optimum porosity for delivering small drug molecules, another major
challenge is obtaining macropores for loading large biomolecules and cells into hydrogels [149,150].
If the pores are aligned in well-oriented geometries, the hydrogels can be used for directional cell
growth and the creation of arrays [151]. Also, pore size and geometry define the nutrition transfer rate
and cell migration pattern [152–154]. With all these aspects taken into account, developing methods
for accurate control over the porosity of the hydrogel and size and morphology of pores in polymers
has always been regarded as a main research topic for a range of various applications. France et al.
recently reviewed the major methods developed for creating macroporous hydrogels [143].
3.2.2. Sustained Delivery
Mucoadhesive Carriers
The maintenance of a constant concentration of the drug in the blood stream is a favorable
situation for the great majority of treatment cases [155]. On the other hand, severe fluctuations in
drug concentration can cause serious problems such as toxicity or ineffective treatment, reflecting
the possible negative effects of burst release and the need for sustained delivery approaches [156].
Although sustained delivery can be barely achieved in some administration routes, like transdermal
approaches, oral delivery is known as one of the potential candidates for this goal. Materials developed
for sustained delivery are either positively charged, in order to attach to mucus through electrostatic
binding (e.g., cationic hydrogels made from chitosan), or thiol-functionalized hydrogels, to attach to
the mucin glycoprotein through disulfide bonding [157,158]. Although these approaches have shown
higher levels of attachment to mucus compared to the control samples, these particles can only slightly
increase the delivery time (in the range of a few hours), due to the short turnover cycle of mucus in the
intestine [67,80]. Furthermore, MPs employed for oral delivery are usually made of pH-responsive
polymers, releasing their cargo only at pH values above the pKa of the hydrogel, which is usually
>6 for oral applications. Although the pH in most of the spots of the intestine is usually above 6
inside the lumen (Table 1), which in turn may significantly affect the ionization/swelling/dissolution
of the MPs embedded in the mucus [159]. As such, there are in vivo studies that report intact MPs
made of Eudragit L100/S100 leave the body without releasing their cargo. Notably, mucoadhesion is
sometimes described as increasing the friction between the drugs or the delivery device with the GI
tract walls [160,161]. This approach may also extend the delivery time, however, only in the order of
few hours, which may still not be long enough for many cases [160].
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Recent Gastric-Resident Architectures
Apart from the two approaches already discussed, Traverso and Langer proposed the idea to make
delivery architectures larger than specific gates along the GI tract, which would in turn substantially
increase the retention time of the carrier inside the GI tract and achieve a prolonged delivery regime.
They introduced two potential spots for this scheme: The cavity right before the anus and the pyloric
sphincter (the end part of the stomach) [160]. Extended retention behind the pylorus (~1.5 cm in
diameter) was first implemented by producing expandable structures, where the expanded size would
reach up to more than 2 cm in diameter [162]. However, the original versions of this device were
causing serious problems, such as damaging fractured pieces or causing lumen obstruction, due to the
non-degradable/non-dissociable nature of the materials used, necessitating surgery for removal [163].
In a comprehensive study, Zhang et al. built an elastic foldable O-ring made of various
hydrogels [164]. They controlled the degradation rate and the mechanical properties of the structure
by modifying the chemical composition and adjusting the ratio of the hydrogels, finally encapsulating
it in a degradable capsule. The capsule dissolved in the stomach, leaving the opened O-ring in the
stomach cavity. The drug-loaded segments of the ring degraded gradually and released the drug over
several days [164]. By controlling the degradation rate of the samples, one can tune the release pattern
of the samples. There might be two concerns associated with this new design: (1) If the ring stays in the
stomach, it may block/affect the passage of the digested food through the GI tract. (2) If such structures
reside in the GI tract for a long time, they may cause or help spread adverse effects. As for the first
issue, no negative effect on the stooling pattern was observed in the animals that were experimented
on in the study. Regarding the second concern (the device staying in the stomach for a long time),
this was compared with indigestible food masses trapped inside the GI tract, which do not cause
serious problems unless they grow very large. Although there have been answers to these concerns,
the issue of how to remove the device from the pylorus in the case of toxicity or adverse reaction by
the drug being released needs to be addressed. Also, the possibility that the ring accidentally passes
by the pylorus and enters the intestine lumen remains [160].
3.3. Solvent-Free Microencapsulation
3.3.1. Multiemulsion Systems
MPs have been the main candidates for oral microencapsulation systems [96,165–167]. MPs can be
classified into two main categories: (1) Solid MPs, which are solid polymeric MPs with drug molecules
dispersed in their matrix, and (2) hollow MPs, which are polymeric shells with hollow interior spaces
that accommodate the delivered drug molecules [168,169]. In most of the protocols developed for the
fabrication of MPs, drug molecules are directly involved in the fabrication process of the carrier, leading
to direct contact between the drug molecules and the harsh organic solvents, raising concerns over
drug denaturation, especially for biopharmaceuticals [170]. As such, the development of solvent-free
microencapsulation technologies is of primary importance in drug delivery applications.
Multiemulsion systems (W/O/W and O/W/O) were originally developed to minimize contact
between the drug and solvents, however, the traditional versions of these systems were difficult to
make, control and stabilize, additionally being inefficient in terms of throughput [171–177]. While these
systems minimized the contact between the drug molecules and organic solvents, they were not able
to completely eliminate it due to partial contact at the O/W phase interface. For a wide range of
applications of the emulsion technology, it is important to fully characterize and address the issues
of drug denaturation along the fabrication process of the carriers, such as shear stresses caused by
mechanical agitation or sonication and local temperature increases due to sonication.
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Microfluidic devices were successful in addressing a number of fundamental problems associated
with the emulsion technique: highly uniform MPs with very small polydispersity index and
considerable stability in liquid state emulsion [178,179]. Also, making multi-channel devices with
various geometries is more straightforward and significantly more efficient in terms of minimizing
O/W phase contact. Furthermore, there is no need for sonication or mechanical agitation to stabilize
the emulsion made by microfluidic devices, resolving various problems associated with traditional
emulsification techniques [180]. Due to these advantages, this new approach has attracted considerable
attention for cell encapsulation/delivery. For example, pancreatic islet cells, as one of the most
significant treatments for type 1 diabetes, can be successfully encapsulated and delivered using
microfluidic devices [181]. The size, morphology and loads of the carriers can be controlled by
regulating the flow rate of the phases (flow rate of the continuous phase and infusion rate of
the dispersed phase), the geometry of the channels and nozzles and the concentrations of the
emulsifiers [182]. Although microfluidic devices contributed to advance the emulsion technology,
there are still problems with these systems, including the clogging of channels, attachment of oil
phase/polymer fragments to the channel walls and also O/W contact at the interface [183,184].
As the main challenge against the widespread application of these systems is their low throughput,
this prevents them from being scaled up to commercial extents and entering the pharmaceutical
industry for mass production.
3.3.2. Pored and Hollow Microencapsulation Systems
Another strategy for solvent-free microencapsulation is to employ separate processes for MP
fabrication and drug encapsulation. That is, the drug can be loaded into the MPs in their favorable
environmental conditions after the MP fabrication is complete, minimizing the possibility of drug
denaturation due to the formation of MPs in the presence of the drug [185]. For this aim, several
fabrication methods were previously developed, almost all of which were based on the same idea:
coating solid spheres as templates with the desirable polymer material [186–188]. The templates (solid
cores) were subsequently removed from the inside through either calcination or etching, leaving hollow
polymeric spheres behind as the final product. These methods could hardly be successful due to
the complications associated with diffusional material flow through the solid state polymeric shells.
Since the drug can be loaded only by soaking the particles in a concentrated solution of drug, this method
does not yield satisfactory levels of loading efficiency, limiting its general application [186,189,190].
Hyuk Im et al. proposed an idea to fabricate hollow polymeric microspheres with single surface
pores using a solvent evaporation method [148]. Swollen solid polystyrene particles in organic solvents
were plunged in liquid nitrogen, followed by slow evaporation of the solvent. The solvent would
diffuse into the particles throughout the incubation step and would expand due to freezing, creating a
hollow interior space inside the particles. The evaporation step would also generate surface pores,
allowing for encapsulation of the cargo. It was demonstrated that the surface pores could then be
closed through the thermal treatment of the particles above their glass transition temperature.
More recently, a simplified method of making single pored-MPs was reported by Kumar et al.
based on ultrasonic O/W emulsification [185]. The obtained macropores could be used for the direct
loading of the drugs in their favorable conditions by applying vacuum cycles, and then closed to
protect the drug during transition inside the stomach (Figure 4) [185]. In this method, the surface
pores were sealed through freeze drying, thus eliminating the concern over the possible thermal
denaturation of the biopharmaceuticals during the heat treatment of the MPs. It has been proposed
that the pore closure mechanism is due to polymer-polymer interactions, followed by the removal of
water. This new design was later modified to make larger MPs with larger surface pores, suitable for
the delivery of large biomolecules and cells.
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Figure 4. The schematic sequence of polymeric pored microencapsulation/release behavior.
3.4. Co-Delivery Systems
Although the co-delivery of drugs is not one of the core challenges associated with delivery
systems, the administration of different drugs at the same time can play crucial roles in treatment
efficacy in many cases. Delivering multiple drugs to target different sites at the same time can
significantly reduce treatment time and the risk of failure [191]. Chemotherapy provides an example
of co-delivery and its importance [191–194]. As another example, insulin delivery systems may cause
a drop in the release of insulin due to frequent administration of the drug. The co-delivery of insulin
and cyclic adenosine monophosphate (cAMP) was proposed to enhance the secretion of further insulin
by activating the Ca2+ channels in beta cells of the pancreas [195]. It is thus of importance to develop
co-delivery systems for the encapsulation and delivery of multi-target drugs.
A straightforward solution for co-delivery is the simultaneous administration of different drugs
in separate delivery carriers [196]. Another solution is the concurrent encapsulation of different
drugs in micelles, liposomes or MPs. The implementation of this idea dates back to 2011, when an
anticancer drug (MEK inhibitor PD0325901) and a therapeutic gene (Mcl1-specific siRNA (siMcl1))
were concurrently loaded into N′,N”-dioleylglutamide-containing cationic liposomes [197]. This new
co-delivery strategy exhibited significantly enhanced anticancer activity both in vitro and in vivo.
Cao et al. also simultaneously incorporated adenovirus encoding for murine interleukin-12 (Ad5) and
paclitaxel (PTX) into anionic liposomes and performed in vitro/in vivo analyses, confirming that their
co-delivery system (AL/Ad5/PTX) is an effective platform for treating melanoma [198].
Oral carriers based on SiO2 are also one of the most commonly used delivery vehicles, especially
for co-delivery purposes [192,194,199]. Mesoporous silica nanoparticles (MSNs) and halloysite
nanotubes (HNTs) are the principal examples of SiO2 structures investigated for such applications
(Figure 5). HNTs are naturally forming structures, available in sufficient amounts in North America,
China and New Zealand, making them a valuable candidate material in the pharmaceutical industry by
meeting the requirements for scaling up and commercialization. As opposed to HNTs, MSNs require
a time-consuming and expensive manufacturing process, although they have attracted significantly
more attention as drug carriers compared to HNTs, mostly due to their larger interior space and
higher loading capacity [200]. MSNs are nanoparticles made of silica with high chemical stability,
a porous structure and the ability for surface modification/decoration [199,201]. Contrary to naturally
forming HNTs, MSNs are artificially fabricated using a sol-gel method through the use of surfactants
(Figure 5A). The idea of the addition of surfactants was first proposed by Kresge et al. and then
modified by Inagaki et al. [202,203]. Concisely, hexagonal arrays of surfactant molecules are formed as
micelles in a continuous aqueous phase, with hydrophobic segments in the center and hydrophilic
fragments on the surface. Aluminosilicate is added afterwards to be adsorbed on the surface of the
micelles and form the inorganic walls of the nanoparticles, and the organic core is finally extracted
through thermal treatment. Co-delivery using MSNs has been investigated extensively by many
researchers for the purpose of simultaneously delivering multiple drugs, and at the same time to
minimize the multidrug resistance risk and lower the failure risk of the treatment. As an example,
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Chen et al. designed a co-delivery system for the simultaneous administration of siRNA and DOX,
considerably modified the toxic effects of DOX (by ~132 times) [191].
Figure 5. Oral delivery devices based on silica. (A) Fabrication of mesoporous silica nanoparticles
(MSNs) (adapted with permission from [202]), (B) halloysite nanotube (HNT) microstructure ((i)
schematic representation of a HNT, (ii) transmission electron microscopy (TEM) image and (iii)
scanning electron microscopy (SEM) image).
HNTs are known as nonhazardous, non-degradable and biocompatible materials with no
negative effects on different human cell lines, such as dermal fibroblasts and epithelial cells, making
them favorable carriers for oral delivery, dermal treatments and cosmetics [191,204–206]. Notably,
HNTs may not be suitable candidates for transdermal injections due to their size (0.4 to 1.5 μm
long, which is slightly larger than the optimal length for biosafety, 1 μm). HNTs are spiral sheets
of aluminosilicate kaolin, rolled 15–20 times over a single axis (15 nm inner diameter and 40–60 nm
outer diameter) and have attracted attention as drug carriers, mainly for oral administration, however
(Figure 5B) [200]. The inner and exterior sides of the lumen walls are made of alumina and silica,
respectively. This double-layer structure enables the simultaneous loading of oppositely charged
biomolecules. These are molecules with a negative zeta potential inside the lumen and those with
a positive charge on the outer surface [207]. The outer negative charge can disperse particles in
organic/aqueous environments and allow for further functionalization. The inner diameter of the
lumen is also large enough to encapsulate both small drug molecules and larger macromolecules such
as proteins [208].
To apply HNTs and MSNs to drug delivery systems, it is required to seal their pore gates
using a third material, known as a cap or gate keeper. Stimuli-responsive hydrogels have been
mainly investigated as sealing materials to confer target-specificity to MSNs (Figure 6) [209–213].
Different types of stimuli (i.e., magnetic, light, thermal and pH) have been employed to date for MSN
systems. Stimuli-responsivity in this microencapsulation scheme can be implemented through two
main approaches: (1) Cleavable covalent bonding/crosslinking between the carrier and the drug
in response to stimuli, such as the cleavable bonding at pH values below the plasma pH, and (2)
functionalization of the surface or coating of the channels, which can switch conformation based on the
surrounding properties and stimuli-responsive caps [192]. As an example, doxorubicin was conjugated
to the interior walls of the channels in MSNs through pH-sensitive hydrazine bonds, which can prevent
any untimely release of the drug. That is, upon being taken up into the cell through endocytosis,
the acidic conditions of the endosomal/lysosomal environment can trigger the release of drugs due
to the protonation of the bonding [214]. Another example includes light-responsive MSNs, made by
Mekaru et al. using photoactivated azobenzene, which triggered release upon excitation by an external
source of light [215]. These light-responsive MSNs are among the most common carriers used for
cancer therapies. Magnetic-responsive MSNs later replaced them for the same purpose, since light
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could not penetrate deep enough into the tissue, while magnetic fields could address any kind of tissue
at any desirable depth. Iron oxide was one of the best options for inducing magnetic-responsivity
in MSNs [216,217]. Although these systems were not specifically targeted for oral drug delivery,
they demonstrate the versatile stimuli-responsive properties that can embedded into these materials,
which would be advantageous to oral drug carriers.
Figure 6. Different types of sealing strategies used for stimuli-responsive MSNs.
It should be noted that HNTs have attracted less attention than MSNs, although they are more
readily available. HNTs would mainly be useful for applications requiring a small drug dosage due
to their limited loading efficiency. The inner lumen usually shows about an 8–12% loading capacity,
which can be increased to 30–40% by etching the HNTs in mild acidic environments [200]. Furthermore,
MSNs structures can be modified to provide better control over the release pattern due to their tunable
inner geometry.
3.5. Scaling up and Throughput
The technical challenges discussed so far mainly concern health-related issues. The throughput of
the system, however, is the major challenge associated with the commercial implementation of the
discussed technology. In general, almost all microencapsulation systems and protocols developed for
the fabrication of microcarriers at a lab-scale suffer from low throughput and difficulty in scaling up.
Among the microencapsulation approaches under current investigation, spray drying generally
shows the highest throughput, fastest production rate and greatest ease of operation [218]. However,
the direct contact between the drug molecules (genes, proteins, vaccine, biopharmaceuticals) and the
organic solvents can readily denature/deactivate the drugs. In addition, spraying/dispersing the drug
molecules in hot chambers may easily lead to thermal denaturation, and not all kinds of drugs may
have satisfactory solubility in volatile organic solvents [219]. As a result, there has been a constant
need to develop a universal, scalable drug delivery system without modification of the drugs.
Despite the many advantages emulsion microencapsulation techniques provide, their general
application to drug delivery systems faces major challenges to be overcome. These challenges relate to
problems including yield, polydispersity and sonochemistry. As discussed previously, microfluidic
systems could properly address most of the problems associated with traditional emulsification
methods at the expense of yielding a lower output [220]. Regardless of its geometry, a single
microfluidic channel can yield a throughput of emulsion droplets in the range of 0.1–10 mL/h with a
very narrow size distribution (<5%), while the pharmaceutical industry is looking for much higher
values (above 1 L/h) [221]. Traditional emulsification techniques may show a much higher yield
(100–20,000 L/h) at the expense of the quality of the droplets and polydispersity range [222]. Ofner et al.
proposed a multi-parallel channel microfluidic device to improve the throughput of microfluidic
systems, reporting promising values that would satisfy commercial needs [219]. Tendulkar et al.
implemented the same idea of the parallelization of several channels in a more complex design of
microfluidic devices for the encapsulation of islet cells to treat type 1 diabetes [223]. They included
256
Pharmaceutics 2019, 11, 129
an air jet supply to aid the detachment of the droplets from the T-junction nozzles and increase
the throughput of the system, reporting a 8–64-fold increase in the production rate. Although
multi-channel designs look to be a promising solution for increasing the throughput of MP fabrication,
when comparing with the commercially required flow rates with bench-scale infusion rates from a
single channel, about 1000 channels may be needed for attaining a satisfactory level of throughput.
Nisisako et al. [224] and Conchouso et al. [225], in separate studies, proposed 3D circular arrays of
channels to both minimize the flow rate distribution among the channels and increase the throughput
of the system. These complex microfluidic devices can be made of metal, polymer or glass, and 3D
printing, acid etching and computer numerical control CNC engraving are common practices for
forming the channels [219,221,223–225]. It should be noted that systems’ output in microfluidic devices
is usually reported as the volume produced per minute [220,226], which may not be the ideal way
for reporting the throughput of the system. In this regard, it would be necessary to better evaluate
the performance of the system in terms of what fraction of the volume reported really represents the
MPs produced, and what fraction is due to the contribution of other components of the system (e.g.,
continuous phase or random polymer fragments).
4. Conclusions
Although oral delivery is considered to be the most promising administration route due to its
specific advantages, it faces substantial challenges that need to be addressed before oral systems
can be commercially available for the delivery of biopharmaceuticals. Fabrication protocols of
the carriers should adequately avoid any destructive effect (such as contact with organic solvents,
shear stresses and local temperature increases) on the drug molecules, especially for biopharmaceutical
encapsulation/delivery. Concurrently, the delivery material, design, size and polydispersity must be
accurately controlled, due to their significant influence on treatment efficacy. Oral carriers deal with
various biological barriers (the lumen, mucus and tissue of the GI tract) to successfully deliver drugs.
Sustained delivery, solvent-free microencapsulation and co-delivery have also been major focuses
in oral delivery studies. Nonetheless, the most significant issue against the commercialization of
the oral systems is their low throughput. This review introduced the most promising solutions
recently proposed for each barrier, which point to a positive progress in the field of oral drug
delivery. In addition, the recent solutions proposed for scaling up the microencapsulation techniques,
the parallelization of the microfluidic channels, are both significantly increasing the systems yield and
addressing the other challenges as well. Due to the broadness, as well as the variety of the challenges
against the oral drug delivery systems, we expect several different focuses for future research in this
field. Considering the recent achievements in the case of technological challenges, we believe that
future research in this field will mainly target biological barriers, especially the barriers associated
with tissues. The main advantages of oral delivery systems, include sustained delivery, interaction
with mucus and the capability for solid formulations that preserve pharmaceuticals, still making this
the most attractive administration route for pharmaceuticals.
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Abstract: This review explores the use of energy sources, including ultrasound, magnetic fields,
and external beam radiation, to trigger the delivery of drugs from liposomes in a tumor in a
spatially-specific manner. Each section explores the mechanism(s) of drug release that can be achieved
using liposomes in conjunction with the external trigger. Subsequently, the treatment’s formulation
factors are discussed, highlighting the parameters of both the therapy and the medical device.
Additionally, the pre-clinical and clinical trials of each triggered release method are explored. Lastly,
the advantages and disadvantages, as well as the feasibility and future outlook of each triggered
release method, are discussed.
Keywords: triggered drug release; liposomes; ultrasound; magnetic fields; radiation
1. Introduction
Spatially Specific Liposomal Cancer Therapy Utilizing Medical Devices as Triggering Mechanism
There are many factors that contribute to the successful treatment of cancer and maximize tumor
control. Surgery, chemotherapy, and radiotherapy are used in combination depending on tumor stage
and grade. Molecular interrogation of the tumor highlights therapeutic targets specific to the patient’s
tumor, and treatment options are optimized accordingly [1]. The importance of accurately imaging
changes in the tumor volume and physiological functions has grown in tandem with the increasing
use of targeted therapeutics [2]. Typically, the primary tumor is removed surgically, whenever possible,
followed by adjuvant chemotherapy or radiation therapy. Chemotherapy is generally delivered
systematically to kill cancer cells that may have migrated from the tumor, whereas radiation therapy is
used locally to sterilize the surgical site. Unfortunately, each procedure carries its own adverse effects
and risks; clinicians and patients must weigh the benefits against the risks before proceeding with a
specific treatment regimen. In particular, using cytotoxic agents is associated with many unacceptable
side-effects because these agents are potent cytotoxins that do not differentiate between normal and
malignant cells. Unfortunately, despite efforts to mitigate the side effects, these negative effects can
limit the drug dose that can be used with certain patients or reduce treatment compliance. Maximizing
the anti-cancer activity of cytotoxic agents but minimizing their systemic toxicities, therefore, remains
an important goal in optimizing chemotherapy treatments.
Liposomes have been particularly successful in modulating the biodistribution of cytotoxic drugs
used in cancer treatment. In part, this is due to the versatility and classes of lipids that can be used
to modify their distribution and release characteristics [3,4]. Liposomes are designed to encapsulate
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drugs, minimize drug release in circulation, accumulate at the tumor, and release drug locally when
the bilayer is destabilized. This strategy enables drugs with proven activity to be preferentially
delivered to the tumor site and reduce systemic side effects. However, the challenge is to balance drug
encapsulation and release in a liposome so that the majority of the drug is released in the tumor, and
not while in circulation.
More recently, there is growing interest in using external stimuli to trigger drug release from
liposomes. The concept utilizes lipid carriers that are extremely stable and do not release significant
amounts of drug at normal physiological conditions. However, the liposome would also be designed
to be vulnerable to an external trigger that causes the liposome bilayer to become unstable and
subsequently release its contents. Ideally, the stimuli would be focused on the tumor to ensure that
only liposomes trapped there will release drug. Ultrasound (US) and magnetic fields (MF) used in
magnetic resonance imaging (MRI) are primarily utilized for diagnostic purposes whereas radiation
(RT) is used for imaging and treatment. These sources of external energies are of obvious interest
for triggering drug release as they are already used clinically. The parameters for clinical imaging or
therapy with US, MF, and RT are generally standardized whereas parameters used for drug release can
vary greatly. Nonetheless, it is intriguing to speculate that clinically used parameters for US, MF, and RT
could be modified to release drug from liposomes after imaging or concurrently during radiotherapy.
Using imaging or therapeutic modalities to trigger intratumoral drug release on-command would help
confine drug activity in the tumor and reduce systemic toxicities. However, clinical development of
the strategies described could also open up novel treatments whereby, for example, imaging is used to
confirm the presence of the drug carrier in the disease site before release. Furthermore, RT could be
used to release drugs that potentiate the cell-killing effects of RT within the tumor. The latter strategy
would facilitate drug-RT synergies that kill more cells than the sum of each separate approach. In this




US triggered therapy relies on US waves compromising the integrity of a drug-loaded liposome
to release its payload. By focusing the US transducer on the disease site, the emitted waves disrupt
the bilayers of liposomes present in a defined area to release drug in a spatially-specific manner.
The mechanisms causing drug release from the liposomes depends on the acoustic intensity, pulse
frequency, pressure, duty cycle, and length of treatment. The effect of these parameters on the
mechanism of release will also change depending on the tissue surrounding the drug carrier [5].
For example, tissues such as bone have a high absorption coefficient for acoustic waves and heat up
more rapidly relative to other tissues with a low absorption coefficient [6,7]. Thus, a US treatment
that is appropriate for soft tissue could potentially heat bone to lethal or damaging temperatures. In
US-triggered drug release, acoustic parameters safe for the disease site must be matched to a liposome
formulation that provides the desired mechanism of drug release. In the following section of the
review, the mechanisms of drug release from liposomes using US and a summary of contributions
from early pioneers in the field of US triggered release will be discussed.
2.2. Mechanism of Release
2.2.1. Thermally Induced Release
As US waves are propagated through tissue, the acoustic wave can be reflected, transmitted,
scattered, or absorbed. When absorbed, the acoustic wave energy is transformed into heat; however,
to create localized heat within the area of interest, absorption of the acoustic energy must be greater
than its diffusion [8]. In most cases, local heat can be generated using moderate intensities (several
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W/cm2), high duty cycles (up to 100%), moderate pressures (hundreds of kPa to MPa range), high
frequencies (>0.5 MHz), and long treatment times (minutes to hours) [5]. Focused ultrasound (FUS)
transducers are preferred because they generate heat more specifically, and at deeper tissue depths
than transducers which emit planar, less-focused wave patterns. This helps mitigate heat generation
in non-disease areas and reduce damage to normal tissues. It should be noted that high intensity
frequency ultrasound (HIFU), in the context of drug delivery, can be undesirable as it has the potential
to cause tissue ablation [5,9,10]. Thus, there is interest in using US with temperature sensitive liposomes
(TSLs) that have a Tm higher than physiological temperatures for controlled drug release.
TSLs release their payloads at temperatures near or above their Tm [11]. This is due to
fluidity changes within the liposomal membrane as it transitions from its gel (solid-like) phase to
its liquid-crystalline phase. Within the gel phase, the permeability of the lipid bilayer is orders of
magnitude less than that of the liquid-crystalline phase. The drug, therefore, remains within the
liposome while it circulates throughout the body, and the liposome only releases the drug when
surrounding temperatures rise to, or above, its Tm [12,13].
Pioneers of TSLs, Yatvin et al., explored temperature-sensitive liposomes in the 1970s
which were composed of 1,2-dipalmitoyl-sn-glycerophosphocholine (DPPC, Tm = 41.5 ◦C) and
1,2-distearoyl-sn-glycerophosphocholine (DSPC, Tm = 54.9 ◦C) for temperature-induced neomycin
release in E. coli. Initially, work in temperature-sensitive liposomes displayed relatively slow drug
release kinetics [11]. Despite this limitation, the DPPC DSPC TSL liposomes were tested in an in vivo
subcutaneous Lewis lung tumor model where an implanted thermocouple maintained the temperature
of the tumor at 42 ◦C. Although the authors were able to achieve a higher concentration of methotrexate
(MTX) at the tumor site, confounding variables, such as increased blood flow and increased endothelial
permeability, which occur due to continuous heating, made it unclear whether the increased MTX
concentrations were due to the increased liposome accumulation at the site of the tumor or the
increased liposomal drug release [14]. This study prompted further investigations of TSLs, such as
improving the liposome’s drug release kinetics as well as identifying a method that could heat the
tumor rapidly and locally. Since then, the original thermo-sensitive liposome formulations by Yatvin
have been modified to improve drug release. This was mainly achieved through the alteration of
the liposome’s lipid composition, such as including lysophospholipids, but the same has also been
demonstrated through other methods, such as incorporating leucine-zippers to the membrane of the
liposomes [12,15]. TSLs were later used with US induced heating to trigger drug release, as depicted
in Figure 1, in the 1980s by Tracker and Anderson. It was then that the potential of using US to induce
drug release in TSLs was first recognized due to the astounding 12-fold increase of drug accumulation
at the site of interest under rapid, local US heating [16].
Figure 1. This figure depicts the accumulation of liposomes at the tumor site. Thermally induced
release triggered by US then delivers the liposome’s drug payload.
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2.2.2. Mechanically Induced Release
Mechanical disruption of the liposome occurs via two mechanisms: stable cavitation coupled
with radiation forces (RTFs) and inertial cavitation. Mechanical disruption of liposomes using US,
however, requires the inclusion of compressible gaseous components, such as micelles, microbubbles
(MBs), or liquid perfluorocarbon (PFC) droplets in the liposomal system. During cavitation, naturally
nucleated or man-made gaseous materials contract and expand in response to the compression and
refraction cycle of the acoustic wave. This, in turn, leads to a sustained oscillation of the bubble
(stable cavitation) or to the rapid growth and ultimate collapse of the bubble (inertial cavitation).
The type of cavitation that occurs depends highly upon the amplitude and frequency of the acoustic
wave, as well as the size and material properties of the bubble [17–19]. The mechanical index (MI),
the ratio of the in situ peak negative pressure (PnP) and the square root of the center frequency (Fc),
is a predictor of which process will dominate. Typically, an MI less than 0.8 MPa·MHz−1/2 results
in stable cavitation while a higher MI leads to inertial cavitation [20]. Applications of cavitation not
only include triggered release, as seen in Figure 2, but also include the modulation of blood perfusion,
the permeabilization of the blood brain barrier (BBB), and even the breakdown of clots [21–23]. The
modulation of perfusion and the permeabilization of the BBB allows for the modification of the
nanoparticle’s biodistribution so that it may accumulate preferentially at the tumor and cross the BBB,
respectively [21,24].
Figure 2. Schematic of the mechanisms associated with US that can be used to mechanically destabilize
liposomes. The mechanisms are as follows: (A) US induced stable cavitation of a MB (B) US induced
inertial cavitation of a MB; (B1) The production of a liquid microjets from a MB undergoing inertial
cavitation; (B2) The production of shockwaves from a MB undergoing inertial cavitation; (B3) A MB
collapsing and undergoing sonochemical changes.
Stable Cavitation and Radiation Forces: During stable cavitation, a bubble expands and
contracts about an equilibrium value; the oscillation about the bubble’s radius creates local swirling and
fluid convection, termed micro-streaming, which induces shear stresses in the surrounding fluid [17].
This bubble-induced micro-streaming promotes the extravasation and delivery of circulating agents
to target tissue [25]. Mechanistically, the shear stresses associated with US induced micro-streaming
can rupture and deform liposomes or lyse the cell membrane (Figure 2B). These findings suggest
that micro-streaming plays a pivotal role in drug delivery during instances of stable cavitation [26].
Micro-streaming caused by acoustic waves is a subset of forces, termed RTFs, that occur within the
US field. These forces are able to displace particles and fluids not only via micro-streaming, but also
through bulk streaming [25,27]. Bulk streaming occurs on a macro level where there is bulk, rather
than local, fluid movement in the direction of the propagating acoustic wave. The RTFs generated
via a stably cavitating bubble is highest at the driving frequencies near the microbubble’s resonance
frequency [20,25,26]. This concept has driven the design of the liposome carriers to include bubbles
with a larger radius that will generate greater acoustic forces and require a lower resonance frequency.
These bubbles commonly range in size from 0.8–3 μm [28,29].
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The most prominent drug delivery method, capitalizing on the effects of stable cavitation and
RTFs, is lipid coated microbubbles, also known as gas filled lipospheres. One of the rationales for
this construct was to increase the loading capacity of hydrophobic drugs despite the large size of the
bubbles needed. This, in turn, resulted in the inner membrane of the liposome being replaced with
a layer of oil so that hydrophobic small molecule agents could be dissolved and encapsulated at the
interface between the bubble and lipid layer. This configuration of monolayer lipids is outside of
the scope of this paper and reviews on this subject can be found elsewhere [30]. It should be noted,
however, that many similar applications involving liposomes, such as tumor drug delivery and gene
therapy, and targeted imaging are being pursued in this field [31–36].
Inertial Cavitation: Unlike stable cavitation where bubbles oscillate around an equilibrium point,
bubbles undergoing inertial cavitation oscillate with increasingly large amplitudes. The radius of the
bubble increases until it exceeds a critical limiting value, the bubble resonant radius (BRR), whereupon
it collapses [18]. Inertial cavitation is facilitated by rectified diffusion, a process where liquid vapors
diffuse into the bubble faster than they diffuse out of the bubble. The differential in incoming and
outgoing vapors arises when the bubble’s radius and surface area increase due to the drop in internal
pressure, which favors incoming over outgoing liquid vapors. Rectified diffusion is also affected by
the change in concentration of the vapors in the bubble as the bubble oscillates due to the variation in
the concentration gradient across the gas/liquid interface [18,19]. Factors that impact the resonant size
of a bubble prior to collapse include the type of gas within the bubble, the surrounding medium, and
the properties of the acoustic wave [18,37].
The three potential outcomes of inertial cavitation are (1) sonochemistry, (2) shockwaves, and
(3) liquid microinjections [17,38] (Figure 2B). Sonochemistry is a sudden collapse of the bubble which
generates momentarily high temperatures within the bubble’s core. These temperatures have been
shown to reach 5000 K but last only microseconds due to rapid cooling rates (1010 K/s) [39–41].
A secondary effect of these high temperatures is to generate reactive oxygen (ROS) species in the
surrounding area [42,43]. Sonochemistry, and specifically sonodynamic therapy, was first introduced
by Umemura et al. in 1989 where the synergistic effect of hematoporphyrin and US were observed
during the treatment of both in-vivo and in-vitro tumor models [44]. Extensive work has since been
performed within this field that has subsequently identified the types and levels of ROS produced, and
the impact of the MB concentration, US irradiation time, amplitude, and pressure on the production
of the ROS species [38,43,45–47]. For example, an in vitro study by He et al. used the change in the
absorption and fluorescence spectra of bovine serum albumin (BSA) in the presence and absence of
ROS scavengers to indicate the extent of the ROS induced damage of the protein. In this study, it was
demonstrated that higher bubble concentrations and longer treatment times led to greater protein
damage [45]. Although these effects were studied using proteins, both lipid and membrane damage
has also been reported in the literature [48–50]. One of the most pre-clinically relevant studies, which
gives insights to the parameters that generate the greatest radical production in vivo, was performed
by Prieur et al. in 2015. The lipid-radical byproducts of internal cavitation, malondialdehyde (MDA)
and hydroxyterephthalic acid (HTA), were quantified using varying US fields in freshly excised pig
tissue. Briefly, they found that cavitation related oxidative stress increases with an increasing amount
of bubbles present, treatment exposure time, and peak negative pressure [51]. Additional studies
focusing on mechanically triggered drug release from liposomes will be discussed in the formulation
factors section.
Inertial cavitation is also able to generate shockwaves that can exceed amplitudes of 10,000
atmospheres depending on the size of the bubbles. These shock waves increase the permeability
of membranous structures (sonoporation) [52]. This effect is twofold when using liposomes as
it not only encourages the release of the therapeutic agent from the liposome but also increases
the cell’s uptake of liposomes due to sonoporation [52,53]. Although the shock waves exist only
for a short period of time, i.e., seconds to minutes, they have the ability to form large-spanning
spatio-temporal pressure gradients [52]. Sonoporation has been demonstrated in vitro by Yudina et
273
Pharmaceutics 2019, 11, 125
al. in 2010 where cell impermeable optical chromophores were added to a monolayer of C6 cells
and were subjected to US. Only cells exposed to the US demonstrated fluorescent enhancement and
this increased cell permeability phenomenon persisted even 24 h after exposure to US [54]. In vivo
studies have further validated the presence of sonoporation, including delivering cell impermeable
macromolecules (Bleomycin) to tumors, enhancing small molecule chemotherapy uptake in tumors,
enhancing the blood brain barrier’s permeability to previously poorly permeable chemotherapies, and
delivering genetic material, such as DNA plasmids, siRNA, and pDNA [55–67].
Liquid microjets form in non-uniform environments where bubbles collapse near a surface and
produce high-velocity projections. The velocity of these microjets can reach hundreds of meters per
second and deposit significant energy densities at the site of impact. In doing so, it is thought that the
microjet can penetrate the tissue or generate secondary stress waves in the tissue [37,38,68,69]. One
of the first ever recorded evidence for microjets via US induced cavitation was demonstrated and
characterized by Bowden and Brunton in 1958 and 1961. In this pioneering work, they demonstrated
that (1) the jet velocities of bubbles above a few hundred m/sec acted like solid projectiles, (2) damage
to the surface of impact contained two parts, an irreversible and often erosive deformation and
a secondary shearing and tearing of the surface with subsequent fracturing, and (3) the pressure
generated at impact could be approximated with the liquid density, velocity of the acoustic wave,
and jet velocity [70]. Since then, extensive mathematical and experimental modeling has been
performed [71–74]. In particular, a pivotal paper was released in 1998 by Kodama and Takayama which
not only elucidated how the characteristics of the bubble impacted the microjet produced but also how
the microjets interact and influence excised tissues. Briefly, they identified that the initial radius of the
bubble had a logarithmic correlation to the penetration depth and pit size (i.e., the size of the damaged
area) achieved. They also demonstrated that the liquid jet penetration into the liver induces a shear
force between the hepatocytes, thereby leading to the elongation and splitting of the nuclei [75]. In the
context of cancer, liquid microjets and their secondary shockwaves have been shown to (1) induce
permeability of the cell to enhance chemotherapy uptake, and (2) cause cell death, membrane damage,
and alterations in cellular metabolism [76,77].
Although the three outcomes of inertial cavitation have been discussed separately, identifying the
primary mechanism of drug release is often difficult and it is thought that the therapeutic outcome
results from two or more of the possible consequences of inertial cavitation. For the purposes
of this review, inertial cavitation will be considered as a single entity regardless of the multiple
mechanisms at play.
2.3. Formulation Factors
2.3.1. US Device Factors
As shown in Table 1, treatment parameters that can vary during treatment include (1) acoustic
amplitude, (2) acoustic frequency, (3) duty factor, (4) pressure, and (5) treatment time. Often, varying
one parameter will change the influence of another parameter on the type of triggered therapy
achieved. An example of this was portrayed in Section 2.2 when describing the pressure and
frequency parameters that would predict either stable or inertial cavitation. Table 1 also describes the
common parameters used to achieve in vivo triggered release via the different mechanisms described
in this review.
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Low to Moderate (a few
hundred mW/cm2 or less) [78]
Low to Moderate (a few





Low to Moderate Frequencies
(1 MHz or less) [51,78]
Low to Moderate Frequencies
(1 MHz or less) [51,78]
Duty Factor High duty cycles(up to 100%) [5]
Low duty cycles
(as low as 1%) [51,78]
Low duty cycles
(as low as 1%) [51,78]
Pressure Moderate Pressure(100’s of kPa to MPa) [5]
Low Pressure
(below 500 kPa) [79]
Moderate Pressure




(minutes to hours) [5]
Short treatment times
(a few minutes or below) [51]
Short treatment times
(a few minutes or below) [51]
Examples of detailed in vivo parameters can be seen in Table 2. Experimental, in-vitro tests
and mathematical modeling have been performed to determine how US parameters impact drug
release from liposomes [80]. Cavitation induced release will be discussed first, followed by thermal
triggered release. Briefly, Schroeder et al. demonstrated that clinically approved liposomes, including
Doxil®, StealthTM Cisplatin, and methylpredinisolone hemisuccinate (MPS), when delivered under
low frequency US (20 kHz), had a strong positive correlation of the % drug released with higher
acoustic amplitudes (up to 7 W/cm2) and irradiation time (up to 180 s). The impact of the increasing
amplitudes continued with no maximal value achieved, while the irradiation time began to level off
after 120 s of exposure. Additionally, the duty cycle, whether it be pulsed (<100%) or continuous
(100%), had no impact on the % of drug released. It should be noted, however, that these experiments
were performed in a glass scintillation vial with an immersed US probe [81]. Due to this experimental
setup, the pressure was not varied or made to mimic conditions of the body, such as that found in the
capillary vessels. A later study by Afadzi tested similar parameters in an insonication chamber on
liposomes composed of 52 mol% DEPC, 5 mol% DSPC, 8 mol% DSPE-PEG, and 35 mol% cholesterol.
Similar to Schroeder, they identified a positive correlation using low frequency US (300 kHz) between
the % drug released and higher acoustic frequencies, with maximal release at 10 W/m2, as well as a
logarithmic correlation with exposure time. Contrary to Schroeder et al., however, they identified a
positive correlation between the % drug released and the duty cycle (MI 2.4, 1.3 MPa, 180 s exposure,
duty cycle ranged from 0–20%) [82]. This contrary finding could have been due to the % of duty cycles
used. Further studies using a larger range of duty cycles should be performed.
Other US factors that can impact drug release include the (1) pulse duration (PD, i.e., the number of
cycles multiplied by the inverse of the frequency), (2) pulse repetition frequency (PRF, i.e., the number
of pulses per second), and (3) number of acoustic cycles (i.e., the number of acoustic oscillations per
US pulse). Often, these parameters will not be specified, as they are related to the parameters in Table 1.
For example, the duty factor and the PFR are directly related. Additionally, the PD is equivalent to
the number of cycles multiplied by the inverse of the frequency. Therefore, because these factors are
related to the initial five stated parameters, they will be covered only briefly in this review.
In the same study by Afadzi as described above, the % of drug release was also positively
correlated with the PD and PRF [82]. A later study in 2016 by Lin et al. explored PD, PnP, and PRF in
the context of the type and magnitude of cavitation induced. Here, they discovered that the onset of
both stable and inertial cavitation exhibited a strong dependence on the PnP and PD and a relatively
weak dependence on the PRF. Moreover, the amount of stable and inertial cavitation varied with
the PRP. The amount of stable cavitation initially increased with increasing PnP until the pressure
reached 0.5 MPa, where it rapidly decreased. By contrast, the amount of inertial cavitation recorded
continuously increased with increasing PnP. Lastly, both PRF and PD positively correlated with both
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stable and inertial cavitation [83]. Another variable that was not previously discussed is the number of
acoustic cycles applied. A paper by Mannaris and Averkiou identified the influence of the number of
acoustic cycles applied on the microbubble by suspending the bubble in an enclosure that resembled
capillaries. When applying the same acoustic parameters to a bubble (PRF = 100 Hz; f = 1 MHz)
with an MI of 0.4, they found that increasing the number of cycles from 200 cycles to 1000 cycles had
minimal effects on when the bubbles experienced inertial cavitation; this was likely caused by the high
acoustic pressure used in the experiment. The authors speculate that the number of cycles could have
a greater impact on the bubble’s oscillation when exposed to nondestructive pressures [84]. However,
it should also be noted that specific parameters of the experiment, such as the presence and size of the
bubble used, will also impact the parameters utilized with the US device [28,29].
When considering heat induced release, many of the US parameters are limited by physiological
factors. For example, although higher temperatures can be achieved with greater pressures, such
as between 2–3 MPa at 1 MHz, kidney and lung hemorrhaging begin to appear at 3–5 MPa and
2 MPa respectively and can, therefore, not be achieved safely in vivo [85–87]. Additionally, the
treatment time is dependent on the biology of the tumor and can range drastically based on the volume
and location of the tumor tissue. Small, superficial tumors will take a fraction of the time to heat
(approximately 1 h) relative to deep lying larger tumors (can be more than 6 h based on size and
location) [88]. The influence of the acoustic amplitude, also known as intensity, with respect to the
heating of tissue was mathematically derived by Pierce in 1981. Put simply, the power deposited
per unit volume of tissue was found to equal two times the local acoustic intensity multiplied by the
absorption coefficient of the tissue [7]. Therefore, higher intensities would lead to a greater energy
deposition, and thus, a greater generation of heat. Reviews that detail the mathematical modeling of
heat transfer and heat deposition using US can be found elsewhere [20]. The high intensities necessary
to heat tissues is reflected in the first two preclinical trials listed in Table 2. Lastly, the duty cycle
will influence how often the tissue is exposed to these high intensity US waves. The higher the duty
cycle, the more energy deposition there is with the highest being a continuous wave (100% duty
cycle) [87]. The duty cycle used will often reflect the amount of heat necessary at the site of the tumor.
For instance, using a continuous exposure can result in the thermal ablation of tissue (>60 ◦C) while a
pulsed exposure can achieve mild hyperthermia (37–45 ◦C) [89]. Controlling the energy deposition
in vivo, whether it be through the intensity of the US wave and/or the duty cycle used, is critical as
vascular damage is suggested to appear at a local energy density of 0.3 mJ/mm2 [90].
2.3.2. Liposomal Factors
The major liposomal factors that contribute to the liposome’s response to US include
(1) the liposome’s composition, and (2) the physical state of the liposome’s bilayer.
The liposome’s composition can be further broken down into three categories: (a) the presence
of thermo-sensitive lipids, such as 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or
1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), (b) the presence of surface-active
molecules, such as detergents, and (c) the presence of cholesterol and polyethylene glycol (PEG).
In a paper studying the impact of thermosensitive lipids on TSLs, Needham et al. identified that
MPPC and DMPC lipid-containing liposomes, which lower the phase Tm, enabled enhanced drug
release by local hyperthermia. The enhanced drug release at the liposome’s Tm was thought to
occur due to the coexistence of the gel and liquid phase domains within the membrane. At the
boundary regions between the two domains, a mismatch in molecular packing would occur, thereby
facilitating the enhanced drug release. This phenomenon would be further enhanced by kinetically
trapped MPPC lipids in the solid phase which, upon the gel-liquid crystalline phase transition, would
leave the bilayer and enhance the permeability. In vitro findings by Needham et al. were later
translated in vivo, and demonstrated significantly reduced tumor growth using Dox TSLs relative to
the free Dox and a non-temperature sensitive Dox-containing liposome formulation [91]. Introducing
structural irregularities within the membrane to disrupt the packing of the acyl chains is also the
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mechanism behind the increased drug release when introducing other unsaturated phospholipids.
This hypothesis was tested by Huang and McDonald who showed that incorporating unsaturated
diheptanoylphosphatidyl-choline (DHPC) into liposomes increased the release of encapsulated calcein
upon US irradiation [92]. Surfactants, such as Triton and Tween, are also thought to destabilize the
lipid bilayer. Indeed, a study involving two Triton and two Tween detergents showed a dramatically
increased susceptibility of liposomes to US irradiation at concentrations that caused no observable
increase in permeability in the absence of US [93]. Additionally, it was demonstrated that in
cholesterol-free liposomes, Pluronic P105 sensitized liposomes to US irradiation when it was either in
the presence of or directly incorporated with liposomes. The observed 10-fold increase in dye release,
however, disappeared once cholesterol was incorporated into the lipid bilayer. This suggests that
cholesterol has a protective effect between the interaction of Pluronic P105 and the lipid bilayer [94].
Interestingly, it was later demonstrated that increasing the cholesterol present in the lipid bilayer had
a minimal but still statistically significant impact on dye release [95]. Lastly, the addition of PEG
moieties will be discussed. While there are different methods of incorporating PEG into liposomal
samples, such as the addition of PEG micelles or free PEG to the sample, PEGs covalently linked to
phospholipids (PEG-lipids) and incorporated in the liposome’s bilayer will solely be discussed due
to their clinical relevance. The effect of the PEG length and molar ratios of PEG-lipids was studied
using low frequency US (LFUS) by Lin and Thomas. Briefly, they identified that the length of the
PEG (PEG350-DPPE and PEG2000-DPPE) had no impact on the amount of dye released when using
concentrations below a mole ratio of 0.1 PEG-lipid to PC were utilized [93,94]. The influence of the PEG
length on liposomal release only occurred when high molar ratios of PEG-lipid, above 0.1 PEG-lipid to
PC, were used. These studies demonstrated that a shorter PEG length at high molar ratios yielded
higher levels of dye release than a longer PEG length at high molar ratios [93]. It was speculated
that this phenomenon occurred in part due to the acoustic absorption of PEG moieties as well as the
potential of shorter PEGs hindering the resolution of deformities in the liposomal bilayers [93,96].
More research is required to confirm the mechanism behind this observation.
It should be noted that the above studies utilized liposomes primarily comprised of
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), DPPC, or egg phosphocholine (egg PC). Recent
studies have explored replacing the major lipid constituent with dioleoylphosphatidylethanolamine (DOPE)
in order to create a sonosensitive liposomes. A study by Evjen et al. demonstrated a 30% increase in Dox
release using DOPE liposomes compared to liposomes comprising DSPE, and a 9-fold improvement in
release extent when compared to L-α-phosphatidylcholine (HSPC) pegylated liposome when irradiating
with US for 6 min at 40 kHz [97]. When investigating the interaction of the physical state of the liposome’s
bilayer and US, Dunn and Tata and Maynard et al. identified enhanced US absorbance at the DMPC and
DPPC liposome’s Tm. Briefly, they subjected liposomes comprised of DMPC or DPPC to 1.42 and 2.11 MHz
US, respectively, and recorded the ultrasonic absorption and velocity of the samples. Enhanced ultrasonic
absorbance only occurred at the phase Tm; below the phase transition, it was observed that US was hardly
absorbed by the membrane [98,99]. These findings suggest that, when working at temperatures below the
phase transition of the liposome, the mechanism of release is independent of the liposome’s absorbance of
US but is dependent on the local cavitation and RTFs as well as heating of the surrounding tissue.
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2.4. Future Perspectives
US is an emerging technology with the potential to be incorporated in the clinic for triggered
delivery of liposomal drugs. As seen in Table 2, only the thermal release mechanism has proceeded to
clinical trials at the time of writing of this review. This is in part due to the fact that US induced heating,
such as HIFU, has already undergone multiple Phase II and III clinical trials and is currently in clinical
practice in China [100]. Additionally, the safety of HIFU has been well documented experimentally
in vivo and in patients. It was of initial concern that inertial cavitation and the shear forces produced
using US would increase the cancer cell’s ability to dissociate from the primary tumor and form a
metastatic site at a distal location. This, however, was found not to be the case as HIFU treatment
did not increase the number of metastatic sites nor the number of circulating tumor cells [89,101].
In fact, HIFU has demonstrated such promise that it may one day serve as an alternative to the
surgical resection of tumors. It has been well documented that when primary malignant tumors
are surgically resected, their distal metastases begin to rapidly progress. Although there are many
proposed mechanisms, such as the secretion of growth factors in response to the surgery or a shift in
the pro- and anti-angiogenic factors secreted from the tumor itself, the best understood mechanism for
this phenomenon thus far is the suppression of the immune system. Recent studies have suggested that
HIFU can enhance cancer-specific immunity after treatment. Specifically, HIFU is thought to enhance
the T cell-mediated immune response [102,103]. Currently, the prevailing two mechanisms are (1) that
the ablated tumor tissue acts as an antigen source for the generation of antitumor immunity and (2) that
HIFU enhances the release of heat-shock proteins which can then stimulate cytotoxic T-cells [103–106].
Thus far the benefits of HIFU have been described but an important clinical consideration is the safety
and side effect profile of the treatment. The most frequently occurring adverse events are moderate
pain, with approximately <15% of patients experiencing this symptom, followed by transient fever and
skin toxicities [107–110]. Interestingly, the Phase I clinical trials using mild hyperthermia for liposomal
drug release (TARDOX and DIGNITY) reported either no adverse events or a low prevalence of grade
3–4 adverse events respectively. [111–113] This was likely due to the parameters used as the recorded
level of tumor heating was found to be 40 ◦C rather than the 60 ◦C needed for tissue ablation [112,113].
Another advantage of US that was not discussed previously, but that is prevalent in these clinical
trials, is the ability of the US treatments to be administered in a single treatment session rather than
in multiple sessions as seen in radiotherapy. [111–113] While US does have obvious advantages as
a treatment method, such as being minimally invasive and displaying a low adverse effect profile,
there are some limitations to the technology. Specifically, there are three major disadvantages of US
as a treatment method. The first is the inability of US to penetrate air-filled viscera. This will limit
the ability of US to be utilized with tumors located in areas such as the lungs, intestines, or bladder.
The second disadvantage also involves the tumor’s location, particularly if there is no acoustic window
for the US to reach the tissue of interest. For example, if there is a structure obscuring the tumor with a
high absorption coefficient, such as bone, the acoustic wave may be unable to reach its intended target.
The third major disadvantage to US is the long treatment times discussed in Section 2.3.1 [88]. Despite
these limitations, the results of the clinical trials thus far and the benefits seen in HIFU treatment
highlight the potential of combining liposomal triggered release, in conjunction with either mild or
moderate hyperthermia, as a promising option for cancer treatment. While mechanically triggered
release has shown promising results preclinically, more research is required to better evaluate this
mechanism of release as an alternative option for cancer treatment.
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3. Magnetism for Triggered Drug Release
3.1. Introduction
MFs are an attractive way to release drugs from liposomes due to the technique’s non-invasiveness,
absence of ionizing radiation, and physiologically benign field frequencies and amplitudes [123]. In the
clinical management of cancer, MFs are used primarily with contrast agents to diagnose and stage
tumors. The technique is commonly used in cases where the tumor is made of softer tissue, as MRI
scans provide images that enhance soft tissue contrast [124]. Aside from MRI, one of the best-known
uses of magnetism in cancer is alternating magnetic field (AMF) induced hyperthermia. AMFs are
characterized by rapid and regular changes in the MF’s direction. Radiofrequency (low frequency
AMFs) can penetrate deep into the body unhindered. However, high frequency, high amplitude
AMFs will induce electric currents in tissue and can raise bulk tissue temperatures to lethal limits
because of the tissue’s resistance to electrical currents. If lethal temperatures are reached (>42 ◦C),
the heat-induced damage to cancer cells cannot be repaired and the cells die [125]. Unfortunately, the
effects of AMFs are not specific to malignant tissue and the surrounding normal tissue in the field
may also be damaged, thereby limiting the maximum frequency and amplitude of AMFs that can
be safely used in humans. Currently, there is no consensus on the safety limits for AMFs, but AMFs
of 100 kHz and amplitude <10 kA/m have been used safely in clinical trials [126,127]. Additionally,
the penetration depth and safety profile of low energy AMFs are advantageous when compared to
other external triggers for activating nanomaterials, such as light or X-rays, which are limited by their
shallow penetration depths and ionizing damage to normal tissue, respectively. [128].
The heat generated by magnetic nanoparticles (MNPs) upon application of AMFs has been
used to raise the bulk temperatures of malignant tissue to lethal limits in a process called magnetic
hyperthermia [129]. The bulk heating of tissue with magnetic hyperthermia has also been used to
release drug from nano-composites, liposomes, polymers lipid structures, or cyclodextrin conjugated to
MNPs [130–137]. In the following section of the review, the use of MFs to disrupt liposomes associated
with MNPs, by either inducing heat or by mechanical motion to cause the release of their payload, will
be discussed (Figure 3).
Figure 3. Schematic of the mechanisms associated with MR that can be used to destabilize liposomes.
The mechanisms are: (A) MR induced mechanical disruption; (B) MR induced hyperthermia.
3.2. Delivery Using Heating and Mechanical Motion
In the field of temperature induced drug delivery, liposomes have been used to deliver drugs
to tumors by taking advantage of the slightly elevated temperatures in malignant tissue. With a
Tm only a few degrees above physiological temperatures, these liposomes were able to release their
encapsulated drugs within the malignant tissue [138]. However, due to the liposome’s Tm, these TSLs
did not prevent drug loss as the liposomes circulated throughout the body. To circumvent the issue of
nonspecific drug release, liposomes with Tms significantly higher than normal tissue temperatures
were subsequently used in conjunction with tissue heating. Drug release would, therefore, not be
triggered by normal body temperatures until they reached the disease site where temperatures were
increased past the liposome’s Tm with induced hyperthermia. Tissue hyperthermia can be induced
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in various ways, including the use of US (as seen previously in Section 2.2.1) and, in some cases,
magnetism—particularly MFs interacting with liposomes and magnetic particles (MPs) [139–141].
Using MNPs in the tumor to potentiate the tissue heating effects of AMFs can raise tissue
temperatures at lower magnetic frequencies and amplitudes that spare normal tissue from
damage [127]. The incorporation of MNPs within the liposome itself has the potential to limit
AMF-induced heating to within the drug carrier so that bulk heating of the tissue is unnecessary.
A study demonstrated selective hypothermia in vivo and in vitro using magnetoliposomes under
a low-frequency AMF to promote lipid membrane permeability from local heating. However,
the relatively high heating of the composite particles led to concerns of overheating normal body
tissues [142]. In order to overcome injury to healthy tissues caused by the overheating of the particles,
other groups embedded the MNPs within the drug carrier to minimize heating of the tissue directly
for their drug release studies. For example, Amstad et al. encapsulated iron oxide particles (IOPs)
within liposomes and succeeded in controlling the timing of release by increasing the permeability of
the liposomes without destroying them [143]. They concluded that AMF-induced heat was confined to
the liposomes and subsequently spared normal tissue. Similarly, another study triggered the release of
carboxyfluorescein from TSLs containing IOPs through AMF induced local heating [144].
Disrupting a liposome’s lipid bilayer by local heating using encapsulated MNPs (magnetic fluid
hyperthermia) to release drugs is common, but efforts to mechanically disrupt the bilayer with MFs
have also been made. Most work investigating drug release by mechanical means have been done with
MNPs located within the lipid bilayer. In an article studying the toxicity effects on cells, Kim et al. used
microdiscs that oscillated when an alternating magnetic force is applied. Cell membrane integrity was
compromised partly due to the oscillating microdiscs attached to the cell surface; therefore, it is not
inconceivable that liposomal membranes containing MPs under the field would also be disrupted [145].
Drug release has also been observed from magnetoliposomes due to the mechanical vibrations of the
IOPs [146]. Furthermore, the rotation of IOPs, induced through a dynamic magnetic field (DMF), can
injure cell membranes. In contrast to using AMFs, DMF uses lower frequency parameters that cause
unique rotations of individual particles around their own axes. This produces rotational shear forces
that lower membrane integrity, without thermal effects [147]. Mechanical disruption of the membrane
can also be achieved with pulses of an MF, as opposed to an alternating one. In this study, the authors
showed drug release from liposomes after treatment with short magnetic pulses that disrupted the
lipid bilayer. They further concluded that drug release from mechanical disruption of the liposomes
was less harmful to the drug payload as an increase in temperature could potentially damage the
drug [148].
3.3. Mechanisms of Release
The inherent magnetism of MNPs distinguishes them from other types of particles. MNPs behave
as a single magnetic moment with an absolute value several orders of magnitude higher than that of
single atoms, and can be remotely actuated or detected by an MF [149]. When MNPs are exposed to
AMFs, their magnetic moments move to align with the field direction, but ‘relax’ or rotate back to their
original alignment when the field is removed. The realignment or ‘relaxation’ of the magnetic moment
represents a net energy loss that is released as heat. The MNP can physically rotate in the tissue
and release heat into the surrounding tissue (Brownian relaxation), or the MNP remains stationary
while its internal magnetic moment rotates with the field and releases heat at the surface of the MNP
(Néel relaxation) [150]. Under the action of AMFs, this process happens many times, causing significant
increases in temperature [151]. The amount of heat released by MNPs depends on the core magnetic
material, the hydrodynamic diameter and shape of the particle, and the frequency and amplitude of the
AMFs [152]. Brownian relaxation forms the basis for heating up bulk tissue in magnetic hyperthermia
and the subsequent release of drug from TSLs. In contrast, Néel relaxation is thought to have less
impact on the surrounding tissue; reports indicate that temperatures >40 ◦C have been estimated at
MNP surfaces when subjected to AMFs, but that the temperature gradients between MNPs and their
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surroundings fall off very steeply [153,154]. The use of magnetic nanoparticles that undergo Néel
relaxation for local heating of the lipid bilayer with AMFs benign to normal tissue would alleviate
unintended heating of normal tissue.
MNPs can also behave as nanomagnets that align themselves to the plane of an MF, and this
alignment can also be used to kill cancer cells. When the field is rotated or changes its direction, the
particles move along with the field. Studies in which the particles are attached to cell membranes
indicate that the particles can create mechanical forces strong enough to rupture the cell and cause cell
death [155,156].
3.4. Formulation Factors
MNP induced liposomal drug release relies on both the properties of the MNP as well as the
liposome. These components, therefore, allow for a range of conditions that can be tuned to change the
release characteristics of the delivery system. The three main parameters that can be modified for drug
release include (1) the MF’s frequency and amplitude, (2) the composition of the lipid bilayer, and (3)
the properties of the MNP such as the shape, size and composition. The tunability of these parameters
are important and must be considered when developing delivery systems that are biocompatible and
only release drug at the disease site in response to a magnetic field.
The properties of the MF are important when considering the thermal or mechanical disruption of
the liposome for drug release [148,157]. The frequency of the MF is perhaps the factor most commonly
changed, and a range of AMF frequencies have been used in studies for drug release, with higher
frequencies leading to the higher motion of the nanoparticles as well as local heat production. This is
also true of the strength of the field [158]. MFs can generate enough heat to irreversibly damage tumor
cells yet may also damage healthy tissue at very high strengths. The suggested safe range for strength
and frequency is up to 37 kA/m and 500 kHz [159]. Alternatively, pulses of strong MFs can be used to
disrupt the lipid bilayer by using the motion of the nanoparticles, as opposed to generated heat [148].
Lipid bilayers used in drug delivery vary greatly in composition, due to the vast selection of
fatty acids available for liposome production. To ensure that the liposomes destabilize at the proper
temperature and release their drug payload, it is important to choose bilayer components carefully.
Pradhan et al. used a liposomal formulation of DPPC:cholesterol:DSPE-PEG2000:DSPE-PEG2000-Folate at
an 80:20:4.5:0.5 molar ratio in a delivery system containing MNPs. Their experiment demonstrated
a significant release of the drug payload when exposed to an MF that increase the temperature a
few degrees above ambient body temperature [160]. Peller et al. also used a DPPC, DSPC, and
1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2) liposome (Tm~43 ◦C) at a molar ratio of 50:20:30,
respectively, for their TSLs in a magnetic hyperthermia study observing drug release using MRI markers.
Here, they were able to successfully target drug delivery using temperature control [161].
MNPs can have an infinite number of formulations, with options including, but not limited to,
their size, shape and composition. Generally, their size ranges from 1 to 100 nm in diameter [162].
These particles are commonly made from multiple elements including iron, cobalt, nickel and platinum.
MPs are mainly classified based on their structure between magnetic alloy particles and magnetic
metal oxide particles, the latter of which is used in drug delivery [163]. Metal oxides, particularly iron
oxides, have already been seen as a promising candidate in magnetic hyperthermia, demonstrating
abilities to kill cells locally through magnetically induced heating [129]. The properties of the IOPs
impact the efficiency of these particles to confer heating to their immediate environments. For example,
there is an increase in the specific absorption rate (SAR), the rate at which radiofrequency energy is
absorbed, when nanorods are used compared to spherical and cubic forms due to their 1-dimensional
nature. SAR is an important aspect to triggering the release of drugs as a higher absorption rate equates
to particles heating up more as a certain amount of energy is applied. Therefore, lower energies and
fewer particles are needed within the tissues for drug release. Das et al. found that the SAR can be
changed by adjusting the aspect ratio of nanorods; higher aspect ratio of nanoparticles resulted in
higher SAR values [164]. Furthermore, the ellipsoidal shape of magnetic nanorods can influence two
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effects when in an AMF; extra heat is released compared to nanospheres due to shape anisotropy
and the nanorods dynamically reorient to the field [165]. These two properties are important as the
former equates to extra heat release efficiency meaning fewer particles and lower field intensities are
required during hyperthermia treatments, while the latter effect could be used to develop nanorobots
in magnetic hyperthermia through controlled motion and orientation. The hyperthermic efficiency
of nanorods, relative to their cubic and spherical counterparts of similar magnetic volumes, was
further confirmed elsewhere. One study also compared the heating efficiency of nanospheres versus
deformed cubes (orthopods) ranging from 17–47 nm. Throughout this size range, orthopods had a
higher heating capacity and changing the size and shape of these particles changes the SAR [166].
Additonally, iron oxide nano-octopods were found to have better heating efficiency as compared to
spheres [167]. Another factor that can impact the SAR of the NPs is their composition. A 2018 paper
by Espinosa et al. compared the SAR values of maghemite-based IONPs (Fe3O4) and cobalt ferrite
NPs (CoFe2O4) at clinically relevant settings (470 kHz) and found a small, but statistically significant,
increase in SAR using CoFe2O4 NPs [168]. While other compositions have been studied, including
MnFe2O4 and NiFe2O4, another factor that has been suggested to impact the IONP’s SAR value is the
iron oxide’s oxidation state [169]. Overall, these experiments demonstrate that the heating efficiencies
of MNPs can be modulated by the MNP’s shape, size, and composition.
3.5. Future Perspectives
Using MFs as a release trigger is relatively new. The use of AMFs and IOPs encapsulated within
liposomes has not yet been examined in clinical trials. Using MNPs in conjunction with thermosensitive
liposomes for triggered release is a promising modality for cancer treatment. Some challenges, however,
remain in the clinical application of these systems. One of the most pressing is determining the optimal
MF parameters that maximize targeted heating of tissue or particles without damage to healthy cells.
In this case, using MNPs to potentiate the heating effects of the MF are an advantage. Increasing MF
strength may increase the SAR or heating potential of injected MPs, but too high of a field strength
would lead to non-specific heating of the tissues [126]. Because of this, there has been much interest in
producing MNPs with superior SAR values [164].
It is important to understand the toxicity, biocompatibility, and biodistribution of MNPs when
using them in a triggering system. The biocompatibility of MNPs is linked to both the immune
system response following its administration and to the intrinsic toxicity of the MNP and/or of its
biodegradation metabolites. Factors that can influence the MNP’s toxicity include their surface coating,
size, and surface charge. Typically, toxicities can be avoided using compatible coatings (such as PEG
and starches), small sizes (within the nanoparticle range) with appropriate doses, and nearly neutral
charges (+/−10 mV). The chemical composition of MNPs also plays a role in their toxicity. IOPs,
for example, have been found to be safe at high doses (100 s to 1000 s of mg/kg) via oral, intravenous,
intraperitoneal, and subcutaneous administration. Once IOPs are injected, the IOPs are exposed to
opsonization and accumulate in macrophages of the reticuloendothelial system. This includes organs
such as the liver, spleen, and bone marrow. Despite this accumulation, major toxic side effects are rare
as cells are able to incorporate the iron from the IOPs into their endogenous iron metabolism. If an
iron overload does occur, however, the tissues may experience oxidative stress and injury to their cell
membrane [149]. Cellular iron overload is rare but can be overcome by changing the biodistribution
of IOPs through their magnetic properties. This allows the MNPs, via an external MF, to be guided
to the site of interest [170–173]. Although MNPs may accumulate in tissues that are not of interest in
the absence of guiding MFs, there seems to be promise in the sequestering capabilities of the particles
in the context of cancer. One study done on fibrosarcoma tumor bearing mice looked at a novel
formulation of co-encapsulated La0.75Sr0.25MnO3 and IOPs that, under hyperthermia, resulted in
tumor reduction by up to 3.6 fold, with little to no drainage of the particles to other organs in the
body [140]. Future prospects of utilizing MNPs in conjunction with liposomes is promising as both
components have been clinically approved as single agents (such as Doxil®, ThermoDox®, Caelyx®
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Feraheme®, Feridex®, Gastromark®, etc.). There is potential for developing MPs as agents that react
to hyperthermia and release liposome encapsulated drugs on-demand. At present, however, most
studies are pre-clinical and much work remains to identify specific applications that take advantage of
their unique, synergistic properties for clinical use.
4. X-ray Radiation
4.1. Introduction
Radiation therapy is one of the most effective modes of cancer treatment given the recent
advancements in defining the spatial precision and depth penetration of ionizing radiation. More than
50% of all cancer patients receive radiotherapy over the course of their treatment with a curative or
palliative intent [174]. By irradiating tumors with high energy photons or ion beams, cancer cells and
the surrounding vasculature are irreparably damaged leading to tumor death [175,176]. Although
radiotherapy is non-specific and can damage healthy tissue along the path of the photons, it remains
the major course of treatment for primary non-metastasized solid tumors [174,177]. Concurrent RT
and chemotherapy are also used in cancer treatment, particularly for unresectable tumors. Clinically,
head and neck cancer patients with unresectable disease are treated with concurrent RT and cisplatin
(CPT) to take advantage of drug-X-ray synergies for tumor control [178,179]. Unfortunately, in
many patients, the systemic toxicity of CPT (hearing loss, kidney and nerve damage) is dose
limiting [179,180]. Thus, using a delivery system where CPT is released locally at the irradiated
site by X-rays would (1) minimize systemic chemotoxicity; (2) potentiate the efficacy of X-rays, and
(3) potentially control the tumor with lower doses of radiation, chemotherapy, or both. Liposomes
have demonstrated utility in chemotherapy as drug delivery vehicles by prolonging circulation time
and increasing drug retention in tumors with several formulations used clinically [181]. Thus, it is not
inconceivable that radiation-sensitive liposomes could be incorporated into pre-existing treatment
plans for concurrent use with traditional radiotherapy. In comparison to other spatially-specific release
systems, X-ray-triggered liposomal drug release is a relatively new concept. However, based on recent
research focused on radiosensitization with gold nanoparticles, there is strong evidence suggesting
that more efficient and effective systems can be designed to use radiation as a modality for triggered
drug release [182].
The mechanism responsible for inducing the destabilization of the liposomal membrane is the
radiosensitization effect [183,184], Figure 4. Radiosensitizers, such as gold nanoparticles, enhance
the local radiation dose through the increased absorption of low and medium-energy X-rays and
subsequent ejection of reactive secondary electrons [185]. A study by Sicard-Roselli et al. describes
the direct and indirect mechanisms by which hydroxyl radicals are produced from gold nanoparticles
irradiated in water. The direct mechanism produces hydroxyl radicals through the emission of
electrons or lower energy photons from gold nanoparticles which interact with water, while the
indirect mechanism involves the interaction of radiolysis products with gold nanoparticles which
then eject electrons that interact with water [184]. The hydroxyl radicals produced through both
pathways react with nucleic acids, proteins, and lipids located within their vicinity. In particular,
reactive oxygen species are known to simultaneously: (i) initiate lipid peroxidation, a process which
entails the abstraction of hydrogen atoms from lipid fatty acid chains, (ii) form peroxyl radicals,
and (iii) convert fatty acid side chains into lipid hydroperoxides [183]. Although there have been
no direct studies examining the mechanisms of radiosensitization in conjunction with liposomes, in
theory, the local production of hydroxyl radicals and secondary electrons mediated by embedded
radiosensitizers should cause lipid peroxidation and liposomal bilayer destabilization when irradiated,
thereby triggering drug release [183,184].
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Figure 4. Schematic of the mechanisms associated with RT that can be used to destabilize liposomes.
The mechanisms are as follows: (A) The interaction of radiation with water to produce radiolysis
products that can interact with AuNPs to amplify hydroxy radical production. These radicals can then
destabilize liposome bilayers for triggered drug release; (B) The interaction of radiation with AuNPs
to produce secondary electrons (such as Compton scattering and Auger electrons) which can then
interact with water to produce hydroxy radicals. These radicals can then destabilize liposome bilayers
for triggered drug release.
To date, there have been several hundred studies exploring the potential therapeutic use of gold
nanoparticles for radiosensitization [186]. The effect was initially shown by Hainfeld et al. who
found a four-fold increase (86% versus 20%) in one-year survival rates for mice receiving both gold
nanoparticles and X-ray therapy versus X-ray therapy alone. The mice were injected with 1.9 nm
diameter gold nanoparticles (up to 2.7 g of Au/kg body mass) and irradiated with a 250 kVp X-ray
beam [187]. In 2005, a Monte Carlo study, based on the aforementioned mouse study, was published by
Cho, estimating a physical dose enhancement factor (DEF) of at least two-fold [188]. More than thirty
reports have demonstrated radiosensitization effects in vitro with DEFs generally ranging from 1.1
to 1.9, while more than ten reports have shown radiosensitization effects in animal studies, showing
that treatment with gold nanoparticles and X-ray cause tumor regression, or increased cell kill [189].
The initial understanding of the mechanism behind radiosensitization was attributed to physical
factors, such as the high atomic number and photoelectric cross section of gold [190]. Monte Carlo
simulations were used to discern the type and number of electrons emitted depending on variables
such as the source, type, and energy of X-rays, as well as the size, concentration, and coating of
gold nanoparticles. Generally, it was found that small gold nanoparticles at a high concentration,
when irradiated with keV photon beams, generate the highest DEFs. However, as the in vivo and
in vitro radiosensitization effects were often greater than predicted DEF values, it has now become
well understood that complex chemical and biological interactions, such as the generation of hydroxyl
radicals as mentioned above, are also involved radiosensitization, and therefore, require further
investigation [189].
4.2. Formulation Factors
4.2.1. Radiation Type and Energy
Physical dose enhancement depends largely upon the energy and type of the incoming radiation.
Kilovoltage (KV) photons with energies above the k-edge of gold (80.7 keV) have been shown to
produce maximal dose enhancement due to the ability of these photons to excite the lowest-lying
K-shell electrons. These electrons are ejected by the photoelectric effect and cause the subsequent
emission of lower energy secondary electrons from the gold atom, known as the Auger cascade.
Although a majority of the electrons are reabsorbed by other atoms in the gold nanoparticle, 1 to
7 electrons from each gold atom ultimately escape to interact with the environment [191]. Leung et al.
reported that these electrons could travel 3 μm to 1 mm from the gold nanoparticle, while Jones et al.
found that the dose enhancement effect was significant only a few microns away [192,193]. Photons
with energies under the k-edge of gold (for example, 40–50 keV) have also been shown to produce
radiosensitization effects through the ejection of higher shell (L, M, N) electrons and a localized Auger
cascade, as the mass energy absorption coefficient of gold is over 100 times greater than soft tissue in
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the 40 to 50 keV energy range. However, due to the poor penetration of lower energy X-ray beams
through soft tissue, this strategy would not be clinically feasible unless brachytherapy seeds were
implanted in close proximity to the nanoparticles [190].
Although higher dose enhancement factors were observed using kilovoltage photon beams,
megavoltage (MV) photons have also been shown to produce gold nanoparticle-mediated
radiosensitization [194,195]. For 4 and 6 MV photon beams, dose enhancement factors ranging
from 1.01 to 1.07 were predicted by Cho, and therefore, were not initially considered for dose
enhancement [188]. However, in an in vivo mouse study, Chang et al. demonstrated that 25 Gy
of 6 MeV radiation could produce significant tumor volume reduction in the presence of gold
nanoparticles [196]. This could be explained by the increased absorption of secondary species produced
by the ionization of water [177,190]. More recently, Yang et al. showed that the incorporation of gold
nanoparticles into a chemoradiation regiment using cisplatin and 2 Gy of 6 MV radiation caused a 19%
decrease in cell survival compared to cisplatin and radiation therapy alone [197]. Again, the observed
dose enhancement was greater than predicted by Monte Carlo stimulations, indicating that physics
dosimetry plays a smaller role in MV radiosensitization [191]. As MV photon beams are often used for
radiotherapy and have a greater depth penetration in tissue, they are important for clinical applications
of radiosensitization [198].
Gold nanoparticles have also been shown to interact with ion beams which is being explored for
treatment because of its specificity in dose deposition attributed to its defined Bragg peak [199]. In a
theoretical study, Verkhovtsev et al. showed that ion beams caused the collective electronic excitation
of the surface plasmon in metal nanoparticles [200]. This effect was found to be particularly strong for
noble metals due to the high excitability of the surface plasmon where the relaxation energy released
causes the subsequent ejection of reactive electrons [177,200].
4.2.2. Gold Nanoparticle Size and Concentration
The size and concentration of the nanoparticles affect the degree of radiosensitization, since
a greater number of gold atoms being irradiated generally causes greater dose enhancement [186].
Thus, higher concentrations of gold nanoparticles of the same size or larger gold nanoparticles
at the same concentration produce greater dose enhancement effects [190,191]. However, when
considering the optimal size of gold nanoparticles for a given mass of gold, smaller nanoparticle
clusters produce greater dose enhancement effects. As the diameter of the gold nanoparticles increases,
more of the secondary electrons and radiation are absorbed by the nanoparticle core, thereby reducing
the energy available to interact with the surrounding environment [191]. In a Monte Carlo study,
Lechtman et al. (2011) showed that a greater number of low energy Auger electrons were released by
smaller nanoparticles while a greater number of high energy photoelectrons were released by larger
nanoparticles [191]. This size effect has also been shown in a simulated cell study where 2 nm gold
nanoparticles produced greater cell deaths than 50 nm gold nanoparticles when irradiated [201].
4.3. Future Perspectives
Currently, studies on X-ray triggered liposomal drug release are very limited. To our knowledge,
only one study exists—that by Deng et al.—in which the authors used X-rays to trigger release from
liposomes in vitro and in vivo. The system consisted of liposomes embedded with gold nanoparticles
and verteporfin, a photosensitizer, where 19% of encapsulated calcein was released upon irradiation
with 4 Gy of 6 MeV photons. Increased gene silencing and cell death were observed in vitro with the
triggered release of antisense oligonucleotides and chemotherapy drugs, respectively. In a xenograft
mouse model, X-ray triggered liposomes were shown to produce a 74% reduction in colorectal
tumor volume compared to the control with phosphate buffered saline [182]. In a different study by
Lukianova-Hleb et al., the authors relied on the increased endosomal uptake of AuNPs and liposomes
in cancer cells to colocalize the NPs for triggered release. This paper demonstrated the synergy between
liposomes, AuNPs, low-energy short laser pulses, and X-rays to induce plasmonic nanobubbles and
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ROS formation for the destabilization of the liposomes. Despite the absence of AuNP conjugation
or encapsulation within the liposome, this paper alludes to the possibility of relying on the tumor’s
biology to bring a carrier and triggering component in close enough proximity to each other to allow for
triggered release [202]. Although these studies showed that X-rays are a promising modality for X-ray
triggered liposomal drug release, many areas of possible development remain to increase the amount
of drug released. For example, the amount of drug released could be improved using liposomal
formulations containing higher concentrations of embedded gold nanoparticles [190]. Additionally,
protein nanoparticles, such as Albumin, could possibly be used in place of liposomes since hydroxyl
radicals interact strongly with proteins as well [203].
As X-ray-triggered drug release is still in its early stages of development, a better understanding
of gold nanoparticle embedded liposomes, their toxicities, and the effects of radiotherapy fractionation
is needed before clinical translation can be considered. Formulation factors affecting radiosensitization
using gold nanoparticles have been well studied, but not in the context of liposomes. Since the
incorporation of more gold nanoparticles increases local dose enhancement but destabilizes the
membrane at high concentrations, an optimization of the two factors is needed [190,204]. To date,
there has been one study outlining the in vitro pharmacokinetics of gold nanoparticle embedded
liposomes. The intravenous injection of gold nanoparticle embedded liposomes (100 to 120 nm)
into a fibrosarcoma mouse model resulted in the accumulation of gold nanoparticles in the liver,
spleen, kidney, and intestines, but none in the tumor site [205]. This could possibly be due to the
specific formulation of the liposome, as liposomes with diameters ranging from 100 to 300 nm have
typically been found to accumulate near tumors due to the enhanced permeability and retention (EPR)
effect [206,207]. Additionally, actively targeting the tumor using targeting ligands could increase the
uptake efficiency of NPs in cancer cells. Significant progress has been made in this area of research
both at the preclinical and at the clinical level and can be found in detail elsewhere [208]. A better
understanding of the long-term toxicology of gold nanoparticles is also necessary, especially at the
clinical level. Since surface chemistry, routes of administration, and dosages used vary extensively
across pre-clinical toxicology studies, different results are found in the literature for nanoparticles of a
given size [209]. For example, one study showed that gold nanoparticles ranging from 8–37 nm caused
hepatocellular toxicities, while another showed that 13 nm PEG-capped gold nanoparticles caused
no systemic toxicities [210,211]. Although the FDA has not approved any gold nanoparticle-based
drugs for clinical use, a clinical trial of Aurimune®, which carries tumor necrosis factor into tumors,
has successfully passed its first phase [212,213].
As radiotherapy can cause damage to normal tissue surrounding the tumor, careful consideration
must be taken to limit the dose of radiation delivered during RT [177]. Therefore, the use of liposomes
in conjunction with gold nanoparticles that promote radiosensitization is an attractive triggered therapy
approach when taking into account the negative side effects that come from high dose RT. A feasible
strategy for clinical translation would be to incorporate X-ray triggered drug release into existing
treatment plans which use concurrent radiotherapy with chemotherapy. Examples include head
and neck cancers, upper esophagus cancers, small cell lung cancer, and cervical cancer [179,214–217].
In particular, head and neck cancers and small cell lung cancer treatment plans recommend the use of
over 60 Gy of radiation with concomitant chemotherapy where the total dose is fractionated to 2 Gy
daily [217]. To maximize X-ray triggered drug release, irradiation should occur when the greatest
concentration of drug loaded liposomes are found in the tumor site. Additionally, larger doses of
radiation could be incorporated at this point to increase drug release if the treatment allows. Lastly,
synergistically radiation-activated drugs, such as those used for photodynamic therapy, could be
encapsulated and used for deep lying tumors that near infrared or visible light would be unable to
reach [218]. Future prospects in this field are promising and experimental simulation of a clinical
dosing schedule should be explored to better characterize the X- ray triggered liposomal release system
as a whole.
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5. Conclusions
This review explores the use of energy sources, including US, MFs, and external beam
radiation, to trigger the delivery of drugs from liposomes in a tumor in a spatially-specific manner.
The mechanism(s) of drug release that can be achieved using liposomes in conjunction with the external
trigger were investigated for each of the energy sources. Figure 5 summarizes the mechanisms that
can be achieved in each modality and the commonalities, such as hyperthermia and hydroxyl radical
formation, found between some of the devices. While this paper identified the growing interest and
advantages in using external stimuli to trigger drug release from liposomes, it also demonstrated the
drawbacks associated with each method. Themes such as the range of penetration depth and off-target
tissue damage, or lack thereof, were discussed in the advantages and disadvantages for each of the
energy sources. Considerations such as these must be taken into account on a case by case basis and
will impact the types of cancers that can be targeted with each modality. Furthermore, this review also
detailed the treatment’s formulation factors and explored the parameters of both the therapy and the
energy source. Each energy source identified a correlation between the size and concentration of their
corresponding mutually exclusive particle (such as the MB’s, IONPs, or AuNPs) with the treatment’s
experimental impact. Understanding each method’s formulation factors will aid in the development of
future therapies which are susceptible to influence from external stimuli. Additionally, the pre-clinical
and clinical trials of each triggered release method were explored. At the time of writing this review,
only US used in conjunction with liposomes, specifically HIFU induced liposomal release, had clinical
trials in motion as a method for cancer therapy. While these represent only three clinical trials, this
only further highlights the feasibility and positive future outlook of utilizing the energy sources found
in medical devices as external stimuli to induce liposomal release in the context of cancer therapy.
 
Figure 5. Schematic of the mechanisms associated with MR, US, and RT that can be used to destabilize
liposomes. The mechanisms are as follows: (A) MR induced mechanical disruption; (B) MR induced
hyperthermia; (C) US induced hyperthermia; (D) US induced stable cavitation of a MB; (E) US induced
inertial cavitation of a MB; (E1) The production of a liquid microjets from a MB undergoing inertial
cavitation; (E2) The production of shockwaves from a MB undergoing inertial cavitation; (E3) A MB
collapsing and undergoing sonochemical changes; (F,G) The interaction of radiation with AuNPs and
water to produce hydroxyl radicals that destabilize liposome bilayers.
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Abstract: Liposomes are considered one of the most successful drug delivery systems (DDS) given
their established utility and success in the clinic. In the past 40–50 years, Canadian scientists have
made ground-breaking discoveries, many of which were successfully translated to the clinic, leading
to the formation of biotech companies, the creation of research tools, such as the Lipex Extruder and
the NanoAssemblr™, as well as contributing significantly to the development of pharmaceutical
products, such as Abelcet®, MyoCet®, Marqibo®, Vyxeos®, and Onpattro™, which are making
positive impacts on patients’ health. This review highlights the Canadian contribution to the
development of these and other important liposomal technologies that have touched patients. In this
review, we try to address the question of what drives innovation: Is it the individual, the teams,
the funding, and/or an entrepreneurial spirit that leads to success? From this perspective, it is
possible to define how innovation will translate to meaningful commercial ventures and products
with impact in the future. We begin with a brief history followed by descriptions of drug delivery
technologies influenced by Canadian researchers. We will discuss recent advances in liposomal
technologies, including the Metaplex technology from the author’s lab. The latter exemplifies how
a nanotechnology platform can be designed based on multidisciplinary groups with expertise in
coordination chemistry, nanomedicines, disease, and business to create new therapeutics that can
effect better outcomes in patient populations. We conclude that the team is central to the effort;
arguing if the team is entrepreneurial and well positioned, the funds needed will be found, but likely
not solely in Canada.
Keywords: liposomes; drug delivery systems; innovation; lipid nanoparticles; Metaplex
1. Perspective
Reviews are biased and this one is no exception. The senior author of this review completed his
PhD training in the laboratory of Pieter Cullis, an innovator and serial entrepreneur. Although the
PhD research was focused on gaining a better understanding of lipids in membranes, the outcome
of this research changed the senior author’s research directions and highlighted the importance of
the team, solutions-oriented thinking, entrepreneurialism, and determination. In the past 30 years,
the senior author has been pursuing his research under a common theme: There was never enough
money. Yet the team that Cullis created chose to take on challenges that many told us were misguided.
The underlying message—if one does not take on the task oneself, then it is very likely to never move
forward and be successful. Of course, it is necessary to define success, which, from the perspective of
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the senior author (an academic by nature), is when the research efforts of trainees and collaborators
touch a human. In this context, success can only be made in teams that were not intimidated by the
initiation of companies that recognized innovative capabilities and captured intellectual property
while continuing despite rejection. Money, always being an issue, is secondary. The question now
is how success can be achieved faster and more frequently, noting that delays and innovation are
mutually exclusive events.
2. A Brief History
The concept of liposomes was first described by Alec Bangham in the 1960s when he demonstrated
the spontaneous assembly of egg lecithin into multilayer vesicular structures as phospholipids
were introduced to aqueous solutions [1]. Liposomes first garnered scientific interest because
of their structural similarity to cellular membranes [2]. This led to extensive studies exploring
membrane structure, permeation, adhesion, and fusion as well as the roles of lipids within biological
membranes [1,2]. Some of these works were pioneered by the Cullis group at the University of British
Columbia (UBC) in collaboration with Ben de Kruijff (Utrecht University): Investigators who are
internationally recognized for their discovery of lipid polymorphisms and the various behaviours of
membrane phospholipids [3–5]. In the early 1970’s, many compounds, such as lysozyme, chlorophyll a,
and beta-fructofuranosidase, were investigated as candidates for liposomal encapsulation [6–8]. At this
time, it became clear that certain compounds were not stored in the internal aqueous compartment;
rather, they were associated with the lipid bilayer, suggesting that these compounds could become
associated with liposomes by interacting with the hydrophobic regions of liposomes or by simple
binding to the lipid membrane [6,7]. Additionally, it was found that encapsulation in liposomes resulted
in localized cargo delivery [8]. This provided motivation for further investigation on compounds, such
as actinomycin D and penicillin, by early pioneers, like Gregoriadis et al. from the United Kingdom [9].
His group also investigated the use of liposomes to carry other enzymes, as liposomes had the potential
to protect enzymes from protease in the serum as well as the body’s immune response [10,11]. Later, it
was observed that packaging antigens into positively-charged liposomes lowered immune responses,
suggesting that liposomal formulations could be key to preventing the development of severe allergic
reactions [12,13]. Eventually, researchers became interested in examining the pharmacokinetic properties
of liposomal drug formulations. Arakawa et al. used encapsulated 131I-insulin, 14C-sucrose, 14C-inulin,
and 14C-cefazolin sodium as markers to evaluate the liposome elimination rate [14]. It was observed
that drug-containing liposomes were eliminated more slowly than the unencapsulated “free” drug.
However, drug absorption was also delayed, as the release of the drug from the liposome depended
on the liposome’s membrane composition and the loss of its structural integrity over time. To further
complicate matters, it became apparent that the liposome composition, dose, size, and charge all affect
the rate of elimination from the bloodstream [15,16]. These findings constitute the initial understanding
of how liposomes interact with the body when given intravenously.
Anti-cancer drugs have been commonly selected for liposomal formulations, often in an attempt
to reduce their toxic effects while maintaining or even enhancing antitumor activity. Initial attempts
include the work by Steerenberg et al. demonstrating that the nephrotoxicity of cisplatin (CDDP) was
decreased when the compound was encapsulated in liposomes. However, not only did antitumor
activity decrease upon encapsulation, the tumors recurred and resistance to CDDP developed [17].
In contrast, the work by Sharma et al. showed a drastic increase in potency against models of ovarian
cancer when N-(phosphonoacetyl)-L-aspartate was encapsulated in liposomes [18]. Aside from the
typical preparation of liposomes for parenteral administrations [14,15,19], topical formulations were
considered and these reduced the encapsulated drug’s side effects due to the liposome’s ability to
increase the drug concentration at the target site while decreasing the drug exposure at off-target
sites that often suffer from adverse effects [20,21]. One such example is the work completed by
Harsani et al. from Michael Mezei’s group in Dalhousie University, where they demonstrated that
a liposomal formulation of radioactive triamcinolone acetonide palmitate (3H-TRMAp) could be
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used as an effective topical treatment for oral ulcers [21]. Similarly, localization of the drug in the
desired area improved the local anaesthetic effect of lidocaine when it was applied as a liposomal
formulation instead of the conventional cream [22]. The preparation of lidocaine liposome for skin
delivery continues to be of interest based on the recent development of penetration enhancer-containing
vesicles by Fadda’s group in Italy [23,24]. Liposomal antibiotics and antiviral drugs have also been
successfully used in intravitreal applications to treat Propionibacterium acnes endophthalmitis and
cytomegalovirus retinitis [25]. The years between 1980–2000 were fruitful in the context of liposomal
pharmaceuticals as numerous products received regulatory approval for the treatment of cancer
(Doxil®, DaunoXome®, Depocyt®, Myocet®), infectious diseases (Abelcet®, Ambisome®, Amphotec®),
macular degeneration (Visudyne®), as well as for the prevention of viral infections in the form of
virosomal vaccines (Epaxal® and Inflexal®) [26].
The development and advancement of liposomal technologies has proven successful in part due
to the development of liposomal pharmaceuticals, but their real impact has been felt in the cosmetic
industry, with products including Capture (C. Dior), Niosomes (L’Oréal), Revision (Revision SkinCare),
and others. This review, however, will focus on Canada’s contribution to the liposomal pharmaceutical
field as a number of liposomal technologies have been developed in Canada, ranging from methods of
liposome preparation to drug loading strategies, storage strategies, and targeted delivery. This focus is
on how Canadian investigators and entrepreneurs impacted the field, but the success of this technology
is global. We hope those reading this paper accept its focus and understand that we needed to neglect
many other key individuals that made this field what it is today: Particularly teams in the USA, Japan,
the Netherlands, and Israel. A timeline of the highlighted technologies is provided in Figure 1.
Figure 1. Canadian contribution to the development of liposomal technologies, formation of companies,
and development of clinically approved formulations. Selected liposomal technologies are listed on
the timeline based on the patent literature (top panel). These technologies led to the formation of
companies, which are shown based on the year when they were established (middle panel). Regulatory
approved liposomal formulations that were developed by Canadian researchers are shown on the
timeline based on their year of approval (bottom panel).
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3. Technologies for the Production of Liposomes
While liposomes are known to consist of phospholipids that self-assemble into multi-layer vesicles,
uniformity of the liposomal structure is necessary for further pharmaceutical development. Liposomes
for pharmaceutical applications are typically up to 200 nm in diameter, composed of a unilamellar or
bilamellar bilayer and an aqueous core (Figure 2) [27,28]. Preparation of these homogeneous liposomal
formulations was pioneered by Olson et al. from the laboratory of one of the pioneer liposomologists,
Demetrios Papahadjopoulos (University of California San Francisco), where multilamellar vesicles
were sequentially passed through polycarbonate membranes of 1.0, 0.8, 0.6, 0.4, and 0.2 μm pore sizes to
yield a homogeneous preparation of liposomes with a mean diameter of about 270 nm [29]. Extrusion
using this method could be completed using 10–12 mM lipid suspensions at low pressures (about
50 psi). While this method was sufficient to generate bench-scale formulations, it was challenging
and time-consuming to prepare larger batches, which would be required for preclinical or clinical
studies. Hope et al. from Pieter Cullis’ group at UBC further advanced the extrusion technology: Lipid
concentrations up to 300 mM could be used to extrude multilamellar vesicles through 100 nm pore size
polycarbonate filters [30,31]. Using higher pressure (up to approximately 500 psi), unilamellar vesicles
with a mean diameter of 60–100 nm could be produced within 10 min. This invention led to the creation
of the Lipex® Extruder, which was first marketed by the spin-off company, Lipex Biomembranes,
created in 1984. Lipex Biomembranes was bought by Northern Lipids, another biotechnology venture
created in Vancouver, Canada. Northern Lipids was eventually purchased by Evonik Industries, a
German multinational company. Evonik still retains the Northern Lipids enterprise in British Columbia
and still markets the Lipex® Extruder today. This extrusion technology, ranging from simple devices
for laboratory scale production to larger extrusion systems that can handle more than 100 L, continues
to be the industrial standard for preparing pre-clinical and clinical batches of liposomal formulations.
 
Figure 2. Structure of a liposome. A liposome consists of a phospholipid bilayer with an aqueous core.
As the technology of microfluidics emerged in the last two decades, novel methods of
manufacturing liposomes have also been developed. Microfluidics systems manipulate and control
the flow of fluids through networks of channels having cross-sectional dimensions of approximately
5 to 500 μm [32]. The first use of microfluidics mixing to generate liposomes was described by
Jahn et al., where they demonstrated that hydrodynamically focusing of alcohol-dissolved lipids
between two sheathed streams of aqueous buffer in a microfluidic channel could yield monodispersed
liposomes ranging from 50 to 150 nm depending on the flow rate [33]. To better control the mixing
process and to generate liposomes even more rapidly, Zhigaltsev et al. from the Cullis group here
in Canada designed a microfluidic mixing device based on the concept of staggered herringbone
mixing [34–36]. Using this method, liposomes of 20–50 nm in size could be prepared and loaded with
small molecules, such as doxorubicin [35]. This work led to the creation of the NanoAssemblr™ device,
which is commercialized by Precision NanoSystems (Vancouver, BC, Canada) for the preparation
of liposomes encapsulating small molecules as well as macromolecules, such as nucleic acids and
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proteins, at bench and production scales [34,37]. This device is particularly well-suited for the
self-assembly process used to prepare cationic lipid/anionic polymer (e.g., DNA, RNA, antisense
oligonucleotide, siRNA, peptides, etc.) complexes, often referred to as lipid-nanoparticles (LNP).
The ability of anionic polymers to bind cationic lipids to form complexes was first disclosed by Dr.
Bally’s team [38–40], and was later employed by Cullis and associates to define what is now a US Food
and Drug Administration (FDA) approved siRNA formulation called Patisiran. It has been postulated
that these structures are better defined as a particle, rather than a liposome because they likely do not
comprise a lipid-bilayer structure.
4. Technologies for the Storage of Liposomes
Another practicality issue associated with the pharmaceutical development of liposomal
formulations was the shelf-life of the products. Liposomal formulations typically require storage at
4 ◦C and are relatively unstable for long term (>2 years) storage compared to other pharmaceuticals
that can be prepared as dried products. A discovery by J. Crowe, Louis Crowe, and Dennis Chapman
overcame this problem. Crowe’s team were trying to better understand membrane stability in the
presence of carbohydrates, known to be secreted by anhydrobiotic organisms (e.g., nematode) that
were able to survive drying/freezing conditions. They showed, in 1984, that carbohydrates, such as
trehalose and sucrose, were able to stabilize the model membrane structure at low water contents [41].
This observation was applied by Madden et al. working in Vancouver, and it was shown that
multiple types of sugars, including trehalose, sucrose, and lactose, could be effective at protecting
liposomes during the dehydration-rehydration process when the sugar content was appropriately
adjusted [42–45]. The first publication on this was released in July of 1985 by the Vancouver team, but
was followed shortly thereafter by a publication from Crowe et al. in October of that year, showing
that trehalose can be used to prevent liposomes from fusing during the freeze-drying process [41].
The use of carbohydrates to protect liposomes was disclosed in a patent with the Vancouver inventors
and the technology was commercialized and functionalized with lactose being incorporated as a
cryoprotectant in Amphotec®, Myocet®, and Visudyne®, and sucrose being added to AmBisome® to
enable the preparation of lyophilized liposomal products. Perhaps most interesting, this approach
worked very well in liposomes with no or low (<20 mol%) levels of cholesterol, where the ability
to prevent aggregation and fusion during a freeze/thaw cycle was first demonstrated, even in the
absence of carbohydrates, by Dos Santos et al. [46,47]. The first low-cholesterol product, Vyxeos®, is
stored as a dehydrated powder using sucrose and has a shelf life of 2 years at 4 ◦C to 8 ◦C.
5. Optimization of Liposomes for Pharmaceutical Use
A summary of the main approaches discussed in this section is listed in Table 1.
Table 1. Strategies developed to optimize liposomal products for pharmaceutical use.
Method Developed Utility References
Dehydration-rehydration method Improve passive encapsulation efficiency [48]
Modulation of lipid fluidity Improve passive encapsulation efficiency [49]
pH gradient loading Remote loading [50–53]
Use of ionophore to load small molecules Improve remote loading efficiency [54]
Use of ethanol to load small molecules Improve remote loading efficiency [46]
Microencapsulation method Improve loading efficiency of water soluble and insoluble compound [55]
Layersomes Improve liposome stability and oral delivery [56]
Hyaluronan coating of liposomes Enable topical applications [57]
Use of metal ion gradient Stabilize water-soluble compounds [58,59]
Metaplex technology Enable development of poorly soluble metal-binding compounds [60,61]
Use of cationic lipids Deliver nucleic acids [39,40]
Lipid nanoparticle (LNP) technology Optimize delivery of nucleic acids for clinical use [62–64]
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5.1. Improvement of Encapsulation Efficiency of Passive Loading
Following the initial forays into liposomal drug delivery, it became increasingly clear that more
efficient ways to encapsulate drugs were needed. Typical drug entrapment efficiencies were at best 10%
and this was due to a number of limitations [65,66]. In particular, given an optimal size of 100–200 nm
for nanomedicines that attempt to leverage the enhanced permeability and retention (EPR) effect, a
trapped volume of 1.5–2.5 μL/μmole, and a workable lipid concentration of 10–20 mM, it was just
not possible to achieve trapping efficiencies above 10% [67]. Of course, methods that used increased
lipid concentrations and/or association of the drug candidate with the membrane could be designed
to achieve an improved trapping efficiency. In some cases, increasing the aqueous drug solubility of
the compound of interest by changing the pH of the medium in which the compound is suspended
or by increasing the temperature greatly enhanced the encapsulation efficiency. Regarding lipid
concentration, the high pressure extrusion method allowed for the manufacturing certain liposomes
at lipid concentrations of 300 mM and this could achieve trapping efficiencies as high as 80% [30].
Alternatively, in 1984, Kirby and Gregoriadis introduced the dehydration-rehydration method, where
dehydrated liposomes were rehydrated in a small volume to increase the drug encapsulation efficiency
to as high as 40–50% [48]. As suggested above, depending on the hydrophobicity of the compound
being used, its association with the lipid membrane could be increased or the membrane’s “fluidity”
could be altered to enhance the association of these drugs [46,49,66]. However, these strategies came at
a cost: Low drug-lipid ratio, which in one aspect meant a great deal of liposomal lipid was required to
administer an effective dose of the therapeutic agent. Given the cost of lipids and drugs at the time,
this made it unreasonable to pursue liposomal drugs as pharmaceuticals.
5.2. Development of Remote Loading Methods
In 1976, Nichols and Deamer demonstrated that catecholamines can accumulate within liposomes
that have an established transmembrane pH gradient [68]. This concept was confirmed in 1985
by Bally et al., who discovered that lipophilic cations, like safranine O, could accumulate inside
liposomes in response to an Na+/K+ electrochemical gradient where the liposome’s interior was
negative [50]. This resulted in an interior safranine concentration over 80 mM, many times greater than
the solubility of the safranine. Research completed by Deamer’s (USA) and Cullis’ (Canada) groups
set the foundation for remote or active loading, where it was possible to achieve a >98% encapsulation
efficiency [46,50–53]. The pH gradient loading method, and varieties thereof, remains to be one of
the most employed methods to encapsulate a drug or drug candidate in liposomes. Several methods
for creating these gradients exist, such as using citrate buffer in the aqueous compartment, using an
ionophore-mediated ion gradient to generate a pH gradient as originally described by the Vancouver
team [54,69,70], or using transmembrane ammonia gradients as described by the Israel/US teams.
Depending on the properties of the compound of interest, the Canadian team led by Marcel Bally
showed that encapsulation efficiencies could be further improved by the addition of solvents, such
as ethanol. While the use of ethanol could potentially double the encapsulation efficiency at lower
temperatures, an excessive amount of ethanol could cause the liposomal structure to break down and
collapse the pH gradient [46].
Although remote loading of small molecules in response to a transmembrane pH gradient has
been widely applied, three issues still remain to be addressed: (1) Many small molecules do not
have a protonizable amine function, which is required for efficient pH gradient loading; (2) some
compounds, which are amenable to pH gradient loading, are associated with poor trapping efficiencies,
which could be due to issues, such as proton leakage through the bilayer [53,71]; and (3) many
therapeutically interesting compounds are poorly soluble in aqueous solution, but are not necessarily
“hydrophobic”. To increase drug encapsulation efficiency for various types of compounds, new
encapsulation methods have been established. One was referred to as a microencapsulation method,
in which a water/organic/water emulsion is agitated and used to prepare a liposomal suspension [55].
Other approaches to increasing the stability of liposomes include the development of “layersomes”,
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where multiple layers of polyelectrolytes are added to conventional liposomes; this proved effective
for the encapsulation of piroxicam [56]. Liposomes, functionalized with hyaluronanic acid, have also
been produced and were found to increase the bilayer packing order, reducing membrane flexibility
and improving drug penetration in topical applications [57].
Another strategy that has been employed to improve the trapping efficiency of small molecules is
the use of metal complexation. Initial studies were completed by the Cullis group in which doxorubicin
was encapsulated into Sphingomyelin/Chol liposomes in response to a manganese (trapped MnSO4)
ion gradient [58]. Greater than 98% trapping efficiency was achieved, but the stability of the MnSO4
solution required the use of a low pH. Although it was suggested that doxorubicin was capable of
forming a metal complex with Mn2+, the fact that the liposomes used also had a pH gradient confused
the interpretation of the results. The observation was confirmed by Abraham et al. from the Bally
group [59] in a manner that allowed that group to conclude that metal complexation could be the
sole driver of encapsulation. Further, the technology appeared suitable for use with a number of
other different metal ions, including copper and zinc [72], but the method always relied on the use of
compounds that exhibited a solubility >1 mg/mL and the use of compounds that had a protonizable
amine. The role of the pH gradient versus metal to encapsulate the drug was further confused by the
Bally team, who discovered and patented that transition metals could be used in conjunction with a
divalent metal ionophore (A23187) to generate a pH gradient. However, there was something about
the use of copper that enhanced drug retention that was surprising and unexpected [73]. The product
generated using this technology was focused on the camptothecins (irinotecan and topotecan) [54,74,75]
and one of the resulting products, Irinophore C, was more active than any other previously described
irionotecan formulations. It was disappointing that the resultant formulation never made it to the
clinic. There are many reasons for this, including the development of another formulation of irinotecan
(now approved and called Onivyde® [76]) that was clinically more advanced than the one created
in Canada and the fact that the technology developed in Canada was licensed: The company that
licensed the technology was not in a position to develop the product. The resulting delays and the
early filing of intellectual property (which was granted in several countries) made it unlikely that
further investments in funding clinical trials would result in meaningful returns to those that made
that investment. The Bally’s group was too slow to develop the technology.
It is worth noting that the incorporation of a transition metal into liposomes was critical to the
creation of Vyxeos®: A copper-containing formulation wherein the formation of a copper-anthracycline
complex is used to reduce the leakage rate of daunorubicin, while the use of low cholesterol liposomes
was required to enhance the retention of cytrarabine. The resulting product was designed such that the
two cytotoxic agents could be released from the liposomes at identical rates, ensuring the maintenance
of a synergistic drug-to-drug ratio in vivo [77].
This transition metal-complexation technology has further evolved through works completed by
the Bally’s group, who is now working with other founders (Ada Leung and Thomas Redelmeier),
the Vice President of research (Michael Abrams), and the entrepreneurial group at UBC (e@UBC
and HATCH) to lead the development of what is referred to as Metaplex technology. The Metaplex
technology is an active loading platform wherein a transition metal ion gradient is established across
the membrane and used as the primary driving force to accumulate drugs inside liposomes; drugs that
exhibit limited water solubility, may not contain a protonizable amine, but do contain a metal binding
function [60,61]. In this technology, there is clear evidence that the selected drug has a metal binding
function. By using lipid nanotechnology and metal coordination chemistry, this new formulation
method created by the Bally group enables the development of drugs that are typically relegated
to medicinal chemistry groups. Initial studies by Wehbe et al. explored formulation strategies for
diethyldithiocarbamate (DDC), a metabolite generated after disulfiram is administered. Disulfiram
is an anti-alcoholic agent known to inhibit aldehyde dehydrogenase [78]. DDC has long been known
as a copper binding compound [79] and it has been shown to have copper-dependent anticancer
activity [80–82]. Metaplex technology has been further expanded at the Vancouver-based Cuprous
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Pharmaceuticals Inc. for two different classes of compounds: (1) Sparingly soluble small molecules
that have metal-coordinating motifs, which could benefit from drug delivery technology; and (2)
relatively inactive small molecules that become therapeutically active upon complexation with metal
ions, such as Cu2+. The preparation of nanoformulations for metal-dependent therapeutics was
originally inspired by the increase in the number of publications in recent years demonstrating the
therapeutic activity of copper complexes against a variety of disease indications, including cancer,
inflammatory diseases, neurodegenerative diseases, and infectious diseases [83–88]. While metal
complexes, or specifically copper complexes, hold promise as therapeutic agents based on in vitro data,
there is a lack of preclinical evidence supporting their utility. The major reason for this is likely due to the
fact that most of these therapeutically active metal complexes have poor solubility in aqueous solutions
under physiological conditions, making it a challenge to test these agents in animals. The Metaplex
technology addresses this problem by using liposomes as nano-scale reaction vessels in which metal
coordination occurs [60]. Furthermore, these nanoparticles can be suspended in biocompatible aqueous
buffers for parenteral administration into relevant preclinical models. The Bally group and Cuprous
validated the concept of metal-dependent anticancer activity for copper-coordinating compounds
through an in vitro screen on platinum-sensitive and platinum-resistant cell lines and prepared injectable
copper-based formulations of DDC and clioquinol [80,89,90]. The Metaplex technology can also be
used to reformulate sparingly soluble compounds that have metal-binding properties with the goal
of either reducing toxicity or improving therapeutic activity. This was demonstrated by preparing
liposomal formulations, CX-5461, an investigational compound that interacts with copper and when
formulated using Metaplex technology, is more efficacious than the low pH clinical formulation currently
used [91,92]. Cuprous is currently developing this technology for immuno-oncology treatments reliant
on the use of small molecules rather than the more expensive antibody-based or cell-based therapeutics.
Immunogenic cell death (ICD), a phenomenon wherein dying cancer cells emit specific molecular
signals that ultimately lead to an anti-tumour adaptive immune response followed by long-term
protection against recurrence, is a concept of immunotherapy that has recently garnered much attention
due to its potential to treat metastatic disease and/or bring about long-term survival or cures [93,94].
Anthracyclines, like doxorubicin, are known to induce ICD as a secondary mechanism [93,95]. Most
interestingly, metallic copper itself, is known to generate reactive oxygen species (ROS) and induce
endoplasmic reticulum (ER) stress, which is required for ICD induction [96,97]. Cuprous is exploring
exciting new opportunities for enhancing the delivery of such compounds using its proprietary platform
technology [73,74].
Metaplex has the potential to work with a more diverse array of compounds than conventional
pH gradient loading due to a larger chemical space that would satisfy the requirement for metal-ligand
coordination to occur [86,87]. While the focus has thus far been on the use of Metaplex for
oncology-based formulations, the potential application of this technology is much broader. Copper
complexes of non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be associated with
reduced toxicity and increased therapeutic activity [88,98]. Various copper complexes have exhibited
hypoglycemic effects and may be suitable as diabetic treatments [99,100]. Other studies demonstrated
that copper complexes could have potent antimicrobial activity and could be useful against infections
by superbugs, which are becoming a global health concern [101,102]. Finally, it is known that
metal imbalance is strongly associated with neurodegenerative diseases, such as amyotrophic lateral
sclerosis, Alzheimer’s, and Parkinson’s diseases [83,103,104]. Strategies to adjust these imbalances
using metal chelators are being evaluated [105,106]. All of these represent opportunities for the
development of novel metal-based therapeutics, where the Metaplex platform could be used to design
formulations for specific indications, further expanding the application of liposomal technologies
non-oncology-based indications.
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5.3. Development of Liposomes for Encapsulation of Nucleic Acids
The utility of liposomes has also been extended to nucleic acid delivery (DNA, mRNA, Antisense
oligonucleotides, siRNA, etc.), typically for the purpose of genetic modification of target cells. Nucleic
acids alone cannot pass through cellular bilayers, but liposomes have been designed to fuse with
membranes and successfully deliver associated payloads [107]. The earliest examples of nucleic
acid encapsulation were in the late 1970s: Dimitraidis et al. encapsulated mRNA, rRNA, and
tRNA in large unilamellar liposomes, and Fraley et al. focused on the delivery of pBR322 bacterial
plasmids [108,109]. Continued research demonstrated that factors, such as the presence of polyethylene
glycol (PEG) or glycerol, liposome charge, and the number of lamellae, all affect nucleic acid infectivity
or sequestration [110]. While early work supported the use of cationic liposomes as delivery agents of
plasmid DNAs for transfection purposes, the physical characteristics of these liposome/DNA complexes
were not well-defined. In 1995, Reimer et al. from the Bally group prepared and characterized, for the
first time, hydrophobic complexes of cationic lipids and plasmid DNA that can be readily extracted in
organic solvents [39,40]. They proposed these cationic lipid/DNA complexes as potential intermediates
for the formation of particles suitable for gene delivery to cells [38–40]. This work was extended to
the complexation of cationic lipids with antisense oligonucleotides designed for gene silencing and
subsequently the addition of PEG to prevent aggregation of these lipid/nucleic acid complexes [111–113].
These works were further developed in the 1990s and 2000s through the Cullis group (UBC) and
Vancouver-based companies, including Acuitas Therapeutics (formerly AlCana Technologies) and
Inex Pharmaceuticals (now Arbutus Biopharma) [64,114]. These efforts led to the use of ionizable
amino lipids for the delivery of nucleic acids [63] and the development of fusogenic liposomes:
Liposomes that have an exchangeable PEG-lipid conjugate, which contributes to the in vivo stability
of nanoparticles, particularly those encapsulated with antisense oligodeoxynucleotides [115,116].
These technologies seeded the evolution of nucleic acid drug delivery, leading to the creation of new
lipids designed specifically for the encapsulation of RNA-based therapeutics and the development of
the lipid nanoparticle (LNP) technology platform: The most advanced and currently the only clinically
validated nucleic acid delivery system through the regulatory approval of the RNA interference (RNAi)
therapeutic Onpattro® [5,62,64,114,117–120].
6. Other Key Canadian Discoveries that Impacted the Development of Therapeutically
Interesting Drugs
Table 2 below highlights some of the Canadian discoveries that helped the development of
liposomal pharmaceutical products evolve over time.
Table 2. Canadian discoveries that were involved in driving the advancement of liposomal
pharmaceutical products.
Canadian Discoveries References
Use of antibodies to mediate targeting with liposomes [121,122]
Selective targeting of liposomes to the blood compartment [123]
Use of GM1 ganglioside in liposomes, leading to the development of “PEGylation” [122]
Role of PEG in preventing liposome aggregation [124]
Development of low-cholesterol liposomes with lipids that prevent aggregation [124]
Maintenance of the drug-drug ratio for two drugs encapsulated in one liposome [77]
6.1. Selective Drug Delivery with Liposomes
Shortly after liposomes were first described, their promise as selective delivery agents was
considered. To this end, Gregoriadis et al. associated molecular probes to drug-containing liposomes
and found that probes (Immunoglobulin G’s (IgGs) raised against different types of cells) could mediate
selective cellular uptake [125]. In the early 1980s, Leserman et al. coupled monoclonal antibodies
to liposome surfaces, successfully demonstrating cell-specific liposome interaction [126]. A third
309
Pharmaceutics 2019, 11, 124
example by Guru et al. demonstrated significant increases in the efficacy of sodium stibogluconate
via encapsulation in tuftsin-bearing liposomes. Even liposomes carrying only tuftsin were found
to make animals resistant to Leishmania donovani infections [127]. In addition to these early studies,
Ryman’s team explored the imaging potential of liposomes, highlighting the ability of liposomes to
localize in lymph nodes by injecting technetium-99m labelled liposomes into rats and then studying
tissue distribution via γ-camera imaging and radioassay [128], and Morgan et al. demonstrated that
liposomes could be used to image staphylococcal infections [129]. Finally, Baldeschwieler’s group
highlighted the potential for liposomes to image tumours. All these studies were completed well
before Matsumura and Maeda first published and described the EPR effect: Selective accumulation
due to abnormally permeable vasculature found in tumours [130]. It is also worth noting that drug
release mechanisms, such as endocytosis and fusion, were investigated early in the development of
liposomal pharmaceuticals, where it was postulated that different uptake mechanisms could allow for
selective delivery depending on how specific liposome formulations interacted with cells [65].
Clearly, an important rationale for developing more selective liposomes was based on strategies
designed to increase interactions between the nanoparticles and target/disease cells while minimizing
toxicities against healthy cells. One of the most commonly employed approaches still used today
concerns the use of surface coatings. Liposomes with attached antibodies could bind to specific cell
populations. Some of the earliest works by Papahadjopoulos’ group demonstrated that liposomes
coated with antibody fragments or immunoliposomes were able to bind human erythrocytes much
more efficiently compared to non-targeting liposomes [131,132]. In Canada, some of the early studies
investigating the use of antibody-mediated targeting of liposomes to treat cancer were conducted
by Theresa (Terry) Allen’s group at the University of Alberta [121]. For instance, Ahmad and
Allen demonstrated that liposomes coated with antibodies targeting squamous carcinoma cells
resulted in increased uptake and cytotoxic effects against KLN-205 lung squamous carcinoma cells
relative to non-targeting liposomes [133]. Several studies have demonstrated that actively targeted
liposomes may contribute to improved therapeutic activity in vivo [123,134,135]. While the initial
focus was to alter the biodistribution of targeted liposomes for more efficient delivery to the target
site (i.e., the tumour), it was discovered that delivery to the tumour for both immunoliposomes
and conventional liposomes was primarily dependent on the EPR effect [136]. The differences in
therapeutic activity reported were likely due to an increased uptake of immunoliposomes by cancer
cells as a result of receptor-mediated endocytosis followed by the escape of the cytotoxic agent from
endosomal/lysosomal degradation [136–139]. In recent years, researchers have also explored the use
of peptide-mediated targeting [138,140,141]. Several excellent review articles are available describing
the various functionalization strategies that have been employed in the development of active targeting
nanomedicines [142–144]. Although first envisioned 40 years ago, there has yet to be a successful
targeted formulation approved for clinical use. However, it is notable that the limitations for targeting
solid tumours are clear. Allen’s team was able to highlight the potential of targeting liposomes to
cells within the vascular compartment [123]. It is hoped that this may prove to be of therapeutic
value, particularly in light of some of the recent findings from the Bally group, which emphasize
that therapeutic antibodies may exhibit improved therapeutic effects when attached to liposomes.
These studies consider the potential of liposomes to deliver antibodies rather than antibodies to target
liposomes [123].
6.2. The “PEGylation” Technology
The effects of various lipid compositions on the pharmacokinetics of liposomes were also explored
with the goal of prolonging the presence of liposomes in the plasma compartment. The first attempt was
made by Terry Allen’s group through the addition of GM1 ganglioside into liposomes, which reduced
mononuclear phagocyte system (MPS) uptake, allowing the liposomes to remain in the blood stream
for several hours [145–147]. Based on this pioneering work, scientists explored the incorporation of
PEG into formulations as a steric stabilizer lipid (i.e., 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-
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polyethylene glycol (DSPE-PEG)) [147]. This “PEGylation” technology, otherwise known as stealth
liposome technology, has been the most widely employed strategy since the 1990s [26,148–150]. Yet the
role of surface coating of liposomes with PEG has likely been well overstated. It was the Canadian Bally
group along with Christine Allen, Nancy Dos Santos, and others that first highlighted that the primary
role of PEG on the surface of the liposomes was not to prevent protein association or even association
with phagocytic cells, but to prevent surface–surface interactions that could lead to aggregation of
liposomes [124]. This was elegantly proven by the work of Dos Santos, who demonstrated that selected
liposomes could be prepared in the absence of cholesterol or low levels of cholesterol as long as they
incorporated lipids that prevented their aggregation, such as PEG-modified lipids [124]. As suggested
above, this technology was key to the development of Vyxeos®, a combination liposomal drug product
now approved for treatment of acute myeloid leukemia.
6.3. Strategies to Encapsulate Multiple Agents
Related to the previous statement and existing evidence that cancer is a heterogeneous
disease, which is most effectively treated with a combination of multiple therapeutic agents, there
was significant interest in encapsulating multiple drugs in the same liposome. For example,
daunorubicin and 6-mercaptopurine are a pair of chemotherapeutic compounds that were thought to
act synergistically—one being a hydrogen acceptor and the other being a hydrogen donor. While this
particular interaction was not observed, combining the two compounds in a dual drug liposome did
appear to show synergistic cytotoxic effects [151]. Researchers in Vancouver (BC Cancer and Celator
Pharmaceuticals) extensively studied the impact of drug-to-drug molar ratios on therapeutic outcomes
in vitro. Drug combinations could result in synergistic or antagonistic treatment effects depending
on the ratio used. It was logical to assume that if the effects of the anticancer drug in vitro were
dependent on the drug-drug molar ratio in vitro then the same would hold true in vivo [152,153].
When encapsulating multiple drugs in the same liposome, or even different liposomes, the relative
release rates of the two compounds must be considered, as the goal is to achieve an ideal ratio at
which they could be administered (a fixed ratio product) and to maintain that ratio over time after
administration to achieve optimal therapeutic effects [154]. Tardi et al. illustrated an example of a
system in which cholesterol was used to control drug leakage rates and with this system, they were able
to maintain a 1:1 synergistic ratio of irinotecan and floxuridine in vivo [72]. This observation proved
to be a “patenting moment” that led to the development of liposomal combination products protected
under the “Combiplex” patent [155]. This patent described the use of various drug delivery systems to
be used to prepare products in a manner where the combination ratio could be maintained in vivo;
a patent that first contemplated the use of daunorubicin and cytarabine as a liposomal combination
product that eventually became Vyxeos [77].
7. The Canadian Impact on Regulatory Approved and Investigational Liposomal Formulations
Here, we provide a list of approved liposomal products and reiterate some of the information
above to highlight how Canadian scientists influenced these products. An up-to-date list of all
regulatory approved liposomal formulations is provided in Table 4.
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7.1. Liposomal Formulations of Amphotericin B: Abelcet® and iCo-019
Amphotericin B is an antifungal agent used to treat serious fungal infections and
leishmaniasis. Multiple lipid-based formulations of amphotericin B (i.e., AmBisome®, Abelcet®,
Amphotec®) are approved for use in various countries, of which Abelcet® presents a unique
formulation wherein amphotericin B is complexed with dimyristoylphosphatidylcholine (DMPC) and
dimyristoylphosphatidylglycerol (DMPG) at a 7:3 molar ratio, forming ribbon-like structures (hence
known as amphotericin B lipid complexes), which are believed to have contributed to its favourable
toxicity and therapeutic profiles [186]. The formation of Abelcet® was designed by Drs. Thomas
Madden, Andrew Janoff, and Pieter Cullis at UBC. Abelcet® was the first drug from the Cullis group
to reach the market. It was developed by The Liposome Company in association with the Canadian
Liposome Company, a wholly owned subsidiary, and was approved in 1995 for the treatment of invasive
fungal infections to which patients are non-responsive or cannot tolerate conventional amphotericin B
treatments. Abelcet® is currently a Leadiant Biosciences product.
iCo-019 is an oral liposomal formulation developed by Kishor Wasan’s group
(from UBC and University of Saskatchewan). The formulation comprises Peceol and
distearoylphosphatidylethanolamine (DSPE-PEG) and the resulting oral formulation was found
to reduce the number of fungal colony formation units by more than 80% relative to untreated
controls [187]. While the existing intravenous formulation of amphotericin B is effective at treating
invasive fungal infections, safety issues associated with parenteral administrations, such as infection at
the catheter, haemolysis, and renal toxicities, are concerning [187]. The oral formulation was designed
to overcome these issues as well as to address the problem of these drugs being costly and difficult to
administer in remote locations, where fungal infections are more problematic. The oral amphotericin B
formulation is currently being developed by the Vancouver-based company, iCo Therapeutics, which
has recently announced positive Phase I data on iCo-019.
7.2. Liposomal Formulations of Doxorubicin: Myocet® and Doxil®
Doxil® (Caelyx®) and Myocet® are perhaps the most well-known liposomal anticancer agents.
Doxil® was first approved in 1995 for the treatment of acquired immunodeficiency syndrome (AIDS)
related Kaposi’s sarcoma [139]. It is now also being used to treat relapsed ovarian cancer, multiple
myeloma, and locally advanced or metastatic breast cancer. Myocet® is another liposomal formulation
of doxorubicin, which was approved in 2000 to be used in combination with cyclophosphamide
to treat metastatic breast cancer in Europe. The main difference between Doxil® and Myocet® lies
in their lipid composition, which ultimately affects their safety, drug release, and biodistribution
profiles [188–190]. Doxil® is composed of hydrogenated soya phosphatidylcholine, cholesterol (Chol),
and PEG-modified phosphatidylethanolamine (55:40:5 molar ratio) while Myocet® is a non-PEGylated
liposomal formulation consisting of egg phosphatidylcholine (EPC) and Chol (55:45 molar ratio).
Myocet® increases the circulation lifetime of doxorubicin by approximately three times relative to
the free agent in mice [189,191]: An effect thought to be due to the toxicity of doxorubicin being
delivered to phagocytic cells [192]. This is also known to occur for Doxil® because it is prepared with
lipids that enhance drug retention, resulting in an increased blood residence time of doxorubicin and
increased drug delivery to the skin, which made it an ideal formulation for the treatment of skin
localized cancers, like Kaposi’s sarcoma [189,193,194]. However, the increased skin delivery caused
dose-limiting toxicities attributed to hand-and-foot syndrome [189]. Both liposomal formulations
reduce cardiotoxicity, a major concern associated with free doxorubicin. Myocet was developed by the
Vancouver group in association with the Canadian Liposome/The Liposome Company [173]. Doxil®
originated from research completed by groups in California and Israel, but this product was greatly
influenced by Terry Allen. The product was initially developed by Liposome Technology Inc. and is
now owned by Johnson & Johnson. Myocet®, on the other hand, is now a product owned by Teva
Pharmaceutical Industries [150,195].
314
Pharmaceutics 2019, 11, 124
7.3. Visudyne®
Aside from Abelcet®, another liposomal formulation that was not designed for oncology use
is Visudyne® or liposomal verteporfin, which is a benzoporphyrin derivative that serves as a
photosensitzer for photodynamic therapy in the treatment of age-related macular degeneration.
The formulation consists of a mixture of DMPC and egg phosphatidyl glycerol (EPG) [196] and
was designed by the Canadian scientist, Thomas Madden. Visudyne® is known for its selectivity
against choroidal neovasculature arising from macular degeneration while minimizing the risk of
severe visual acuity loss [197]. The product was developed by QLT Inc. (a spin-off company from UBC
established in 1981) and is now a product owned by Bausch & Lomb Incorporated.
7.4. Marqibo®
Marqibo® is the liposomal formulation of vincristine developed to address dosing and
pharmacokinetic limitations of the free agent. This formulation was designed by Bally, Mayer, and Cullis
in the late 1980s and early 1990s. Although the product that arose from this research was originally
owned by The Liposome Company through their agreements with UBC and the Canadian Liposome
Company, the technology was eventually licensed back to a Vancouver-based start-up called Inex
Pharmaceuticals. While the original product was prepared using DSPC/Chol liposomes, this product
had an unacceptable storage life. This problem was overcome by using a new lipid composition of
sphingomyelin and Chol in a 55:45 molar ratio [182,198]. This particular formulation exhibited a better
storage shelf-life, and was associated with a surprising increase in drug retention and a profound
improvement in therapeutic activity, exhibiting cures in multiple murine models of leukemia [181,199].
Marqibo® was originally developed by the Canadian company, Inex Pharmaceuticals Corporation,
and is now a product of Spectrum Pharmaceuticals approved (2012) for the treatment of Philadelphia
chromosome-negative acute lymphoblastic leukemia in adults.
7.5. Vyxeos®
Vyxeos® (formerly known as CPX-351) is the first dual-drug liposomal formulation to receive
regulatory approval. It comprises cytarabine and daunorubicin packaged at a fixed 5:1 molar
ratio inside 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)/1,2-distearoyl-sn-glycero-3-phospho-
(1′-rac-glycerol) (DSPG)/Chol (70:20:10 molar ratio) liposomes [200]. Vyxeos® was developed based on
the original concept of the CombiPlex® platform technology invented by Lawrence Mayer and Marcel
Bally’s group (Vancouver), where drug combinations exhibit synergistic anticancer activity when given
at certain molar ratios and drug carriers could be used to maintain those ratios in vivo [152,201,202].
This technology demonstrated that (1) two drugs can be co-encapsulated into liposomes at a fixed
molar ratio and (2) liposomes can be designed to optimize release kinetics such that the optimal
therapeutic ratios can be achieved and maintained in vivo [203]. In 1999, Celator Pharmaceuticals Inc.,
was formed (Vancouver, BC, Canada) to develop the CPX product line. CPX-351(Vyxeos®) received
regulatory approval for the treatment of treatment-related or secondary acute myeloid leukemia (AML)
and AML with myelodysplasia-related changes in 2017. Just prior to this the company was acquired
by Jazz Pharmaceuticals.
7.6. Onpattro®
The most recently approved liposomal formulation is Onpattro®, a nanomedicine that is
revolutionary in multiple ways. Onpattro®, also known as patisiran, consists of an siRNA targeting
the production of the transthyretin (TTR) protein, packaged inside LNPs, as described above.
The lipid component contains Chol, DLin-MC3-DMA, DSPC, and PEG2000-C-DMG at weight ratios of
6.2:13:3.3:1.6 per 2 mg of siRNA. By suppressing the production of wild-type and mutant TTR, patisiran
reduces the accumulation of amyloid deposits in peripheral nerves, which would otherwise cause
peripheral neuropathy [204]. Onpattro® is the first and only medication approved for the treatment
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of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. It is also the first and
currently the only RNA interference therapeutic approved. Onpattro® is a product developed by
Alnylam Pharmaceuticals using their proprietary siRNA and the LNP technology that originated from
work completed by Jayaraman et al., including experienced Canadian scientists in the field: Pieter
Cullis, Thomas Madden, Muthiah Manoharan, Steven Ansell, Jianxin Chen, and Michael Hope [64].
The development of Onpattro® resulted from collaborative efforts between Alnylam Pharmaceuticals
and Acuitas Therapeutics (then AlCana Technologies). All commercialization work was conducted by
Alnylam Pharmaceuticals.
8. Conclusions
Since the first description of liposomes in 1965, our knowledge about lipids and the role of lipids
in membranes has expanded enormously. With this increase in understanding came innovations and
discoveries that were impactful on patient treatment outcomes and quality of life, from reductions in
adverse effects to controlled-release combinatory formulations. Nearly half of all regulatory approved
liposomal formulations are Canadian inventions, highlighting the efforts of liposomologists from coast
to coast. Researchers from Canada and around the world will endeavour to use liposomes to increase
the therapeutic activity of promising compounds, making many more efficacious nanomedicines
available to patients in the years to come.
There is a common theme to the success of the liposome technology developed by Canadians.
First is the recognition of innovation and an aggressive patenting strategy that can protect the idea
and its use. Next comes the “do it yourself” attitude: One that is most readily expressed in the
context of new company formation. Finally, come partnerships, ones that include scientists, business
development personnel, quality control staff, clinical trial specialists, clinicians, etc. However, the
funding to develop this technology is great and, therefore, the efforts of venture capitalists and
existing companies resourced to develop and commercialize therapeutic agents of value are also
needed. Whether it is necessary to have a large company developed in Canada remains a question.
In this context, success could be defined by partnerships with existing companies, even those in other
countries. These partnerships should be highlighted as a Canadian success. Perhaps the only negative
to all this is the fact that Canadian patients may be second, third or even fourth in line to have the
opportunity to participate in clinical trials and access to the drug, if approved. It is more likely that
successful products will be first marketed in larger economic markets, like the USA and Europe, before
they reach Canadians. Further, in the absence of really compelling data, it is sometimes difficult to
adopt new technology. Myocet®, for example, is approved in Europe and Canada, but it is rarely used
in Canada, in part because it is not marketed there. This is despite evidence demonstrated in a large
patient population that Myocet® does reduce the cardiotoxicity of doxorubicin and is a safer product.
While Canadian access to new technology created in Canada may be limiting, the training opportunities
here in Canada are fantastic, resulting in an international reputation of excellence and skills.
Finally, if one looks to the future, the strength of the liposome community as well as the drug
delivery communities in general is very strong in Canada. The number of drug delivery/polymer/
lipid technology based companies in operation are significant and these include the BC–based
companies, Evonik, Precision Nanosystems, iCo Therapeutics, Acuitus, Sitka Biopharma, Cuprous
Pharmaceuticals, Integrated Nanotherapeutics, Genevant Sciences, as well as Nanostics Precison
Health (Alberta) and Nanovista (Ontario). The technology is creating jobs, training highly qualified
personnel, and, most importantly, creating new products that are improving the health care of
patients internationally.
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Abstract: Parenteral amphotericin B has been considered as first-line therapy in the treatment of
systemic fungal and parasitic infections, however its use has been associated with a number of
limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently,
it has been very challenging to develop a bioavailable formulation of amphotericin B due to its
physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective
reviews several novel oral Amphotericin B formulations under development that are attempting to
overcome these limitations.
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1. Preamble
One of the authors (KMW) was presenting grand rounds to the infectious disease group at
Vancouver General Hospital, discussing combination therapies to treat systemic fungal infections,
particularly those patients who were about to go through organ transplantation. An infectious disease
physician asked if it was possible to develop an oral formulation of amphotericin B to treat patients.
This physician commented that if an oral formulation could be developed, then it would be widely used,
because it would have the potential to overcome many of the limitations of intravenous administration.
These limitations include affordability, accessibility, and the well-known systemic toxicities associated
with amphotericin B. At the time, KMW considered it extremely challenging to develop a bioavailable
formulation of amphotericin B that would achieve the tissue concentrations required to have a
pharmacological effect and ameliorating the dose-dependent nephrotoxicity associated with the drug.
Factors include the large molecular weight of amphotericin B, its amphoteric physical chemical nature,
very poor water and lipid solubility, as well as acid lability.
However, as KMW thought about it, it became clear that with a growing understanding of dietary
and excipient lipid processing in the gastrointestinal tract (GIT) as well as associated new drug delivery
technologies, it could in fact be possible to develop an efficacious oral formulation.
2. Purpose
The aim of this perspective is firstly to provide sufficient background information on both
amphotericin B (AmB) and the target disease leishmaniasis, as well as to explain the need for an
oral formulation of this life-saving medication. Secondly, our purpose is to describe pharmaceutical
advances that have led to several novel AmB formulations which have emerged over the last decade.
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Equally important is to discuss the role of formulation in reducing specific barriers to treatment in
highly endemic regions of visceral leishmaniasis, such as cost and storage considerations.
3. Chemistry of AmB
3.1. Structure Overview
AmB has a large, highly complex structure (Figure 1). It is classified as a polyene macrolide
antibiotic; specifically, it is known as a macrolide because it contains a polyketide that is linked to
a mycosamine sugar. Furthermore, it is classified as a polyene macrolide due to the presence of the
hydrophobic polyene subunit, which is attached to the hydrophilic polyol portion of the molecule [1].
Overall, it consists of a 38-membered macrolactone ring, which is β-glycosylated with mycosamine at
the C-19 hydroxyl position [1]. Seven conjugated double bonds comprise the polyene subunit, while
an ester and a ketone separated by 12 carbons and substituted with six hydroxyl groups comprise the
polyol subunit of the molecule.
Figure 1. Structure of amphotericin B in zwitterionic form.
3.2. Structure-Activity Relationship
The structure-activity relationship of AmB has been the focus of numerous studies over the
last three decades, which are briefly outlined below. Generalizations can be made with regard to
the pharmacophore of this molecule: The positively charged amino group is required for activity;
the polyene subunit is important for activity; if the carboxyl group is negatively charged, it leads
to decreased selectivity for ergosterol over cholesterol; and conversely, N-aminoacylation leads to
improved selectivity [1].
3.3. Mechanism of Action of AmB
Polyene antifungals such as AmB act by binding with ergosterol of the fungal cell walls and
forming pores which permit leakage of cell contents, which eventually results in apoptosis [2,3]. This
binding of AmB to ergosterol occurs through hydrophobic interactions, disrupting the lipid membrane
integrity and resulting in the formation of pores [4,5]. These channels in the cell membrane allow
efflux of small ions and other macromolecules, such as potassium and magnesium [6,7]. Simulation
of the AmB–ergosterol structure finds that the formed pores promote water transport across the cell
membrane, which might further disrupt the intracellular environment [8]. Recent evidence indicates
that ergosterol binding and pore formation may not be the only mechanism leading to fungal cell
death. It has been reported that AmB could kill yeasts by extracting ergosterols from cell membrane
lipid layers [9,10]. Furthermore, it has been proposed that AmB causes accumulation of intracellular
reactive oxygen species (ROS), which also contributes to the antifungal effect of this drug [11]. Several
studies have described elevated ROS in fungal cells treated with AmB [12,13]. However, it is still not
clear how AmB induces ROS production.
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3.4. Bioavailability of AmB
The complexity of the AmB molecule is partly due to the individual functional groups present
but also due to the asymmetry of the important subunits that make up the molecule. For instance, the
polyol subunit is highly hydrophilic with many hydrogen bond donors and acceptors available to
interact with molecules of water. By contrast, the polyene subunit is highly hydrophobic, as it consists
of seven conjugated double bonds in a hydrocarbon chain 14 carbons in length. In addition to the
amphiphilic nature of AmB, it also has a zwitterionic character on one portion of the molecule with
the carboxylic acid and primary amine functional groups, which can be negatively and positively
charged, respectively [14]. Therefore, overall, this asymmetric, amphiphilic molecule with zwitterionic
character demonstrates a poor aqueous solubility of less than 1 mg/L at physiological pH, leading to its
precipitation in aqueous media [14]. Lipinski’s rule of five, which describes drug features that increase
the probability of oral bioavailability based on passive diffusion though cellular membranes, can be
applied to AmB with predictable results. AmB violates three out of four rules: AmB has more than
5 H-bond donors, more than 10 H-bond acceptors, and a molecular weight greater than 500 Da [14].
Thus, AmB will not easily be absorbed through the gastrointestinal mucosal membranes by passive
transport following oral administration, which is confirmed by AmB’s known low oral bioavailability
of 0.2–0.9% [14]. Together with the aforementioned chemical complexities of AmB, there are significant
barriers that must be overcome for an oral formulation of AmB to be developed.
4. Treating Visceral Leishmaniasis (VL)
Leishmaniasis is one of 20 conditions listed in the World Health Organization (WHO)’s list of
“Neglected Tropical Diseases” [15]. Despite having effective treatments for the various presentations
of the infection since the late 1950s, leishmaniasis is still a major concern in the 74 endemic countries
identified by the WHO’s Global Health Observatory data repository in 2016 [16]. Although the
distribution of the disease is quite widespread, the large majority of new cases are limited to
the following hyperendemic regions: Brazil, Ethiopia, India, Kenya, Somalia, South Sudan, and
Sudan [17,18]. In 2016 alone, the number of reported cases of VL (or kala-azar), the most severe form
of the disease, was: 6249 in India; 4285 in South Sudan; 3810 in Sudan; 3200 in Brazil; 1593 in Ethiopia;
and 911 in Somalia [19].
Leishmaniasis is a vector-borne parasitic protozoan infection caused by more than 20 species
of the Leishmania genus [20]. The known vectors of these parasites are the female sand flies of the
genus Phlebotomus, which have a broad geographical distribution ranging from areas of the tropics,
subtropics, and even temperate regions [21]. Additionally, domestic dogs are known reservoir hosts in
the Mediterranean and New World regions [17].
Leishmania has a digenetic life cycle, switching between sand fly stages and human stages
transmitted by sand flies biting humans. During a blood meal, the metacyclic promastigotes
inoculated into the human skin immediately invade into macrophages, dendritic cells, fibroblasts, and
keratinocytes and subsequently deactivate the host’s complement system, suppressing the production
of microbicidal molecules, such as superoxide and nitric oxide [22–24]. Although the parasites
are found in these various cell types, macrophages are the main host cells where the metacyclic
promastigotes differentiate into amastigotes [25]. The amastigotes continue to proliferate and
disseminate into other tissues and organs, including the liver, spleen, and bone marrow. The existence
of cutaneous or visceral leishmaniasis symptoms in humans depends on the parasite species, host
conditions, and other factors [20]. At this point, if the sand fly bites the infected host again, the
circulating amastigote-infected macrophages are likely to transmit to the new vector. In the gut of sand
flies, amastigotes transformed into extracellular promastigotes, which takes approximately 7–14 days
for transmissible infection to develop in the vector [26]. The promastigotes then migrate anteriorly
to the stomodeal valve of the sand fly and undergo a series of developmental transitions to form
infectious metacyclic promastigotes. Finally, during a blood meal on an appropriate host, a new
digenetic cycle of leishmaniasis will begin.
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4.1. Amphotericin B Parenteral Formulations
Amphotericin B (AmB) is a polyene macrolide antibiotic administered parenterally in the
treatment of a variety of systemic fungal infections including candidiasis, aspergillosis, fusariosis,
and zygomycosis [27]. In addition, AmB has exhibited antiparasitic activity for certain protozoan
infections, including leishmaniasis as well as primary amoebic meningoencephalitis [28]. Prior to
the development of lipid based formulations, the commercially available formulation used in the
clinic was Fungizone®, a conventional micellar form of AmB in a complex with deoxycholate [29].
Unfortunately, the conventional form is associated with renal toxicity, which led to the development
of other nonconventional formulations [30]. Nonconventional or lipid-based formulations have been
developed to overcome some of the toxicity problems associated with the conventional formulation.
There are several lipid-based parenteral formulations which have been marketed to treat fungal
infections, which include the liposomal formulation AmBisome®, the lipid complex formulation
Abelcet®, and a colloidal dispersion formulation Amphocil® (Amphotec) [31–33]. More recently, an
emulsion form of AmB (Amphomul®) was developed and completed its Phase III clinical trial in
2014 [34]. The aim of this trial was to assess the safety and efficacy of the parenteral lipid emulsion
formulation compared to AmBisome® as a single infusion treatment for VL [34]. Overall, the drawbacks
of the conventional parenteral formulation are the administration route, treatment duration, infusion
time, and most importantly, the toxicities associated with treatment. It is, however, still widely used in
developing nations where patients do not have access to the safer yet more expensive nonconventional
formulations [27].
4.2. Visceral Leishmaniasis Treatment Options and Limitations
Over the past few decades, treatment for VL is limited to pentavalent antimonials, AmB
deoxycholate and pentamidine, and more recently, liposomal AmB, mitefosine, and paromomycin [35].
At present, in developed countries, the first-line therapy for VL in both immunocompetent
and immunocompromised patients is short-course intravenous liposomal AmB, which has been
demonstrated to have improved efficacy with reduced nephrotoxicity compared to conventional
formulations [36]. However, more than 90% of global VL cases occur in developing countries,
where conventional AmB is still considered first-line therapy for VL because it is the most affordable
option [37,38]. An oral formulation of AmB would improve access to safe and effective treatment for VL
in these affected regions worldwide by removing the barriers of high costs, the need for hospitalization,
and a requirement for cold chain transport and storage conditions.
Cost of treatment is an important consideration for most patients; since liposomal AmB is 30 times
more expensive than the conventional formulation, it is a huge limitation for patients in developing
countries [17]. In 2010, the WHO released the “Costs of medicines in current use for the treatment of
leishmaniasis” that included drug prices per unit and their estimated prices per VL treatment [39].
This document has the price per unit provided by the manufacturer, or the WHO-negotiated prices
where applicable. They stated that the median cost per 50 mg of AmB deoxycholate to be $7.5 USD in
comparison to the WHO negotiated price of $18 USD per 50 mg vial of AmBisome®. The estimated
price per VL treatment was $252 USD per 2–4 day treatment with 20 mg/kg AmBisome® in comparison
to $20 USD for a 30 day treatment (alternating days) with 1 mg/kg AmB deoxycholate [39]. However,
these estimates were done for a patient weighing 35 kg (or 77 lbs); therefore, many patients’ treatment
would be appreciably more expensive. Moreover, the treatment regimen used for the estimation
includes a shorter treatment duration than what is recommended, as previously described. It remains
unclear which guidelines WHO used to determine the treatment regimen as it was not disclosed, and
standard treatment regimens will vary by country. If the manufacturer recommendations for treatment
duration were used, the estimated cost of treatment would undoubtedly increase. A reduction in
the cost of treatment, in the form of an oral formulation of AmB, would greatly improve access to
treatment for those where the financial burden of treatment is simply unreasonable.
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Additionally, parenteral formulations must be administered in a hospital setting under the
supervision of health care professionals. Beyond the direct costs of in-patient treatment, including
admission, medical supplies, and charges for physician and laboratory services, there are numerous
indirect costs which make this form of treatment impossible for many low-income populations [17,40].
Indirect costs may include: Travel to the healthcare facility, food for the patient and caregiver while
in hospital, loss of income of the patient and/or their family members which accompany them, as
well as any other unforeseen miscellaneous costs [17]. Oral AmB would permit out-patient treatment
where patients could stay in their rural communities for the duration of their treatment, reducing the
economic burden of in-patient health care costs and the detrimental indirect costs of treatment for
patients and their families.
Although nonconventional formulations have improved the safety profile of AmB, there are
some inherent drawbacks to using a parenteral formulation of any kind in the developing nations
which are most affected by VL. The storage and transportation of liposomal AmB is a limitation, as
the intact vials must be stored ≤25 ◦C and reconstituted vials are only stable for 24 h in 2–8 ◦C [41].
This is an important limitation if one considers that all of the hyperendemic regions occur in tropical
or subtropical climates where proper refrigeration may not be feasible. In general, compared with
parenteral formulations, oral dosage forms are more flexible with their required storage conditions
in terms of temperatures and sterility, making them an attractive alternative. Another important
limitation is the different aggregation states of AmB. This amphipathic molecule has the ability to
self-aggregate in aqueous solution, which affects the safety profile of the different formulations of this
drug [42]. For instance, the monomeric form of AmB remains the safest due to its ability to target
ergosterol; thus, many formulations attempt to deliver AmB to target tissues in this form [42–44].
Conversely, the dimeric form of AmB, which is the most common state of reconstituted Fungizone®, is
associated with the worst toxicity of AmB [42,45]. Furthermore, the poly-aggregated state is safer than
the dimeric form [46,47].
5. Oral Formulations of AmB Currently in Development
5.1. Solid Lipid Nanoparticles
Chaudhari et al. (2015) developed solid lipid nanoparticles (SLNs) loaded with AmB (AmbiOnp)
to overcome the poor oral bioavailability and kidney toxicity issues with AmB [47] (Table 1).
The authors argued that producing a formulation that keeps AmB in its monomeric and/or
super-aggregated form will keep the drug in a form which preferentially targets ergosterol, as
opposed to its dimeric or oligomeric form, with its high affinity for cholesterol, which is responsible
for the toxicity associated with conventional AmB. The AmbiOnp formulation was prepared by
a probe sonication-assisted nanoprecipitation technique which produced a greater proportion
of super-aggregated AmB that accumulated to a lesser extent in the kidneys, as reported in
in biodistribution studies. This oral formulation was found to have a greatly improved safety
profile compared to conventional IV-administered Fungizone®, with kidney tissue concentrations
of approximately 84.5 ± 22.9 ng/g and 518.6 ± 31.5 ng/g, respectively, eight hours following
administration [47]. Furthermore, the authors did not report any adverse reactions with the new
formulation. In vivo pharmacokinetic studies demonstrated that orally administered AmbiOnp had a
1.05 relative bioavailability compared to intravenous Fungizone®, the long-standing gold standard of
therapy for systemic fungal infections and VL. AmbiOnp demonstrated an optimal sustained release
of AmB from the SLN delivery system, with 60% encapsulated in simulated intestinal fluid (SIF) over
a period of 6 h. This formulation had the added benefit of an improved stability profile for storage
conditions compared to conventional AmB:AmbiOnp was shown to be stable in 2–8 ◦C for 3 months
or around 15 days when stored at 25 ◦C and 40 ◦C [47].
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5.2. PLGA–PEG Nanoparticles
In contrast to the super-aggregate form of AmbiOnp, Radwan et al. (2017) formulated a
nanoparticle formulation in the hopes that it would release AmB solely in its monomeric form [43]
(Table 1). This formulation consisted of a poly(lactide-co-glycolide)–poly(ethylene glycol) (PLGA–PEG)
copolymer loaded with AmB and glycyrrhizic acid as an absorption enhancer. This delivery system
was formulated in hopes of an increase in the solubility of AmB, lessened toxicity, and the delivery
of monomeric AmB to ensure the efficacy of the formulation. In vivo efficacy was not investigated;
however, in vitro investigations found that the PLGA–PEG formulation had a greater antifungal
activity with a minimum inhibitory concentration (MIC) reduction of fourfold or greater than that of
Fungizone® 24 and 48 h after inoculation with Candida albicans in rats [43]. Pharmacokinetic studies
found that the formulation had a 1.3 relative bioavailability compared to Fungizone® [43]. Kumar et al.
(2015) also developed a PLGA–PEG encapsulated AmB formulation and tested the efficacy against
Leishmania donovani in hamsters [48]. According to the report, this formulation was able to inhibit the
parasite load in the liver by 93.2% compared to the free Amb group (74.6%) [48].
5.3. Chitosan-Coated Nanostructured Lipid Carriers
Ling Tan et al. (2018) designed a formulation consisting of a mixture of solid lipids and
lipid oils, which they called nanostructured lipid carriers (NLC), with added chitosan coating
for mucoadhesion [42] (Table 1). The authors’ aim was to maximize lymphatic transport of their
formulation to improve the oral bioavailability of AmB. Additionally, this formulation aimed to deliver
AmB in its less toxic monomeric form. By one of the preparation methods tested, both the uncoated
and chitosan coated NLC formulations were found to be stable in a predominantly monomeric form
and, to a lesser extent, a poly-aggregate form for a 120-day period [42]. Encapsulation efficiency
of the AmB-NLC formulation was 83.4 ± 0.72% and with a drug loading of 12.3 ± 0.11%, with the
encapsulation efficiency significantly increasing with the chitosan coated form [42]. Both coated and
uncoated forms demonstrated a biphasic release profile: An initial burst release phase followed by
sustained release. The authors concluded that their formulation addressed the concerns of toxicity by
keeping AmB in its monomeric and polyaggregated forms and that it has the potential to improve
AmB’s oral bioavailability due to the mucoadhesive properties of the NLCs which permit uptake in
the small intestine. They plan to follow up with in vivo pharmacokinetic studies and safety studies to
confirm their findings [42].
5.4. Lecithin-Based Mixed Polymeric Micelles
Chen et al. (2015) prepared a self-assembling lecithin-based mixed polymeric micellar
formulation as an oral delivery system of AmB [49] (Table 1). This micellar formulation
uses lecithin as the lipid component with a number of polymers (including but not
limited to Pluronic® and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(poly(ethylene
glycol)-2000 (DSPE–PEG2K ), which are loaded with AmB using a thin film method. Specifically, the
authors’ optimal formulation, which they named Ambicelles, consisted of AmB:lecithin:DSPE–PEG2K
in a 1:1:10 mass ratio. Ambicelles were shown to increase the solubility of AmB from 0.001 to 5 mg/mL
in addition to an improved relative oral bioavailability of 1.50 compared to that of Fungizone® in rats,
which the authors attributed to the optimal sustained delivery of monomeric AmB. In vitro cytotoxicity
studies showed that Ambicelles were less cytotoxic than Fungizone® and free AmB in a human colon
adenocarcinoma cell line (HT29) [49].
5.5. O/W Microemulsion
Another approach to the oral delivery of AmB is in the form of an oil-in-water microemulsion
(O/W ME) [50] (Table 1). Silva et al. (2013) prepared an O/W ME using a surfactant mixture of
Tween 80® and Span 80® with a hydrophilic–lipophilic balance of approximately 13 and an oil phase
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consisting of Capryol® 90 or Capryol® PGMC. This ME formulation was able to increase the solubility
of AmB 1000-fold when compared to the aqueous solubility of AmB as well as providing favorable
rheological behavior for an oral delivery system. Time-dependent cytotoxicity results found the ME
formulation to be slightly less toxic than AmB in DMSO at concentrations up to 25 μg/mL in a murine
macrophage cell line [50]. The authors attributed this time-dependent toxicity to the discovery of the
formation of AmB aggregates which must be addressed before the development of this formulation
progresses [50].
5.6. Pickering Emulsion
In contrast to the traditional emulsion, a Pickering emulsion uses solid particles instead of
surfactants or other emulsifiers in order to stabilize its internal phase [51]. Richter et al. (2018)
formulated an AmB-loaded Pickering emulsion stabilized by self-assembled cashew tree gum grafted
with polylactide nanoparticles [51] (Table 1). The results demonstrated a novel formulation which
permitted the incorporation of this poorly water-soluble drug into their emulsions with a process
efficiency of up to approximately 47% and without suboptimal aggregation of the drug, as seen in
some commercial preparations. The authors plan to continue the development of this formulation
with subsequent in vitro release and toxicity studies [51].
5.7. Tragacanth/Acrylic Acid Copolymer
Mohamed et al. (2017) prepared a hydrogel drug carrier consisting of tragacanth and acrylic acid
(Aac) using gamma-irradiation [52] (Table 1). This pH-sensitive copolymer formulation was shown to
protect the AmB in an aggregated form in simulated gastric fluid (pH = 1) while drug was released as
the formulation dissociated in SIF (pH = 7). The authors suggested that the release rate and total amount
of drug released was dependent on pH and the Aac content of the copolymer with the aforementioned
variables increasing with Aac content. In vivo antifungal efficacy investigations against candidiasis in
mice showed that the oral (Trag/Aac)–AmB formulation (dose equivalent to 1 mg/kg) resulted in 0%
mortality compared to the 10% mortality eight days post intravenous inoculation when administered
intravenously with free AmB (1 mg/kg). Oral administration of (Trag/Aac)–AmB had similar efficacy
to that of free AmB as shown by the measured reduction of colony forming units (CFU) found in kidney
and liver tissues; free AmB reduced CFUs by 93% in the kidneys and 95% in the liver, comparatively
(Trag/Aac)–AmB reduced CFUs by 97% and 93%, respectively [52]. Moreover, assessment of serum
antibodies against C. albicans found no significant difference between the formulation of interest
and free AmB, thus providing further evidence of the comparable efficacy of the (Trag/Aac)–AmB
formulation. Furthermore, the authors did not find that that their formulation produced significant
levels of the cytokines: Tumor necrosis factor-αβ, interleukin-1β, and nitric oxide in the kidney and the
liver when compared to the free AmB-treated animals, which they interpreted as evidence supporting
the superior safety of their formulation. In vivo toxicity investigations found (Trag/Aac)–AmB to be
relatively safe, with negligible reported nephrotoxicity as demonstrated by no significant increase in
creatinine or blood urea nitrogen (BUN) levels when compared with the AmB-treated control. Similar
results were reported for liver toxicity as measured by serum aspartate aminotransferase and alanine
aminotransferase enzymes. Further histopathological examinations were completed by the authors,
which demonstrated that their oral formulation caused minimal renal damage and notable reduction
of injury of hepatocytes when compared with the degenerative effects following treatment with free
AmB on the renal glomerular tuft and hepatocyte necrosis [52].
5.8. Chitosan (CS) and Porphyrin (POR) Polymeric Nanocarrier
Bhatia et al. (2014) suggested that loading AmB as a polyelectrolyte complex into a biodegradable
polymeric nanocarrier is an optimal solution to the delivery of this problematic drug [53] (Table 1).
Specifically, they chose to use chitosan and porphyrin as two oppositely charged polymers with
AmB associated with them. Stability studies showed that their polyelectrolyte complex formulation
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(i.e., with or without tripolyphosphate as a crosslinking agent) showed less degradation in simulated
gastric fluid and a superior release profile for up to 12 h, when compared to plain AmB and
chitosan-only nanoparticles. Moreover, an in vitro antifungal activity study found the formulated
nanoformulations to yield significantly higher antifungal activity, as measured by their IC50, than the
marketed formulations (AmB, Fungizone®, and AmBisome®) in the chosen fungal strains: Aspergillus.
fumigatus, Aspergillus. niger, Aspergillus. flavus, and Candida. albicans. The most effective formulation
was found to be the CS–POR–AmB formulation, with 23-fold greater activity than Ambisome® in
A. fumigatus and 12- to 15- fold greater activity in A. niger, A. flavus, and C. albicans. An in vitro
hemolytic study found the authors’ nanoformulations to have less hemolytic toxicity than plain AmB
and the chosen marketed formulations, proving the polyelectrolyte complexation (PEC) ormulation
to be nontoxic up to concentrations of 55.5 μg/mL and with only approximately 4.1% hemolysis in
the CS–POR–AmB formulation (compared to ~39.9% for plain AmB). However, the investigation into
the in vivo toxicity of their POR formulations discovered an unexpected increase in platelet count
and minimal decrease in red blood cell count, white blood cell count, hemoglobin, and hematocrit
values when compared to the control. The authors suggested the platelet activation response may
be due to the high sulfur content or due to the high anhydrogalactose (AGR) per mole concentration
in their samples [53]. In vivo toxicity studies based on serum creatinine and blood urea nitrogen
levels found that the renal toxicity at maximum dose was worst for Fungizone® followed by CS–AmB,
CS–POR–AmB, CS, and lastly POR. The authors proposed this result may be due to the associated
release rate of each formulation as the AGR and sulfur present in POR produce a gelling effect which
may be better suited for a gastroretentive release of AmB [53].
5.9. Chitosan–Ethylenediamine Tetraacetic Acid (EDTA) Microparticles
Singh et al. (2013) characterized a novel solid self-nanoemulsifying drug delivery system
(S-SNEDDS) formulation of AmB using spray dried covalently crosslinked EDTA–chitosan (COECH)
microparticles for oral administration [54] (Table 1). They synthesized and characterized this
formulation in hopes of developing an adequate delivery system for poorly water soluble and
thermolabile drugs, such as AmB [54]. The authors reported that their formulation was indeed
able to self-nanoemulsify into a thermodynamically stable delivery system once in contact with an
aqueous environment. This formulation demonstrated a 12-fold improvement in in vitro dissolution
relative to pure AmB. Overall, the authors concluded that their COECH–S-SNEDDS formulation
prepared by spray drying technology was a reasonable approach which provided a solid substrate for
the development of an AmB nanoemulsion for oral administration [54].
5.10. Carbon Nanotubes
Prajapati et al. (2012) used carbon nanotubes (CNTs), which they covalently attached AmB in
order to create a potential formulation for oral administration [55] (Table 1). In this study addressing
the in vivo antileishmanicidal efficacy of their oral formulation, the authors found that their nanovector
delivery system, known as f-CNT–AmB, was able to inhibit the parasite load within the spleen in
a dose-dependent manner with 90.2%, 96.5%, and 98.2% inhibition for 5 mg/kg, 10 mg/kg, and
15 mg/kg doses, respectively [55]. In addition, in this small study using a hamster model of infection
at the highest oral dose of f-CNT–AmB at 15 mg/kg, it demonstrated comparable efficacy to a 5 mg/kg
dose of interperitoneally administered liposomal AmB. Furthermore, the lowest administered dose
of their oral formulation (5 mg/kg) had greater efficacy than the same dose of a currently marketed
oral treatment for VL, namely miltefosine [55]. Previous work published by these researchers reported
on the characterization of their formulation as well as the in vitro cytotoxicity (IC50 0.00234 μg/mL
compared to 0.03263 μg/mL for AmB, in a macrophage model), and in vivo safety and efficacy of their
formulation following intraperitoneal administration in mice and hamster models (no evidence of
toxicity and percent suppression of 89.8% for f-CNT–AmB compared with 68.9% for AmB) [56].
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5.11. Cubosomes
Yang et al. (2012) formulated cubosomes as a lipid-based delivery vehicle for AmB, as they
believed that their formulation would be able to overcome the molecule’s major inherent drawback,
i.e., poor bioavailability [57] (Table 1). In a small animal model, the authors found no indication of
nephrotoxicity following a single dose of the oral AmB-loaded cubosomes at doses of 10–20 mg/kg, as
measured by plasma BUN and plasma creatinine concentrations. Pharmacokinetic results determined
that the cubosome formulation (10 mg/kg) had increased the oral bioavailability of AmB 285%
compared with the oral administration of Fungizone®. In contrast with the nephrotoxicity results, a
biodistribution study showed that the high dose of AmB-loaded cubosomes (20 mg/kg) demonstrated
higher uptake of the drug in the kidneys in comparison with the liver and spleen. The liver and the
spleen had the highest uptake of the lower dose of AmB-loaded cubosomes. The authors hypothesized
that these results may indicate that their formulation would not be able to reduce the kidney toxicity
associated with AmB. However, as previously mentioned, this is contradictory to their findings that
neither dose caused an abnormal increase plasma BUN and creatinine concentrations 24 h following
oral administration [57].
5.12. GCPQ Nanoparticles (Quaternary Ammonium Palmitoyl Glycol Chitosan)
Serrano et al. (2015) encapsulated AmB in quaternary ammonium palmitoyl glycol chitosan
(GCPQ) nanoparticles in hopes that this self-assembling nanoparticle forming polymer would improve
the oral bioavailability of AmB by exhibiting drug delivery to target organs while bypassing toxicity
in nontarget organs [58] (Table 1). In order to test their hypothesis, the authors undertook detailed
investigations in murine and canine animal models evaluating the efficacy of their formulation
in systemic fungal infections, i.e., candidiasis and aspergillosis, in addition to VL. For all tested
disease states, AmB–GCPQ had similar efficacy to the marketed parenteral lipid-based formulation
AmBisome®. Serrano et al. (2015) found that their formulation improved the dissolution of AmB in
simulated gastrointestinal fluid compared to conventional AmB. Pharmacokinetic studies showed that
AmB–GCPQ delivered more drug to the target organs of pathology, namely, the liver, lung, and spleen,
with relatively less delivered to the kidneys. Moreover, the formulation also delivered AmB to the
bone marrow and the brain, which the authors argued would be beneficial for the clearance of the
Leishmania parasite and the treatment of systemic infections, respectively. The reported relative oral
bioavailability of the formulation was 24.7% [58].
The aforementioned studies have developed promising formulations which offer a wide range of
diverse approaches to overcome the limitations in the development of a viable oral AmB formulation.
However, to the best of our knowledge, these formulations have not progressed into the clinical trial
stage of development. Conversely, the following two formulations to be discussed are the furthest in
the advancement towards achieving the ultimate goal of developing an oral formulation of AmB and
bringing it to the market, as they have successfully commenced clinical trials.
5.13. Cochleates
Zarif et al. (2008) published results from multiple investigations into the in vitro and in vivo safety
and efficacy of their formulation which utilized lipid-based cochleates as a delivery system for AmB
for use in Candida infections [59] (Table 1). The cochleates consist of solid lipid bilayers arranged in
rolled-up sheets that are composed of phospholipid-cation precipitates, specifically phosphatidylserine
and calcium, respectively [59]. The AmB encapsulated in the cochleates is thus protected from
degradation in the GIT, permitting their use as an oral delivery system. The amphotericin B cochleates
(CAMB) formulation was prepared using a hydrogel method and was found to be stable; no drug was
lost from the delivery system for four months when stored at 4 ◦C. In murine models, biodistribution
studies provided evidence that absorption through the GI mucosa had occurred, permitting adequate
amounts of AmB to reach the target organs affected by systemic fungal infections (i.e., lungs, liver,
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spleen, and kidneys) following a 10-day oral administration of CAMB (10 mg/kg). The authors believe
this absorption occurred due to the involvement of the gut associated lymphatic tissue (GALT), as a
large concentration of AmB was found in the liver and spleen. The in vivo studies performed in murine
models of Candida albicans infection demonstrated that at 0.5 mg/kg/day (up to 2.5 mg/kg/day),
CAMB resulted in 100% survival 16 days post-infection compared to 30% mortality in mice treated
with 1 mg/kg/day of parenteral Fungizone® (however, 2 mg/kg/day resulted in 100% survival),
and 10% mortality resulted from 10 mg/kg/day AmBisome®. In addition, CAMB appeared to have
comparable efficacy at 2.5 mg/kg/day with that of parenteral Fungizone® at 2 mg/kg/day, resulting
in 3.5 log CFU count reduction in the kidneys and no detectable CFUs present in the lungs [59].
In vitro safety studies found no hemolytic effect of CAMB at concentrations up to 500 μg/mL AmB
on RBCs. In vivo safety investigations found no abnormal changes in BUN levels and histopathology
following 14 day treatment of 50 mg/kg doses of CAMB [59]. Further investigations include the
in vivo efficacy in a murine model of Aspergillus infection [60]; the in vitro activity in Leishmania chagasi;
and toxicokinetic studies in vivo in both rat and dog models [61]. All these studies had promising
results, which resulted in approval for human trials on CAMB, now known as MAT2203, which is
being investigated for the prevention of invasive fungal infections in patients with acute lymphoblastic
leukemia [62]. Preliminary results from the Phase I study evaluating the safety, efficacy, tolerability
and pharmacokinetics (PK) of CAMB in healthy volunteers has been released [63], demonstrating the
potential use of the formulation in single doses of 200 and 400 mg. This study found these doses to be
well tolerated with no serious adverse events or laboratory abnormalities and predictable plasma levels
comparable to previous animal studies, thus providing evidence that will progress this formulation to
the Phase II efficacy trials [63].
5.14. SEDDS (iCo-010/019)
Wasan et al. have also worked to solve the seemingly impossible task of developing an oral
AmB formulation for many years [44]. Their approach was to develop a lipid-based self-emulsifying
drug delivery system (SEDDS) for AmB to permit oral administration of this poorly bioavailable
drug with an additional aim of lessening its nephrotoxicity while maintaining optimal antileishmanial
activity [44,64–66]. The authors employed mono- and di-glycerides in addition to D-alpha-tocopheryl
poly(ethylene glycol) succinate (vitamin E–TPGS). An additional goal was to provide stability for AmB
in their delivery system in order to withstand tropical temperatures, considering the clinical target [66].
Before deciding on the iCo-010 formulation, which has recently completed Phase I clinical trials,
many versions of the formulation were developed and tested for stability, safety, and efficacy [44,66].
iCo-010 was determined to be the most promising formulation with optimal stability (>75% over
60 days in 30 ◦C; >95% after 4 h in SIF) antileishmanial activity was observed in a murine model of VL,
where <99% reduction in parasitic infection was achieved following 5 days of treatment with 10 mg/kg
po bid and 95% inhibition following treatment with 20 mg/kg po qd for 5 days, relative to the control.
This formulation also exhibited more desirable self-emulsifying properties compared to other versions
of the formulation, namely, iCo-011, -012, -013 [66] (Table 1). The authors hypothesized that the
desirable efficacy of their oral AmB formulation was likely a result of improved solubility, stability
in the gastrointestinal tract, membrane permeability, and its ability to target the lymphatic transport
system. The latter improvement may permit this formulation to target the greatest sites of infection
in VL-infected organisms [66]. iCo-10 was also found to maintain AmB in monomeric form upon
emulsification in simulated gastric fluid (Wasan lab, unpublished data). Further investigation into the
safety of the iCo-010 formulation found no evidence of GI toxicity, hepatotoxicity, or nephrotoxicity
following the oral administration of multiple doses in a murine model [65]. The biodistribution of the
formulation in a mouse model showed uptake in the organs of the reticuloendothelial system at levels
above the IC50 for the leishmania organism [65], which propelled iCo-010 into Phase I clinical trials.
Furthermore, the potential use of iCo-010 for indications other than VL was explored, e.g., systemic
candidiasis, which was found to be an effective once daily 5 day treatment for this indication in a rat
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model [67]. On June 27th, 2018, iCo Therapeutics announced a positive clinical outcome, as the primary
safety and tolerability endpoint was met in the Phase I clinical trials of this oral AmB formulation, now
known as iCo-019, further supporting the potential of iCo-019 to make it to the market and become
accessible to those most affected by VL in endemic regions to have a safe and effective treatment with
an oral form of AmB [68].
Table 1. AmB oral formulation summary.
AmB oral formulation Efficacy Stability
Solid lipid nanoparticle [47] Lower kidney tissue concentration, 2–8
◦C for 3 months,
105% Fo of Fungizone® 15 days ≥ 25 ◦C
PLGA–PEG nanoparticle [43,48]
Increase antifungal activity 4-fold
in vitro
N/AInhibit parasite load by 93.2% compared
with free AmB group (74.6%)
130% Fo of Fungizone®
Chitosan-coated nanostructured lipid
carriers [42] N/A
63.9% AmB retained encapsulated after
30 min incubation in SIF
Lecithin-based mixed polymeric
micelles [49]
Less toxic in HT29 cells Increase solubility
150% Fo of Fungizone®
O/W microemulsion [50] Slightly less toxic than free DMSO Increase the solubility by 1000 folds
Pickering emulsion [51] N/A Stable one month under refrigeration
Tragacanth/acrylic acid copolymer [52]
No mortality observed in mice
comparing with free AmB N/A
Improve oral bioavailability comparing
with free AmB
Chitosan and porphyrin polymeric
nanocarrier [53]
23-fold antifungal activity than
Ambisome®
Less degradation in SIF and a superior
release profile for up to 12 h
Slightly less toxic than Fungizone®
Chitosan–EDTA microparticles [54] N/A 12-fold improvement in in vitrodissolution relative to pure AmB
Carbon Nanotubes [55,56]
Inhibit the parasite load in a
dose-dependent manner N/A
No evidence of toxicity in mice and
hamster models
Cubosomes (cubic liquid crystal
nanoparticles) [57]
low dose of AmB-loaded cubosomes
shows low kidney concentration than
Fungizone® 74% detectable AmB after 3h in SIF
285% bioavailability of Fungizone®
GCPQ nanoparticles [58] Absolute Fo is 24.7% Stable for a year on storage
Higher concentration in liver, lung and
spleen
Cochleate–CAMB/MAT2203 [59,60]
100% survival comparing with
Fungizone® and AmBisome® Stable for 4 months at 4 ◦C
No serious adverse event in Phase I
study
SEDDS (iCo-010/019) [66]
<99% reduction in parasitic infection in
a murine model >75% over 60 days in 30
◦C; >95% after
4 h in SIF95% inhibition when compared to
control
Abbreviations: SIF, simulated intestinal fluid; Fo, oral bioavailability.
6. Discussion and Concluding Remarks
The abundance of data published on the topic of developing an oral form of AmB for the treatment
of systemic infections such as VL alone supports the urgent need for a formulation to make it to the
market. A number of researchers felt inclined to find a solution to overcome the barriers imposed by
physicochemical properties of AmB. However, the majority of these formulations were unsuccessful,
which demonstrates the difficulty of this task. Nevertheless, the two formulations which have made it
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to clinical trials with positive preliminary results provide us with evidence that a solution may finally
be found which absolves the myth that an oral AmB formulation could not be developed.
Funding: The Wasan Lab was funded by the Canadian Institutes of Health Research (CIHR), iCo Therapeutics
Inc. and the Consortium for Parasitic Drug Development via the Bill and Melinda Gates Foundation for the
development of iCo 010/019.
Conflicts of Interest: The authors declare no conflict of interest in writing of this manuscript. The funders of the
iCo 010/019 work that was reported in this manuscript had no role in the writing of the manuscript, or in the
decision to publish this perspective.
Abbreviations
Acrylic acid AAc Anhydrogalactose AGR
Amphotericin B AmB Blood urea nitrogen BUN





Carbon nanotubes CNTs Ethylenediaminetet-raacetic acid EDTA
Gut associated lymphatic tissue GALT Oral bioavailability Fo




Minimum inhibitory concentration MIC
Polyelectrolyte complexation PEC Poly(lactide-co-glycolide)–poly(ethylene glycol) PLGA–PEG
Phamacokinetics PK Porphyrin POR
Quaternary ammonium palmitoyl
glycol chitosan
GCPQ Reactive oxygen species ROS
Self-emulsifying drug
delivery system
SEDDS Simulated intestinal fluid SIF
Solid lipid nanoparticles SLNs Visceral leishmaniasis VL
References
1. Cereghetti, D.M.; Carreira, E.M. Amphotericin B: 50 years of chemistry and biochemistry. Synthesis 2006, 6,
0914–0942. [CrossRef]
2. Fernandez-Garcia, R.; de Pablo, E.; Ballesteros, M.P.; Serrano, D.R. Unmet clinical needs in the treatment of
systemic fungal infections: The role of amphotericin B and drug targeting. Int. J. Pharm. 2017, 525, 139–148.
[CrossRef] [PubMed]
3. Mesa-Arango, A.C.; Scorzoni, L.; Zaragoza, O. It only takes one to do many jobs: Amphotericin B as
antifungal and immunomodulatory drug. Front. Microbiol. 2012, 3, 286. [CrossRef] [PubMed]
4. Gray, K.C.; Palacios, D.S.; Dailey, I.; Endo, M.M.; Uno, B.E.; Wilcock, B.C.; Burke, M.D. Amphotericin
primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. USA 2012, 109, 2234–2239.
[CrossRef] [PubMed]
5. Kaminski, D.M. Recent progress in the study of the interactions of amphotericin B with cholesterol and
ergosterol in lipid environments. Eur. Biophys. J. 2014, 43, 453–467. [CrossRef] [PubMed]
6. Kinsky, S.C. Antibiotic interaction with model membranes. Annu. Rev. Pharmacol. 1970, 10, 119–142.
[CrossRef] [PubMed]
7. Palacios, D.S.; Dailey, I.; Siebert, D.M.; Wilcock, B.C.; Burke, M.D. Synthesis-enabled functional group
deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proc. Natl. Acad.
Sci. USA 2011, 108, 6733–6738. [CrossRef] [PubMed]
8. Wu, H.-C.; Yoshioka, T.; Nakagawa, K.; Shintani, T.; Tsuru, T.; Saeki, D.; Shaikh, A.R.; Matsuyama, H.
Preparation of Amphotericin B-Ergosterol structures and molecular simulation of water adsorption and
diffusion. J. Membrane Sci. 2018, 545, 229–239. [CrossRef]
9. Grela, E.; Wieczor, M.; Luchowski, R.; Zielinska, J.; Barzycka, A.; Grudzinski, W.; Nowak, K.; Tarkowski, P.;
Czub, J.; Gruszecki, W.I. Mechanism of Binding of Antifungal Antibiotic Amphotericin B to Lipid Membranes:
338
Pharmaceutics 2019, 11, 99
An Insight from Combined Single-Membrane Imaging, Microspectroscopy, and Molecular Dynamics.
Mol. Pharm. 2018, 15, 4202–4213. [CrossRef] [PubMed]
10. Anderson, T.M.; Clay, M.C.; Cioffi, A.G.; Diaz, K.A.; Hisao, G.S.; Tuttle, M.D.; Nieuwkoop, A.J.; Comellas, G.;
Maryum, N.; Wang, S.; et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat.
Chem. Biol. 2014, 10, 400–406. [CrossRef] [PubMed]
11. Mesa-Arango, A.C.; Trevijano-Contador, N.; Román, E.; Sánchez-Fresneda, R.; Casas, C.; Herrero, E.;
Argüelles, J.C.; Pla, J.; Cuenca-Estrella, M.; Zaragoza, O. The production of reactive oxygen species is an
universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal
effect of this drug: AMPHORES study. Antimicrob. Agents Chemother. 2014, 58, 6627–6638. [CrossRef]
[PubMed]
12. Guirao-Abad, J.P.; Sánchez-Fresneda, R.; Alburquerque, B.; Hernández, J.A.; Argüelles, J.-C. ROS formation
is a differential contributory factor to the fungicidal action of amphotericin B and micafungin in Candida
albicans. Int. J. Med. Microbiol. 2017, 307, 241–248. [CrossRef] [PubMed]
13. Phillips, A.J.; Sudbery, I.; Ramsdale, M. Apoptosis induced by environmental stresses and amphotericin B in
Candida albicans. Proc. Natl. Acad. Sci. USA 2003, 100, 14327–14332. [CrossRef] [PubMed]
14. Serrano, D.R.; Lalatsa, A. Oral amphotericin B: The journey from bench to market. J. Drug Deliv. Sci. Tech.
2017, 42, 75–83. [CrossRef]
15. World Health Organization. Neglected Tropical Diseases. Available online: https://www.who.int/
neglected_diseases/diseases/en/ (accessed on 15 September 2018).
16. Global Health Observatory Data Repository. Status of Endemicity of Visceral Leishmaniasis Data by
Country. Available online: http://apps.who.int/gho/data/view.main.NTDLEISHVENDv (accessed on
15 September 2018).
17. Thornton, S.J.; Wasan, K.M.; Piecuch, A.; Lynd, L.L.D.; Wasan, E.K. Barriers to treatment for visceral
leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Drug Dev. Ind. Pharm.
2010, 36, 1312–1319. [CrossRef] [PubMed]
18. World Health Organization. Leishmaniasis: Epidemiological Situation. Available online: https://www.who.
int/leishmaniasis/burden/en/ (accessed on 15 September 2018).
19. Global Health Observatory Data Repository. Number of Cases of Visceral Leishmaniasis Reported Data
by Country. Available online: http://apps.who.int/gho/data/node.main.NTDLEISHVNUM?lang=en
(accessed on 15 September 2018).
20. Torres-Guerrero, E.; Quintanilla-Cedillo, M.R.; Ruiz-Esmenjaud, J.; Arenas, R. Leishmaniasis: A review.
F1000Research 2017, 6, 750. [CrossRef] [PubMed]
21. Maroli, M.; Feliciangeli, M.D.; Bichaud, L.; Charrel, R.N.; Gradoni, L. Phlebotomine sandflies and the
spreading of leishmaniases and other diseases of public health concern. Med. Vet. Entomol. 2013, 27, 123–147.
[CrossRef] [PubMed]
22. Walker, D.M.; Oghumu, S.; Gupta, G.; McGwire, B.S.; Drew, M.E.; Satoskar, A.R. Mechanisms of cellular
invasion by intracellular parasites. Cell Mol. Life Sci. 2014, 71, 1245–1263. [CrossRef] [PubMed]
23. Mosser, D.M.; Edelson, P.J. The third component of complement (C3) is responsible for the intracellular
survival of Leishmania major. Nature 1987, 327, 329–331. [CrossRef] [PubMed]
24. Kima, P.E. The amastigote forms of Leishmania are experts at exploiting host cell processes to establish
infection and persist. Int. J. Parasitol. 2007, 37, 1087–1096. [CrossRef] [PubMed]
25. Beattie, L.; Kaye, P.M. Leishmania–host interactions: What has imaging taught us? Cell Microbiol. 2011, 13,
1659–1667. [CrossRef] [PubMed]
26. Bates, P.A. Revising Leishmania’s life cycle. Nat. Microbiol. 2018, 3, 529–530. [CrossRef] [PubMed]
27. Thornton, S.J.; Wasan, K.M. The reformulation of amphotericin B for oral administration to treat systemic
fungal infections and visceral leishmaniasis. Expert Opin. Drug Deliv. 2009, 6, 271–284. [CrossRef] [PubMed]
28. Grace, E.; Asbill, S.; Virga, K. Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrob.
Agents Chemother. 2015, 59, 6677–6681. [CrossRef] [PubMed]
29. Belkherroubi-Sari, L.; Adida, H.; Seghir, A.; Boucherit, Z.; Boucherit, K. New strategy for enhancing the
therapeutic index of Fungizone((R)). J. Mycol. Med. 2013, 23, 3–7. [CrossRef] [PubMed]
30. Pham, T.T.; Loiseau, P.M.; Barratt, G. Strategies for the design of orally bioavailable antileishmanial
treatments. Int. J. Pharm. 2013, 454, 539–552. [CrossRef] [PubMed]
339
Pharmaceutics 2019, 11, 99
31. Stone, N.R.; Bicanic, T.; Salim, R.; Hope, W. Liposomal amphotericin B (AmBisome®): A review of the
pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016, 76, 485–500.
[CrossRef] [PubMed]
32. Lister, J. Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: The North American
experience. Eur. J. Haematol. Suppl. 1996, 57, 18–23. [CrossRef] [PubMed]
33. Clemons, K.V.; Stevens, D.A. Comparative efficacies of four amphotericin B formulations—Fungizone,
Amphotec (Amphocil), AmBisome, and Abelcet—against systemic murine aspergillosis. Antimicrob. Agents
Chemother. 2004, 48, 1047–1050. [CrossRef] [PubMed]
34. Sundar, S.; Pandey, K.; Thakur, C.P.; Jha, T.K.; Das, V.N.; Verma, N.; Lal, C.S.; Verma, D.; Alam, S.; Das, P.
Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral
leishmaniasis: A randomized, open-label study. PLoS Negl. Trop. Dis. 2014, 8, e3169. [CrossRef] [PubMed]
35. World Health Organization. Control of the leishmaniases. World Health Organ. Tech. Rep. Ser. 2010, 949,
57–59.
36. Sundar, S.; Chakravarty, J. Liposomal amphotericin B and leishmaniasis: Dose and response. J. Glob.
Infect. Dis. 2010, 2, 159–166. [CrossRef] [PubMed]
37. Sundar, S.; Chakravarty, J. An update on pharmacotherapy for leishmaniasis. Expert Opin. Pharmacother.
2015, 16, 237–252. [CrossRef] [PubMed]
38. Alvar, J.; Velez, I.D.; Bern, C.; Herrero, M.; Desjeux, P.; Cano, J.; Jannin, J.; den Boer, M.; WHO Leishmaniasis
Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012, 7, e35671.
[CrossRef] [PubMed]
39. World Health Organization. Costs of Medicines in Current Use for the Treatment of Leishmaniasis. 2010.
Available online: https://www.who.int/leishmaniasis/research/978_92_4_12_949_6_Annex6.pdf?ua=1
(accessed on 15 September 2018).
40. de Assis, T.S.; Rosa, D.C.; de Morais Teixeira, E.; Cota, G.; Azeredo-da-Silva, A.L.; Werneck, G.; Rabello, A.
The direct costs of treating human visceral Leishmaniasis in Brazil. Rev. Soc. Bras. Med. Trop. 2017, 4,
478–482.
41. Jensen, G.M. The care and feeding of a commercial liposomal product: Liposomal amphotericin B
(AmBisome((R))). J. Liposome Res. 2017, 27, 173–179. [CrossRef] [PubMed]
42. Ling Tan, J.S.; Roberts, C.J.; Billa, N. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral
delivery of amphotericin B. Pharm. Dev. Technol. 2018, 26, 1–9. [CrossRef] [PubMed]
43. Radwan, M.A.; AlQuadeib, B.T.; Siller, L.; Wright, M.C.; Horrocks, B. Oral administration of amphotericin B
nanoparticles: Antifungal activity, bioavailability and toxicity in rats. Drug Deliv. 2017, 24, 40–50. [CrossRef]
[PubMed]
44. Wasan, E.K.; Bartlett, K.; Gershkovich, P.; Sivak, O.; Banno, B.; Wong, Z.; Gagnon, J.; Gates, B.; Leon, C.G.;
Wasan, K.M. Development and characterization of oral lipid-based amphotericin B formulations with
enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or
Candida albicans. Int. J. Pharm. 2009, 372, 76–84. [CrossRef] [PubMed]
45. Barwicz, J.; Tancrede, P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol-
or ergosterol-containing phosphatidylcholine monolayers. Chem. Phys. Lipids 1997, 85, 145–155. [CrossRef]
46. Espada, R.; Valdespina, S.; Alfonso, C.; Rivas, G.; Ballesteros, M.P.; Torrado, J.J. Effect of aggregation state on
the toxicity of different amphotericin B preparations. Int. J. Pharm. 2008, 361, 64–69. [CrossRef] [PubMed]
47. Chaudhari, M.B.; Desai, P.P.; Patel, P.A.; Patravale, V.B. Solid lipid nanoparticles of amphotericin B
(AmbiOnp): In vitro and in vivo assessment towards safe and effective oral treatment module. Drug Deliv.
Transl. Res. 2016, 6, 354–364. [CrossRef] [PubMed]
48. Kumar, R.; Sahoo, G.C.; Pandey, K.; Das, V.; Das, P. Study the effects of PLGA-PEG encapsulated amphotericin
B nanoparticle drug delivery system against Leishmania donovani. Drug Deliv. 2015, 22, 383–388. [CrossRef]
[PubMed]
49. Chen, Y.C.; Su, C.Y.; Jhan, H.J.; Ho, H.O.; Sheu, M.T. Physical characterization and in vivo pharmacokinetic
study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int. J. Nanomed.
2015, 10, 7265–7274. [CrossRef]
340
Pharmaceutics 2019, 11, 99
50. Silva, A.E.; Barratt, G.; Cheron, M.; Egito, E.S. Development of oil-in-water microemulsions for the oral
delivery of amphotericin B. Int. J. Pharm. 2013, 454, 641–648. [CrossRef] [PubMed]
51. Richter, A.R.; Feitosa, J.P.A.; Paula, H.C.B.; Goycoolea, F.M.; de Paula, R.C.M. Pickering emulsion stabilized
by cashew gum- poly-l-lactide copolymer nanoparticles: Synthesis, characterization and amphotericin B
encapsulation. Colloids Surf. B Biointerfaces 2018, 164, 201–209. [CrossRef] [PubMed]
52. Mohamed, H.A.; Radwan, R.R.; Raafat, A.I.; Ali, A.E. Antifungal activity of oral (Tragacanth/acrylic acid)
Amphotericin B carrier for systemic candidiasis: In vitro and in vivo study. Drug Deliv. Transl. Res. 2018, 8,
191–203. [CrossRef] [PubMed]
53. Bhatia, S.; Kumar, V.; Sharma, K.; Nagpal, K.; Bera, T. Significance of algal polymer in designing amphotericin
B nanoparticles. Sci. World J. 2014, 2014, 564573. [CrossRef] [PubMed]
54. Singh, K.; Tiwary, A.; Rana, V. Spray dried chitosan–EDTA superior microparticles as solid substrate for the
oral delivery of amphotericin B. Int. J. Biol. Macromol. 2013, 58, 310–319. [CrossRef] [PubMed]
55. Prajapati, V.K.; Awasthi, K.; Yadav, T.P.; Rai, M.; Srivastava, O.N.; Sundar, S. An oral formulation of
amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental
visceral leishmaniasis. J. Infect. Dis. 2011, 205, 333–336. [CrossRef] [PubMed]
56. Prajapati, V.K.; Awasthi, K.; Gautam, S.; Yadav, T.P.; Rai, M.; Srivastava, O.N.; Sundar, S. Targeted killing of
Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
J. Antimicrob. Chemother. 2011, 66, 874–879. [CrossRef] [PubMed]
57. Yang, Z.; Tan, Y.; Chen, M.; Dian, L.; Shan, Z.; Peng, X.; Wu, C. Development of amphotericin B-loaded
cubosomes through the SolEmuls technology for enhancing the oral bioavailability. AAPS PharmSciTech
2012, 13, 1483–1491. [CrossRef] [PubMed]
58. Serrano, D.R.; Lalatsa, A.; Dea-Ayuela, M.A.; Bilbao-Ramos, P.E.; Garrett, N.L.; Moger, J.; Guarro, J.; Capilla, J.;
Ballesteros, M.P.; Schatzlein, A.G.; et al. Oral particle uptake and organ targeting drives the activity of
amphotericin B nanoparticles. Mol. Pharm. 2015, 12, 420–431. [CrossRef] [PubMed]
59. Zarif, L.; Graybill, J.R.; Perlin, D.; Mannino, R.J. Cochleates: New lipid-based drug delivery system.
J. Liposome Res. 2000, 10, 523–538. [CrossRef]
60. Delmas, G.; Park, S.; Chen, Z.W.; Tan, F.; Kashiwazaki, R.; Zarif, L.; Perlin, D.S. Efficacy of orally delivered
cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob. Agents Chemother. 2002,
46, 2704–2707. [CrossRef] [PubMed]
61. Kalbag, S.; Lu, R.; Ngoje, J.; Mannino, R.J. Oral Administration of Amphotericin B: Toxicokinetic Studies in
Animal Models. Antimicrob. Agents Chemother. 1992, 12, 2681–2685.
62. Matinas Biopharma. MAT2203: LNC Formulation of Amphotericin B. Available online:
https://www.matinasbiopharma.com/pipeline/mat2203-lnc-formulation-of-amphotericin-b (accessed
on 15 September 2018).
63. Mannino, R.; De, B.; Teae, A. Oral Administration of Amphotericin B (CAmB) in Humans: A Phase
I Study of Tolerability and Pharmacokinetics Preliminary Pharmacokinetics. Available online:
https://content.equisolve.net/_db6027646f523d19fe795801a0b7aff1/matinasbiopharma/db/128/
510/pdf/Oral_Dosing_of_Encochleated_Amphotericin_B_%28CAmB%29__Rapid_Drug_Targeting_to_
Infected_Tissues_in_Mice_with_Invasive_Candidiasis.pdf (accessed on 21 February 2019).
64. Wasan, K.M.; Wasan, E.K.; Gershkovich, P.; Zhu, X.; Tidwell, R.R.; Werbovetz, K.A.; Clement, J.G.;
Thornton, S.J. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
J. Infect. Dis. 2009, 200, 357–360. [CrossRef] [PubMed]
65. Sivak, O.; Gershkovich, P.; Lin, M.; Wasan, E.K.; Zhao, J.; Owen, D.; Clement, J.G.; Wasan, K.M. Tropically
stable novel oral lipid formulation of amphotericin B (iCo-010): Biodistribution and toxicity in a mouse
model. Lipids Health Dis. 2011, 10, 135. [CrossRef] [PubMed]
66. Wasan, E.K.; Gershkovich, P.; Zhao, J.; Zhu, X.; Werbovetz, K.; Tidwell, R.R.; Clement, J.G.; Thornton, S.J.;
Wasan, K.M. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against
visceral Leishmaniasis in a murine model. PLoS Negl. Trop. Dis. 2010, 12, e913. [CrossRef] [PubMed]
341
Pharmaceutics 2019, 11, 99
67. Ibrahim, F.; Sivak, O.; Wasan, E.K.; Bartlett, K.; Wasan, K.M. Efficacy of an oral and tropically stable
lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
Lipids Health Dis. 2013, 12, 158. [CrossRef] [PubMed]
68. Rae, A. iCo Therapeutics Announces Positive Oral Amphotericin Study. 2018. Available online: https:
//ceo.ca/@newsfile/ico-therapeutics-announces-positive-clinical-outcome (accessed on 15 September 2018).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Tel. +41 61 683 77 34






St. Alban-Anlage 66 
4052 Basel 
Switzerland
Tel: +41 61 683 77 34 
Fax: +41 61 302 89 18
www.mdpi.com ISBN 978-3-03928-005-6 
